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A b s t r a c t
Critical illness, constituting an acute illness or injury resulting in organ 
dysfunction and failure, is associated with a profound, systemic activation of 
the immune system and inflammation-mediated organ damage. However, 
critically ill patients suffer a high rate of nosocomial infection with 
secondary sepsis being a common cause of death. This high prevalence of 
secondary infections argues for the influence of an immune suppression that 
may, at first glance, appear paradoxical in light of the pro-inflammatory 
nature of critical illness. Although immune cell hypo-function has been 
noted in clinical and experimental critical illness, the mediators of these 
effects remain poorly defined. In this thesis, neutrophil function was 
examined in the context of clinically suspected ventilator-associated 
pneumonia, a common and lethal intensive care acquired infection (ICU-AI], 
This demonstrated impaired bactericidal functions [phagocytosis and 
reactive oxygen species production) in neutrophils from both the peripheral 
and pulmonary compartments; however there was ample evidence of co­
existent neutrophil activation [both cell surface markers and soluble 
mediators) and inflammation. An investigation of possible mediators of 
neutrophil dysfunction revealed a major role for C5a, the pro-inflammatory 
anaphylotoxin derived from complement C5. Recombinant C5a applied to 
healthy donor neutrophils was able to drive the defect in phagocytosis by 
phospho-inositol 3 kinase delta-mediated inhibition of RhoA and 
subsequent down regulation of actin polymerisation. The defects in RhoA 
and actin function were reversible with granulocyte-macrophage colony 
stimulating factor [GM-CSF) applied ex vivo, restoring phagocytic function to 
normal. Similar defects in RhoA and actin, and effective treatment with GM- 
CSF, were found in neutrophils from critically ill patients. In a second cohort 
of critically ill adults recruited prior to developing any ICU-AI, C5a-mediated 
neutrophil dysfunction was an independent predictor of acquiring 
nosocomial infection, being associated with a 5.4 fold increased risk [95% 
Confidence interval 1.4-21.0). The same cohort of patients also displayed 
two other features of immune suppression, namely monocyte deactivation 
and elevated proportions of regulatory T-cells that were also associated 
with increased risk of infection [relative risk of infection 3 [95%CI1.3-6.9) 
and 2.4 [95%CI1.3-4.2) respectively). These measures acted additively with 
C5a-mediated dysfunction, those with no immune impairment having a zero 
rate of nosocomial infection with cumulative increases in impairments being 
associated with a progressive increase in risk of infection [p=0.0004 by Chi 
squared for trend). In conclusion, critical illness is characterised by a 
complex inflammatory state with features of simultaneous hyper- and hypo- 
activation. This remarkable duality is illustrated by the ability of a pro- 
inflammatory molecule, C5a, to drive neutrophil dysfunction, with this 
dysfunction being associated with a serious adverse event -nosocomial 
infection.
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A b b r e v i a t i o n s
AC Adenylate cyclase
ALI Acute lung injury
A M Alveolar macrophage
ANOVA Analysis of variance statistical test
APACHE-II Acute physiology and chronic health evaluation, second iteration
ARDS Acute respiratory distress syndrome
BSI Blood stream infection
BAL Broncho-alveolar lavage
BALF Broncho-alveolar lavage fluid
C3a Anaphylotoxin formed by cleavage of complement component C3
C5a Anaphylotoxin formed by cleavage of complement component C5
cAMP Cyclic adenosine mono-phosphate
CARS Compensatory anti-inflammatory response syndrome
CD Cluster of differentiation
CD4 Cluster of differentiation 4
CD25 IL-2 receptor
CD88 C5a receptor type 1 (also denoted C5aRl)
CGD Chronic granulomatous disease
CRBSI Catheter-related blood stream infection
CVC Central venous catheter
DC Dendritic cell
‘desarg’ Metabolite of C3/5a formed by carboxypeptidase removal of terminal 
arginine
DIC disseminated intravascular coagulation
DM E M Dulbecco’s modified Eagle’s medium
D02 Delivery of oxygen
EDTA Ethylenediaminetetraacetic acid
ERK Extra-cellular signal-regulated kinase
ETT Endo-tracheal tube
FCS Fetal calf serum
fMLP formyl methionyl leucyl phenylalanine (also abbreviated to fMLF)
FOXP3 Forkhead box protein 3
GM-CSF Granulocyte-macrophage colony stimulating factor
HAI Hospital-associated infection
FIAP Hospital-associated pneumonia
HLA-DR Human leucocyte antigen-DR
HIV Human Immunodeficiency virus
HNE Human neutrophil elastase
HV Healthy volunteers (not age/sex matched cf Matched Volunteers)
i c x Inhibitory concentration X, where x denotes the reduction in 
activity relative to unihibited enzyme
ICU Intensive care unit
ICU-AI Intensive care unit associated infection
IL-ip Interleukin 1 beta
IL-6 Interleukin 6




IPEX Immune dysregulation polyendocrinopathy enteropathy X-linked 
syndrome
IQR Inter-quartile range
LAD Leucocyte adhesion deficiency
LPS Lipopolysaccharide
LTB4 Leukotrine B4
MARS Mixed anti-inflammatory response syndrome
MIF Macrophage migratory inhibitory factor
MODS Multi-organ dysfunction syndrome
M V Age and sex matched volunteers
NADPH Nicotinamide adenine dinucleotide phosphate
NG Naso-gastric
PAF Platelet activating factor
PBN Peripheral blood neutrophil
PI3K Phosphatidylinositol 3-Kinase
PKA Protein Kinase A
PKB Protein Kinase B
PKC Protein Kinase C
PR3 Proteinase 3
rhC5a Recombinant human C5a
ROC Receiver-operator characteristic
ROS Reactive oxygen species
sCD62L Soluble CD62L, also known as L-selectin
SOFA Sequential organ failure assessment score
SARS Severe acute respiratory syndrome
SAPS Simplified acute physiology score
SDD Selective digestive decontamination
SIRS Systemic inflammatory response syndrome
SSI Surgical site infection
s v o 2 Mixed venous oxygen saturation
T-cell Thymic matured lymphocyte
TLR Toll-like receptor
T-reg Regulatory T-cell (CD4+CD25+FOXP3+)
TNF-ci Tumour necrosis factor alpha
TPN Total parenteral nutrition
UTI Urinary tract infection
VAP Ventilator-associated pneumonia
VILI Ventilation-induced lung injury
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A r t i c l e  I .  I n t r o d u c t i o n  a n d  l i t e r a t u r e  r e v i e w
S e c t i o n  1 .0 1  C h a p t e r  o v e r v i e w
This chapter will present the background to the thesis, setting out the 
background to the hypotheses, which will be pursued in subsequent 
chapters. First is a description of the problems of nosocomial infections in 
intensive care units, and reasons for suspecting a role for specific host 
factors in their acquisition. Then follows a discussion of such potential host 
factors and an illustration of the issues through an exemplar infection, 
ventilator-associated pneumonia. Next is an exposition of the concept of 
'critical illness’, representing a common final pathophysiological pathway 
characterised by systemic immune activation. The apparently paradoxical 
finding of concurrent immune dysfunction will be presented, with 
discussion of the current state of knowledge in this field. This is followed by 
a discussion of two crucial aspects of physiological immune function; 
namely neutrophil functions (with specific reference to phagocytosis) and 
the complement cascade, and their role in killing invading microorganisms. 
Finally I will set out my principal hypotheses, which will be tested in the 
subsequent chapters.
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S e c t i o n  1 .0 2  N o s o c o m i a l  i n f e c t i o n
(a) Epidemiology of hospital- and intensive care-associated 
infections
Hospital-associated infections [HAI) have been recognised as a cause for 
concern for a considerable period, being highlighted by 19th century doctors 
including Ignaz Semmelweis (1847) and Joseph Lister (1867), and remain a 
significant issue in many healthcare systems in the 21st century. The 
concerns arise from several considerations. First, such infections commonly 
involve multi-resistant organisms (McGowan, Tenover 2004) that require 
potent, potentially toxic anti-microbial therapy (Davey, Marwick 2008). 
Second, these infections are associated with increased rates of mortality, 
morbidity, duration of admission and costs (Vincent 2003). Thirdly, there is 
a belief that such infections represent an avoidable form of iatrogenic harm 
(Bailey, Ries 2005).
Defining the exact nature of the HAI problem remains problematic.
Although a convention exists to define only those infections occurring 48 
hours or more after admission as 'hospital-associated' (Suetens et al. 2007, 
American Thoracic Society, Infectious Diseases Society of America 2005), 
different studies and organisations use different diagnostic criteria (Suetens 
et al. 2003). This results in considerable variability in reported rates of 
infections between studies, units and countries that significantly limits the 
ability to undertake comparative analyses. Simply changing the method of 
obtaining microbial cultures can alter rates of diagnosis of diseases such as 
ventilator-associated pneumonia (VAP) (Conway Morris etal. 2009)
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However, these issues notwithstanding, clear differences exist between 
certain groups of patients. Estimates of the prevalence of nosocomial 
infection amongst general medical and surgical patients range from 4-6% 
(Pellizzer et al. 2008, Reilly et al. 2008). In striking contrast, amongst 
patients requiring organ support in intensive care units (ICU), the 
prevalence rises to 25-40% (Vincent 2003, Vincent et al. 1995). These latter 
rates are similar to those found in neutropaenia (G1MEMA investigators 
1991, Schimpff et al. 1978). Although attributing direct mortality to 
nosocomial infection remains problematic (see below), one infection alone, 
VAP, has an estimated mortality of 20-30% (Chastre, Fagon 2002). Each 
episode prolongs ICU stays by 4.5 days (Chastre, Fagon 2002) and adds 
$40,000 in costs (Baker, Meredith & Haponik 1996). This impact has led to 
concerted efforts to prevent and even eradicate infections such as VAP and 
catheter-related blood stream infections (CRBS1) from ICUs (Institute for 
Health Care Improvement 2005 a, Scottish Intensive Care Society Audit 
Group, 2008).
(b) Microbiology of ICU associated infections
The microbiology of nosocomial infections in general, and ICU-associated 
infections (ICU-AI) in particular, provokes further questions. ICU-AIs are 
caused by a variety of organisms. Sixty-two per cent of infections are caused 
by Gram-negative bacteria, 47% Gram-positive, and 19% by fungi, with 
anaerobes and viruses making up a small number (Vincent et al. 2009). As 
some infections are polymicrobial the percentages quoted are >100% in
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total. A comparison of the organisms found in ventilator-associated 
pneumonia compared with severe (i.e. ICU-managed) community-acquired 
pneumonia is shown in Table 1-1 below, indicating marked differences both 
in categories of organisms and the specific species. Many of the VAP 
organisms exhibit both intrinsic and acquired resistance to antimicrobials, 
reflecting the selective pressures exerted by the widespread use of such 
drugs (Jones 2010].
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Other Streptococcus spp. 8% 3%
Gram-negative 65% 26%




Haemophilus spp. 10% 11%
Acinetobacter spp. 8% 0.2%




Other Gram-negative 4% 4%
‘Atypical’ bacteria 0% 8%
Anaerobes 1% 0.2%
Fungi 1% 0%
Table 1-1: Common organisms involved in venltilator-associated and
severe community-acquired pneumonia.
N u m b e r s  a r e  d e r i v e d  f r o m  2 4  s t u d i e s  o f  V A P  ( r e v i e w e d  b y  ( C h a s t r e ,  
F a g o n  2 0 0 2 )  a n d  4  s t u d i e s  o f  s e v e r e  ( i . e .  r e q u i r i n g  I C U  a d m i s s i o n )  
c o m m u n i t y - a c q u i r e d  p n e u m o n i a  ( W i l s o n ,  F e r g u s o n  2 0 0 5 ,  R e l l o  e t  a l .  
2 0 0 3 ,  R u i z  e t  a l .  1 9 9 9 ,  M o i n e  e t  a l .  1 9 9 4 ) .  R e m a i n i n g  p e r c e n t a g e  m a d e  
u p  o f  o t h e r  l o w  f r e q u e n c y  o r g a n i s m s  i n c l u d i n g  v i r u s e s .  M R S A  - 
M e t h e c i l l i n  r e s i s t a n t  S ta p h y lo c o c c u s  a u re u s .
Although the precise nature of the infecting organisms and their resistance 
patterns are undoubtedly influenced by local environmental prevalence and 
antimicrobial use (Kates et al. 1991, van Loon et al. 2005), this alone cannot 
explain the differences between hospital/ICU-associated and community- 
associated infections. First, it is notable that, despite being exposed to the same 
microbial ecology, hospital staff seldom acquire infections from such organisms,
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despite frequently being vectors (Morgan et al. 2010, Mermel et al. 2003) and 
earners (Whitman et al. 2008, Suffoletto et al. 2008). The experience of novel 
viruses such as influenza A/H1N1 2009 and the SARS coronavirus (Cheng et al. 
2010, Lai, Yu 2010) demonstrate that hospital staff can and do acquire infections 
from their work environment. Second, at least some of the organisms 
responsible for ICU-AIs such as coagulase-negative Staphylococci and Candida 
albicans are, in immuno-competent adults, seldom more than commensals.
The high prevalence of nosocomial infections and the microbiological features 
noted above suggest that there are specific host factors involved in their 
acquisition. The great majority of ICU patients do not suffer from classic 
immunocompromise such as that produced by human immunodeficiency virus 
(HIV) infection, neutropaenia or immunosuppressive drugs. However, the rates 
of nosocomial infection are similar to those described in such patients, thus 
pointing towards less well-recognised and less overt immune dysfunction.
(c) Risk factors for intensive care-associated infection
Studies by various groups have identified a variety of factors that are associated
with increased risk of acquiring infections within the ICU (Vincent 2003, 
Pellizzer et al. 2008, Al-Rawajfah, Stetzer & Hewitt 2009, Gastmeier et al.
2007). These can be broadly divided into intrinsic and extrinsic factors, as listed 
in Table 1-2 below.
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Extrinsic factors Presence of invasive devices (e.g. ET 
tube, CVC, urinary catheters, NG tube)
Prior use of broad-spectrum 
antimicrobials












Pre-existing co-morbid conditions, e.g. 
structural lung disease or diabetes 
mellitus
Type of presenting illness - e.g. bums 
or major trauma
Severity of precipitating illness
Lifestyle factors (smoking, alcohol, 
illicit drug use)
Nutritional status
Immune dysfunction - both pre-existing 
and ICU-acquired
Table 1-2: Factors associated with nosocomial infection in ICU.
E T - e n d o t r a c h e a l ,  C V C - c e n t r a l  v e n o u s  c a t h e t e r ,  N G - n a s o g a s t r i c .
The putative mechanisms by which these risk factors exert their influence are 
subject to debate, however the reasonable suppositions are as follows. The 
placement of foreign bodies, such as endotracheal tubes, indwelling central 
venous devices and urinary catheters breach the physical defences of skin and 
mucous membranes and provide nidi for microorganisms to colonise and hence 
infect (Passerini et al. 1992). This is supported by the relationship between
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organisms found to be colonising that later cause infection (Kerver et al. 1988, 
Luft et al. 2010), and the effectiveness of aseptic insertion (Raad et al. 1994) and 
antimicrobial coatings on reducing device associated infections (Wang et al. 
2010, Kollef et al. 2008b, Karchmer et al. 2000). Organisms themselves 
contribute by changing phenotype, and forming biofilms that are resistant to 
antimicrobial penetration and immune cell attack (Singh et al. 2010, Fux et al.
2005). However it should be noted that many non-critically ill patients also 
have indwelling devices, such as tracheostomy tubes for home ventilation or 
long-term vascular access devices and do not experience the same rate of 
infections (Splaingard et al. 1983, Morar et al. 1998, Jean et al. 2001). The 
requirement for endotracheal intubation, central venous catheter insertion and 
urinary catheterisation is also associated with severity of illness (and in the case 
of endotracheal intubation, sedation and analgesia), so additional influences are 
undoubtedly present beyond the simple existence of a foreign device.
Broad-spectrum antimicrobials are also associated with nosocomial infection. 
This association is in part due to their common use in hospital environments, 
where infections are acquired, as well as with their effects on commensal flora 
allowing colonisation, overgrowth and frank infection by more pathogenic 
organisms (McNulty et al. 1997, Scannapieco, Stewart & Mylotte 1992). Broad- 
spectrum antimicrobials also worsen the severity of infection by inducing 
resistance and selecting out organisms that have already developed resistance 
(Trouillet et al. 1998, Barza et al. 1987), so making infections harder to treat, 
necessitating higher doses of more toxic antimicrobials. However several groups 
of patients perceived to be at higher risk of infection, such as those with bums or
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fulminant hepatic failure, commonly receive prophylactic antibiotics with 
evidence of reduced infections and improved survival (Avni et al. 2010, Rolando 
et al. 1993). Indeed a systematic review of antibiotic prophylaxis for respiratory 
infections in critically ill patients found a survival benefit and reduced infections 
for combined systemic and topical antimicrobials (D'Amico et al. 1998).
What is more certain is the finding of oropharyngeal colonisation preceding the 
occurrence of YA P  caused by the same organisms (Bonten et al. 1996), with 
micro-aspiration past the cuff of the endo-tracheal tube being the most likely 
route of infection (reviewed in Estes, Meduri 1995). Enhanced dental hygiene 
(Sona et al. 2009), oral decontamination with chlorhexidine (Garcia et al. 2009), 
selective digestive decontamination (SDD) (Schultz, Haas 2011) and 
endotracheal tubes with subglottic suction and improved cuff seal (Bouza et al.
2008) have demonstrable benefits on VAP, supporting this as a significant factor.
Renal replacement therapy is also associated with nosocomial infection, not only 
secondary to invasive devices required for dialysis or haemofiltration but also 
due to the effects of renal failure and uraemia on immune cell function (Kato et 
al. 2008). Interestingly, in end-stage renal disease at least, there appears to be 
concomitant hypercytokinaemia/inflammation and immune dysfunction. 
(Stenvinkel et al. 2005) Despite recent improvements in dialysis and filtration 
membranes, extracorporeal circulation can result in immune cell and protein 
activation, including complement activation (Royston 1997).
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Blood transfusion remains an area of considerable controversy in critical care 
(Walsh, Wyncoll & Stanworth 2010), with only a single randomised trial 
published (Hébert et al. 1999) and conflicting data from epidemiological studies 
(Vincent 2002, Vincent et al. 2008). Blood transfusion is linked to length of stay 
in the IC U  (Vincent 2002) and can occur at various time points throughout the 
stay, both of which may confound any specific link with nosocomial infection. 
However heterologous blood is linked to immune depression (Triulzi et al. 1992) 
and therefore could be mechanistically linked to nosocomial infection, although 
this relationship is less clear in the post-leukodepletion era (Jensen, Hokland & 
Nielsen 1996).
Amongst the various drugs given to IC U  patients, several classes have been 
linked to nosocomial infection. For obvious reasons drugs used as 
immunosuppressants have the clearest links to nosocomial infection 
(Ylipalosaari et al. 2006), with this also being the case for Tow’/’replacement’ 
dose steroids in septic shock (Sprung et al. 2008). Perhaps less obviously 
several other classes of drugs are also associated with nosocomial infection. 
Antacids such as H 2 antagonists and proton pump inhibitors have a significant 
effect on reducing stress ulcers and upper gastro-intestinal (U G I) bleeding, but 
are associated with an increased risk of pneumonia (Beck-Sague et al. 1996). 
This is likely to be related to increased bacterial colonisation of stomachs with 
alkaline content (Forster et al. 1982). Critically ill patients, even without antacid 
therapy, have alkaline stomach fluid resulting from failure to secrete H + ions 
(Higgins, Mythen & Webb 1994). The gastric stasis and gut failure, which is
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commonly found in critical illness, can further exacerbate this, providing a 
reservoir for bacterial growth and aspiration (Fruhwald, Holzer & Metzler 2008). 
Sedatives and paralysing agents have also been linked to an increased risk of 
nosocomial infection. This is thought to relate to the effects these have on 
duration of mechanical ventilation, IC U  stay and impairment of protective 
reflexes such as coughing (Quenot et al. 2007). Some agents used, such as 
propofol and opioids, have direct effects on immune cell function (Huttemann et 
al. 2006, Clark et al. 2007) although the relevance of this is uncertain (Rittner, 
Roewer & Brack 2010). However there may be non-mechanistic explanations 
for the association, as limiting sedation results in reduced ventilation and reduced 
rates of VAP (Quenot et al. 2007).
Amongst other drugs used in critical illness, several have noted 
immunomodulating activities. Beta-adrenoceptor agonists, including 
catecholamines and synthetic selective agonists such as dobutamine, can impair 
neutrophil functions (Ignarro, Lint & George 1974) as well as altering 
lymphocyte and dendritic cell functions (reviewed in Montmollin et al. 2009). 
Aside from any antimicrobial activity, macrolide antibiotics such as 
clarithromycin can reduce neutrophil transmigration and reactive oxygen species 
production (Akamatsu H et al. 1996). The HM G-CoA reductase inhibitors, 
known collectively as statins, also have demonstrable immunomodulatory effects 
(Weant K A  & Cook A M  2007) that are currently under investigation as 
therapeutic options in critical illness, and significant numbers of patients 
admitted to the IC U  are on statin therapy prior to admission (O'Neal HR Jr et al.
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2011 ). However to date none of these immunomodulatory effects have been 
shown to influence the acquistion of nosocomial infection within the ICU.
Total parenteral nutrition (TPN), with its high lipid load, tendency to cause 
hyperglycaemia, requirement for administration via a central vein and large 
external reservoir of a medium supporting microbial growth involves a variety of 
risk factors for nosocomial infection and has shown up in several 
epidemiological studies as an associated factor (Chow et al. 2008, Chen et al.
2006).
Tracheostomy remains a controversial risk factor for nosocomial infection, with 
studies conflicting as to its effects. Some indicate an increased risk (Ibrahim 
2000), where others demonstrate more rapid weaning, lower sedation 
requirements and hence a reduction in ventilator-associated pneumonia (Moller 
et al. 2005).
Both TPN and tracheostomy tend to occur in patients remaining in IC U  for 
longer periods of time, which may confound any relationship with nosocomial 
infection. Furthermore infections themselves often prolong IC U  stay, leading to 
a requirement for such interventions (as with other factors such as blood 
transfusion). A  failure to account for the temporal relationship between IC U -A I 
and these interventions (i.e. ensuring that they occur p r i o r  to infection) could 
also lead to erroneous conclusions about the direction of causation.
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Intrinsic patient factors make up the second group of variables associated with 
nosocomial infection. Pre-morbid health, and co-morbid conditions have a 
significant impact on outcomes from intensive care (Hofhuis et al. 2007), with an 
impact on physiological reserve and potential for recovery. Some factors have a 
specific association with nosocomial infection, including structural lung disease 
and diabetes (Celis et al. 1988). These associations extend beyond the intensive 
care unit and probably reflect both physical factors, such as abnormal lung 
anatomy allowing pooling of secretions and impaired clearance (Jeffery 1998), 
and impaired immune responses secondary to these diseases (Arcavi, Benowitz 
2004, Turina, Fry & Polk 2005).
As will be discussed below, critical illness can arise from a variety of 
precipitating illnesses, which tend to produce a stereotyped immune response 
irrespective of the pathogenic origins (Bianchi 2007). However certain 
underlying illnesses do appear to bring a greater risk than others. Bums (Wurtz
1995) and trauma (Vincent et al. 1995) are both associated with an increased risk 
of nosocomial infection. Bums involve a profound inflammatory response 
(Bloemsma et al. 2008), as well as disruption of the protective barrier of the skin. 
Why trauma should be a risk factor for H A I remains a moot point, but it appears 
to remain an independent risk factor even when increased device utilisation, 
organ failures and illness severity are accounted for (Vincent et al. 1995).
The severity of the presenting illness, often assessed by scores such as the Acute 
Physiology and Chronic Health Evaluation (APACH E) Score, Sequential Organ 
Failure Assessment (SOFA) Score and Simplified Acute Physiology Score
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(SAPS), is also associated with nosocomial infection. Disease severity itself 
cannot cause infections, but it is associated with the requirements for 
interventions noted above, as well as resulting from multi-organ dysfunction 
which is the hall-mark of severe systemic inflammatory response syndrome 
(SIRS) and critical illness (see below). It appears likely that immune failure 
represents another organ system failure (see below). It should be noted that 
several large studies (Vincent et al. 1995, Craven et al. 1988) did not 
demonstrate an independent effect of severity of illness once other factors had 
been corrected for.
Tobacco smoke has a widely acknowledged deleterious effect on a range of body 
systems, including the lungs and heart. Smoking is a well-established risk factor 
for pulmonary and extra-pulmonary infections, due to its effects on mucociliary 
clearance and immunomodulatory impact (Sopori 2002). This risk also extends 
into nosocomial infections in the IC U  (George et al. 1998), although this may to 
some extent reflect long-term health damage from smoking in addition to acute 
tobacco toxicity (Delgado-Rodriguez et al. 2003).
Alcohol similarly has a direct immunotoxic effect (Zambell et al. 2004, Nilsson 
et al. 1996), and is also linked in epidemiological studies to nosocomial infection 
(Gacouin et al. 2008). Once again the long-term damage induced by excess 
alcohol on multiple organ systems may play as significant a role as the acute 
impact on immune cell function. Intravenous drug use, perhaps surprisingly, is 
not a widely reported risk factor for H AI, although it is associated with H IV
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infection and acquisition of multi-drug resistant P s e u d o m o n a s  infections 
(Tacconelli et al. 2002).
Malnutrition is a predictor of a variety of complications of intensive care, 
including prolonged length of stay, delayed weaning and critical illness 
myoneuropathy (Giner et al. 1996). Each of these can result in increased risk of 
nosocomial infection, which is associated with malnutrition in epidemiological 
studies (Schneider et al. 2004). Determining the immunological effects of 
malnutrition in humans can prove difficult, as infections can result in 
malnourishment as well as v i c e  v e r s a .  In addition malnourishment is a 
heterogeneous collection of conditions ranging from protein-energy malnutrition 
through to specific absence of key macro- or micronutrients. Anorexia nervosa 
reflects a fairly ‘pure’ malnourishment, with defects found in lymphocyte 
function that reverse on re-feeding (Allende et al. 1998). Interestingly results 
from the per-protocol subgroup of the SiGNET trial of selenium supplementation 
of TPN revealed a 10-15% reduction in nosocomial infection (Andrews et al. 
2011).
Specific immune defects may arise prior to IC U  admission, or during it. As 
noted above a variety of drugs and similar treatments used in IC U  have 
immunomodulatory effects, as may pre-admission factors such as smoking, 
alcohol and nutritional status.
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There are a number of acquired and in-born diseases of immune function, 
including HIV infection, haematological malignancies and associated 
cytopaenias, and ‘primary’ immunodeficiency arising from congenital and 
genetic defects (of which approximately 200 have now been described) 
(Casanova, Abel 2007). These diseases are associated with acquisition of 
infection, both in the community and in hospital. However it is suggested that 
critical illness itself is associated with, and indeed generates, a state of immuno­
suppression, which may prove to be one of the most important factors in the 
development of nosocomial infection in ICU.
The above points about IC U -A I will now be discussed in the context of a 
common and serious infection, ventilator-associated pneumonia (VAP). A  
section will then follow this on the concept of critical illness and finally a review 
of the current state of knowledge on critical illness-induced immune defects.
S e c t i o n  1 . 0 3  V e n t i l a t o r - a s s o c i a t e d  p n e u m o n i a ,  a n  e x e m p l a r  
n o s o c o m i a l  i n f e c t i o n
Infections of the respiratory tract form the commonest group of infections found 
in the intensive care unit (Vincent et al. 1995, Vincent et al. 2009). O f the 
nosocomial infections VAP is the commonest (Vincent et al. 1995), occurring in 
between 8-30% of ventilated patients (Chastre, Fagon 2002). The prevalence of 
VAP is influenced by variations in diagnostic technique (Conway Morris et al.
2009), as well as varied patient and staff factors (George et al. 1998, Blot et al. 
2011). The issue ot VAP diagnosis, and hence prevalence, has become further
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complicated by the use of VAP rates as a ‘care quality’ indicator (Institute for 
Healthcare Improvement, 2005 b).
The risk factors associated with VAP arc largely those identified above, 
especially those associated with the pulmonary system such as intubation, 
mechanical ventilation and micro-aspiration (reviewed in Chastre, Fagon 2002). 
Interventions to reduce these, such as using non-invasive ventilation to avoid 
intubation, head of bed elevation and sub-glottic suction have demonstrated 
reductions in VAP rates (reviewed in Relio et al. 2010).
Pneumonia is, strictly speaking, a histological diagnosis (Rouby et al. 1992), 
however this is seldom achievable a n t e - m o r t e m , especially in mechanically 
ventilated patients who would tolerate open lung biopsy poorly. In the absence 
of a tissue sample, pneumonia is diagnosed on a combination of clinical, 
radiological and laboratory criteria. Although specific criteria vary from source 
to source, all include the requirement for evidence of inflammation (e.g. elevated 
or suppressed white cell count, elevated or suppressed temperature, acute phase 
proteins or tachycardia/tachypnoea), clinical pulmonary signs (e.g. muco­
purulent sputum, auscultatory findings, impaired gas exchange) and radiological 
evidence of new (and persistent) consolidation, usually by plain radiograph or 
computed tomography (CT). This would then constitute ‘clinical’ or ‘suspected’ 
VAP. Most diagnostic criteria then look to identification of an infecting 
organism, either by direct culture or indirect methods such as antigen testing or 
serology. Some organisms, such as anaerobes and the ‘atypical’ respiratory 
bacteria, are difficult to culture, and others such as viruses are now routinely
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detected by polymerase chain reaction (PCR) rather than complex cell culture 
methods used previously. The detection of organisms can be further complicated 
by inter-current antimicrobial therapy (Souweine et al. 1998), as conventional 
cultures can only detect live organisms. Those with positive microbiology are 
then generally termed ‘confirmed’ VAP. A  diagrammatic representation of one 
of the diagnostic schemes, from the Hospitals in Europe Link for Infection 
Control through Surveillance (HELICS) program is shown in figure 1-1.
(HELICS 2004)




Inflam m ation , 
one  o f
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>38°C or 
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>12xlOv
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an o th e r  sou rce  (B lood, 
p leu ra l flu id) 
PN 4:Pos it ive  endo-tra ch ea l 
a sp ira te  
PN 5: N o  positive  cu ltu re
Figure 1-1: HELICS method of VAP diagnosis.
The HELICS method requires clinical and radiological signs of pneumonia 
(left hand side) and microbiological sampling (right hand side). W C C - 
white cell count, CFU-colony forming unit, BALF-broncho-alveolar lavage 
fluid. ‘Positive’ chest x-ray being one with new alveolar shadowing 
consistent with consolidation. (H ELICS 2004)
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Mechanically ventilated patients present a number of problems in this diagnostic 
‘triad’ of clinical inflammation, respiratory focus and radiological consolidation. 
The causes of inflammation in critically ill patients are legion, as discussed 
below, and a range of non-infective conditions can produce radiographic alveolar 
shadowing with associated lung signs. Acute lung injury (A LI) / acute 
respiratoiy distress syndrome (ARDS) in particular can not only mimic 
pulmonary infection, but can also be complicated by secondary infection in up to 
60% of cases (reviewed in Chastre, Fagon 2002). In this setting, the addition of 
microbial cultures is vital for diagnosis rather than just guiding therapy. Many 
patients without clinical VAP have microbial colonisation of the endotracheal 
tube and trachea (Feldman ct al. 1999). It is therefore not surprising that various 
studies suggest that use of endotracheal aspirate cultures produces a significantly 
higher rate of positivity compared to more protected sampling of the distal 
airways by broncho-alveolar lavage (B A L) or protected specimen brush (PSB). 
P o s t - m o r t e m  studies suggest that culture of organisms at 104 colony forming 
units (CFU)/ml from lavage fluid (and 103 CFU/ml from PSB samples) is 
associated with a histological diagnosis of pneumonia (Marquette ct al. 1995), 
and hence these are widely used cut-offs for the diagnosis of VAP. However the 
use of invasive specimens for diagnosis and treatment remains restricted due to 
conflicting trial results (Fagon ct al. 2000, Canadian Critical Care 2006), and the 
requirement for specialist skills and resources for bronchoscopy.
The effect of VAP on patient outcomes remains a hotly debated area. Although 
the consistent findings of prolonged mechanical ventilation, increased burden of
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antibiotics and increased duration of stay suggest these are definite associations 
(reviewed by Chastre, Fagon 2002), the impact on mortality is less clear. Some 
studies suggest no impact on mortality, once other confounders are included 
(Papazian et al. 1996), while others suggest an independent increase (Vallès et al.
2007). Inappropriate or delayed antibiotics are associated with mortality, 
however, suggesting that these infections are not a benign epiphenomenon of 
critical illness (Iregui et al. 2002, Kollef et al. 2008a). One might expect the 
results of VAP prevention studies to shed some light on this area, however to 
date these reports have been too flawed to allow an effective judgement 
(Zilberberg, Shorr & Kollef 2009). Therefore at present the best estimate of 
attributable mortality increase in VAP is in the order of 20-30% (Chastre, Fagon
2002), but this remains an uncertain figure.
VAP therefore illustrates several of the issues around ICU-acquired infection. It 
is highly prevalent, presents a diagnostic challenge amongst the pro- 
inflammatory milieu of the critically ill patient and results in a significant burden 
of morbidity, pro-longed length of stay, antibiotic treatment and cost and 
probably also impacts on mortality. Although there are established risk factors, 
far from all patients exposed to such factors develop VAP and hence there is 
considerable scope to investigate the role of host factors such as immune 
suppression in V A P ’s causation.
3 8
(a) Critical illness
Patients are admitted to intensive care units for a variety of reasons, and in a
manner that will vary from institution to institution and country to country. For 
instance admission policies in the United States, where there are 20 ICU beds per 
100,000 head of population, are likely to differ from the United Kingdom where 
there are only 3.5 beds per 100,000 (Adhikari et al. 2010). As a result one cannot 
simply define ‘critical illness’ as ‘a requirement for intensive care admission’, 
and yet many of the studies of ICU-acquired infection simply look at all 
admissions which may, in part, explain the apparent correlation between 
nosocomial infection rates and mortality seen between countries (Vincent et al. 
1995, Vincent et al. 2009).
With the origins of critical illness care in intensive/critical care units arising from 
the invasive ventilation of patients during the 1953 Danish polio epidemic (Ibsen 
1954), intensive care has focused on support for failing organ systems resulting 
from acute illness. Although various critical illness syndromes have been 
defined, such as sepsis (American College of Chest Physicians/Society of 
Critical Care Medicine 1992), ARDS (Bernard et al. 1994) and more nebulously 
‘multi-organ dysfunction syndrome’ (MODS) (Marshall 2000), an overall, 
precise consensus definition of critical illness is missing (Adhikari et al. 2010, 
McLellan, McClelland & Walsh 2003). In the absence of this definition, it is 
generally accepted that ‘critical illness’ constitutes an acute illness resulting in 
organ dysfunction and failure. What constitutes ‘organ failure’ is a further area 
of debate, with definitions ranging from physiological parameters (Bellomo et al. 
2004) to the requirement for exogenous organ support (Vincent et al. 1996). For
Section 1.04 Critical illness: defining a concept
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the purposes of this thesis, ‘Critical Illness’ is defined as an acute illness 
precipitating organ dysfunction severe enough to necessitate exogenous organ 
support.
(b) Pathogens, danger and inflammation
Critical illness is frequently associated with a systemic inflammatory response
syndrome (SIRS), characterised by physiological manifestations of inflammation 
(altered temperature, leukocytosis or bone marrow suppression, tachycardia and 
tachypnoea). This is accompanied by biochemical and immunological evidence 
of immune system activation (Sakamoto et al. 2010, McILwain et al. 2010, 
Miyaoka et al. 2005). SIRS can arise from both infective and non-infective 
causes, with infective SIRS being referred to as sepsis, and associations with 
organ failure and shock further defining ‘severe SIRS/sepsis’ and ‘SIRS/septic 
shock’ (American College of Chest Physicians/Society of Critical Care Medicine 
1992).
A  range of microbial ligands, including lipopolysaccharide (LPS), peptidoglycan, 
flagellin and lipoteichoic acid, are collectively known as pathogen-associated 
molecular patterns (PAMPS). These are able to induce inflammation by 
activating toll-like receptors (TLRs), associated with activation of intracellular 
signalling pathways such as the nuclear factor kappa B (NF-KappaB) pathway, 
which transduce signals into an inflammatory response (reviewed by Beutler
2009). The activation of this response is crucial to the elimination of microbial 
invaders and the resolution of infection (Dennis et al. 2008). Until more 
recently, what was less clear was the mechanisms by which sterile insults such as
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trauma, pancreatitis and ischaemia-reperfusion injury were able to stimulate a 
similar response. It is apparent that tissue damage, such as that arising from the 
above listed sterile insults, results in the release of endogenous molecules 
capable of eliciting similar responses to PAMPs. These endogenous molecules 
include high-mobility group box 1 (HMGB-1), a non-histone nuclear protein 
released following cell death and also by active secretion, which can activate NF- 
kappaB-dependent pathways via the receptor for advanced glycosylation end- 
products (RAGE) (reviewed in Sims et al. 2010). A  variety of other such 
‘alarmins’ have been identified, including heat shock proteins (HSP) (Wheeler et 
al. 2009), interleukin-1 alpha (IL-la) (Joosten et al 2010), SlOO/calgranulin 
proteins (Ehrchen et al. 2009), cathelicidins such as LL-37 (Yu ct al. 2007) and 
uric acid (Liu-Bryan et al. 2005), which can activate a variety of receptors 
including RAGE, TLRs and specific receptors such as IL-1R (Reviewed in 
Bianchi 2007). Further developments in the field of sterile inflammatory 
activation have come from the recent identification of released mitochondrial 
contents following trauma (Zhang et al. 2010a), which are capable of ligating 
formyl-peptide receptors. These also respond to similar ligands derived from 
bacteria, which are thought to share common ancestry with mitochondria prior to 
their inclusion in eukaryotic cells. It has been proposed that PAMPs and 
alarmins should be classified into a larger group, termed damage-associated 




Whilst the concept of DAMPs, and their down-stream pathways, may indicate
how inflammatory responses are triggered, how this leads to uncontrolled 
systemic inflammation, critical illness and multi-organ failure requires further 
explanation. The suggestion is of a progression from local inflammation at the 
site of injury/infection to systemic activation of inflammation, which if 
unchecked progresses to organ dysfunction (i.e. critical illness) and ultimately 
multi-organ failure (Matsuda, Hattori 2006).
How inflammation becomes uncontrolled and systemic remains a matter of 
debate. Although bacterial toxins, and bacteria themselves, can enter the 
circulation, bacteraemia is neither a pre-requisite nor a guaranteed precipitant of 
systemic inflammation and sepsis (Jones, Lowes 1996). Therefore outwith 
specific situations such as Staphylococcal toxic shock syndrome, systemic 
release of bacterial PAMPs may not be the crucial event. Several genetic 
polymorphisms have been associated with the development of severe SIRS and 
sepsis, including TLR-4 (Kumpf et al. 2010), tumour necrosis factor alpha (TN F- 
a) (Surbatovic et al. 2010), mannose binding lectin (Gordon et al. 2006) and IL - 
10 (Shu et al. 2003). It seems likely that differential regulation of the host 
response, by a combination of genetic and environmental factors, interacts with 
the initial insult to trigger the systemic activation of inflammation that 
characterises the early phases of sepsis and SIRS.
Defining the mediators involved in sepsis and SIRS, the sequence of events and 
the points at which adaptive inflammatory responses descend into maladaptive 
processes, are difficult, especially in human sepsis. Firstly it is rare to encounter
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patients prior to their insult, and with most precipitating events even determining 
the time between onset and presentation can be problematic. Furthermore, 
events and mediators in some body spaces may not be reflected by changes in the 
blood (Conway Moms et al. 2010, Hart et al. 1986), although blood is the most 
commonly studied body fluid in critical illness. Investigators are therefore 
obliged to rely in part on data acquired from animal models, which are imperfect 
guides to diseases in humans (Mestas, Hughes 2004, Dyson, Singer 2009).
Animal models and human studies suggest a very early rise in pro-inflammatory 
molecules such as IL-1 and TNF-alpha, which in blood at least, tend to peak 
early (within minutes) before declining (reviewed inThijs, Hack 1995). Slightly 
later responses involve molecules such as IL-6 (Darnas et al. 1992), monocyte 
chemotactic proteins 1 and 2 (MCP-1 and 2) (Bossink et al. 1995), IL-8 (Hack et 
al. 1992) as well as anti-inflammatory molecules such as IL-10 and the soluble 
TN F and IL-1 receptors (reviewed in Thijs, Hack 1995), alongside later 
mediators such as HM GB-l(Gibot et al. 2007). Interestingly, as predictors of 
outcome in sepsis, it appears that it is the magnitude of the anti-inflammatory 
response (as estimated by IL-10 concentrations) rather than the pro-inflammatory 
response (as estimated by TNF-alpha, IL-1, -6 and -8) that performs best (Gogos 
et al. 2000).
Several proteolytic plasma cascades activated in sepsis and SIRS are also 
implicated in the pathogensis of multi-organ failure. Specifically, sepsis and 
SIRS are accompanied by dysregulated, systemic activation of the complement, 
coagulation and fibrinolytic cascades (reviewed in Rittirsch, Flierl & Ward
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2008). These pathways activate each other, so driving positive feedback 
mechanisms and exacerbating the damage and dysfunction (Amara et al. 2010a). 
The normal function of the complement cascade is discussed below (Section 
1.08). However, in sepsis it undergoes massive activation with spillover of 
complement products into the systemic circulation, which results in a range of 
deleterious effects detailed in Table 1-3 below, most of which are mediated by 
the anaphylotoxins and specifically C5a (Ward 2004). Almost all of this work is 
derived from animal models or i n - v i t r o  examination of human cells, rather than 
from patients with sepsis or SIRS.
Activated complement products, and C5a in particular, activate the coagulation 
system via tissue factor (Kambas et al. 2008) and stimulate the production of 
inflammatory cytokines such as HMGB-1 (Rittirsch et al. 2008). C5a is also 
directly chemo-attractive to neutrophils as well as stimulating the release of 
reactive oxygen species (ROS) (Jia et al. 2010) and lytic enzymes such as human 
neutrophil elastase (HNE) (Binder et al. 1999, Zeerleder et al. 2003). Both have 
been implicated in sepsis-associated organ damage and outcomes (Gardinali et 
al. 1992). Much as complement activation can activate the coagulation cascade, 
thrombin can also cleave C5 into C5a and C5b independent of its upstream 
pathways (Wetsel, Kolb 1983) (see section 1.08 below), so illustrating how these 
two systems can positively reinforce one another and contribute to their 
dysregulation and inappropriate systemic activation. The systemic activation of 
the coagulation system results in deposition of fibrin and formation of 
microthrombi in the microcirculation, and thus possibly contributes to the 
impaired tissue perfusion seen in sepsis (Zhou et al. 2003, Gaskins, Dalldorf
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1976). Indeed, to date, the only therapy aimed specifically at sepsis-induced 
multi-organ failure, which has successfully completed phase three trials, is 
activated protein C, which targets the coagulation system amongst other effects 
(Bereczky, Kovacs & Muszbek 2010, Bernard et al. 2001). Concurrent 
activation of the fibrinolytic system results in the characteristic disseminated 
intravascular coagulation (DIC), which combines the microthrombotic problems 
noted above with a systemic coagulopathy and increased risk of haemorrhage 





Neutrophil recruitment1 C5a (Shuster, et al. 1997)
Neutrophil activation2, 
neutrophil elastase releaseJ
C3/C5 (Zeerleder et al. 2003, 
Brekke et al. 2007)
Bacterial opsomsation C3b (Brekke et al. 2007)
Direct bactericidal effects1 C5b-9 (Membrane 
attack complex)
(Flierl et al. 2008c)
Macrovascular dysfunction1 C5a (Hugli, Marceau 1985)
Tissue factor
activation/hypercoagulation1
C5a (Laudes et al. 2002a)
Release of alarmins (e.g. 
H M G B -1)1
C5a (Rittirsch et al. 2008)
Neutrophil dysfunction ’ C5a (Huber-Lang et al. 
2002b)
Lymphocyte apoptosis1 C5a (Riedemann et al. 2002)




C5a (Flierl et al. 2009)
Table 1-3: Effects of complement during sepsis.
1-animal models, 2 - i n - v i t r o  studies, 3-human studies.
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The various immune cells display altered functioning during sepsis and SIRS. 
Neutrophils containing proteolytic enzymes such as HNE and cathepsins (Boxer, 
Smolen 1988) as well as being a major source of ROS (Starr et al. 2011), 
typically become ‘activated’ by the soluble mediators found in sepsis including 
both endogenous molecules such as C5a and IL-8, and bacterial ligands such as 
LPS and formylated peptides. As noted above, mitochondria also express 
formylated peptides, releasing these upon tissue damage, and this may be one 
mechanism of neutrophil activation in sterile SIRS (Raoof et al. 2010). Although 
there remain discrepancies within the literature, it is generally accepted that 
sepsis and SIRS are accompanied by neutrophil activation (Sakamoto et al. 2010, 
Rosenbloom et al. 1995), so preparing them to fight actual or potential microbial 
invaders and remove damaged tissue (Borregaard 2010). However, high levels 
of activated neutrophils are linked to organ damage (Borregaard 2010) and 
failure as discussed below. Furthermore, in the setting of sepsis, neutrophils 
frequently display dysfunctions in key anti-microbial activities (see section 1.05 
c below).
Monocytes and macrophages play a central role in co-ordinating immune 
responses, promoting neutrophil recruitment (Kreisel et al. 2010) and acting as 
antigen presenting cells to stimulate adaptive immune responses (Wolk et al. 
2000). Monocytes exist in at least three sub-populations, each of which release 
specific profiles of cytokines and are relatively pro- or anti-inflammatory 
(reviewed in Ziegler-Heitbrock 2007). During systemic inflammation and sepsis 
these sub-populations alter in size, with expansion of the CD14+CD16+ sub­
population (Fingerle et al. 1993). Interestingly, although this sub-population is
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classically described as being ‘hyper-inflammatory’ (Ziegler-Heitbrock 2007), 
analysis of their function in patients with sepsis revealed d e c r e a s e d  rather than 
increased TN F -a  production (Horelt et al. 2002).
Macrophages can also exist in at least two different forms, termed M l and M2, 
with M l being predominantly pro-inflammatory and provoking a T H1 response 
from T-lymphocytes, whilst M2 phenotypes promote inflammatory resolution 
and a predominant T h2 response (reviewed inMege, Mehraj & Capo 2011). 
Sepsis is associated with alterations in the M1/M2 polarisation of macrophages; 
with the suggestion that unbalanced M 1 activation is associated with poor 
outcomes (Benoit, Desnues & Mege 2008, Mehta et al. 2004).
T-lymphocytes are classically thought to be acted upon by the innate immune 
system, responding to stimuli from antigen presenting cells before either 
facilitating humoral or cytotoxic defence mechanisms. However in animal 
models of sepsis, there appears to be evidence of very early T-cell activation, 
which contributes to inflammation, innate immune activation and mortality (van 
Schaik, Abbas 2007). This is mirrored by findings of T  cell activation in trauma 
(Walsh et al. 2000).
It must of course be noted that sepsis/SIRS do not simply affect immune cells, 
but also provoke dysfunction in a variety of other tissues including endothelium, 
muscle and secretory cells. Endothelial cells specifically play a role in initiating 
and amplifying inflammation with both PAMPS and alarmins ‘activating’ 
epithelial cells (reviewed in Aird 2003), resulting in initiation of coagulation,
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inhibition of fibrinolysis (Moore et al. 1987) and increased immune cell adhesion 
and activation (Bauer et al. 2000, Katayama et al. 2000). Further endothelial 
responses include increased permeability and vasomotor relaxation, provoking 
the hypotension, tissue oedema and vascular stasis seen in sepsis (reviewed in 
Aird 2003).
(d) Mechanisms of multi-organ failure
It has been established above that critical illness is largely defined by systemic
immune activation, however the second crucial part of the definition is the 
presence of organ dysfunction and failure. During critical illness, impairment 
can occur in any body system, however the predominant ones seen clinically are 
the respiratory, cardiovascular, renal, hepato-gastrointestinal and cerebral 
systems (Vincent et al. 1996). More recent work has identified failures in neuro­
endocrine regulation (Beishuizen, Thijs 2004), muscular function (Callahan, 
Supinski 2010) and, most pertinently to this thesis, the immune system (van der 
Poll, Meijers 2010).
Considerable debate continues as to the causes of organ failure in critical illness. 
There are several competing theories, which can be broadly grouped into 
‘inflammatory organ damage’, ‘gut-driven’, ‘tissue hypoperfusion/hypoxia’ and 
‘mitochondrial dysfunction’ theories. Each of these will be discussed briefly.
Inflammation
Given the finding of profound, systemic inflammatory activation in critical 
illness, it seems likely that the secondary effects are at least partly related to this
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phenomenon. Pulmonary failure, in the form of acute lung injury (A L I) or 
ARDS, is certainly characterised by an influx of inflammatory cells, mostly 
neutrophils, coupled with loss of alveolar barrier function and non-cardiogenic 
oedema (Segel, Halterman & Lichtman 2010). Indeed, tissue damage by 
neutrophil-derived enzymes such as HNE seems to be a major 
pathophysiological feature of ARDS/ALI (Wang et al. 2009), although 
treatments aimed at neutralising these in humans have so far proved 
disappointing (Iwata et al. 2010). During sepsis neutrophils are also found to 
infiltrate some other tissues, particularly the kidneys (Kabay et al. 2007), gut 
(Taner et al. 2001) and liver (Shih et al. 2008), and through attachment to 
endothelium in the microcirculation alter blood flow and increase the risk of 
clotting and microvascular obstruction (Ferri et al. 2009). Removing neutrophils 
can reduce or prevent end-organ damage (Poggetti et al. 1992), as can the 
elimination of circulating monocytes (Kreisel et al. 2010). However it should be 
noted that ARDS has been found in neutropaenic patients (Heyll et al. 1991), and 
that the degree of neutrophilic infiltration does not always correlate well with 
severity of organ damage (Raj, Hazinski & Bland 1985). Immune damage may 
not result solely from cellular actors. The anaphylotoxins C3a and C5a can 
produce systemic vasodilatation and increased capillary pore size, so mimicking 
the redistributive shock which commonly accompanies sepsis and severe SIRS 
(Lundberg, Marceau & Hugli 1987). C5a has also been implicated in septic 
cardiac failure (Niederbichler et al. 2006), pituitary failure (Flierl et al. 2009) and 
dysregulated coagulation pathways (Laudes et al. 2002b).
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Monocytes and their resident tissue derivatives, macrophages, play a key role in 
the immune defence against microbial invasion (Cote et al. 2004, Osterloh et al.
2007). Macrophages are key mediators of the response to PAMPs and DAMPs 
(Osterloh et al. 2007), and play an important early role in triggering systemic 
inflammation (reviewed in Laudanski, Wyczechowska 2005), as well as acting as 
antigen presenting cells to stimulate the adaptive arm (reviewed in Martinez- 
Pomares, Gordon 2007). Monocytes are also intimately involved in marshalling 
neutrophil recruitment to sites of inflammation (Kreisel et al. 2010). However 
there is considerable evidence of monocytes and macrophages expressing an 
anti-inflammatory phenotype (Newton et al. 2004, Flohe et al. 2008, Mokart et 
al. 2010), which will be discussed below .
It should not, however, be assumed that sepsis simply involves activation of the 
innate immune system. Various animal models have implicated T  cells in the 
pathogenesis of organ dysfunction. IL-17, the key mediator of the Th17 
response, has been associated with impaired outcomes in a murine caecal ligation 
and puncture (CLP) model (Flierl et al. 2008b). Th17 cells have also been 
implicated in the formation of intra-abdominal abscesses following intra- 
peritoneal injection of B a c i l l u s  f r a g i l i s  in mice (Chung et al. 2003b). CD8+ve, 
cytotoxic T  cells are also involved in Fas/Fas ligand-mediated liver and splenic 
cell apoptosis, so contributing to tissue loss and failure in these organs (Wesche- 
Soldato et al. 2007). Similar findings are noted in sterile insults such as bums 
(Toth et al. 2004) and ischaemia-reperfusion injury (Miyazawa et al. 2002). 
Interestingly, although the study of T  cells in human sepsis and SIRS remains 
limited, what data there are suggest that CD4 numbers are depressed (Venet et al.
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2010), T  cell function reduced (Heidecke et al. 1999) and that there are 
frequently elevated proportions of immunosuppressive regulatory T  cells (T - 
regs) (Venet et al. 2009), somewhat akin to the situation with monocytes. 
However when the experimental drug TGN1412 was used to modulate T  cells, 
the resultant dysregulation of the immune system resulted in an intense SIRS, 
cytokine storm and multi-organ dysfunction (Suntharalingam et al. 2006). The 
aim of TGN1412 was to expand the T-reg population, so enhancing their 
immunosuppressive qualities, although the resultant response was the complete 
opposite of that intended, emphasising the potential risks of modulating the 
adaptive immune system.
Natural killer (N K) cells are cytotoxic cells whose primary role is thought to be 
the removal of malignant and infected cells (Farag, Caligiuri 2006). Depletion 
of N K  cells has been associated with reduced inflammation, reduced organ 
damage and improved survival in murine polytrauma/sepsis models (Barkhausen 
et al. 2008). Similar to CD8+ve T  cells, some of which also display N K  type 
markers (so called N K -T  cells), N K  cells have also been associated with 
hepatocyte damage following bacterial sepsis (Seki et al. 2000).
Inflammation, both through proteolytic cascades and activated immune cells, is 
therefore likely to be a key part of the mechanisms underpinning multi-organ 
failure following the triggering of acute, uncontrolled inflammation in sepsis and 
SIRS.
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Gastro-intestinal source of organ failure
Animal models of bum injury (Woodruff et al. 1973) demonstrated increased 
bowel permeability and translocation of bacteria. This, along with the finding of 
LPS or bacteria in the circulation and lymphatics of patients with critical illness 
(van Deventer et al. 1988, MacFie et al. 2006), led to the concept of gut 
hypoperfusion, bacterial translocation and gastro-intestinal immune failure 
driving systemic inflammation and multiple organ dysfunction (Munster AM, 
2000). Interestingly cytokine levels have been found to be grossly elevated in 
the lymphatic drainage of the gut although this is not always accompanied by 
endotoxin detection (Deitch et al. 1994). Thus it is possible that factors other 
than simple translocation of bacteria and bacterial products are driving this 
inflammatory response. It is now well established that injurious ventilation of 
the lungs drives an inflammatory response termed ‘biotrauma’ (to combine volu- 
traurna, barotrauma and atelectasis as mechanisms of ventilator-induced lung 
injury (V ILI) (Gattinoni et al. 2010), and that this is associated with multi-organ 
failure. Gut hypoperfusion may well produce a similar immune response 
(Tarnion et al. 2003), so driving systemic inflammation and the mechanisms 
noted above in immune-mediated organ damage.
Tissue hypoperfusion
Shock has long been recognised as a severe accompanying feature of sepsis and 
SIRS. Although classically described as a redistributive shock associated with 
vasodilatation and increased capillary permeability (Parrillo 1993), it is not 
unusual to find a state of peripheral vascular shutdown, diminished blood volume 
and impaired cardiac output (Gahhos et al. 1981, Amiane, Bellissant & Cavaillon
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2005, Maeder et al. 2006). Until recently efforts at resuscitation have been 
aimed solely at macro-vascular end-points such as mean arterial pressure, cardiac 
output and global oxygen delivery (da Silva Ramos, Azevedo 2010). However 
intra-vital microscopy and tissue oxygenation studies in both humans and 
animals (Sair et al. 1996, Spanos et al. 2010) reveal considerable heterogeneity in 
micro-vascular blood flow, suggesting complex regulatory failure of micro- 
vascular homeostasis and resultant tissue hypoxia. As noted above, 
inflammatory mediators such as C5a (Hugli, Marceau 1985), dysregulated 
coagulation (Sivula et al. 2009), microthrombus formation (Baskurt, Temiz & 
Meiselman 1997), and clumping of adherent leukcoytes (Hwang, Han 2003) all 
contribute to this picture, alongside endothelial failure (Ait-Oufella et al. 2010). 
Tissue hypoxia can result in cellular death, with the release of alamiins such as 
HMGB-1 and further exacerbation of the inflammatory cascade (Sims et al.
2010), as well as directly contributing to organ failure. Early therapy aimed at 
improving tissue perfusion and oxygen delivery have shown considerable benefit 
in reversing microvascular dysfunction and preventing organ dysfunction (Rivers 
et al. 2001, Ospina-Tascon et al. 2010, Jhanji et al. 2010), suggesting that this 
mechanism plays an important role in initiating damage. However Tate’ therapy 
aimed at the same ends does not produce similar results (Ospina-Tascon et al. 
2010, Hayes et al. 1994), suggesting that once one is past a certain threshold the 
processes initiated become irreversible.
Cellular toxicity and mitochondrial deactivation
One of the remarkable features of critical illness-associated organ failure is how
often there is little histological evidence of organ damage, such as widespread
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necrosis or dense inflammatory infiltrates (Brealey et al. 2004). Although, as 
ARDS and some forms of acute renal failure demonstrate, this finding is not 
universal. This has provoked examination of the cellular mechanisms of organ 
failure (Singer 2007). Indeed survivors of critical illness seldom display chronic 
organ dysfunction on recovery (Mongardon, Dyson & Singer 2009, Schiffl, 
Fischer 2008), even in organs that have little regenerative capacity (Knoester et 
al. 2008). It is also notable that whilst early stage shock demonstrates increased 
oxygen extraction, as measured by mixed venous oxygen content (CyCk), the 
later stages are characterised by increased Cv02 content. This suggests impaired 
oxygen utilisation, and indeed such findings are associated with poorer outcomes 
(Shoemaker et al. 1993). It therefore seems that cellular respiration is impaired, 
and indeed there is growing evidence from both animal and human studies of 
defects at the mitochondrial level (Brealey et al. 2004, Singer 2007). These may 
be driven by a range of neuro-humoral mediators from nitric oxide to 
catecholamines, thyroid hormones to cortico-steroids, levels of all of these being 
altered in shock states arising from sepsis and SIRS (reviewed in Singer et al. 
2004).
Although each of these hypotheses are presented separately, it is highly probable 
that they operate in an integrated manner, each one capable of driving the others. 
As a result the patient gets locked into the vicious cycle of immune activation, 
tissue damage, organ dysfunction and further immune activation that seems to 
characterise critical illness. The emerging picture is one of complex 
dysregulation of key body systems, from immunity to coagulation, micro- and 
macro-vascular functioning to individual solid organs, locking the patient into a
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maladaptive state which frequently proves fatal. However what is remarkable, 
given the central role for immune activation, is the compelling and growing 
evidence of immune failure, which may, in part, explain the extremely high rate 
of secondary infection. It is to this topic that we turn next.
S e c t i o n  1 . 0 5  I m m u n e  d e f e c t s  i n  c r i t i c a l  i l l n e s s
(a) SIRS and CARS
As the preceding section has demonstrated, critical illness is characterised by
immune activation and organ failure. However, to date, there have been no 
positive phase III trials of immunosuppressive therapies in sepsis or sterile SIRS 
and indeed some have shown harm (Fisher et al. 1994, Abraham et al. 1995, 
Bone et al. 1987). Activated protein C, arguably the only specific therapy for 
severe sepsis with organ failure, has immunomodulatory effects (Nick et al. 
2004) but the extent to which these are responsible for the survival benefit 
remains controversial (Eichacker, Natanson 2003). It was the failure of anti­
inflammatory therapies that prompted Bone to propose the concept of a 
compensatory anti-inflammatory response syndrome (CARS) in 1996 (Bone 
1996). He proposes that the uncontrolled, maladaptive systemic inflammation of 
SIRS provokes an equally uncontrolled, maladaptive counter-regulatory 
immunosuppression.
Evidence of immunosuppression in sepsis and SIRS is found in both numbers 
and functions of immune cells as well as anti-inflammatory soluble mediators. 
The following section will discuss each of the cell types in turn, followed by a
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discussion of possible mediators and mechanisms. Finally we will turn to the 
time course, and its relationship to episodes of hyper-inflammation.
(b) Monocyte/macrophage hypoactivity
The hypoactivity of peripheral blood monocytes is one of the best-characterised
aspects of sepsis-related immune suppression. Patients with sepsis and other 
critical illnesses including head injury, pancreatitis and fulminant hepatic failure, 
have monocytes that produce low levels of pro-inflammatory cytokines, such as 
TNF-alpha. When stimulated e x - v i v o  with ligands including LPS (Wolle et al. 
2000, Asadullah et al. 1995, Flo et al. 2006, Berry et al. 2011) they enter a state 
termed ‘monocyte deactivation’ (Volk et al. 1996). This state is accompanied by 
diminished H LA-D R  expression (Höflich et al. 2002), so impairing antigen 
presentation and stimulation of the adaptive arm of the immune system. Low 
monocyte H LA-D R  has been associated with increased risk of nosocomial 
infection (Landelle et al. 2010) and mortality (Mebazaa et al. 2004). Animals 
subjected to caecal ligation and puncture (CLP) also display hyporesponsive 
alveolar and peritoneal macrophages (Chung et al. 2003a, Attalah et al. 2002), 
and impaired clearance of organisms such as P s e u d o m o n a s  a e r u g i n o s a  when 
administered as a ‘second hit’ (Muenzer et al. 2006). Apoptosis is generally 
reported to be enhanced amongst monocyte/macrophage populations in sepsis 
(reviewed in Wesche et al. 2005).
What mediates monocyte deactivation remains disputed, although IL-10 is 
almost certainly a pivotal player (Sfeir et al. 2001b). However IL-10 is not
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sufficient, as levels similar to those found in sepsis are found in other patients 
such as patients with severe psoriasis (Deeva et al. 2010). These patients do not 
display monocyte deactivation, and indeed there is some evidence that 
deactivation can occur in the absence of elevated serum levels of IL-10 (Volk
2003). It therefore seems likely that other factors such as transforming growth 
factor beta (TGF-beta) (Czarniecki et al. 1988), cortisol (Le Tulzo et al. 2004) 
and/or catecholamines (van der Poll et al. 1996) may also be involved in 
mediating this response.
(c) Neutrophils
Neutrophils in patients with sepsis tend to display surface markers of
‘activation’, notably elevated levels of CD1 lb and CD64 and diminished CD16 
(Berger et al. 1984, Muller Kobold et al. 2000, Eksioglu-Demiralp et al. 2001). 
However some studies have also demonstrated diminished inducibility of these 
receptors (Rosenbloom et al. 1999), indicating the potential for impaired 
activation in severe infections. Despite their accumulation and damage of organs 
(see above), neutrophils from septic patients display impaired transmigration 
(McGill et al. 1996) and chemotaxis (Arraes et al. 2006). Other key anti­
bacterial functions, such as ROS production and phagocytosis, show a more 
variable picture, with studies showing both increases (Martins et al. 2003) and 
decreases (Kaufmann et al. 2006) in these functions. As with monocytes, 
dysfunctional neutrophils are associated with secondary infections (Stephan et al. 
2002) and sepsis-related mortality (Danikas et al. 2008). However, in contrast to 
monocyte inflammatory cytokine release, septic patients demonstrate enhanced 
release of proteolytic enzymes such as NE in response to e x - v i v o  LPS (Ertel et al.
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1994), as well as showing higher levels in plasma (Nuijens et al. 1992). Similar 
findings are made when examining other neutrophil granule contents such as 
myeloperoxidase (Kothari et al. 2010). In contrast to monocytes, neutrophils in 
patients with sepsis have diminished apoptosis (Taneja et al. 2004), which may 
lead to persistence and hence worsening organ damage (Paunel-Gorgulu et al. 
2011).
Several mediators have been proposed as key to these effects. Animal models 
and i n - v i t r o  work have identified an apparently paradoxical effect of the 
inflammatory molecule C5a in impairing phagocytosis and the generation of 
ROS (Huber-Lang et al. 2002b) as well as inhibiting apoptosis (Guo et al. 2006) 
and stimulating degranulation (Gardinali et al. 1992). These effects have also 
been shown in non-septic models such as trauma (Flierl et al. 2008a, Amara et al. 
2010b). In decompensated alcoholic liver disease, a condition that bears some 
comparison with sepsis (Sen, Williams & Jalan 2002), circulating LPS and 
ammonia have been linked to defects in phagocytosis (Mookerjee et al. 2007, 
Shawcross et al. 2008). Impairment of IL-17 signalling has been linked, in 
knock-out animal models, to impaired neutrophil migration (Cho et al. 2010), 
although the relevance of this to human SIRS (which typically reveals elevated 
levels of IL-17 (Fimierty et al. 2008)) remains uncertain. Elevated levels of IL - 
10 have also been associated with impaired neutrophil recruitment (Sun et al.
2009), although whether this is a direct effect or mediated by impairing other 
cellular actors is uncertain.
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(d) Dendritic cells
Alongside macrophages, dendritic cells (DCs) play a key role in antigen
presentation and activation of the adaptive immune system (Steinman 1991). 
Human p o s t - m o r t e m  studies reveal depletion of lymph node DCs in sepsis 
(Hotchkiss et al. 2002), whilst animal models of sepsis confirm this finding and 
demonstrate similar depletion of splenic and pulmonary DCs (Efron et al. 2004). 
In addition animal models show DCs skewed towards an anti-inflammatory 
phenotype, releasing IL-10 and suppressing the release of IL-12 in response to 
LPS (Karp et al. 1998, Yanagawa, Onoe 2007). The mediators of depletion 
remain uncertain, although interestingly the PAMP receptors TLR 2 and 4 are 
involved in the process, mediating apoptosis of DCs (Pene et al. 2009).
(e) T  lymphocytes
T  lymphocytes can be divided into cytotoxic (CD8 positive) and helper (CD4
positive, T h) subsets, with the former mediating lysis of infected and malignant 
cells, whilst the latter act to stimulate adaptive immune responses following 
exposure to specific antigens. T  cells also have important interactions with 
innate immune cells, such as monocytes, macrophages and neutrophils (Pelletier, 
Micheletti & Cassatella 2010, Walz et al. 2009, Tiemessen et al. 2007). As noted 
above, T H cells come in several different sub-types, each of which produces 
distinct groups of cytokines, which invoke distinct responses. T H1 cells produce 
cytokines including interferon gamma (IFN-y), and TNF-beta stimulating a 
predominantly cytotoxic response. In contrast T H 2 cells produce IL-4, IL-5 and 
IL-10 which stimulate more B-cell/humoral mediated responses (Mosmann, 
Coffman 1989) whilst also dampening down functions of other immune cells
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such as monocytes (Yoshida et al. 2001). T H 17 cells, a more recently identified 
subset, produce IL-17 and IL-6, and appear to be involved in the clearance of 
bacterial and fungal pathogens (Cho et al. 2010). Given this role, it is 
unsurprising that IL -17 receptor deficiency is associated with poor outcomes in 
sepsis (Freitas et al. 2009), although as noted above systemic release of IL-17 is 
associated with organ failure and mortality (Flierl et al. 2008b).
A  further subset of T r cells is the regulatory T  cells (T-regs), which are thought 
to arise from several lineages (reviewed in Langier, Sadc & Kivity 2010). These 
cells have immunosuppressive effects, limiting T  cell proliferation in response to 
antigen, secreting IL -10, switching macrophages to an M2 phenotype and 
impairing neutrophil functions (Venet et al. 2009, Tiemessen et al. 2007, Suri- 
Payer, Cantor 2001, Lewkowicz et al. 2006). Most T-regs arise from the thymus, 
and unusually appear to be generated by recognition of self-MHC molecules, a 
response which would normally result in clonal deletion (reviewed in Langier, 
Sade & Kivity 2010). These natural T-regs (nT-regs) are supplemented by the 
generation of regulatory phenotype in the periphery by CD4+ T-cells exposed to 
high levels of TGF-(3, so called induced T-regs (iTregs) (Shevach et al. 2008). 
Both n and i T-regs are characterised by the expression of Forkhead box P3 
(FOXP3), a cytoplasmic transcription factor that is crucial to T-reg function 
(reviewed in Langier, Sade & Kivity 2010). Deletion of FOXP3 results in multi­
system autoimmune disease in mice (Brunkow et al. 2001) and, in humans, the 
fatal immune disorder immune dysregulation polyendocrinopathy enteropathy X - 
linked syndrome (IPEX) (Bennett et al. 2001). Most of the work on T-regs to 
date has focused on their role in auto-immunity, with several auto-immune
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diseases showing depressed levels of these cells including rheumatoid arthritis, 
diabetes, multiple sclerosis and systemic lupus erythematosus (reviewed in 
Langier, Sade & Kivity 2010).
Sepsis induces T  cell anergy (Heidecke et al. 1999), although until recently the 
mechanisms underlying this remained obscure. However recent work has 
indicated a role for elevated levels of T-regs in this process (Venet et al. 2009). 
Indeed several groups have now identified elevated levels of T-regs in patients 
and animals with sepsis (Venet et al. 2009) and following major trauma (Venet et 
al. 2008). Lymphocytes also reportedly undergo enhanced apoptosis in sepsis, 
potentially contributing to impaired immune responses (Schwulst et al. 2006).
As with the other cell types discussed above, it appears likely that multiple 
mechanisms are involved in the impairment of T  cell functioning. As examples, 
T  cell apoptosis is enhanced by C5a (Guo et al. 2000), as well as by ligation of 
the peroxisome proliferator-activated receptor y (PPARy) (Soller 2005) and 
endogenous corticosteroids (Ayala et al. 1999) all of which are relevant to sepsis. 
As noted above T-reg levels are elevated in some patients with sepsis (Venet et 
al. 2009) and major injury (Venet et al. 2008), and impair proliferative responses 
of both CD4 and CD8 positive cells (Venet et al. 2009). Polarisation of T-cells 
towards a regulatory phenotype is induced by cytokines including IL-6, IL-10 
and TGF-beta (Shevach et al. 2008), levels of which are commonly elevated in 
sepsis and other forms of critical illness (Leonidou et al. 2007).
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Although presented by cell type above, it is likely that these defects and 
dysfunctions co-exist although to date few studies have attempted to examine the 
function of more than one immune cell at any one time. Furthermore it is likely 
that simultaneous immune defects are not simply the result of common 
mediators, but also the interactions between dysfunctional cells resulting in 
complex synergies, which amplify and enhance existing defects.
(f) Time course of immunosuppression and hyperinflammation
One possible reason for the variable and apparently contradictory findings of
immune cell function from different reports may be the time point at which the 
measurement is made. In animal models, where pre-morbid sampling is feasible 
and there is certainty over time and severity of onset, most studies indicate a 
rapid pro-inflammatory response with immune cell activation/hyperactivity with 
later onset of hypoactivity (Hotchkiss, Karl 2003). In human studies, monocyte 
deactivation is largely reported to occur several days after admission to intensive 
care (Meisel et al. 2009), as are T  cell impairments (Venet et al. 2009). However 
this is not universally the case and apparently ‘early onset’ immune suppression 
is noted in some reports (Danikas et al. 2008, Lukaszewicz et al. 2009). In these 
latter cases it is possible that the early ‘hyperactive’ phase may well have been 
missed in the pre-ICU period. What is also clear is that the ‘immune status’ (i.e. 
hyper- or hypo-active) may depend on which aspect is examined, with increasing 
evidence that both pro- and anti-inflammatory mediators may be elevated at the 
same time (Osuchowski et al. 2006), leading to the coining of the terms ‘mixed 
anti-inflammatory response syndrome’ (MARS) (Bone 1996). 
Immunophenotyping of cellular functions has lagged some distance behind
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measurement of serum cytokines and adds further complexity to any assessment 
of ‘immune system functioning’. Questions remain over whether hyper­
inflammation can be recrudesced following second or third ‘hits’ (such as 
nosocomial infections), and indeed whether immune cells such as neutrophils 
may be able to be simultaneously tissue-toxic but unable to combat microbial 
invasion?
S e c t i o n  1 . 0 6 T h e  i m m u n e  s y s t e m  i n  c r i t i c a l  i l l n e s s -  a  s u m m a r y
The section 1.04 above describes an emerging picture of critical illness, triggered 
by an initial immune-activating response which, if not rapidly treated and 
terminated, leads on to immune-mediated organ damage and a downward spiral 
of maladaptive processes which further exacerbate the immune stimulation, as 
well as directly and indirectly damaging organ systems. The immune system 
itself is not protected from this damage, and can also in turn suffer impaired 
functioning leading to inability to deal with microbial invaders and so facilitating 
the nosocomial infections discussed earlier in this chapter.
S e c t i o n  1 . 0 7  P h y s i o l o g i c a l  f u n c t i o n i n g  o f  n e u t r o p h i l s  i n  c l e a r a n c e  
o f  m i c r o o r g a n i s m s
(a) Neutrophil priming and activation
We now turn to the physiological functioning of one particular immune cell, the
neutrophil, to discuss its anti-microbial functions in health in contrast to the 
pathological situations described above.
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The neutrophil is the most abundant blood leukocyte, existing in a circulating 
pool and a smaller number of marginated cells ready to enter extra-vascular 
tissues should they be required (Kuebler 2005, Summers et al. 2010). On 
stimulation by factors such as C5a (Kubo et al. 1998), leukotriene B4 (LTB4) 
and granulocyte-macrophage colony-stimulating factor (GM -CSF) (reviewed in 
Jagels, Hugh 1994), the bone marrow pool releases neutrophils into the 
circulation. Myelopoeisis is stimulated, leading to the neutrophilia, which is 
common to a variety of septic and sterile insults. Acquired or congenital absence 
of neutrophils leads to enhanced susceptibility to a variety of infections, mostly 
bacterial and fungal (Julia et al. 1991, Shiohara et al. 2009).
On exposure to molecules such as formylated peptides, C5a, IL-8 or platelet 
activating factor (PAF), neutrophils adopt a ‘primed’ form (Condliffe et al.
1996), with enhanced expression of adhesion molecules, phagocytic receptors 
and readiness to produce ROS. A  second ‘hit’ by another activating molecule 
can then provoke release of ROS or proteolytic enzymes such as FINE (Condliffe 
et al. 1996, Bhatia et al. 2006). These ‘activating’ molecules can also act as 
chemoattractants, allowing cells to move towards targets (reviewed in Walker, 
Ward 1992). Neutrophils need to exit the circulation to enter tissues to combat 
microbial invaders or remove dead tissue. This process requires adhesion to the 
endothelium, rolling and then transmigration, again moving down chemotactic 
gradients (reviewed in Borregaard 2010). Various in-born errors of neutrophil 
metabolism have been identified, including leukocyte adhesion deficiency 
(LAD ), where the adhesion molecule CD 18 is absent or non-functional and 
neutrophils experience impaired adhesion and transmigration resulting in
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increased susceptibility to infection (Kuijpers et al. 1997, Hayward et al. 1979). 
Defects in the NADPH oxidase machinery required for the production of ROS, 
which results in chronic granulomatous disease (CG D ) (Winkelstein et al. 2000), 
whilst defects in beta-actin polymerisation are associated with impaired 
chemotaxis, phagocytosis and recurrent infections (Nunoi et al. 1999).
(b) Mechanisms of phagocytosis
Phagocytosis, the process by which cells engulf or ingest particulate matter, was 
first described in mammalian cells by Metchnikoff in 1883 (Metchnikoff, 1883). 
Although often referred to as a single process, it is in reality a collection of 
different processes, each of which operate via differing receptors, differing 
signalling pathways and with differing cellular responses. For the purposes of 
this discussion, the focus will be on neutrophil phagocytosis of micro-organisms, 
and most specifically that mediated by complement opsonisation.
Although neutrophils can recognise and phagocytose invading micro-organisms 
by non-specific scavenger receptors, phagocytosis is far more efficient when the 
target has been coated in an ‘opsoniser’ (Blorn, Hallstrom & Riesbeck 2009, 
Palecanda, Kobzik 2001, Nimmerjahn, Ravetch 2006). Two main classes of 
opsonin exist, immuno-globulin and especially the gamma sub-class (IgG), and 
complement component C3b. IgG production, as with all antibody responses in 
the mature animal, relies on exposure of B-cells to the triggering molecular 
pattern alongside co-stimulation signals from the presenting cell. However 
circulating antibody levels and rapid mobilisation of memory B-cells can result
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in a rapid response if the target has been encountered before (Nagafuchi 2010). 
Complement is discussed below (section 1.08), although it is worth noting that 
anti-bodies bound to pathogens can activate complement, providing further links 
between the innate and adaptive immune responses.
Phagocytosis is initiated by the appropriate binding of a target to a phagocytic 
receptor. The predominant receptors are the Fey receptors for IgG, which bind to 
the common ‘Fc’ portion where the ‘specific’ portion has bound to the 
phagocytic target, and the complement receptors, specifically CR3 (also known 
as Mac-1 or CD1 lb/CD 18). Binding to a phagocytic receptor triggers clustering 
of further phagocytic receptors, intracellular signalling and resultant actin 
polymerisation and cellular morphology change to permit phagocytosis (Lee, 
Harrison & Grinstein 2003). There is an apparent morphological divergence in 
mechanisms of phagocytosis, with Fey activation producing a pseudopodal 
engulfment whilst CR3 activation results in the target ‘sinking’ into the cell 
(Kaplan 1977). Fey receptors are activated as soon as a target binds to them. In 
contrast CR3 requires prior activation (e.g. by C5a, LPS or similar) (Jones et al. 
1998, Fallman, Andersson & Andersson 1993) leading to conformational change 
and exposure of the activation epitope (Diamond et al. 1993) before binding will 
activate phagocytosis.
Binding of ligands to CR3 induces tyrosine kinase activity, specifically syk, 
which in turn activates protein kinase C, initiating RhoA activation, actin 
polymerisation and phagocytic ingestion (Caron, Hall 1998, Shi et al. 2006b). In 
contrast Fey activates both syk and Lyn tyrosine kinases (Strzelecka-Kiliszek,
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Kwiatkowska & Sobota 2002), resulting in a variety of intracellular pathways 
including phospholipase C, PI3K and phospholipase A2 (Garcia-Garcia, Rosales 
2002)) and then Rac-1 and CDC42 ,which mediate the distinct actin 
polymerisation and pseudopodal formation noted above (Kaplan 1977, Caron, 
Hall 1998).
Following ingestion the cell forms a ‘phagosome’, an intracellular inclusion 
containing the target. This is fused with intracellular granules containing 
proteolytic enzymes such as NE, and ROS generators such as myeloperoxidase 
and NADPH oxidase complex translocation, which then kill the organism 
ingested in the ‘mature’ phagolysosome (Lee, Plarrison & Grinstein 2003).
There is also extracellular release of proteolytic enzymes and ROS, aimed at 
killing organisms that have not been ingested (Ohlsson, Olsson 1977). It is this 
extracellular release that is thought to lead to tissue damage, such as that seen in 
critical illness (Matsuda, Hattori 2006, Yao et al. 1998). Disruption of any of the 
above processes, from ligation of phagocytic receptors through actin 
polymerisation and maturation of the phagolysosome can impair phagocytosis 
and/or intra-cellular killing.
S e c t i o n  1 . 0 8  C o m p l e m e n t  f u n c t i o n  i n  i n f l a m m a t i o n  a n d  i n f e c t i o n
The complement system consists of a collection of plasma proteins,
predominantly manufactured in the liver, which ordinarily exist in an inactivated 
form (zymogens). On activation there is a cascade of proteolysis, each preceding 
molecule activating the next in the chain in a manner analogous to the 
coagulation cascade (Walport 2001a, Walport 2001b). The final endpoint of the
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complement cascade is the membrane attack complex (M AC), which is formed 
by components C5-C9, and which acts to punch holes in membranes, so 
producing cellular lysis. However along the pathway a number of other products 
are produced, which play key roles in anti-bacterial defence.
The complement system can be triggered by one of three pathways, namely the 
‘classical’, ‘alternative’ and ‘mannose binding lectin’ (M BL) pathways (Walport 
2001a). Each of these are triggered by different stimuli, the classical pathway by 
IgG antibody bound to an antigen or immune complex, the alternative pathway 
by LPS and the M B L pathway by lectins bound to mannose on bacterial cell 
walls. These three pathways then converge on C3. C3 is continually being 
activated even without up-stream stimulation, as the enzyme is subject to 
hydrolysis (Pangburn, Muller-Eberhard 1983), although this happens at a low 
level. On activation C3 splits into 2 products, C3b and the smaller C3a. C3b 
acts as an opsonising agent, facilitating phagocytosis via the CD1 lb/CD 18 
integrin (see 1.07 b above). Once C3b is deposited on a cell wall it can bind to 
factor D, resulting in autocatalytic deposition of further C3b - facilitating 
phagocytosis - and triggering of M A C formation (Forneris et al. 2010, Fearon, 
Austen & Ruddy 1973). To prevent C3b undergoing this process on healthy host 
cells several inhibitors exist. These include factors H and I that bind and 
inactivate C3b (Brown et al. 1983), as well as decay accelerating factor 
(DAF/CD55) and CD59 which are cell surface inactivators of C3b (Harris et al. 
2007, Brooimans et al. 1992). C3a is an anaphylatoxin, which although less 
potent than C5a (Ehrengruber, Geiser & Deranleau 1994), is none the less 
capable of producing vasodilatation, vascular leak and hypotension. It is also
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chemotactic for eosinophils, although only indirectly so for neutrophils (Hugli, 
Vallota & Muller-Eberhard 1975, Daffern et al. 1995). Activated C3 forms C5 
convertase, which splits inactive C5 into two products, C5b and C5a. C5b forms 
the first part of the M AC, whilst C5a is the more potent anaphylatoxin producing 
similar responses to C3a (Hugli, Marceau 1985, Lundberg, Marceau & Hugli 
1987).
C5a has a very short plasma half-life (2-3 mins) (Webster, Larsen & Henson 
1982), and is removed by binding to its predominant receptor CD88 (Chenoweth, 
Hugli 1978). Bound C5a is internalised by CD88-bearing cells such as 
neutrophils, where it is metabolised prior to CD88 being recycled to the cell 
surface (Oppermann, Götze 1994). Plasma carboxypeptidases cleave the 
terminal arginine from C5a to form the ‘des-arg’ product (Campbell et al. 2002), 
which is less potent than intact C5a (Webster et al. 1980) and is cleared by 
binding to CD88 (Webster et al. 1980, Marder et al. 1985). There is also some 
non-neutrophil contribution to plasma C5a clearance from highly perfused 
organs including the lung, liver and kidneys (Webster, Larsen & Henson 1982).
As well as activation at the start of the cascade, several non-complement proteins 
can lyse C5 into its split products. These include thrombin, from the coagulation 
cascade (Amara et al. 2010a), and NE released by activated neutrophils (Wetsel, 
Kolb 1983). Both of these can themselves be activated/triggered by activated 
complement (Karnbas et al. 2008, Binder et al. 1999). Although the majority of 
C5a is generated by the complement cascade described above, macrophages and 
neutrophils can also generate it from C5 directly (Huber-Lang et al. 2002a). 
These non-complement-mediated activators of C5 are not constrained by the
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factors that inhibit C3 (see above) and therefore may provoke less controlled 
complement release. This illustrates how disparate inflammatory mechanisms 
triggered during sepsis and SIRS can amplify each other and so drive the 
maladaptive processes seen in critical illness.
CD88 is a hepta-helical, transmembrane receptor that is coupled to G-proteins, 
the G„ subunit being G„i2 (Chenoweth, Hugh 1978, Skokowa et al. 2005). On 
C5a binding to CD88 a number of intra-cellular pathways are triggered, 
including the adenylate cyclase/cyclic AMP/protein kinase A  pathway, PI3K 
pathway, extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase C 
(PKC) pathways (Tsu, Allen & Wong 1995, Riedemann et al. 2004, Wrann et al. 
2007b). C5a binding also results in receptor phosphorylation and desensitisation 
(Christophe et al. 2000), as well as receptor sequestration and consequent 
diminution of cell-surface expression (Bock et al. 1997, Braun 2003). 
Interestingly these processes (desensitisation and sequestration) appear to be 
mediated by divergent pathways (Christophe et al. 2000). There is a second C5a 
receptor, termed C5L2, which is not coupled to G-proteins. As a result this was 
long thought to be a ‘decoy’ receptor, which was present simply to mop-up C5a 
and reduce CD88 activation. However recent work using knock-out models and 
receptor inhibitors have indicated a functional role for C5L2 in the pathogensis 
of several diseases including sepsis induced multi-organ failure (Rittirsch et al.
2008) and allergic asthma (Zhang et al. 2010b). Interestingly the greater 
proportion of C5L2 appears to be contained in intra-cellular granules, with the 
suggestion that it exerts its effect on C5a transported intra-cellularly by CD88 
(Bamberg et al. 2010), although what the precise effects mediated by C5L2 on 
intra-cellular pathways are remains uncertain (Ward 2009).
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S e c t i o n  1 . 0 9  C h a p t e r  s u m m a r y  a n d  h y p o t h e s e s
Critical illness presents the clinician with something of a paradox. It is
characterised by systemic inflammation, resulting in organ failure, in which 
activated immune cells and proteolytic cascades are highly implicated.
However, these patients are also highly susceptible to nosocomial infections, and 
whilst various clinical factors have been proposed to explain this susceptibility, 
none appear to adequately deal with the underlying host susceptibility.
It is notable that despite clinical (e.g. pyrexia, hyperaemia and extravasation of 
plasma) and laboratory (e.g. leukocytosis, hypercytokinaemia) evidence of 
inflammation during critical illness, those studies which have examined immune 
cellular f u n c t i o n  in patients are more likely to show hypofunction, ‘deactivation’ 
and anergy rather than hyperactivity. Indeed it appears that alongside other 
forms of organ failure, we can add ‘immune failure’, to the burden of critical 
illness.
These features produce several hypotheses that will be addressed by this thesis.
1) Critically ill patients exist in a state of simultaneous hyper-inflammation 
and immune failure.
2) Human neutrophil dysfunction in critical illness is driven by excessive 
pro-inflammatory stimulation by C5a.
3) C5a-mediated neutrophil dysfunction is associated with an increased risk 
of nosocomial infection.
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4) C5a-mediated neutrophil dysfunction co-exists with other forms of 
immune hypoactivity, and these factors interact to influence the risk of 
nosocomial infection.
S e c t i o n  l . l O T h e s i s  o v e r v i e w
Chapter 2 will deal with the experimental methods used for this study. Chapter 3 
will present the first results, examining the first hypothesis in patients with 
clinically suspected ventilator-associated pneumonia. Chapters 4 and 5 will 
address the second hypothesis, examining the role of C5a in mediating 
dysfunction in patients and exploring the underlying mechanism by which C5a 
inhibits the key function, phagocytosis. The final results chapter, Chapter 6, will 
address the final two hypotheses by exploring the relationship between immune 
dysfunction and the acquisition of nosocomial infection. The discussion of 
results and conclusions will form the final chapter.
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Article IL Materials and Methods
Section 2.01 I n t r o d u c t i o n  a n d  c h a p t e r  o v e r v i e w
This chapter will present the scientific and statistical methods used in the 
preparation of the thesis. For a variety of reasons some of the techniques used 
differed between different parts of the study (specifically the blood collection, 
flow cytometry and neutrophil extraction protocols) and so sections of the results 
to which the specific method pertains will be detailed, however the methods will 
be ordered by technique and application rather than by the order of the thesis.
Four groups of human subjects were involved in this work, one group of 
critically ill patients with clinically suspected VAP (VAP cohort), one group of 
volunteers who were age- and sex-matched to the VAP cohort (matched 
volunteers), a further group of critically ill patients recruited prior to developing 
nosocomial infection (prospective cohort) and finally a group of healthy, young 
(<50) university employees (healthy volunteers). Each of these groups will be 
reported in more detail below.
Section 2.02 Materials and reagents
The A549 alveolar epithelial cell line was obtained from A TC C  (Teddington, 
UK).
Anti-human CD88/Alexa647 was obtained from AbD Serotec (Kidlington,UK).
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The following materials and reagents were acquired from Abeam (Cambridge, 
UK): murine monoclonal anti-human CD1 lb antibody Ml/70, murine 
monoclonal anti-human CD16 antibody 3G8, murine monoclonal anti-human 
CD88 antibody S5/1, murine monoclonal anti-human antibody CD88 P 12/1.
Recombinant human granulocyte-macrophage colony stimulating factor (G M - 
CSF) was from Affinity Bioreagents (Golden, CO, USA).
Polymorphoprep was acquired from Axis-Shield (Dundee, UK).
The following materials and reagents were acquired from Becton Dickinson (BD 
Bioscience, Oxford, UK): Facslyse™, Futhan, murine Quantibrite™ anti-human 
FILA-DR/monocyte antibody, and Quantibrite™ calibration beads. C3a-des arg, 
C5a-des arg, GM-CSF, G-CSF, IL-1|3, IL-6, IL-8, IL-10, MCP-1, M IP -la  ,TNF- 
a  and soluble CD62L cytometric bead array (CB A ) tests were also acquired from 
BD, as well as ELISAs for C3a-des arg and C5a-des arg.
Quantichrom™ colourmetric urea assay was obtained from BioAssay Systems 
(Hayward, CA, USA).
Platelet activitating factor (PAF) was obtained from Calbiochem (Nottingham, 
UK).
The following materials and reagents were acquired from Coming (Lowell, MA, 
USA): tissue culture plates, and transwell inserts of 3qM and 0.5,nM pore size.
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The following materials and reagents were acquired from Cytoskeleton (Denver, 
CO, USA). RhoA, CDC42 and Rac 1,2,3 G-Lisas™, cell lysis solution, Precision 
Red protein estimation solution.
The following materials and reagents were acquired from Ebioscience (San 
Diego, CA, USA): murine antibody against the activation epitope of CD I lb, 
CBRM1/5 labelled with fluorescein-5-isothiocyanate (FITC), murine anti-human 
CD4/FITC and CD25/Allophycocyanin (APC), murine anti-human FOXP3/R- 
Phycoeyrthrin (R-PE) and R-PE conjugated isotype control, red cell lysis buffer, 
flow staining buffer and cell fixation/permeabilisation solution.
The following materials and reagents were acquired from Hycult biotechnology 
(Uden, N L): neutrophil elastase and myeloperoxidase ELISAs.
The following materials and reagents were acquired from Invitrogen (Paisley, 
UK): Dulbecco’s modified Eagle’s medium (DM EM ), fetal calf serum (FCS), 
FITC-labelled phalloidin, Iscove’s modified Dulbecco’s medium (IM DM ), L- 
glutamine, murine IgGl isotype control, polyvinylidene fluoride (PVDF) 
membrane, murine monocloncal anti-human-CDl lb/PE), -CD llb/FITC, -CD16 
(Fey receptor IIII) /Tricolour (TC ), -CD32 (Fey receptor II)/FITC, -CD62L (L - 
selectin)/TC and -CD64 (Fey receptor I)/R-PE, as well as similarly labelled 
murine isotype controls, and goat-anti mouse antibody/alexa-647.
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Reastain Diff-quik was acquired from Reagena (Toivala, Finland).
The following materials and reagents were acquired from R&D systems 
(Minneapolis, MN, USA): cyclic adenosine monophosphate (cAMP)
Parameter ™ detection kit, polycloncal rabbit anti-human phospho-AKT (S473) 
antibody, horseradish peroxidase-conjugated goat anti-rabbit antibody.
The following materials and reagents were acquired from Sigma-Aldrich 
(Gillingham, UK): recombinant human C5a (rhC5a), calcium chloride, 
cytochrome C, dextran, ethylenediaminetetraacetic acid (E D TA ), formalin, 
lipopolysaccharide (LPS) 0127:B8, Luria-Bertani (LB ) broth and agar, N - 
formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), heparin sodium, 
isoproterenol hydrochloride, Percoll, phosphate buffered saline (PBS), sodium 
citrate, Triton, Tween 20, Tris-buffered saline, wortmannin, and zymosan.
The following small molecule pathway modulators were acquired from Tocris 
Bioscience (Bristol, UK): AS605240, IC87114, LY294002, SQ22536, and 740 
Y-P.
The following materials and reagents were acquired from Thermo Scientific 
(Loughborough, UK): bicinchoninic acid (BCA) protein assay, HALT™protease 
and phosphatase inhibitor with E D TA , M-PER™ cell lysis buffer,
Supersignal chemiluminescent detection reagent, and 12% Pierce Precise 
protein gel.
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Section 2.03 Patient and volunteer recruitment
(a) Settings
Patients were recruited from two university hospital general ICUs. Unit 1 (Royal 
Infirmary of Edinburgh, RIE) is an 18-bedded teaching hospital medical-surgical 
ICU which admits approximately 1000 patients per annum from all specialties 
with the exception of cardiac surgery and isolated neuro-trauma. Around 50% of 
patients admitted to this unit stay for >48 hours (i.e. are at increased risk of IC U - 
AI), and 75% require level 3 care (i.e. invasive ventilation and/or support of two 
or more organ systems) (U K  Department of Health, 2000). Unit 2 (Western 
General Hospital (W GH), Edinburgh) is a mixed ICU/high dependency unit 
(HD U) with 16 beds, admitting approximately 800 patients per annum from a 
mixture of medical, surgical and neurosurgical specialties. 60% require level 3 
care, and approximately 71% stay for more than 48 hours.
(b) Patients with suspected ventilator-associated pneumonia (VAP 
cohort)
(Chapters 3 and 4)
This prospective, observational, cohort study was performed in both unit 1 and 
unit 2. Patients were screened daily for possible VAP, and were assessed for 
enrolment as soon as the clinical diagnosis of VAP was made. Where enrolment 
occurred bronchoscopy took place within 4 hours of clinical diagnosis. All 
patients had demographic details recorded, including co-morbidities and 
prescribed medications. The severity of presenting illness was assessed by an 
acute physiology and chronic health evaluation II (APACHE II) score calculated 
within 24 hours of ICU admission. Patients were eligible if they fulfilled
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recognised criteria for c l i n i c a l l y  s u s p e c t e d  V A P  i.e. mechanical ventilation for at 
least 48 hours, new and persisting infdtrates on a chest radiograph and at least 
two of the following — purulent tracheal secretions, temperature >38°C, or white 
cell count > l lx l0 9 per litre, criteria based on a modification of previously 
published clinical criteria (Chastre, Fagon 2002). Exclusion criteria comprised 
Pa02<8kPa on FiO2>0 7, positive end-expiratory pressure >15cmH20 , active 
bronchospasm, myocardial infarction within the last 3 months, unstable 
arrhythmia, mean arterial pressure <65mmHg on vasopressor therapy, bleeding 
diathesis (including platelet count <20x109 per litre) and initiation or 
modification of antibiotics in the preceding 3 days (Chastre, Fagon 2002). 
Patients who had been on unchanged antibiotics for more than three days were 
included. O f 74 eligible patients, 73 were enrolled with one excluded due to lack 
of a relative’s informed assent.
Eligible patients had fibreoptic bronchoscopy and B A L  performed by a single 
experienced operator using a pre-defined, standardised technique (Meduri, 
Johanson 1992, Baselski, Wunderink 1994). Briefly, where focal infiltrates were 
present, the bronchoscope was wedged in a subsegment corresponding to the 
area of radiological involvement. In the case of diffuse radiographic change the 
bronchoscope was wedged in a subsegment producing visible purulent secretions 
or (in the absence of purulent secretions) in the posterior segment of the right 
lower lobe. Twenty ml of sterile saline were instilled and the aspirate 
(representing a ‘bronchiolar’ sample) discarded, then 200ml of sterile saline was 
instilled in aliquots and the aspirate (representing an alveolar sample) retained. 
Whole blood was collected into 0 38% sodium citrate (final concentration).
8 0
(c) Age- and Sex-matched volunteers
(Chapters 3 and 4)
After recruitment of 40 patients the (anonymised) age and sex of each patient 
was communicated to a local primary care practice, where staff unconnected 
with the study randomly identified matching individuals and sent out invitations 
to participate. The first twenty-one respondents were enrolled to form a reference 
group. Exclusion criteria comprised hypoxia (Sa02 <92% on air), bleeding 
diathesis, anticoagulant therapy, insulin-dependent diabetes mellitus, arrhythmia, 
bronchospasm not responding to nebulised p2 agonist, or clinical evidence of 
respiratory tract infection. Eligible volunteers provided blood and had fibreoptic 
bronchoscopy performed by the same investigator as above.
(d) Patients admitted prior to any acquisition of nosocomial infection 
(Prospective cohort)
(Chapters 5 and 6)
This cohort was recruited solely from unit 1. Critically ill patients, defined as 
those admitted to IC U  and requiring exogenous support of one or more organ 
systems (invasive ventilation, inotropes/vasopressors or haemofiltration) and 
predicted to require such support for 48 hours or more, were screened for 
recruitment. Exclusion criteria were: age <16; pregnancy; known human 
immunodeficiency virus (H IV ) infection; known in-bom errors of neutrophil 
metabolism; haematological malignancy; use of immunosuppressive drugs other 
than corticosteroids; and those thought unlikely to survive for more than 24 
hours. Informed consent was obtained directly from patients where possible, 
otherwise informed assent was obtained from the next of kin. Whole blood was
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collected into heparin or EDTA/Futhan. Subsequent EDTA/Futhan samples were 
taken at 48 hours, then every 2 days until day 7 and then every 3-4 days until a 
study end-point was achieved. Study end-points were ICU-acquiied infection 
(see below for definition), death without ICU-acquired infection or discharge 
from ICU without ICU-acquired infection. Definitions of infection are shown 
below in section 2.03 f, page 76.
(e) Healthy volunteers
(Chapters 4, 5 and 6)
Flealthy members of University of Edinburgh staff were identified from a register 
of research volunteers and asked to provide a sample of blood. For the work 
presented in Chapter 4, blood was collected as per 2.03 b above (i.e. into sodium 
citrate at final concentration of 0.38%). For the work presented in Chapters 5 
and 6 blood was collected as per 2.03 d above (i.e. into heparin or 
EDTA/Futhan).
(f) Defining infections for prospective cohort
(Chapter 6)
For patients recruited into the prospective cohort (section 2.03 d above) the 
outcome oi infection was determined by meeting one of the following criteria, 
based on those provided by HELICS (HELICS 2004).
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Any new infection occurring after 48 hours of ICU admission was deemed ‘ICU- 
acquired’. For consistency infections arising within 48 hours of ICU discharge 
were deemed ‘ICU-acquired’.
Infections were defined prior to the start of the study as follows, based on the 
HELICS criteria.
a )  V e n t i l a t o r - a s s o c i a t e d  p n e u m o n i a : Requires radiographic, clinical and 
microbiological criteria to be met:
i. Radiological criteria.
CXR or C T  scan showing new infiltrates, or worsening infiltrates without 
evidence of pulmonary oedema, and either pyrexia of >38°C or white cells 
> 12000/mm3 or <4000/ mm3.
These must be combined with one or more clinical criteria.
ii. Clinical criteria.
9 Worsening oxygenation — any increase in FiCX to maintain Pa02 target, 
or an increase in PEEP, frequency or tidal volume, proning or paralysis to 
facilitate ventilation.
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• Relevant clinical chest findings -  auscultatory finding of crepitations, 
crackles or decreased air entry.
• Increased/changed sputum -  any increase in volume, presence of muco­
purulent or muco-purulent-bloody sputum.
iii. Microbiological criteria.
The above radiological and clinical criteria must be combined with positive 
quantitative BAL culture of >104CFU/ml or positive pleural fluid or 
pulmonary/pleural abscess culture.
Where the diagnosis of VAP has been suggested by mini-BAL, endotracheal 
aspirate or where growth is below the 104 CFU/rnl B AL threshold or without any 
positive microbiology, adjudication is required.
H o s p i t a l - a c q u i r e d  p n e u m o n i a  ( H A P ) ,  i.e. nosocomial pneumonia in non- 
mechanically ventilated patients, requires the same fulfilment of criteria as VAP 
except that sputum cultures with heavy growth of a single organism constitute a 
confirmed infection.
b )  C a t h e t e r - a s s o c i a t e d  i n f e c t i o n s
Positive culture (semi-quantitative >15CFU) from an indwelling vascular line 
combined with either
• Local inflammation and pus (catheter-related infection (CRI) or
• Improvement of inflammatory markers within 48 hours of removal (CRI) 
or
8 4
• Culture of the same organism from a peripheral blood culture (catheter- 
related blood stream infection (CRBSI).
c )  B l o o d  s t r e a m  i n f e c t i o n
One positive culture of a typical pathogen, coupled with evidence of systemic 
inflammation (W CC >12,000/mnT or <4000/mm3, temperature > 38°C).
d )  U r i n a r y  t r a c t  i n f e c t i o n
Growth of 2 or fewer organisms at> 103 CFU/ml combined with evidence of 
systemic inflammation (W CC >12,000/mm3 or <4000/mm3, temp >38°C or 
shock without another identifiable cause).
e )  S o f t - t i s s n e  o r  s u r g i c a l  s i t e  i n f e c t i o n
Evidence of pus/inflammation at site of presumed infection combined with a 
positive culture.
Suspected infections that did not meet these criteria were referred to the 
consensus panel for adjudication. The panel was constituted from a pool of five 
experienced doctors, 3 intensivists, 1 respiratory physician and 1 microbiologist, 
all of whom had at least 12 years post-registration experience.
Consensus panel members were asked to come to an independent decision as to 
whether an infection was ‘confirmed’, ‘probable’ or ‘unlikely’.
8 5
A  ‘confirmed’ infection was where the panel member was convinced that 
infection was present and would definitely initiate antibiotic treatment and/or 
pursue source control. Positive microbial detection using techniques other than 
culture (e.g. by Gram film or PCR), microbial cultures from a normally sterile 
site or serology confirming a pathogen were obligatory, alongside other clinical 
evidence of infection.
A  ‘probable’ infection is where the panel member thought there was, on the 
balance of probabilities, an infection present and would consider antibiotic 
treatment and/or source control if the patient’s clinical condition merited it. This 
category may include positive microbial cultures. An example would be culture 
of a classically non-pathological organism (e.g. single cultures of coagulase 
negative cocci or diphtheroids) associated with clinical evidence of 
infection/systemic inflammation.
An ‘unlikely’ infection is where the panel member thought there was a low 
probability of infection and would not consider antibiotic treatment and/or source 
control. Although positive microbial cultures could be included in this, this 
would be culture of a classically non-pathological organism (e.g. single cultures 
of coagulase negative cocci or diphtheroids) without evidence of systemic 
inflammation/infection or mixed growth of commensal organisms.
Systemic evidence of infection would require the presence of SIRS -  specifically 
2 or more of the following: heart rate>90 beats per minute, W CC> 12/mm3 or 
<4/mm 0 1  > 10 A> band types, i espiratory rate >20 breaths per minute, or
8 6
mechanical ventilation and temperature of >38°C or <36°C. Additional evidence 
to consider would include reports of large numbers of neutrophils on sample 
microscopy, and clinical examination findings of pus or inflamed tissue.
‘Unlikely’ infection combined with a positive microbial culture would constitute 
colonisation.
The consensus panel was constituted by two members drawn from the pool, and 
asked to arrive at an independent opinion from one of the three categories above. 
Where there was agreement the verdict stood, where there was disagreement the 
panel members met to tiy and agree a consensus view. If this failed a third 
member was drawn from the pool and asked to make an opinion between the two 
options selected by the initial panel members.
(g) Separation and extraction of peripheral blood leucocytes
i )  P e r c o l l  g r a d i e n t s  
(Chapters 3 and 4)
Using a well-established protocol (Haslett et al. 1985), 30 ml of citrated whole 
blood was separated into cellular component and plasma by centrifugation. 
Serum was prepared by adding 1M calcium chloride to plasma. Peripheral blood 
neutrophils (PBNs) and mononuclear cells were isolated from the cellular pellet 
by sequential dextran sedimentation and Percoll gradient extraction. Purity was
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a s s e s s e d  b y  c y t o s p i n  a n d  R e a s t a i n  D i f f - q u i k  s t a i n i n g ,  a n d  c e l l u l a r  n u m b e r  
a s s e s s e d  b y  h a e m a c y t o n r e t e r .  P r e p a r a t i o n s  o l  > 9 5 %  p u r i t y  w e r e  u s e d  f o i  
e x p e r i m e n t a l  a s s a y s  a n d  w e r e  u s e d  f r e s h  ( w i t h i n  3 0  r n i n s  o f  e x t r a c t i o n )  i n  a l l  
c a s e s .  C e l l s  w e r e  s u s p e n d e d  a t  1 0 x l 0 6 / m l  i n  w a m r e d  I M D M  p r i o r  t o  u s e .
i i )  P o l y m o r p h o p r e p  
( C h a p t e r  5 )
N e u t r o p h i l s  w e r e  e x t r a c t e d  f r o m  h e p a r i n i s e d  w h o l e  b l o o d  b y  c e n t r i f u g a t i o n  o v e r  
p r o p r i e t a r y  n e u t r o p h i l  s e p a r a t i o n  m e d i a ,  P o l y m o r p h o p r e p .  H e p a r i n i s e d  p l a s m a  
w a s  a s p i r a t e d  f r o m  t h e  s u p e r n a t a n t .  O n l y  s a m p l e s  y i e l d i n g  > 9 5 %  n e u t r o p h i l  
p u r i t y  w e r e  u s e d  i n  e x p e r i m e n t s  ( a s  a s s e s s e d  b y  R e a s t a i n  D i f f - q u i k  ( R e a g e n a ,  
T o i v a l a ,  F i n l a n d )  s t a i n i n g  o f  c y t o s p i n s  a n d  a n a l y s i s  u s i n g  a  h a e m a c y t o m e t e r ) .  
C e l l s  w e r e  s u s p e n d e d  a t  1 0 x l 0 6 / m l  i n  w a r m e d  I s c o v e ’ s  m o d i f i e d  D u l b e c c o ’ s  
m e d i u m  ( I M D M )  p r i o r  t o  u s e .
(h) Phagocytosis assay
i )  C o r e  p h a g o c y t o s i s  a s s a y
P h a g o c y t o s i s  b y  n e u t r o p h i l s ,  a n d  a l v e o l a r  c e l l s ,  w a s  a s s e s s e d  b y  z y m o s a n  
i n g e s t i o n .  T h e  c o r e  a s s a y  i s  d e s c r i b e d  b e l o w  f o l l o w e d  b y  a  d e s c r i p t i o n  o f  t h e  
v a r i a t i o n s  o n  t h e  t e c h n i q u e  u s e d  t o  e x p l o r e  v a r i o u s  p a r t s  o f  t h e  m e c h a n i s m .
N e u t r o p h i l s  d e r i v e d  a s  d e s c r i b e d  i n  2 . 0 3  g  a b o v e  w e r e  a d h e r e d  t o  t i s s u e  c u l t u r e  
p l a s t i c  i n  I M D M  c o n t a i n i n g  1 %  a u t o l o g o u s  s e r u m .  C e l l s  w e r e  e x p o s e d  f o r  1 h o u r
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t o  z y m o s a n  p a r t i c l e s  t h a t  h a d  b e e n  p r e - i n c u b a t e d  w i t h  5 0 %  a u t o l o g o u s  s e r u m .  
N e u t r o p h i l s  w e r e  a i r  d r i e d ,  f i x e d  w i t h  m e t h a n o l  a n d  s t a i n e d  w i t h  R e a s t a i n  D i f f -  
Q u i k .  L i g h t  m i c r o s c o p y  w a s  u s e d  t o  d i s t i n g u i s h  n e u t r o p h i l s  c o n t a i n i n g  > 2  
z y m o s a n  p a r t i c l e s .  D u p l i c a t e  c o u n t s  w e r e  p e r f o r m e d  o n  f o u r  r a n d o m l y  s e l e c t e d  
f i e l d s  ( m i n i m u m  o f  1 0 0  n e u t r o p h i l s  p e r  f i e l d ) ,  e x a m p l e  f i e l d s  a r e  s h o w n  i n  f i g u r e  
V - l  ( p a g e  1 4 4 ) .
i i )  T i m e  c o u r s e  e x p e r im e n t s  
( C h a p t e r  4 )
T h e  t i m e  c o u r s e  o f  p h a g o c y t o s i s  w a s  e x p l o r e d  b y  e x p o s i n g  c e l l s  t o  z y m o s a n  f o r  
5 ,  1 0 ,  1 5 ,  3 0  a n d  6 0  m i n u t e s ,  a n d  ‘ v e l o c i t y ’  c a l c u l a t e d  b y  c h a n g e  i n  t h e  
p e r c e n t a g e  o f  n e u t r o p h i l s  u n d e r g o i n g  p h a g o c y t o s i s  o v e r  t i m e .
i i i )  T e s t i n g  f o r  d e f e c ts  in  o p s o n i s a t io n  
( C h a p t e r  4 )
Z y m o s a n  w a s  o p s o n i s e d  i n  s e r u m  f r o m  p a t i e n t s ’  k n o w n  t o  e x h i b i t  p o o r  P B N  
p h a g o c y t o s i s  ( < 4 0 % ,  s e e  F i g u r e  I I I - 1 p a g e  1 0 0 )  o r  m a t c h e d  v o l u n t e e r s  ( k n o w n  t o  
e x h i b i t  e f f i c i e n t  P B N  p h a g o c y t o s i s )  f o r  o n e  h o u r  a t  3 7 ° C .  P B N s  f r o m  h e a l t h y  
v o l u n t e e r s  w e r e  t h e n  e x p o s e d  t o  o p s o n i s e d  z y m o s a n  a t  0 . 0 2 m g / m l  i n  I M D M  
w i t h  1 %  p a t i e n t  o r  h e a l t h y  v o l u n t e e r  s e r u m ,  i n c u b a t e d  f o r  1 h o u r  a t  3 7 ° C  a n d  
t h e n  w a s h e d ,  s t a i n e d  a n d  c o u n t e d  a s  p e r  t h e  c o r e  p r o t o c o l  a b o v e .  T o  d e m o n s t r a t e  
t h e  n e e d  f o r  o p s o n i s a t i o n  f o r  e f f i c i e n t  p h a g o c y t o s i s  i n  t h i s  a s s a y ,  s i m i l a r  
e x p e r i e m e n t s  w e r e  c o n d u c t e d  i n  w h i c h  z y m o s a n  w a s  i n c u b a t e d  w i t h  h e a t -  
i n a c t i v a t e d  s e r u m  ( 6 0 ° C  f o r  6 0  m i n u t e s )  o r  w i t h  P B S  ( i . e .  n o n - o p s o n i s e d )  b e f o r e  
b e i n g  e x p o s e d  t o  t h e  P B N s .
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i v )  S e r u m  in h i b i t o r s  
( C h a p t e r  4 )
H e a l t h y  v o l u n t e e r  P B N s  w e r e  i n c u b a t e d  w i t h  s e r u m  f r o m  p a t i e n t s  k n o w n  t o  
e x h i b i t  p o o r  P B N  p h a g o c y t o s i s  ( < 4 0 % )  o r  f r o m  m a t c h e d  v o l u n t e e r s  ( k n o w n  t o  
e x h i b i t  e f f i c i e n t  P B N  p h a g o c y t o s i s )  a t  3 7 ° C  f o r  o n e  h o u r .  T h e  P B N s  w e r e  
a d h e r e d  a s  p e r  t h e  c o r e  p r o t o c o l  a b o v e ,  t h e n  e x p o s e d  t o  z y m o s a n  o p s o n i z e d  w i t h  
e i t h e r  p a t i e n t  s e r u m  o r  h e a l t h y  v o l u n t e e r  s e r u m  f o r  1 h o u r  a t  3 7 ° C .  W a s h i n g ,  
s t a i n i n g  a n d  c o u n t i n g  w e r e  a s  p e r  t h e  c o r e  p r o t o c o l .
v )  A n t i b o d y  b lo c k a d e  o f  p h a g o c y t i c  r e c e p t o r s  
( C h a p t e r  4 )
T o  t e s t  f o r  t h e  r o l e  o f  C D 1  l b ,  a s  t h e  m a j o r  r e c e p t o r  f o r  s e r u m - o p s o n i s e d  
z y m o s a n ,  n e u t r o p h i l s  w e r e  i n c u b a t e d  w i t h  m u r i n e  m o n o c l o n a l  a n t i - C D  1 l b  
f u n c t i o n a l  b l o c k i n g  a n t i b o d y  M E M - 1 7 0 .  T h e  r o l e  o f  C D  1 6  w a s  e x a m i n e d  b y  
b l o c k a d e  u s i n g  m u r i n e  m o n o c l o n a l  a n t i - h u m a n  C D  1 6  f u n c t i o n a l  b l o c k i n g  
a n t i b o d y  3 G 8 .  C o n t r o l  w a s  a c h i e v e d  u s i n g  i s o t y p e  m u r i n e  I g G l .
v i )  I n h i b i t o r s  o f  p h a g o c y t o s i s  
( C h a p t e r  5 )
T o  e x p l o r e  t h e  e f f e c t s  o f  C 5 a ,  a  l i g a n d  o p e r a t i n g  v i a  a  s i m i l a r  G - c o u p l e d  r e c e p t o r  
( f M L P )  a n d  a  l i g a n d  o p e r a t i n g  v i a  a  r e c e p t o r  c o u p l e d  t o  a  d i f f e r e n t  t y p e  o f  G -  
p r o t e i n  ( i s o p r o t e r e n o l )  t h e  l i g a n d s  w e r e  a d d e d  t o  t h e  n e u t r o p h i l s  d u r i n g  t h e  
a d h e s i o n  p h a s e  i n  t h e  f o l l o w i n g  f i n a l  c o n c e n t r a t i o n s :  C 5 a  ( l O O n M ) ,  f M L P  
( l O O n M ) ,  i s o p r o t e r e n o l  ( l O O p M ) .  A  d i r e c t  a c t i v a t o r  o f  p h o s p h o i n o s i t o l  3  
k i n a s e ,  s u b - c l a s s  I A  ( P I 3 K I A ) , 7 4 0  Y - P  w a s  a l s o  u s e d  i n  t h i s  p r o t o c o l .  I n  a  
v a r i a t i o n ,  h e a l t h y  v o l u n t e e r  P B N s  w e r e  i n c u b a t e d  w i t h  e i t h e r  l g g / m l  o f  S 5 / 1  
( A b e a m , )  -  a  m u r i n e  m o n o c l o n a l  a n t i b o d y  k n o w n  t o  b l o c k  C D  8  8  -  o r  w i t h
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l u g / m l  p r e - i m m u n e  m u r i n e  I g G l  ( I n v i t r o g e n )  f o r  3 0  m i n u t e s  a t  3 7 ° C ,  p r i o r  t o  
a d d i t i o n  o f  C 5 a  a t  c o n c e n t r a t i o n s  o f  1 , 1 0  o r  l O O n M  ( o r  c o n t r o l )  a s  a b o v e .  L e v e l s  
o f  c A M P  f o l l o w i n g  s t i m u l a t i o n  w i t h  C 5 a ,  f M L P  o r  i s o p r o t e r e n o l  i n  t h e  
c o n c e n t r a t i o n s  n o t e d  a b o v e  w e r e  d e t e r m i n e d  i n  c e l l  l y s a t e s  u s i n g  a  n o n ­
r a d i o g r a p h i c  c o m p e t i t i v e  b i n d i n g  a s s a y  ( P a r a m e t e r ,  R n D  S y s t e m s ) .
v i i )  I n t r a - c e l l u l a r  s i g n a l l i n g  d o w n  s t r e a m  o f  p h a g o c y t o s i s  in h i b i t o r s  
( C h a p t e r  5 )
T o  e x p l o r e  t h e  e f f e c t s  o f  t h e  a b o v e  l i g a n d s  i n  2 . 0 3  h  v i  o n  i n t r a - c e l l u l a r  
s i g n a l l i n g  p a t h w a y s  c e l l s  w e r e  p r e - i n c u b a t e d  w i t h  a  n u m b e r  o f  s m a l l  i n h i b i t o r s  
o f  k e y  s i g n a l l i n g  m o l e c u l e s  b e f o r e  e x p o s u r e  t o  t h e  l i g a n d  o f  i n t e r e s t .  T h e s e  
m o l e c u l e s  i n c l u d e d  t h e  a d e n y l a t e  c y c l a s e  i n h i b i t o r  S Q 2 2 5 3 6 ,  t h e  n o n - i s o f o r m  
s p e c i f i c  P I 3 K  i n h i b i t o r s  w o r t m a n n i n  a n d  L Y 2 9 4 0 0 2 ,  t h e  P I 3 K y  i n h i b i t o r  
A S 6 0 5 2 4 0 ,  a n d  t h e  P I 3 K 6  i n h i b i t o r  I C 8 7 1 1 4 .
v i i )  G M - C S F  a n d  in t e r f e r o n .
( C h a p t e r  5 )
T o  t e s t  t h e  a b i l i t y  o f  c e r t a i n  i m m u n e  m o d u l a t o r s  t o  r e s u r r e c t  C 5 a - m e d i a t e d  
i m p a i r m e n t  o f  p h a g o c y t o s i s ,  c e l l s  t r e a t e d  w i t h  C 5 a  a s  p e r  2 . 0 3  h  v i  a b o v e  w e r e  
t h e n  e x p o s e d  t o  G M - C S F ,  r e c o m b i n a n t  h u m a n  i n t e r f e r o n  y  o r  c o n t r o l  f o r  3 0  
m i n u t e s  p r i o r  t o  i n c u b a t i o n  w i t h  o p s o n i s e d  z y m o s a n .  T e s t i n g  o f  t h e  r o l e  o f  
P I 3 K 6  i n h i b i t i o n  i n  ‘ t r e a t m e n t ’  ( a s  o p p o s e d  t o  p r e v e n t i o n )  o f  C 5 a - m e d i a t e d  
e f f e c t s  w a s  a c h i e v e d  b y  r e p l a c i n g  G M - C S F  w i t h  I C 8 7 1 1 4  i n  t h i s  p r o t o c o l .
i x )  I n f l u e n c e  o f B A L  f l u i d  o n  p h a g o c y t o s i s
9 1
( C h a p t e r  4 )
T o  t e s t  f o r  a n y  i n h i b i t o r y  e f f e c t s  o f  B A L  f l u i d  f r o m  p a t i e n t s  w i t h  s u s p e c t e d  V A P  
o n  p h a g o c y t o s i s ,  n e u t r o p h i l s  f r o m  h e a l t h y  d o n o r s  w e r e  i n c u b a t e d  w i t h  l a v a g e  
f r o m  f i v e  p a t i e n t s  w i t h  s u s p e c t e d  V A P  w i t h  l o w  ( < 5 0 % )  p h a g o c y t o s i s  b y  B A L  
c e l l s ,  o r  f r o m  a  m a t c h e d  v o l u n t e e r  w i t h o u t  d i s c e r n a b l e  r e s p i r a t o r y  p a t h o l o g y .  
C e l l s  w e r e  i n c u b a t e d  f o r  o n e  h o u r  i n  l a v a g e  w i t h  1 %  a u t o l o g o u s  ( t o  t h e  
n e u t r o p h i l  d o n o r )  s e r u m  b e f o r e  b e i n g  e x p o s e d  t o  z y m o s a n  a s  p e r  t h e  c o r e  
p r o t o c o l .  T o  t e s t  f o r  C D 8 8  d e p e n d e n c e  o f  t h e  l a v a g e - m e d i a t e d  d e f e c t  h e a l t h y  
v o l u n t e e r  P B N s  w e r e  i n c u b a t e d  w i t h  e i t h e r  I u g / m l  o f  S 5 / 1  ( A b e a m , )  -  a  m u r i n e  
m o n o c l o n a l  a n t i b o d y  k n o w n  t o  b l o c k  C D 8 8  -  o r  w i t h  1 u g / m l  p r e - i m m u n e  m u r i n e  
I g G l  ( I n v i t r o g e n )  f o r  3 0  m i n u t e s  a t  3 7 ° C ,  p r i o r  t o  a d d i t i o n  o f  B A L  f l u i d  a s  
a b o v e .
(i) RhoA activation
( C h a p t e r  5 )
F o r  R h o  G T P a s e  a n a l y s i s ,  n e u t r o p h i l s  f r o m  h e a l t h y  d o n o r s  w e r e  a d h e r e d  t o  
p l a s t i c  c e l l  c u l t u r e  p l a t e s  a n d  t r e a t e d  w i t h :  c o n t r o l ;  C 5 a ;  I C 8 7 1 1 4  a n d  C 5 a ;  o r  
C 5 a  a n d  G M - C S F ,  a s  a b o v e ,  b e f o r e  b e i n g  e x p o s e d  t o  z y m o s a n  o r  v e h i c l e  c o n t r o l  
f o r  5  m i n u t e s  ( p r e v i o u s l y  e s t a b l i s h e d  a s  t h e  t i m e  o f  p e a k  R h o  a c t i v a t i o n ) .  C e l l s  
w e r e  t h e n  w a s h e d  i n  i c e - c o l d  p h o s p h a t e  b u f f e r e d  s a l i n e  ( P B S )  b e f o r e  b e i n g  l y s e d  
w i t h  c e l l  l y s i s  s o l u t i o n  ( C y t o s k e l e t o n )  c o n t a i n i n g  1 O x  H A L T ™  p r o t e a s e  a n d  
p h o s p h a t a s e  i n h i b i t o r  w i t h  5 m M  E D T A  ( T h e r m o  S c i e n t i f i c ) .  A l i q u o t s  w e r e  
t a k e n  f o r  p r o t e i n  e s t i m a t i o n  w i t h  t h e  r e m a i n d e r  b e i n g  s n a p  f r o z e n  i n  l i q u i d  
n i t i o g e n  a n d  s t o r e d  a t  - 8 0  C  b e f o r e  f u r t h e r  u s e .  A n a l y s i s  o f  s a m p l e s ,  e q u a l i s e d  
t o i  t o t a l  p i o t e i n  c o n c e n t r a t i o n ,  w a s  b y  e n z y m e - l i n k e d  i m m u n o s o r b e n t  a s s a y  
( E L I S A ,  R h o  G - l i s a ™ ,  C y t o s k e l e t o n ) ,  a s  p e r  t h e  m a n u f a c t u r e r ’ s  i n s t r u c t i o n s .
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S i m i l a r  e x p e r i m e n t s  w e r e  c o n d u c t e d  w i t h  n e u t r o p h i l s  f r o m  c r i t i c a l l y  i l l  p a t i e n t s  
( p r o s p e c t i v e  c o h o r t ) ,  e x p o s i n g  t h e m  t o  v e h i c l e  c o n t r o l  o r  o p s o n i s e d  z y m o s a n .
(j) Actin polymerisation
( C h a p t e r  5 )
H e a l t h y  d o n o r  n e u t r o p h i l s  w e r e  a d h e r e d  a n d  t r e a t e d  w i t h :  c o n t r o l ;  C 5 a ;  I C 8 1 7 7 4  
a n d  C 5 a ;  o r  C 5  a n d  G M - C S F ,  b e f o r e  b e i n g  e x p o s e d  t o  v e h i c l e  c o n t r o l  o r  
z y m o s a n  f o r  0  ( b a s e l i n e ) ,  5 , 1 0 , 1 5  o r  3 0  m i n u t e s .  C e l l s  w e r e  w a s h e d  i n  i c e - c o l d  
P B S  b e f o r e  b e i n g  f i x e d  i n  1 0 %  f o r m a l i n  f o r  1 0  m i n u t e s ,  p e r m e a b i l i s e d  i n  0 . 1 %  
T r i t o n  f o r  3  m i n u t e s ,  w a s h e d  i n  P B S  a n d  t h e n  i n c u b a t e d  w i t h  F I T C - c o n j u g a t e d  
p h a l l o i d i n  ( 2 u / m l ) ,  w h i c h  i r r e v e r s i b l y  b i n d s  t o  p o l y m e r i s e d ,  f i l a m e n t o u s  a c t i n  ( f -  
a c t i n )  b u t  n o t  t o  n o n - p o l y m e r i s e d  a c t i n  ( D a n c k e r  e t  a l .  1 9 7 5 ) ,  f o r  3 0  m i n u t e s .  
C e l l s  w e r e  w a s h e d  o n c e  m o r e  b e f o r e  b e i n g  s u s p e n d e d  i n  P B S .  A n a l y s i s  o f  
f l u o r e s c e n c e  w a s  b y  f l o w  c y t o m e t r y  ( F A C S c a n ,  B D  B i o s c i e n c e ) .  S i m i l a r  
e x p e r i m e n t s  w e r e  c o n d u c t e d  u s i n g  n e u t r o p h i l s  f r o m  c r i t i c a l l y  i l l  p a t i e n t s  
( p r o s p e c t i v e  c o h o r t ) ,  e x p o s i n g  t h e m  t o  e i t h e r  v e h i c l e  c o n t r o l  o r  z y m o s a n  f o r  f i v e  
m i n u t e s .
(k) PKB (AKT) phosphorylation
( C h a p t e r  5 )
T o  t e s t  f o r  P I 3 K  a c t i v i t y  a n d  i n h i b i t i o n ,  c e l l u l a r  l y s a t e s  f r o m  a p p r o p r i a t e l y  
t r e a t e d  h e a l t h y  d o n o r  n e u t r o p h i l s  w e r e  a s s a y e d  f o r  p h o s p h o - P K B .  T h e  e f f e c t  o f  
C 5 a  o n  p h o s p h o r y l a t i o n  o f  A K T  w a s  e x a m i n e d  b y  w e s t e r n  b l o t t i n g .  B r i e f l y ,  
l x l O 7 n e u t r o p h i l s  w e r e  i n c u b a t e d  w i t h  P I 3 K  i n h i b i t o r s  ( L Y 2 9 4 0 0 2 ,  A S 6 0 5 2 4 0  o r  
I C 8 7 1 1 4 )  o r  v e h i c l e  c o n t r o l  f o r  1 5  m i n u t e s  p r i o r  t o  s t i m u l a t i o n  w i t h  C 5 a  f o r  5  o r  
1 5  m i n u t e s  a t  3 7 ° C .  C e l l s  w e r e  p e l l e t e d  a t  4 5 0 g  a t  4 ° C  f o r  5  m i n s ,  f o l l o w e d  b y
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l y s i s  i n  i c e - c o l d  c e l l  l y s i s  b u f f e r  ( M - P E R ™ )  c o n t a i n i n g  1 0 X  H A L T ™  p r o t e a s e  
a n d  p h o s p h a t a s e  i n h i b i t o r  w i t h  5 m M  E D T A  ( T h e r m o  S c i e n t i f i c ) .  F o l l o w i n g  t h i s  
t h e  l y s a t e s  w e r e  c l a r i f i e d  b y  c e n t r i f u g e d  a t  1 4 0 0 0 g  f o r  1 5  m i n u t e s ,  a n d  t h e  
s u p e r n a t a n t  f r o z e n  a t  - 8 0 ° C  f o r  l a t e r  a n a l y s i s .
S a m p l e s  e q u a l i s e d  f o r  p r o t e i n  w e r e  m i x e d  i n  a  1 : 1  r a t i o  w i t h  s a m p l e  b u f f e r  a n d  
d e n a t u r e d  a t  9 5 ° C  f o r  5  m i n u t e s .  S a m p l e s  w e r e  t h e n  r u n  o n  a  1 2 %  P i e r c e  P r e c i s e  
p r o t e i n  g e l  b e f o r e  b l o t t i n g  o n t o  p o l y v i n y l i d e n e  f l u o r i d e  ( P V D F )  m e m b r a n e .  T h e  
m e m b r a n e  w a s  b l o c k e d  f o r  1 h o u r  i n  5 %  s k i m m e d  m i l k  w i t h  0 . 1 %  T w e e n ,  
f o l l o w e d  b y  i n c u b a t i o n  f o r  1 2  h o u r s  w i t h  a  r a b b i t  a n t i - h u m a n  p h o s p h o - A K T  
( S 4 7 3 )  a n t i b o d y  ( R & D  s y s t e m s ,  A b i n g d o n ,  U K ) .  T h e  m e m b r a n e  w a s  t h e n  
w a s h e d  3  t i m e s  i n  T r i s - b u f f e r e d  s a l i n e  w i t h  0 . 1 %  T w e e n  ( T B S T )  b e f o r e  b e i n g  
i n c u b a t e d  f o r  1 h o u r  w i t h  h o r s e r a d i s h  p e r o x i d a s e - c o n j u g a t e d  g o a t - a n t i  r a b b i t  
s e c o n d a r y  a n t i b o d y  ( R & D  s y s t e m s ) .  T h e  m e m b r a n e  w a s  t h e n  w a s h e d  t h r e e  
t i m e s  i n  T B S T  a n d  e x p o s e d  t o  c h e m i l u m i n e s c e n t  s u b s t r a t e  ( S u p e r s i g n a l ,  T h e r m o  
S c i e n t i f i c ) ,  w a s h e d  o n c e  i n  T B S T ,  a n d  e x p o s e d  t o  f i l m .
(I) Flow cytometry
i )  I s o l a t e d  n e u t r o p h i l  f l o w  c y t o m e t r y  
( C h a p t e r s  3  a n d  4 )
S a m p l e s  c o m p r i s e d  f r e s h l y  p r e p a r e d  n e u t r o p h i l s  f r o m  h e a l t h y  v o l u n t e e r  d o n o r s ,  
m a t c h e d  v o l u n t e e r s  o r  V A P  c o h o r t  p a t i e n t s  i n c u b a t e d  i n  I M D M ,  c e n t r i f u g e d  a t  
3 0 0 g  t o i  5  m i n u t e s  a t  4  C  t h e n  r e s u s p e n d e d  i n  P B S  c o n t a i n i n g  4 %  m u r i n e  s e r u m  
( w i t h  t h e  e x c e p t i o n  o f  c e l l s  s t a i n e d  f o r  C D 8 8  w h i c h  w e r e  r e s u s p e n d e d  i n  4 %  
c a p r i n e  s e r u m ) .  P r i m a r y  a n t i b o d i e s  c o n s i s t e d  o f
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•  m u r i n e  m o n o c l o n c a l  a n t i - C D  1 l b ,  - C D 3 2  ( F e y  r e c e p t o r  I I ) ,  a n d  - C D 6 4  
( F e y  r e c e p t o r  I )  l a b e l l e d  w i t h  p h y c o e r y t h r i n  ( P E ) ,  f l u o r e s c e i n - 5 -  
i s o t h i o c y a n a t e  ( F I T C )  a n d  P E  r e s p e c t i v e l y ;
•  m u r i n e  m o n o c l o n a l  a n t i b o d y  a g a i n s t  t h e  a c t i v a t i o n  e p i t o p e  o f  C D  1 1  b ,  
C B R M 1 / 5 ,  l a b e l l e d  w i t h  F I T C ;  a n d
0 m u r i n e  m o n o c l o n a l  a n t i - C D 8 8  P I 2 / 1 ,  u n l a b e l l e d .
I n  t h e  c a s e  o f  a n t i - C D 8 8 ,  a  s e c o n d a r y  g o a t - a n t i  m o u s e  a n t i b o d y  c o n j u g a t e d  w i t h  
a l e x a - 6 4 7  w a s  a p p l i e d .
I n  p a r a l l e l ,  a p p r o p r i a t e  i s o t y p e  c o n t r o l  a n t i b o d i e s  w e r e  a p p l i e d .  C e l l s  w e r e  
w a s h e d  a n d  f i x e d  w i t h  1 0 %  f o r m a l i n  a n d  a n a l y s e d  b y  f l o w  c y t o m e t r y  
( F A C S C a l i b u r ,  B D  B i o s c i e n c e )  w i t h i n  1 8  h o u r s .  E x p r e s s i o n  w a s  q u a n t i f i e d  a s  
g e o m e t r i c  m e a n  f l u o r e s c e n c e .
S t i m u l a t i o n  o f  c e l l s  w i t h  o p s o n i s e d  z y m o s a n  w a s  p e r f o r m e d  t o  a s s e s s  t h e  
a c t i v a t i o n  o f  C D 1  l b .  N e u t r o p h i l s  a t  5 0 0 , 0 0 0 / m l  w e r e  e x p o s e d  t o  z y m o s a n  
o p s o n i s e d  i n  a u t o l o g o u s  s e r u m  a t  0 . 0 2 m g / m l  a t  3 7 ° C  f o r  3 0  m i n u t e s .  C e l l s  w e r e  
t h e n  w a s h e d  a n d  s t a i n e d  w i t h  t h e  a c t i v a t i o n  e p i t o p e - s p e c i f i c  a n t i b o d y  C B R M 1 / 5  
a s  p e r  t h e  p r o t o c o l  a b o v e .
T h e  e f f e c t s  o f  C 5 a ,  p a t i e n t  l a v a g e ,  C 5 a  f o l l o w e d  b y  G M - C S F  a n d  C 5 a  f o l l o w e d  
b y  i n t e r f e r o n  g a m m a  o n  C D 8 8  e x p r e s s i o n  w a s  a s s e s s e d  b y  e x p o s i n g  h e a l t h y  
d o n o r  n e u t r o p h i l s  t o  t h e s e  c o m p o u n d s  a t  t h e  c o n c e n t r a t i o n s  u s e d  i n  t h e  
p h a g o c y t o s i s  e x p e r i m e n t s  a b o v e  ( s e c t i o n  2 . 0 3  h  v i i  p a g e  8 4 )  f o r  1 h o u r  a t  3 7 ° C  
p r i o r  t o  w a s h i n g  i n  i c e - c o l d  P B S  a n d  s t a i n i n g  w i t h  a n t i - C D 8 8  a n t i b o d y  a s  p e r  t h e  
a b o v e  p r o t o c o l .
i i )  W h o l e  b l o o d f l o w  c y t o m e t i y
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( C h a p t e r s  5  a n d  6 )
F i f t y  p i  o f  E D T A - a n t i c o a g u l a t e d  w h o l e  b l o o d  f r o m  h e a l t h y  d o n o r s  o r  c r i t i c a l l y  
i l l  p a t i e n t s  ( p r o s p e c t i v e  c o h o r t )  w a s  i n c u b a t e d  w i t h  p r i m a r y ,  f l u o r o p h o r e - t a g g e d  
a n t i b o d i e s  i n  t h e  f o l l o w i n g  c o m b i n a t i o n s :  a n t i - h u m a n  C D l l b / F I T C ;  a n t i - h u m a n  
C D 6 2 L  ( L - s e l e c t i n ) / t r i c o l o r  ( T C ) ;  a n t i - h u m a n  C D 1 6 / T C ;  a n t i - h u m a n  C D 6 4 - R -  
p h y c o e y r t h r i n  ( R P E )  a n d  a n t i - h u m a n  C D 8 8 / A l e x a 6 4 7 ,  o r  i s o t y p e  c o n t r o l s ,  f o r  3 0  
m i n u t e s  a t  4 ° C .  C e l l s  w e r e  f i x e d  w i t h  F a c s l y s e  a n d  a n a l y s e d  b y  F A C S C a l i b u r  
( B D  B i o s c i e n c e s ) ,  g a t i n g  o n  n e u t r o p h i l s  b y  f o r w a r d / s i d e  s c a t t e r  ( F S C / S S C )  
c h a r a c t e r i s t i c s .  E x p r e s s i o n  w a s  q u a n t i f i e d  b y  t h e  g e o m e t r i c  m e a n  c h a n n e l  
f l u o r e s c e n c e  ( G M F ) ,  w h i c h  i s  e x p r e s s e d  i n  a r b i t r a r y  f l u o r e s c e n c e  u n i t s .  T h e  
e f f e c t  o f  C 5 a  e x p o s u r e  o n  n e u t r o p h i l  C D 8 8  e x p r e s s i o n  w a s  e x p l o r e d  b y  
i n c u b a t i n g  h e a l t h y  d o n o r  n e u t r o p h i l s  w i t h  v a r y i n g  c o n c e n t r a t i o n s  o f  r h C 5 a  
( 1 , 1 0 , 1 0 0  n M  a n d  v e h i c l e  c o n t r o l )  f o l l o w e d  b y  i n c u b a t i o n  w i t h  t h e  f l u o r o p h o r e -  
l a b e l l e d  a n t i - C D 8 8  a n t i b o d y .  M o n o c y t e  H L A - D R  w a s  d e t e r m i n e d  b y  i n c u b a t i n g  
b l o o d  w i t h  Q u a n t i b r i t e  m u r i n e  a n t i - h u m a n  H L A - D R / R - P E  ( B D  B i o s c i e n c e ) ,  
w i t h  q u a n t i f i c a t i o n  u s i n g  p e r i o d i c  c a l i b r a t i o n  o f  t h e  f l o w  c y t o m e t e r  w i t h  
Q u a n t i b r i t e  b e a d s .  T h e  p r o t o c o l  w a s  o t h e r w i s e  a s  p e r  t h e  n e u t r o p h i l  s t a i n s  
a l t h o u g h  g a t e s  w e r e  a d j u s t e d  t o  F S C / S S C  c h a r a c t e r i s t i c s  o f  m o n o c y t e s .  
R e g u l a t o r y  T - c e l l s  w e r e  d e t e r m i n e d  b y  s t a i n i n g  5 0 p l  o f  w h o l e  b l o o d  u s i n g  
m u r i n e  a n t i - h u m a n  C D 4 / F I T C  a n d  C D 2 5 / A P C  f o r  3 0  m i n u t e s  a t  4 ° C .  A l l  
r e a g e n t s  w e r e  o b t a i n e d  f r o m  e b i o s c i e n c e .  R e d  c e l l  l y s i s  b u f f e r  w a s  t h e n  a d d e d  t o  
t h e  c e l l s ,  w h i c h  w e r e  i n c u b a t e d  a t  2 1 ° C  f o r  1 0  m i n u t e s ,  p r i o r  t o  w a s h i n g  i n  f l o w  
s t a i n i n g  b u f f e r  ( F S B )  a n d  r e s u s p e n d i n g  i n  c e l l  f i x a t i o n / p e r m e a b i l i s a t i o n  s o l u t i o n  
a t  4  C  t o r  3 0  m i n u t e s .  C e l l s  w e r e  t h e n  w a s h e d  t w i c e  a n d  r e s u s p e n d e d  i n  F S B  
a n d  i n c u b a t e d  w i t h  m u r i n e  a n t i - h u m a n  F O X P 3 / R - P E  o r  R - P E  c o n j u g a t e d  i s o t y p e
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c o n t r o l  f o r  3 0 m i n u t e s  a t  4 ° C  p r i o r  t o  w a s h i n g  a n d  r e s u s p e n d i n g  i n  F S B  a n d  
a n a l y s i n g  o n  F A C S C a l i b u r  ( B D  B i o s c i e n c e ) .  A n a l y s i s  w a s  b y  g a t i n g  o n  
l e u c o c y t e s  ( b y  F S C / S S C  c h a r a c t e r i s t i c s ) ,  i d e n t i f y i n g  t h e  C D 4 + v e  c e l l s  a n d  
d e t e r m i n i n g  t h e  p e r c e n t a g e  t h a t  w a s  p o s i t i v e  f o r  C D 2 5 +  a n d  F O X P 3 .
(m) Super-oxide production assay
( C h a p t e r  3 )
N e u t r o p h i l  s u p e r o x i d e  a n i o n  p r o d u c t i o n  b y  c e l l s  o b t a i n e d  f r o m  m a t c h e d  
v o l u n t e e r s  a n d  c r i t i c a l l y  i l l  p a t i e n t s  ( V A P  c o h o r t )  w a s  a s s a y e d  b y  a  c y t o c h r o m e  
C  r e d u c t i o n  a s s a y ,  u s i n g  a  s t i m u l u s  o f  1 O O n M  p l a t e l e t  a c t i v i t a t i n g  f a c t o r  ( P A F )  
a n d  l O O n M  N - f o r m y l - m e t h i o n y l - l e u c y l - p h e n y l a l a n i n e  ( f M L P ) .
(n) Pseud om ona s  killing assay
( C h a p t e r  5 )
T h e  a b i l i t y  o f  h e a l t h y  v o l u n t e e r  n e u t r o p h i l s ,  p r e - i n c u b a t e d  i n  v a r i o u s  m e d i a ,  t o  
k i l l  P s e u d o m o n a s  a e r u g i n o s a  w a s  a s s a y e d  i n  t h e  f o l l o w i n g  m a n n e r .  P .  
a e r u g i n o s a  s t r a i n  P A 0 1  w a s  g r o w n  f o r  1 2  h o u r s  i n  L u r i a - B e r t a n i  ( L B )  b r o t h  a t  
3 7 ° C ,  b e f o r e  b e i n g  s u b c u l t u r e d  i n t o  f r e s h  L B  B r o t h  a t  1 : 2 0 0  d i l u t i o n  a n d  g r o w n  
f o r  a  f u r t h e r  3  h o u r s  s o  a s  t o  e n t e r  i n t o  e a r l y  l o g a r i t h m i c  p h a s e .  A n  a l i q u o t  o f  
t h i s  e a r l y  l o g  c u l t u r e  w a s  t a k e n  a n d  d i l u t e d  t o  a n  o p t i c a l  d e n s i t y  o f  0 . 1  a t  5 9 5 n m  
i n  I M D M .  T h i s  w a s  f u r t h e r  d i l u t e d  b y  a  f a c t o r  o f  1 : 1 0 0 0  i n  I M D M ,  w i t h  t h e  
r e s u l t a n t  b a c t e r i a l  s u s p e n s i o n  b e i n g  u s e d  a t  t h i s  c o n c e n t r a t i o n .  D u p l i c a t e s  o f  t h i s  
s u s p e n s i o n  w e r e  d i l u t e d  l x l O 2 a n d  l x l O 4  a n d  p l a t e d  o n  L B  A g a r  f o r  o v e r n i g h t  
i n c u b a t i o n  t o  d e t e r m i n e  b a s e l i n e  c o l o n y  c o u n t s .  S i m u l t a n e o u s l y  l x l 0 6 
n e u t r o p h i l s  s u s p e n d e d  i n  I M D M  w e r e  i n c u b a t e d  w i t h  v a r i o u s  t r e a t m e n t s  
i n c l u d i n g  B A L F  s u p e r n a t a n t  f r o m  p a t i e n t s ,  B A L F  s u p e r n a t a n t s  f r o m  h e a l t h y  
v o l u n t e e r s ,  C 5 a  a t  l O O n M ,  o r  v e h i c l e  c o n t r o l ,  f o r  o n e  h o u r  a t  3 7 ° C .  F o l l o w i n g  
t h i s  1 m l  o f  t h e  P .  a e r u g i n o s a  s u s p e n s i o n  w a s  a d d e d  a n d  t h e  r e s u l t a n t  m i x t u r e
97
i n c u b a t e d  f o r  a  f u r t h e r  t h i r t y  m i n u t e s .  A l o n g s i d e ,  P .  a e r u g i n o s a  w a s  i n c u b a t e d  
w i t h o u t  n e u t r o p h i l s  a s  a  p o s i t i v e  c o n t r o l .  F o l l o w i n g  t h i s ,  t h e  n e u t r o p h i l s  w e r e  
l y s e d  w i t h  T r i t o n  0 . 1 %  a n d  t h e  s u s p e n s i o n  d i l u t e d  l x l 0 2  a n d  l x l O 4  a n d  p l a t e d  o n  
L B  A g a r  f o r  o v e r n i g h t  i n c u b a t i o n  t o  d e t e r m i n e  c o l o n y  c o u n t s .
(o) Transmigration assay
( C h a p t e r  5 )
N e u t r o p h i l s  f r o m  h e a l t h y  v o l u n t e e r s  w e r e  s u b j e c t e d  t o  v a r i o u s  t r e a t m e n t s  
d e t a i l e d  b e l o w ,  w a s h e d  t w i c e  a n d  t h e n  a d d e d  t o  p o l y s t y r e n e  i n s e r t s  ( c o n t a i n i n g  
p o r e s  o f  3 | a m  d i a m e t e r )  a t  1 0 0 , 0 0 0  c e l l s  p e r  i n s e r t .  T h e  i n s e r t s  w e r e  i n  t u r n  
p l a c e d  i n  2 4 - w e l l  p l a t e s  c o n t a i n i n g  a )  s e r u m  f r e e  I M D M  a n d  f M L P  a s  a  p o s i t i v e  
c o n t r o l  f o r  m i g r a t i o n  ( f i n a l  c o n c e n t r a t i o n  l O O n M ) ,  o r  b )  s e r u m  f r e e  I M D M  a l o n e  
( a s  n e g a t i v e  c o n t r o l ) .  P l a t e s  w e r e  i n c u b a t e d  a t  3 7 ° C  f o r  o n e  h o u r .  T h e  u p p e r  
s u r f a c e  o f  e a c h  i n s e r t  w a s  g e n t l y  s c r a p e d  t o  r e m o v e  a d h e r e n t  n e u t r o p h i l s  t h e n  
i n s e r t s  w e r e  f i x e d  i n  m e t h a n o l  a n d  t h e n  s t a i n e d  w i t h  D i f f - Q u i k .  T r a n s m i g r a t i o n  
w a s  q u a n t i f i e d  b y  c o u n t i n g  t h e  n u m b e r  o f  n e u t r o p h i l s  o n  t h e  l o w e r  s u r f a c e  o f  t h e  
i n s e r t ,  c o u n t i n g  t e n  r a n d o m l y  s e l e c t e d  f i e l d s  p e r  i n s e r t .  T h e  p r e - t r e a t m e n t s  w e r e  
a s  f o l l o w s  1 )  v e h i c l e  c o n t r o l ,  2 )  1 8 0 n M  I C 8 7 1 1 4  f o r  1 5  m i n u t e s ,  3 )  3 0 p M  7 4 0  
Y - P  f o r  1 h o u r ,  4 )  l O O n M  C 5 a  f o r  1 h o u r ,  5 )  1 8 0 n M  I C 8 7 1 1 4  f o r  1 5  m i n u t e s  
f o l l o w e d  b y  l O O n M  C 5 a  f o r  1 h o u r ,  6 )  l O O n M  C 5 a  f o r  1 h o u r  f o l l o w e d  b y  0 . 3 n M  
G M - C S F  f o r  3 0  m i n u t e s .
(p) Assaying cytokines, chemokines and related molecules
( C h a p t e r s  3 , 4  a n d  6 )
C o n c e n t r a t i o n s  o f  C 3 a  d e s - a r g  a n d  C 5 a  d e s - a r g ,  t h e  b r e a k d o w n  p r o d u c t s  o f  
c o m p l e m e n t  f a c t o r s  C 3 a  a n d  C 5 a ,  w e r e  e s t i m a t e d  u s i n g  a  c y t o m e t r i c  b e a d  a r r a y
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k i t  ( B D  B i o s c i e n c e s ) .  G M - C S F ,  G - C S F ,  I L - 1  (3 , I L - 6 ,  I L - 8 ,  I L - 1 0 ,  M C P - 1 ,  M I P -  
l a  , T N F - a  a n d  s o l u b l e  C D 6 2 L  l e v e l s  w e r e  a s s e s s e d  b y  t h e  s a m e  m e t h o d .  
N e u t r o p h i l  e l a s t a s e  ( d e t e c t e d  a s  c o m p l e x e d  t o  n a t i v e  i n h i b i t o r s )  a n d  
m y e l o p e r o x i d a s e  p r o t e i n  c o n c e n t r a t i o n s  w e r e  a s s a y e d  b y  E L I S A  ( F l y c u l t  
B i o t e c h ) .  D u e  t o  s u b s e q u e n t  n o n - a v a i l a b i l i t y  o f  t h e  C B A  a s s a y  f o r  C 3 a - d e s  a r g  
a n d  C 5 a  d e s - a r g ,  t h e s e  a s s a y s  w e r e  u n d e r t a k e n  b y  E L I S A  ( B D  B i o s c i e n c e )  f o r  
t h e  d a t a  p r e s e n t e d  i n  C h a p t e r  6 .
L a v a g e  c o n c e n t r a t i o n s  o f  t h e s e  m o l e c u l e s  w e r e  c o r r e c t e d  f o r  d i l u t i o n  b y  
m e a s u r i n g  u r e a  i n  B A L F  a n d  p l a s m a  ( R e n n a r d  e t  a l .  1 9 8 6 ) .
(q) Epithelial cell inflammation assay
( C h a p t e r  3 )
A 5 4 9  c e l l s  d e r i v e d  f r o m  h u m a n  t y p e  I I  a l v e o l a r  e p i t h e l i a l  c e l l s  ( G i a r d  e t  a l .  
1 9 7 3 ) ,  w e r e  g r o w n  t o  c o n f l u e n c e  i n  D u l b e c c o ’ s  m o d i f i e d  E a g l e ’ s  m e d i u m  
( D M E M )  w i t h  L - g l u t a m i n e  a n d  1 0 %  f e t a l  c a l f  s e r u m .  C o n f l u e n t  c e l l s  w e r e  
w a s h e d  i n  D M E M  t h e n  5 0 0 , 0 0 0  f r e s h l y  i s o l a t e d  n e u t r o p h i l s  w e r e  a p p l i e d  i n  
D M E M  +  L - g l u t a m i n e  w i t h  1 0 %  a u t o l o g o u s  s e r u m .  L i p o p o l y s a c c h a r i d e  ( L P S )  
0 1 2 7 : B 8 ,  d e r i v e d  f r o m  E s c h e r i c h i a  c o l i ,  w a s  a d d e d  ( f i n a l  c o n c e n t r a t i o n  
1 O O n g / m l )  f o r  2 4  h o u r s  a t  3 7 ° C .  T o  d i s t i n g u i s h  s o l u b l e  f r o m  m e m b r a n e - m e d i a t e d  
e f f e c t s  e x p e r i m e n t s  w e r e  r e p e a t e d  w i t h  t h e  n e u t r o p h i l s  i n  i n s e r t s  c o n t a i n i n g  
p e r m e a b l e  m e m b r a n e s  ( 0 . 4 u r n  p o r e  s i z e ,  T r a n s w e l l ) ,  p r e v e n t i n g  d i r e c t  c o n t a c t  
b e t w e e n  n e u t r o p h i l s  a n d  A 5 4 9  c e l l s .  I L - 6  a n d  I L - 8  c o n c e n t r a t i o n s  i n  t h e  
s u p e r n a t a n t s  f r o m  t h e s e  e x p e r i m e n t s  w e r e  a s s a y e d  u s i n g  t h e  C B A  a s s a y  n o t e d  i n
2 . 0 3  p  .
99
(r) Monocyte TNF-a production
( C h a p t e r  3 )
M o n o n u c l e a r  c e l l s  o b t a i n e d  f r o m  t h e  c e l l u l a r  p r e p a r a t i o n  p r o t o c o l  p r e s e n t e d  i n
2 . 0 3  g  a b o v e  w e r e  p l a t e d  a t  5 0 0 , 0 0 0  p e r  w e l l  i n  2 4  w e l l  t i s s u e  c u l t u r e  p l a t e s  w i t h  
1 0 %  a u t o l o g o u s  s e r u m  i n  I M D M .  T h e  p l a t e s  w e r e  i n c u b a t e d  f o r  1 h o u r  a t  3 7  C  
b e f o r e  b e i n g  w a s h e d  t w i c e  i n  w a n n e d  I M D M  t o  r e m o v e  n o n - a d h e r e n t  c e l l s  ( i . e .  
l y m p h o c y t e s ) .  T h e  r e m a i n i n g  c e l l s  w e r e  i n c u b a t e d  w i t h  I M D M ,  1 0 %  a u t o l o g o u s  
s e r u m  a n d  l O n g / m l  L P S  0 1 2 7 : B 8  d e r i v e d  f r o m  E s c h e r i c h i a  c o l i  f o r  2 4  h o u r s  a t  
3 7 ° C .  S u p e r n a t a n t s  w e r e  a s s a y e d  f o r  T N F - a  b y  E L I S A ,  a n d  c o r r e c t e d  f o r  
c e l l u l a r i t y  b y  a n a l y s i s  o f  t h e  t o t a l  p r o t e i n  c o n t e n t  o f  t h e  w e l l s  a s  a s s a y e d  b y  B C A  
p r o t e i n  a s s a y .
(s) Defining 'immune dysfunction'
( C h a p t e r  6 )
F o l l o w i n g  t h e  f i n d i n g  o f  a  c l o s e  c o r r e l a t i o n  b e t w e e n  p h a g o c y t o s i s  a n d  n e u t r o p h i l  
s u r f a c e  C D 8 8  e x p r e s s i o n  ( F i g u r e  I V - 1 2  p a g e  1 3 1 ,  a n d  V - 2 7  p a g e  1 6 9 ) ,  C D 8 8  
w a s  a d v a n c e d  a s  a  p r o x y  m e a s u r e  f o r  n e u t r o p h i l  d y s f u n c t i o n .
T h e  e f f e c t  o f  C 5 a  e x p o s u r e  o n  n e u t r o p h i l  C D 8 8  e x p r e s s i o n  w a s  e x p l o r e d  b y  
i n c u b a t i n g  h e a l t h y  d o n o r  n e u t r o p h i l s  w i t h  v a r y i n g  c o n c e n t r a t i o n s  o f  r h C 5 a  
( 1 , 1 0 , 1 0 0  n M  a n d  v e h i c l e  c o n t r o l )  f o l l o w e d  b y  i n c u b a t i o n  w i t h  t h e  f l u o r o p h o r e -  
l a b e l l e d  a n t i - C D 8 8  a n t i b o d y .  T h e  e f f e c t  o f  r e d u c t i o n  i n  C D 8 8  b y  l O n M  C 5 a ,  
t h e  l o w e s t  c o n c e n t r a t i o n  t o  s i g n i f i c a n t l y  a f f e c t  p h a g o c y t o s i s  ( F i g u r e  V - l  p a g e  
1 4 4 ) ,  w a s  e x a m i n e d  t o  d e t e r m i n e  t h e  c u t - o f f .  N e u t r o p h i l  d y s f u n c t i o n  w a s  
t h e r e  f o i e  d e f i n e d  a s  l o w  n e u t r o p h i l  C D 8 8 ,  s p e c i f i c a l l y  a  g e o m e t r i c  m e a n  C D 8 8  
o f  < 2 5 0  a r b i t r a r y  f l u o r e s c e n c e  u n i t s  ( A F U ) .
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M o n o c y t e  ‘ d e a c t i v a t i o n ’  w a s  d e f i n e d  a s  l o w  m o n o c y t e  H L A - D R ,  s p e c i f i c a l l y  a  
g e o m e t r i c  m e a n  o f  < 8 0 0 0  m o l e c u l e s / c e l l  ( M e i s e l  e t  a l .  2 0 0 9 ) .
R e g u l a t o r y  T - c e l l s  ( T - r e g s )  w e r e  i d e n t i f i e d  b y  C D 4 ,  C D 2 5 ,  F O X P 3  p o s i t i v i t y  
( L a n g i e r ,  S a d e  &  K i v i t y  2 0 1 0 )  a n d  e x p r e s s e d  a s  a  p e r c e n t a g e  o f  t o t a l  C D 4  
(Thdpcr) c e l l s .  ‘ E l e v a t e d ’  T - r e g s  w e r e  d e f i n e d  b y  r e f e r e n c e  t o  t h e  l e v e l s  f o u n d  i n  
h e a l t h y  v o l u n t e e r s  a s  > 1 0 %  o f  t o t a l  C D 4  c e l l s  ( s e e  r e s u l t s  s e c t i o n  6 . 0 2  k ,  p a g e  
1 9 7 ) .
(t) Statistical analysis
A n a l y s i s  w a s  c o n d u c t e d  u s i n g  P r i s m  ( G r a p h p a d  S o f t w a r e ,  L a  J o l l a ,  C A ,  U S A )
a n d  P A S W  S t a t i s t i c s  V e r s i o n  1 8  ( I B M  C o i p ,  A r m o n k ,  N Y ,  U S A ) .  C o n t i n g e n c y  
t a b l e s  w e r e  a n a l y s e d  b y  F i s h e r ’ s  e x a c t  t e s t  ( f o r  2 x 2 )  a n d  c h i - s q u a r e d  ( f o r  > 2 x 2 ) .  
D i f f e r e n c e  b e t w e e n  t w o  n o n - n o r m a l l y  d i s t r i b u t e d  d a t a  s e t s  w a s  c o m p a r e d  b y  
M a n n - W h i t n e y  U  t e s t  ( o r  W i l c o x o n  r a n k  s u m  f o r  p a i r e d  d a t a ) .  W h e r e  m o r e  t h a n  
t w o  d a t a  s e t s  w e r e  p r e s e n t  K r u s k a l - W a l l i s  A N O V A  w a s  u s e d  w i t h  D u n n ’ s  p o s t -  
h o c  t e s t  w h i l s t  t w o - w a y  A N O V A  ( w i t h  B o n f e r r o n i ’ s  p o s t - h o c  t e s t )  w a s  u s e d  f o r  
a n a l y s i s  o f  v a l u e s  o v e r  t i m e  b e t w e e n  t w o  g r o u p s .  D a t a  s u m m a r i s e d  b y  G e o ­
m e t r i c  m e a n s  w e r e  l o g - t r a n s f o r m e d  b e f o r e  b e i n g  c o m p a r e d  b y  t - t e s t  ( f o r  t w o  d a t a  
s e t s )  o r  o n e - w a y  A N O V A  w i t h  B o n f e r r o n i ’ s  p o s t - h o c  t e s t  ( f o r  m o r e  t h a t  t w o  
d a t a  s e t s ) .  B i n a r y  l o g i s t i c  r e g r e s s i o n  w a s  u s e d  t o  a n a l y s e  t h e  r e l a t i o n s h i p  
b e t w e e n  i m m u n e  d y s f u n c t i o n s ,  a n d  a  C o x  h a z a r d s  m o d e l  w a s  c o n s t r u c t e d  t o  
e x a m i n e  t h e  e f f e c t s  o f  i m m u n e  d y s f u n c t i o n s  a n d  o t h e r  c l i n i c a l  v a r i a b l e s  o n  
a c q u i s i t i o n  o f  i n f e c t i o n  o v e r  t i m e .  V a r i a b l e s  f o r  i n c l u s i o n  i n  t h e  C o x  m o d e l  
w e r e  s e l e c t e d  t h r o u g h  t h e i r  a s s o c i a t i o n  w i t h  i n f e c t i o n  a c q u i s i t i o n  u s i n g
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u n i v a r i a t e  a n a l y s i s  ( l i n e a r  r e g r e s s i o n  f o r  c o n t i n u o u s / o r d i n a l  d a t a  a n d  p h i  c o ­
e f f i c i e n t  f o r  c a t e g o r i c a l  d a t a ) .  A l l  v a r i a b l e s  w i t h  a  p  v a l u e  o f  < 0 . 1  o n  u n i v a r i a t e  
a n a l y s i s  w e r e  s e l e c t e d  f o r  i n c l u s i o n .  P < 0 . 0 5  w a s  c o n s i d e r e d  s t a t i s t i c a l l y  
s i g n i f i c a n t .  T h e  a s s i s t a n c e  o f  D r  N i a l l  A n d e r s o n  i n  d e v e l o p i n g  t h e  c o x  m o d e l  i s  
g r a t e f u l l y  a c k n o w l e d g e d .
(u) Ethical approval
T h e  s t u d y  w a s  a p p r o v e d  b y  t h e  r e l e v a n t  r e s e a r c h  e t h i c s  c o m m i t t e e s  ( R E C s ) .
T h e  w o r k  o n  c r i t i c a l l y  i l l  p a t i e n t s  ( V A P  c o h o r t )  a n d  m a t c h e d  v o l u n t e e r s  w a s  
a p p r o v e d  b y  t h e  L o t h i a n  R E C ,  s t u d y  n u m b e r s  L R E C / 2 0 0 2 / 8 / 1 9  a n d  0 6 / S  1 1 0 1 / 5 0  
r e s p e c t i v e l y .
T h e  w o r k  o n  c r i t i c a l l y  i l l  p a t i e n t s  w a s  a p p r o v e d  t h e  S c o t l a n d  A  R E C  ( s t u d y  
n u m b e r  0 9 / M R E 0 0 / 1 9 )  a n d  h e a l t h y  v o l u n t e e r s  b y  L o t h i a n  R E C  ( s t u d y  n u m b e r  
0 8 / S  1 1 0 3 / 3 8 ) .
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A r t i c l e  i l l .  A  d e s c r i p t i o n  o f  i n n a t e  i m m u n e  f u n c t i o n  a n d  
d y s f u n c t i o n  i n  p a t i e n t s  w i t h  s u s p e c t e d  v e n t i l a t o r -  
a s s o c i a t e d  p n e u m o n i a  - ' s e p t i c  s u p e r p o s i t i o n ' .
S e c t io n  3 .01  In t r o d u c t io n  a n d  c h a p te r  o v e rv ie w
T h i s  c h a p t e r  i s  b a s e d  o n  a  s t u d y  o f  p a t i e n t s  s u s p e c t e d  o f  h a v i n g  d e v e l o p e d  t h e
c o m m o n e s t ,  s e v e r e ,  I C U - a c q u i r e d  i n f e c t i o n  n a m e l y  v e n t i l a t o r - a s s o c i a t e d  
p n e u m o n i a  ( V A P ) .  A s  n o t e d  i n  t h e  i n t r o d u c t i o n ,  V A P  i s  a s s o c i a t e d  w i t h  a  
n u m b e r  o f  a d v e r s e  o u t c o m e s  i n c l u d i n g  p r o l o n g e d  l e n g t h  o f  s t a y ,  i n c r e a s e d  u s e  o f  
a n t i b i o t i c s  a n d  p r o b a b l y  i n c r e a s e d  m o r t a l i t y .
T h e  a i m s  o f  t h i s  s t u d y  w e r e  t o  c h a r a c t e r i s e  t h e  i n n a t e  i m m u n e  s y s t e m ’ s  f u n c t i o n  
i n  t h e  c o n t e x t  o f  s u s p e c t e d  a n d  c o n f i r m e d  V A P ,  e x a m i n i n g  e v i d e n c e  o f  b o t h  
i m m u n e  d y s f u n c t i o n  a n d  a c t i v a t i o n .  T h e  h y p o t h e s i s  b e i n g  e x p l o r e d  w a s  t h a t  
c r i t i c a l l y  i l l  p a t i e n t s  w i t h  s u s p e c t e d  V A P  w o u l d  e x i s t  i n  a  s t a t e  o f  s i m u l t a n e o u s  
i m m u n e  a c t i v a t i o n  a n d  s u p p r e s s i o n .
T h i s  c h a p t e r  w i l l  e x p l o r e  d a t a  f r o m  f u n c t i o n a l  a s s a y s  o f  i m m u n e  c e l l s ,  n a m e l y  
n e u t r o p h i l s ,  m o n o c y t e s  a n d  a l v e o l a r  c e l l s  ( m i x e d  n e u t r o p h i l / m a c r o p h a g e  
p o p u l a t i o n s ) ,  a l o n g s i d e  c e l l  s u r f a c e  a n d  s o l u b l e  m a r k e r s  o f  c e l l u l a r  a c t i v a t i o n  
a n d  s e r u m  c y t o k i n e  l e v e l s .
T h i s  c h a p t e r  c o n t a i n s  d a t a  f r o m  s a m p l e s  c o l l e c t e d  b y  D r  K a l l i r o i  K e f a l a  a n d  
m y s e l f .
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(a) Patients and volunteers
S e v e n t y - t h r e e  p a t i e n t s  w i t h  c l i n i c a l l y  s u s p e c t e d  V A P  w e r e  r e c r u i t e d ,  o n e  p a t i e n t
d i d  n o t  h a v e  r e c o v e r a b l e  l a v a g e  a n d  t h e r e f o r e  w a s  e x c l u d e d  f r o m  f u r t h e r  
a n a l y s i s .  O f  t h e  r e m a i n i n g  7 2 ,  1 7  ( 2 3 % )  h a d  V A P  c o n f i r m e d  b y  g r o w t h  o f  
o r g a n i s m s  a t  > 1 0 4 C F U / m l .  T h e  p a t i e n t s  w h o  h a d  c l i n i c a l  f e a t u r e s  o f  V A P  ( i . e .  
n e w  a l v e o l a r  s h a d o w i n g  o n  C X R  a n d  e v i d e n c e  o f  s y s t e m i c  i n f l a m m a t i o n )  b u t  
w h o  d i d  n o t  g r o w  o r g a n i s m s  a t  > 1 0 4  C F U / m l  f e l l  i n t o  t w o  g r o u p s ,  t h o s e  w h o  m e t  
t h e  c r i t e r i a  f o r  A R D S / A L I  a n d  t h o s e  w h o  d i d  n o t  ( t e r m e d  ‘ n o n - V A P / n o n - A R D S ’  
g r o u p ) ,  w i t h  2 1  p a t i e n t s  f a l l i n g  i n t o  t h e  A R D S / A L I  g r o u p  a n d  3 4  i n t o  t h e  n o n -  
V A P / A R D S  g r o u p .  A n a l y s i s  o f  t h e s e  t h r e e  s u b - g r o u p s  a l l o w s  c o m p a r i s o n  o f  
p a t i e n t s  w i t h  i n f e c t i o u s  p u l m o n a r y  i n f l a m m a t i o n  ( V A P ) ,  n o n - i n f e c t i o n s  
p u l m o n a r y  i n f l a m m a t i o n  ( A R D S / A L I )  a n d  a  g r o u p  w h o  w e r e  c r i t i c a l l y  i l l  a n d  
v e n t i l a t e d  b u t  w i t h o u t  a  d e f i n e d  p u l m o n a r y  p a t h o l o g y .  2 1  a g e  a n d  s e x  m a t c h e d  
v o l u n t e e r s  w e r e  a l s o  r e c m i t e d  t o  a c t  a s  a  c o n t r o l / r e f e r e n c e  g r o u p .  T h e  
d e m o g r a p h i c  a n d  c l i n i c a l  d e t a i l s  o f  p a t i e n t s  a n d  v o l u n t e e r s  a r e  s h o w n  i n  t a b l e
I I I - 1 ,  t h e  d e t a i l s  o f  t h e  s u b - g r o u p s  a r e  s h o w n  i n  t a b l e  I I I - 2 .
S e c t i o n  3 . 0 2  R e s u l t s
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P a r a m e t e r P a t i e n t s M a t c h e d
V o l u n t e e r s
P  V a l u e
A g e ,  M e a n  ( r a n g e ) 5 8  ( 2 6 - 8 7 ) 6 0  ( 2 4 - 8 4 ) 0 . 8 9 *
%  m a l e 6 4 % 7 9 % 0 . 1 4 +
A p a c h e  II s c o r e ,  
M e d i a n  (IQR)
2 2  ( 2 0 - 2 3 ) N A
D a y s  o f  v e n t i l a t i o n  
p r i o r  t o  e n r o l m e n t ,  
M e d i a n  (IQR)
8 ( 6 - 1 0 ) N A
I C U  m o r t a l i t y 3 5 % N A
%  w i t h  s u r g i c a l  
d i a g n o s i s  o n  
a d m i s s i o n
5 2 % N A
%  w i t h  a  1  c o -  
m o r b i d  c o n d i t i o n s
5 4 % N A
%  r e c e i v i n g  
i m m u n o s u p p r e s s i v e  
d r u g s  ( i n c l u d i n g  
c o r t i c o s t e r o i d s )
1 1 % 0 %
Table 111-1: Clinical and demographic features of patients with 
clinically suspected VAP and matched controls.
IQR-inter-quartile range. * p value by t-test,+ p value by z-test for 
proportions.
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P a r a m e t e r
V A P
s u b g r o u p
( n = 1 7 )
A R D S / A L I
s u b g r o u p
( n = 2 1 )
N o n -
V A P / N o n -
A R D S
s u b g r o u p
( n = 3 4 )
P  v a l u e
A g e ,  M e a n  ( r a n g e )
5 8 ( 3 2 - 8 3 ) 5 5  ( 2 6 - 8 0 ) 5 9  ( 2 5 - 8 7 ) 0 . 6 1 *
%  m a l e
7 6 % 4 8 % 7 1 % 0 . 7 3 '
A p a c h e  I I  s c o r e ,  
M e d i a n  ( I Q R )
2 3  ( 2 0 - 2 6 ) 2 0 ( 1 8 - 2 2 ) 2 2  ( 2 0 - 2 5 ) 0 . 2 7 *
D a y s  o f  v e n t i l a t i o n  
p r i o r  t o  e n r o l m e n t ,  
M e d i a n  ( I Q R )
8  ( 6 - 9 ) 6  ( 4 - 8 ) 9  ( 7 - 1 4 ) 0 . 0 0 7 *
I C U  m o r t a l i t y
3 5 % 4 3 % 3 2 % 0 . 7 3 *
%  w i t h  s u r g i c a l  
d i a g n o s i s  o n  a d m i s s i o n
7 0 % 4 8 % 4 7 % 0 . 2 4 '
%  w i t h  a  1  c o - m o r b i d  
c o n d i t i o n s
5 3 % 5 7 % 5 3 % 0 . 9 5 *
%  r e c e i v i n g  
i m m u n o s u p p r e s s i v e
1 2 % 1 9 % 6 % 0 . 3 1 f
Table 111-2: Demographic and clinical data relating to sub-groups of 
patients.

























(b) Identification of the defect in phagocytosis.
P e r i p h e r a l  b l o o d  n e u t r o p h i l s  ( P B N s )  f r o m  p a t i e n t s  w i t h  s u s p e c t e d  V A P
d e m o n s t r a t e d  i m p a i r e d  p h a g o c y t o s i s  o f  s e r u m  o p s o n i s e d  p a r t i c l e s  c o m p a r e d  t o  
a g e -  a n d  s e x -  m a t c h e d  c o n t r o l s .  T h i s  d e f e c t  i s  i l l u s t r a t e d  i n  f i g u r e  I I I - l  b e l o w .  
P a n e l  A  s h o w s  p o o l e d  r e s u l t s  o f  a l l  p a t i e n t s ,  w h i l s t  p a n e l  B  s h o w s  t h e  r e s u l t s  
f r o m  t h e  3  s u b - g r o u p s  o f  p a t i e n t s  d e m o n s t r a t i n g  n o  s i g n i f i c a n t  d i f f e r e n c e s  
l A t w c c n  t h e  s u b - g r o u p s .
B
Figure 111-1; Phagocytosis by peripheral blood neutrophils (PBNs)
Pa n e l A : Phagocytosis by PBNs from all patients compared to 
matched volunteers. Data are presented as medians, inter-quartile 
ranges (box) and range (whiskers), *** p<0.0001 by Mann-Whitney U- 
test. Data are derived from 89 subjects (68 patients and 21 MV); in the 
remaining 4 patients phagocytosis data was not available because of 
insufficient PBN adherence to tissue culture plates).
P a n e l B : Phagocytosis by PBNs of patients by constituent sub­
groups.
Data presented as medians, inter-quartile ranges (box) and range 
(whiskers), p=0.162 by Kruskal-Wallis test. Data are derived from 68 
patients (16 VAP, 19 ARDS, 33 non-VAP/non-ARDS).
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(c) Phagocytosis by alveolar cells
A l v e o l a r  c e l l s  r e c o v e r e d  f r o m  p a t i e n t s  w i t h  s u s p e c t e d  V A P  b y  a l v e o l a r  l a v a g e
w e r e  s i m i l a r l y  a s s e s s e d  f o r  a b i l i t y  t o  u n d e r t a k e  p h a g o c y t o s i s .  A  s i m i l a r  d e f e c t  
i n  p h a g o c y t o s i s  w a s  n o t e d ,  w h i c h  w a s  a l l  t h e  m o r e  s t r i k i n g  a s  t h e  a l v e o l a r  c e l l s  
f r o m  p a t i e n t s  w e r e  p r e d o m i n a n t l y  n e u t r o p h i l s ,  w h i l s t  t h o s e  f r o m  t h e  m a t c h e d  
v o l u n t e e r s  w e r e  a l m o s t  e x c l u s i v e l y  m a c r o p h a g e s  ( s e e  t a b l e  I I I - 6 ,  p a g e  1 1 1 ) .  T h e  
a l v e o l a r  m a c r o p h a g e  i s  n o t a b l y  l e s s  p h a g o c y t i c  t h a n  t h e  P B N ,  a s  c a n  b e  
a p p r e c i a t e d  f r o m  t h e  i n s e t  i n  f i g u r e  I I I - 2 ,  p a n e l  A .  A s  w i t h  t h e  P B N s ,  t h e r e  w e r e  
n o  s i g n i f i c a n t  d i f f e r e n c e s  b e t w e e n  a l v e o l a r  c e l l  p h a g o c y t o s i s  i n  t h e  t h r e e  s u b ­
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Figure III-2: Phagocytosis by alveolar cells
P a n e l A : Phagocytosis by cells retrieved from BALF in patients and 
in matched volunteers (MV).
Data are presented as medians, inter-quartile ranges (box) and range 
(whiskers), * p=0.03 by Mann-Whitney u-test. Data are derived from 
44 study participants (33 patients and 11 matched volunteers, i.e. all 
subjects for whom sufficient numbers of phagocytes were available and 
adhered to tissue culture plates). Inset shows phagocytosis by PBNs 
from matched volunteers, equivalent to column 2 in figure 111-1, panel A. 
Presence in this graph is simply to illustrate the relative lack of phagocytic 
activity of matched volunteer alveolar macrophages.
P a n e l B. Phagocytosis by lavage cells of patients by constituent 
sub-groups.
Data presented as medians, inter-quartile ranges (box) and range 
(whiskers), p-0.279 by Kruskal-Wallis test. Data are derived from 33 
patients (7 VAP, 12 ARDS, 14 non-VAP/non-ARDS).
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(d) Super-oxide production
T o  e x a m i n e  w h e t h e r  t h e  d e f e c t s  i n  n e u t r o p h i l  f u n c t i o n  e x t e n d e d  b e y o n d
p h a g o c y t o s i s ,  t h e  a b i l i t y  o f  n e u t r o p h i l s  t o  p r o d u c e  t h e  r e a c t i v e  o x y g e n  s p e c i e s  
( R O S )  s u p e r - o x i d e  i o n  i n  r e s p o n s e  t o  c l a s s i c  p r i m i n g  a n d  s t i m u l u s  a g e n t s  ( P A F ,  
a n d  f M L P )  w a s  a s s e s s e d .
i  ------------- I
</)
Figure III-3: Production of superoxide radical by neutrophils primed 
with 100nM PAF and stimulated with 100nM fMLP.
Data shown as median and upper quartile, **p=0.0076 by Mann-Whitney 
test. Data are derived from 16 patients and 12 matched volunteers, 
experiments conducted on a consecutive sub-set of study subjects 
recruited after the initial observations noted above.
T h e  s m a l l  n u m b e r s  i n  e a c h  o f  t h e  s u b - g r o u p s  p r e c l u d e d  e f f e c t i v e  a n a l y s i s  o f  a n y  
d i f f e r e n c e s  b e t w e e n  s u b - g r o u p s  o f  p a t i e n t s .
(e) Monocyte response to LPS
P e r i p h e r a l  b l o o d  m o n o c y t e s  w e r e  a s s e s s e d  f o r  t h e i r  r e s p o n s e  t o  s t i m u l a t i o n  w i t h
E s c h e r i c h i a  c o l i  { E .  c o l i ) - d e r i v e d  L P S ,  i n  t e r m s  o f  s e c r e t i o n  o f  T N F - a  o v e r  a  2 4  
h o u r  i n c u b a t i o n .  T h i s  m e a s u r e  o f  m o n o c y t e  a c t i v i t y  h a s  p r e v i o u s l y  b e e n  s h o w n
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t o  p r e d i c t  i n f e c t i o u s  c o m p l i c a t i o n s  i n  p a t i e n t s  w i t h  s e p s i s  ( L a n d e l l e  e t  a l .  2 0 1 0 )  
a n d  n e u r o - t r a u m a  ( A s a d u l l a h  e t  a l .  1 9 9 5 ) ,  a n d  p o o r  r e s p o n s e  t o  L P S  h a s  b e e n  
t e r m e d  ‘ m o n o c y t e  d e a c t i v a t i o n ’  ( V o l k  e t  a l .  1 9 9 6 ) .
*
Figure 111-4: Supernatant TNF-a levels.
TNF-a corrected for total protein, from peripheral blood monocytes 
stimulated with 10ng/ml of LPS for 24 hours. Data are shown as medians 
and inter-quartile ranges, * p=0.04 by Mann-Whitney test. Data derived 
from 12 patients and 11 matched volunteers. Neutrophil contamination of 
the mononuclear cell layer following blood preparation reduced the 
number of patient cells able to be assessed in this manner.
A s  w i t h  t h e  s u p e r - o x i d e  a s s a y  s m a l l  n u m b e r s  p r e v e n t  m e a n i n g f u l  a n a l y s i s  o f  t h e  
p a t i e n t  s u b - g r o u p s .
(f) Neutrophil activation
U n d i s t u r b e d  n e u t r o p h i l s  i n  t h e  p e r i p h e r a l  b l o o d  e x i s t  i n  a  r e s t i n g  s t a t e ,  h o w e v e r
o n  e x p o s u r e  t o  a  w i d e  v a r i e t y  o f  s t i m u l i  t h e y  u n d e r g o  c h a n g e s  i n  c e l l  s u r f a c e  
c o n f i r m a t i o n  a n d  r e a c t i v i t y  t o  f u r t h e r  s t i m u l i  i n  a  p r o c e s s  t e r m e d  ‘ a c t i v a t i o n ’  
( C o n d l i f f e  e t  a l .  1 9 9 6 ) .  A  n u m b e r  o f  m a r k e r s  o f  ‘ a c t i v a t i o n ’  h a v e  b e e n  
d e m o n s t r a t e d  p r e v i o u s l y ,  i n c l u d i n g  u p - r e g u l a t i o n  o f  t h e  i n t e g r i n  a n d  
c o m p l e m e n t - m e d i a t e d  p h a g o c y t o s i s  r e c e p t o r  G D I  l b ,  s h e d d i n g  o f  F e y  I I I  ( C D  1 6 )
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a n d  e x t r a - c e l l u l a r  r e l e a s e  o f  p r o t e o l y t i c  e n z y m e s  s u c h  a s  h u m a n  n e u t r o p h i l  
e l a s t a s e  ( H N E )  a n d  e n z y m e s  i n v o l v e d  i n  o x i d a t i v e  k i l l i n g  s u c h  a s  
m y l o p e r o x i d a s e  ( M P O )  ( B e r g e r  e t  a l .  1 9 8 4 ,  E k s i o g l u - D e m i r a l p  e t  a l .  2 0 0 1 ,  
P a r t r i c k  e t  a l .  1 9 9 7 ,  D u l a r a y  e t  a l .  1 9 9 0 ) .
S u r f a c e  e x p r e s s i o n  o f  C D 1  l b  ( f i g u r e  I I I - 5 )  a n d  C D  1 6  ( f i g u r e  I I I - 6 )  w a s  
d e t e r m i n e d  o n  n e u t r o p h i l s  f r o m  p a t i e n t s  a n d  m a t c h e d  v o l u n t e e r s ,  a n d  s e r u m  
E 1 N E  l e v e l s  w e r e  d e t e r m i n e d  b y  E L I S A  ( F i g u r e  I I I - 7 ) .  F I N E  i n  s e r u m  i s  a l m o s t  
e x c l u s i v e l y  f o u n d  i n  c o m b i n a t i o n  w i t h  i t s  m a j o r  i n h i b i t o r s ,  i n c l u d i n g  a i -  
a n t i t r y p s i n  ( F r y k s m a r k  e t  a l .  1 9 8 3 ) ,  a n d  u n s u r p r i s i n g l y  n o  e v i d e n c e  o f  f u n c t i o n a l  
H N E  w a s  f o u n d  i n  s e r u m  ( d a t a  n o t  s h o w n ) .  S e r u m  M P O  l e v e l s  w e r e  a l s o  
d e t e r m i n e d  b y  E L I S A  ( F i g u r e  I I I - 8 )  a s  M P O  a c t i v i t y  c a n  b e  v a r i a b l y  a f f e c t e d  b y  
i n h i b i t o r s  s u c h  a s  c e r u l o p l a s m i n  ( G r i f f i n  e t  a l .  1 9 9 9 ) .
Figure 111-5; CD11b expression on PBNs from patients and matched 
volunteers.
Flow cytometric data shown as geometric means and 95%confidence 
intervals ** p=0.006 by t-test. n=20 patients and 12 matched volunteers.
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Figure 111-6 : Neutrophil surface CD16 expression 
P a n e l A : CD16 expression (as determined by flow cytometry) on the 
surface of PBNs from patients and matched volunteers. Data shown 
as geometric means and 95% confidence interval p=0.054 by t-test. n=20 
patients and 12 matched volunteers
P a n e l B : CD16 expression by PBNs from the sub-groups of patients.
. Data shown as geometric means and 95% confidence interval p=0.006 
by one-way ANOVA of log-transformed geometric means, **p<0.01 by 
Bonferroni’s post-hoc test. n=4 VAP, 5 ARDS and 11 non-VAP/non- 
ARDS patients.
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F i g u r e  I I I - 7 :  S e r u m  n e u t r o p h i l  e l a s t a s e  ( H N E )  l e v e l s  a s  d e t e r m i n e d  b y  
E L I S A
Panel A: S e r u m  H N E  l e v e l s  i n  p a t i e n t s  a n d  m a t c h e d  v o l u n t e e r s .  Data shown 
as medians and upper quartile. ***p<0.0001 by Mann-Whitney test n=72 
patients and 21 healthy volunteers.
Panel B: S e r u m  H N E  l e v e l s  i n  t h e  s u b - g r o u p s  o f  p a t i e n t s .  Data shown as 
medians and upper quartile. p=0.0097 by Kruskal-Wallis, **p<0.001 by Dunn’s 
post-hoc test. n=17 VAP, 21 ARDS and 34 non-VAP/non-ARDS.
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Figure 111-8: Serum myloperoxidase (MPO) levels as determined by 
ELISA
P a n e l A :  Serum MPO levels in patients and matched volunteers. Data 
shown as medians and upper quartile. ***p<0.0001 by Mann-Whitney 
test n=56 patients and 18 healthy volunteers.
P a n e l B : Serum MPO levels in the sub-groups of patients. Data 
shown as medians and upper quartile. p=0.2 by Kruskal-Wallls, n=15 
VAP, 13 ARDS and 25 non-VAP/non-ARDS
T h e s e  d a t a  d e m o n s t r a t e  t h a t  d e s p i t e  t h e  d e f e c t s  i n  t h e  k e y  a n t i - b a c t e r i a l  f u n c t i o n s  
o f  p h a g o c y t o s i s  a n d  r e a c t i v e  o x y g e n  s p e c i e s  p r o d u c t i o n ,  b y  s t a n d a r d  a n a l y s e s  t h e  
p a t i e n t  n e u t r o p h i l s  w o u l d  b e  c o n s i d e r e d  t o  b e  i n  a n  ‘ a c t i v a t e d ’  s t a t e .  I t  i s  a l s o  
n o t a b l e  t h a t  f o c a l  l u n g  i n f e c t i o n  i n  t h e  f o n n  o f  V A P  p r o d u c e d  r e l a t i v e l y  h i g h e r  
l e v e l s  i n  s o m e ,  b u t  n o t  a l l ,  p e r i p h e r a l  m a r k e r s  o f  a c t i v a t i o n .
(g) Neutrophil/Epithelial interactions
F u r t h e r  e v i d e n c e  o f  t h e  c o m p l e x ,  a c t i v a t e d  p h e n o t y p e  o f  t h e  p e r i p h e r a l  b l o o d
n e u t r o p h i l s  c o m e s  f r o m  a n a l y s i s  o f  t h e i r  i n t e r a c t i o n s  w i t h  a  c e l l - l i n e  b a s e d  m o d e l  
o f  t h e  a l v e o l a r  e p i t h e l i u m .  N e u t r o p h i l s  f r o m  p a t i e n t s  a n d  m a t c h e d  v o l u n t e e r s  
w e r e  c o - c u l t u r e d  w i t h  A 5 4 9  c e l l s ,  w h i c h  s h a r e  s o m e  s i m i l a r i t i e s  w i t h  a l v e o l a r  































p r o d u c e  s i g n i f i c a n t l y  d i f f e r e n t  r e s u l t s  f r o m  A 5 4 9  c e l l s  a l o n e  ( d a t a  n o t  s h o w n ) ,  
h o w e v e r  s t i m u l a t i o n  w i t h  E .  c o / / - d e r i v e d  L P S  r e s u l t e d  i n  s i g n i f i c a n t  l e l e a s e  o f  
p r o - i n f l a m m a t o r y  m o l e c u l e s  i n c l u d i n g  I L - 6  a n d  I L - 8 .  S t i m u l a t e d  n e u t i o p h i l s  
f r o m  p a t i e n t s  r e s u l t e d  i n  s i g n i f i c a n t l y  m o r e  I L - 6  a n d  I L - 8  r e l e a s e  t h a n  
e q u i v a l e n t l y  s t i m u l a t e d  n e u t r o p h i l s  f r o m  m a t c h e d  v o l u n t e e r s  ( s e e  f i g u r e s  I I I - 9  A  
a n d  B  b e l o w ) .  T h e  r e l e a s e  o f  p r o - i n f l a m m a t o r y  m o l e c u l e s  r e q u i r e d  c l o s e  c e l l u l a r  
p r o x i m i t y ,  a s  d e m o n s t r a t e d  b y  t h e  a b o l i t i o n  o f  a n y  e f f e c t  w h e n  t h e  c e l l s  w e r e  
s e p a r a t e d  b y  a  m e m b r a n e  p e r m e a b l e  t o  m o l e c u l a r  s p e c i e s  b u t  n o t  c e l l s  ( s e e  i n s e t s  
i n  f i g u r e s  I I I - 9  A  a n d  B ) .
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Figure III-9 : IL-6 release by LPS-stimulated neutrophil: A549 co­
cultures.
Panel A : IL-6 release induced by LPS-stimulated neutrophils from 
patients and matched volunteers (MV). Data are expressed as a ratio 
of IL-6 release by stimulated A549 cells to IL-6 release from unstimulated 
A549 cells. The inset shows IL-6 release when the neutrophils were 
separated from A549 cells by a transwell membrane with 0.4micron pore 
size. Data are shown as median and upper quartile, *p=0.017 by Mann- 
Whitney U-test. Data are derived from 71 study participants (57 patients 
and 14 MV, i.e. all subjects from whom sufficient neutrophils and A549 
cells were available to complete the assay). The transwell data are 
derived from 12 study participants.
Pane l B: IL-6 release in the patient sub-groups. p=0.26 by Kruskal- 
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Figure 111-10: IL-8 release by LPS stimulated neutrophil: A549 co­
cultures
P an e l A : from the same experiments shown in figure III-9 panel A.
**p=0.0098 by Mann-Whitney.
P a n e l B : from the same experiments shown in figure III-9 panel B.
p=0.86 by Kruskal-Wallis.
(h) Systemic and pulmonary inflammatory molecules
T h e  a b o v e  d a t a  f r o m  s e c t i o n s  3 . 0 2  f  a n d  g  d e m o n s t r a t e  f e a t u r e s  a s s o c i a t e d  w i t h
n e u t r o p h i l  ‘ a c t i v a t i o n ’ . A l o n g s i d e  t h i s  l e v e l s  o f  s e r u m  i n f l a m m a t o r y  m o l e c u l e s  
w e r e  a l s o  e l e v a t e d  i n  p a t i e n t s  i n c l u d i n g  t h e  p l u r i p o t e n t  p r o - i n f l a m m a t o r y  
m o l e c u l e  I L - 6 ,  a n a p h y l o t o x i n s  C 3 a  a n d  C 5 a ,  c h e m o t a x i n s  s u c h  a s  I L - 8  a n d  M I P -  
l a l p h a  a n d  g r a n u l o c y t e  c o l o n y  s t i m u l a t i n g  f a c t o r  ( G - C S F ) .  N o n e  o f  t h e  s e r u m  
m a r k e r s  d i s t i n g u i s h e d  V A P  f r o m  t h o s e  w i t h o u t  V A P  o r  s h o w e d  s i g n i f i c a n t  
v a r i a t i o n  b e t w e e n  t h e  p a t i e n t  s u b - g r o u p s .  T o  g a u g e  p u l m o n a r y  i n f l a m m a t i o n ,  
t h e  s a m e  m o l e c u l e s  w e r e  a l s o  m e a s u r e d  i n  B A L F .  T h e s e  d a t a  a r e  s h o w n  i n  t a b l e s
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I I I - 3  a n d  I I I - 4  ( f o r  p a t i e n t s  a n d  m a t c h e d  v o l u n t e e r s )  a n d  I I I - 5  a n d  I I I - 6  ( p a t i e n t  
r e s u l t s  d i v i d e d  i n t o  t h e  3  s u b - g r o u p s ) .
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S e r u m  C y t o k i n e P a t i e n t M a t c h e d
v o l u n t e e r
P  v a l u e  b y  
M a n n - W h i t n e y
I L - l ß  ( p g / m l ) 4 ( 3 - 6 ) 2  ( 0 - 5 ) 0 . 0 5
T N F - a  ( p g / m l ) 3  ( 0 - 4 ) 2  ( 0 - 5 ) 0 . 5
I L - 6  ( p g / m l ) 1 0 7  ( 4 1 - 2 8 7 ) 3  ( 0 - 4 ) < 0 . 0 0 0 1
I L - 8  ( p g / m l ) 7 8  ( 3 7 - 2 6 5 ) 3  ( 0 - 1 2 ) < 0 . 0 0 0 1
I L - 1 0  ( p g / m l ) 9 ( 5 - 1 8 ) 0  ( 0 - 3 ) < 0 . 0 0 0 1
M I P - l a  ( p g / m l ) 5  ( 2 . 5 - 1 2 ) 2  ( 0 - 3 ) 0 . 0 0 0 3
M C P - 1  ( p g / m l ) 2 9 4  ( 9 7 - 5 2 7 ) 6 2  ( 4 4 - 5 5 2 ) 0 . 2
G - C S F  ( p g / m l ) 1 7  ( 6 - 4 0 ) 4 ( 0 - 1 9 ) 0 . 0 0 4
G M - C S F  ( p g / m l ) 3  ( 2 - 4 ) 2  ( 0 - 5 ) 0 . 3 4
C 3 a  d e s - a r g  
( n g / m l )
6 0 6  ( 3 8 8 - 8 4 7 ) 3 4 6  ( 2 1 6 - 4 0 0 ) 0 . 0 0 0 6
C 5 a  d e s - a r g  
( n g / m l )
9 0  ( 5 9 - 1 4 1 ) 3 6  ( 2 5 - 4 3 ) < 0 . 0 0 0 1
Table 111-3: Serum cytokine and anaphylatoxin levels amongst 
patients and matched volunteers.
Data shown as median and inter-quartile ranges.
A l v e o l a r
C y t o k i n e
P a t i e n t M a t c h e d
v o l u n t e e r
P  v a l u e  b y  
M a n n - W h i t n e y
I L - l ß  ( p g / m l ) 1 1  ( 0 - 1 2 0 ) 0  ( 0 - 1 . 6 ) < 0 . 0 0 0 1
T N F - a  ( p g / m l ) 0  ( 0 - 5 ) 0  ( 0 - 0 ) 0 . 1 2
I L - 6  ( p g / m l ) 1 3 4 ( 1 3 - 4 6 4 ) 0  ( 0 - 6 ) < 0 . 0 0 0 1
I L - 8  ( p g / m l ) 6 0 2  ( 8 3 - 4 2 2 7 ) 5 7  ( 2 7 - 5 8 1 ) 0 . 0 0 4
I L - 1 0  ( p g / m l ) 1 ( 0 - 1 4 ) 0  ( 0 - 0 ) 0 . 0 2
M I P - l a  ( p g / m l ) 6 ( 1 - 1 5 ) 2 ( 0 - 1 3 ) 0 . 0 7
M C P - 1  ( p g / m l ) 2 2 2  ( 4 9 - 9 8 5 ) 2 1 ( 0 - 5 4 ) < 0 . 0 0 0 1
G - C S F  ( p g / m l ) 3 7  ( 7 - 1 3 8 ) 6  ( 0 - 2 5 ) 0 . 0 0 9
G M - C S F  ( p g / m l ) 2 ( 1 - 9 ) 2  ( 0 - 4 ) 0 . 2 3
C 3 a  d e s - a r g  
( n g / m l )
1 5  ( 4 - 1 3 0 ) 1 ( 0 - 1 ) < 0 . 0 0 0 1
C 5 a  d e s - a r g  
( n g / m l )
6  ( 0 . 5 - 3 0 ) 1 ( 0 - 2 ) 0 . 0 0 5
H u m a n  
n e u t r o p h i l  
e l a s t a s e  ( n g / m l )
3 6 6  ( 1 3 6 - 3 0 9 6 ) 2 1  ( 3 - 3 6 0 ) 0 . 0 0 6
n e u t r o p h i l s 2 . 1  ( 0 . 3 - 6 . 4 ) 0  ( 0 - 0 . 0 3 ) < 0 . 0 0 0 1
m a c r o p h a g e s I  ( 0 . 2 - 2 . 8 ) 2 . 9 ( 1 . 4 - 3 . 9 ) 0 . 0 3
Table 111-4: Alveolar cytokine, anaphylatoxin and inflammatory cell 
levels amongst patients and matched volunteers
Data shown as median and inter-quartile ranges, (corrected for dilution by 
urea method (Rennard et al. 1986).
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S e r u m
C y t o k i n e
V A P A R D S / A L I N o n -
V A P / N o n -
A R D S
P  v a l u e  b y
K r u s k a l -
W a l l i s
I L - l ß  ( p g / m l ) 4 ( 1 - 7 ) 4 ( 0 - 5 ) 4  ( 0 - 5 ) 0 . 9
T N F - a
( p g / m l )
3  ( 1 - 5 ) 4 ( 0 - 5 ) 3  ( 0 - 4 ) 0 . 9
I L - 6  ( p g / m l ) 1 0 6  ( 5 5 - 1 7 4 ) 1 2 7  ( 4 6 - 2 6 2 ) 1 0 0  ( 2 7 - 4 3 9 ) 1 . 0
I L - 8  ( p g / m l ) 8 0 ( 6 2 - 3 2 4 ) 9 0  ( 4 7 - 2 7 7 ) 5 0  ( 2 7 - 2 5 5 ) 0 . 2
I L - 1 0  ( p g / m l ) 8 ( 5 - 1 5 ) 1 0 ( 5 - 3 5 ) 8  ( 5 - 1 4 ) 0 . 6
M I P - l a
( p g / m l )
5  ( 0 - 1 9 ) 9 ( 3 - 1 4 ) 8  ( 4 - 5 0 ) 0 . 6
M C P - 1
( p g / m l )
3 4 3  ( 1 3 6 -  
8 6 8 )
3 2 6  ( 1 8 7 - 5 3 5 ) 2 2 6  ( 5 1 - 4 6 8 ) 0 . 3
G - C S F
( p g / m l )
2 9  ( 7 - 6 9 ) 1 1  ( 7 - 2 5 ) 1 6 ( 6 - 3 1 ) 0 . 2
G M - C S F
( p g / m l )
2  ( 0 - 4 ) 3 ( 2 - 3 ) 2 ( 1 - 4 ) 0 . 4
C 3 a  d e s - a r g  
( n g / m l )
5 8 4  ( 4 9 6 -  
9 1 3 )
7 1 0 ( 3 7 0 - 9 7 2 ) 6 1 2  ( 3 2 6 - 8 2 6 ) 0 . 8
C 5 a  d e s - a r g  
( n g / m l )
1 1 3  ( 6 2 - 1 6 9 ) 1 2 1  ( 6 0 - 1 8 6 ) 7 4 ( 4 3 - 1 3 0 ) 0 . 3
Table 111-5: Serum cytokine and anaphylatoxin levels amongst 
patient sub-groups.
Data shown as median and inter-quartile ranges.
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A l v e o l a r
C y t o k i n e
V A P A R D S / A L I N o n - V A P / N o n -
A R D S
P  v a l u e
b y
K r u s k a l -
W a l l i s
I L - l ß  ( p g / m l ) 9 9  ( 2 1 - 6 9 7 ) 1 ( 0 - 1 0 ) 4 ( 0 - 1 6 6 ) 0 . 0 0 0 3
T N F - a  ( p g / m l ) 1 ( 0 - 1 8 ) 0  ( 0 - 3 ) 0  ( 0 - 7 ) 0 . 4
I L - 6  ( p g / m l ) 2 6 6  ( 1 0 5 -  
5 0 3 )
1 1 8  ( 2 9 - 4 3 1 ) 5 3  ( 1 . 7 - 4 9 8 ) 0 . 2
I L - 8  ( p g / m l ) 6 1 7 2  ( 2 0 6 0 -  
1 0 7 4 2 )
4 3 0  ( 1 8 8 - 8 4 7 ) 1 6 8  ( 6 4 - 9 3 1 ) < 0 . 0 0 0 1
I L - 1 0  ( p g / m l ) 0  ( 0 - 9 ) 1 |S-! 1 ( 0 - 3 3 ) 0 . 7
M I P - l a
( p g / m l )
5 1  ( 1 4 - 2 6 9 ) 3  ( 0 - 2 0 ) 4  ( 1 - 2 7 ) 0 . 0 0 4
M C P - 1
( P g / m l )
2 9 3  ( 9 4 - 5 5 4 ) 5 5 8  ( 1 7 0 - 1 7 8 7 ) 7 8 ( 1 2 - 5 7 3 ) 0 . 0 2
G - C S F  ( p g / m l ) 1 0 7  ( 3 8 - 3 8 3 ) 1 0 ( 5 - 3 2 ) 3 0  ( 6 - 1 6 4 ) 0 . 0 0 9
G M - C S F
( p g / m l )
2 ( 0 - 1 4 ) 1 ( 0 - 6 ) 3 ( 1 - 1 2 ) 0 . 4
C 3 a  d e s - a r g  
( n g / m l )
1 1  ( 3 - 2 2 7 ) 8 ( 4 - 3 4 8 ) 2 0  ( 4 - 1 0 5 ) 1 . 0
C 5 a  d e s - a r g  
( n g / m l )
3  ( 1 - 3 2 ) 3 ( 2 - 2 1 ) 8  ( 0 - 3 5 ) 0 . 8
H u m a n
n e u t r o p h i l
e l a s t a s e
( n g / m l )
2 7 0 8  ( 6 7 5 -  
1 3 2 9 3 )
3 1 1  ( 7 1 - 4 5 5 ) 3 1 5  ( 1 4 3 - 8 1 9 ) 0 . 0 0 3
N e u t r o p h i l s 4 . 6  ( 0 . 2 - 1 7 ) 2 . 7 ( 1 . 1 - 1 1 ) 0 . 8  ( 0 . 0 3 - 4 . 8 ) 0 . 0 9
M a c r o p h a g e s 1 . 1  ( 0 . 4 - 3 . 2 ) 0 . 5  ( 0 . 1 5 - 1 . 5 ) 1 . 4  ( 0 . 2 - 3 . 9 ) 0 . 5
Table lll-6:Alveolar cytokine, anaphylatoxin and inflammatory cell 
levels amongst patient sub-groups.
Data shown as median and inter-quartile ranges, (corrected for dilution by 
urea method (Rennard et al. 1986).
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C r i t i c a l l y  i l l  p a t i e n t s  h a v e  a  w i d e  r a n g e  o f  p r e c i p i t a t i n g  i l l n e s s e s  a n d  i n s u l t s ,  b u t  
o f t e n  e n d  u p  w i t h  w h a t  a p p e a r s  t o  b e  a  c o m m o n  p h e n o t y p e .  T h i s  c o n s i s t s  o f  
f a i l u r e  o f  s e v e r a l  o r g a n  s y s t e m s ,  o f t e n  a w a y  f r o m  t h e  s i t e  o f  t h e  i n i t i a l  i n s u l t  ( e . g .  
r e s p i r a t o r y  a n d  r e n a l  f a i l u r e  i n  p a n c r e a t i t i s  o r  f o l l o w i n g  m a j o r  h a e m o n h a g e )  a n d  
a r e  a t t r i b u t a b l e  t o  s e c o n d a r y  d a m a g e  ( S i n g h ,  E v a n s  2 0 0 6 ) .  A s  n o t e d  i n  t h e  
i n t r o d u c t i o n ,  t h i s  s e c o n d a r y  d a m a g e  i s  m e d i a t e d  i n  p a r t  b y  t h e  p a t i e n t ’ s  o w n  
i m m u n e  s y s t e m ,  f o l l o w i n g  i n a p p r o p r i a t e  s y s t e m i c  a c t i v a t i o n  ( R i t t i r s c h ,  F l i e r l  &  
W a r d  2 0 0 8 ) .  A t  a n  o r g a n i s m  l e v e l  t h i s  m a n i f e s t s  a s  s i g n s  o f  s y s t e m i c  
i n f l a m m a t i o n ,  w i t h  e l e v a t e d  t e m p e r a t u r e  a n d  s i g n s  o f  i n c r e a s e d  m e t a b o l i c  
d e m a n d  ( i n c r e a s e d  c a r d i a c  o u t p u t ,  r e s p i r a t o r y  r a t e ) ,  a c c o m p a n i e d  b y  i n c r e a s e s  i n  
p e r i p h e r a l  b l o o d  n e u t r o p h i l  c o u n t s ,  a c u t e  p h a s e  p r o t e i n s  a n d  o t h e r  m o l e c u l a r  
s p e c i e s  a s s o c i a t e d  w i t h  a  p r o - i n f l a m m a t o r y  r e s p o n s e .  T h i s  s y n d r o m e  h a s  b e e n  
t e r m e d  s y s t e m i c  i n f l a m m a t o r y  r e s p o n s e  s y n d r o m e  ( S I R S )  ( A m e r i c a n  C o l l e g e  o f  
C h e s t  P h y s i c i a n s / S o c i e t y  o f  C r i t i c a l  C a r e  M e d i c i n e  1 9 9 2 ) .
E v i d e n c e  o f  t h i s  s y s t e m i c  i n f l a m m a t o r y  r e s p o n s e  i s  d e m o n s t r a t e d  i n  t h e  d a t a  
s h o w n  a b o v e ,  w i t h  ‘ a c t i v a t e d ’  n e u t r o p h i l s  r e l e a s i n g  h i g h  l e v e l s  o f  t h e  m a j o r  
p r o t e o l y t i c  e n z y m e  H N E ,  a  s p e c i e s  t h a t  h a s  b e e n  a s s o c i a t e d  w i t h  t h e  t i s s u e  
d a m a g e  s e e n  i n  c r i t i c a l  i l l n e s s  ( S a k a m o t o  e t  a l .  2 0 1 0 ) .  S i m i l a r l y  t h e  n e u t r o p h i l s  
e x e r t  a  p r o - i n f l a m m a t o r y  e f f e c t  o n  e p i t h e l i a l  c e l l s  i n  L P S - s t i m u l a t e d  c o - c u l t u r e s ,  
a n d  t h e  s e r u m  d e m o n s t r a t e s  e l e v a t e d  l e v e l s  o f  p r o - i n f l a m m a t o r y  s p e c i e s .  
A l t h o u g h  a l l  p a t i e n t s  d e m o n s t r a t e  e v i d e n c e  o f  t h i s  s y s t e m i c  i n f l a m m a t o r y  
r e s p o n s e ,  t h e r e  a r e  d i f f e r e n c e s  b e t w e e n  t h e  s u b - g r o u p s .  T h e  p a t i e n t s  w i t h  Y A P
S e c t i o n  3 . 0 3  C h a p t e r  s u m m a r y  a n d  d i s c u s s i o n
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e x h i b i t  h i g h e r  l e v e l s  o f  s e r u m  e l a s t a s e  a n d  d i m i n i s h e d  l e v e l s  o f  n e u t r o p h i l  
s u r f a c e  C D  1 6  s u g g e s t i n g  a  h i g h e r  d e g r e e  o f  a c t i v a t i o n  i n  t h e s e  p a t i e n t s .  H o w e v e r  
t h e  l a c k  o f  d i f f e r e n c e s  b e t w e e n  p a t i e n t  s u b - g r o u p s  i n  o t h e r  m e a s u r e s  o f  
i n f l a m m a t o r y  a c t i v i t y  s u g g e s t  t h a t  ‘ a c t i v a t i o n ’  i s  n o t  a  s i m p l e  ‘ a l l  o r  n o t h i n g ’  
p r o c e s s  a n d  t h a t  d i f f e r e n t  a s p e c t s  a r e  d i f f e r e n t i a l l y  r e g u l a t e d .
S t r i k i n g l y ,  a l o n g s i d e  t h i s  h y p e r - i n f l a m m a t i o n ,  t h e r e  i s  a  m a r k e d  d e g r e e  o f  h y p o -  
a c t i v i t y .  K e y  n e u t r o p h i l  f u n c t i o n s  o f  p h a g o c y t o s i s  a n d  s t i m u l a t e d  p r o d u c t i o n  o f  
R O S  a r e  s i g n i f i c a n t l y  d e p r e s s e d  c o m p a r e d  t o  a g e  a n d  s e x  m a t c h e d  c o n t r o l s .
B o t h  t h e s e  p r o c e s s e s  a r e  o f  c r u c i a l  i m p o r t a n c e  f o r  t h e  r e m o v a l  o f  b a c t e r i a  a n d  
f u n g i  ( J u l i a  e t  a l .  1 9 9 1 ,  S h i o h a r a  e t  a l .  2 0 0 9 ) ,  a n d  i n d i v i d u a l s  w i t h  i n - b o r n  
d e f e c t s  i n  t h e s e  f u n c t i o n s  a r e  a t  i n c r e a s e d  r i s k  o f  i n f e c t i o n  ( K u i j p e r s  e t  a l .  1 9 9 7 ,  
W i n k e l s t e i n  e t  a l .  2 0 0 0 ) .
T h e  f i n d i n g  o f  n e u t r o p h i l  h y p o - f u n c t i o n  i n  c r i t i c a l  i l l n e s s  i s  n o t  a  n e w  o n e  
( P a l m e r ,  B o r n s i d e  &  N a n c e  1 9 8 2 ) ,  h o w e v e r  i t  h a s  b e e n  s u g g e s t e d  t h a t  t h i s  m i g h t  
r e s u l t  f r o m  s a m p l i n g  t h e  p e r i p h e r a l  p o o l ,  w h e n  o n e  m a y  e x p e c t  t h e  m o s t  a c t i v e  
n e u t r o p h i l s  t o  b e  f o u n d  i n  i n f l a m e d  t i s s u e  a n d  h e n c e  n o t  r e c o v e r a b l e  
p e r i p h e r a l l y .  T h i s  s u g g e s t i o n  i s  r e f u t e d  b y  t h e  f i n d i n g  t h a t  p h a g o c y t o s i s  i s  
e q u a l l y  i m p a i r e d  i n  c e l l s  r e c o v e r e d  f r o m  t h e  i n f l a m e d  p u l m o n a r y  c o m p a r t m e n t .
A l o n g s i d e  t h e s e  d y s f u n c t i o n a l  n e u t r o p h i l s  i s  f o u n d  e v i d e n c e  o f  h y p o - a c t i v i t y  i n  
a n o t h e r  k e y  i m m u n e  c e l l ,  t h e  m o n o c y t e .  M o n o c y t e s  f r o m  p a t i e n t s  f a i l e d  t o  
m o u n t  a n  e f f e c t i v e  r e s p o n s e  t o  s t i m u l a t i o n  w i t h  L P S ,  s o  c a l l e d  ‘ m o n o c y t e  
d e a c t i v a t i o n ’  ( V o l k  e t  a l .  1 9 9 6 ) .  T N F - a  i s  o f  c r u c i a l  i m p o r t a n c e  t o  t h e  r e m o v a l  
o f  p o t e n t i a l l y  i n f e c t i o u s  o r g a n i s m s  ( M o o r e  e t  a l .  2 0 0 5 ) ,  a n d  p e r h a p s
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u n s u r p r i s i n g l y  a n t i - T N F  t h e r a p i e s  a r e  a s s o c i a t e d  w i t h  i n c r e a s e d  r i s k  o f  i n f e c t i o n  
( B o n g a r t z  e t  a l .  2 0 0 6 ) .
I t  i s  o f  n o t e  t h a t  w h i l s t  t h e  s e r u m  p r o f i l e  o f  c y t o k i n e s  d i d  n o t  d i s p l a y  s i g n i f i c a n t  
d i f f e r e n c e s  b e t w e e n  p a t i e n t s  w i t h  a n d  w i t h o u t  c o n f i r m e d  V A P , t h e  p u l m o n a r y  
c o m p a r t m e n t  s h o w e d  a  m a r k e d  d i f f e r e n c e .  T h e  p r e s e n c e  o f  i n f e c t i v e  o r g a n i s m s  
a t  s u f f i c i e n t  c o n c e n t r a t i o n  ( i . e .  a b o v e  t h e  1 0 4 c o l o n y  f o r m i n g  u n i t  c u t  o f f  
e s t a b l i s h e d  f o r  l a v a g e  b a s e d  d i a g n o s i s  o f  V A P )  i s  a s s o c i a t e d  w i t h  a n  i n t e n s e  
p u l m o n a r y  i n f l a m m a t i o n  a s  i n d i c a t e d  b y  e l e v a t e d  l e v e l s  o f  I L - 1 13, I L - 8 ,  M C P - 1 ,  
M I P 1 - A ,  G - C S F ,  a n d  H N E  w i t h  a  t r e n d  t o w a r d s  g r e a t e r  n e u t r o p h i l i a .  S e v e r a l  o f  
t h e s e  m o l e c u l e s  s h o w  p o t e n t i a l  a s  d i a g n o s t i c  b i o m a r k e r s  ( C o n w a y  M o r r i s  e t  a l .  
2 0 1 0 ) .  H o w e v e r  d e s p i t e  t h i s  i n t e n s e  i n f l a m m a t i o n ,  a l v e o l a r  n e u t r o p h i l  f u n c t i o n  
r e m a i n s  p o o r  ( f i g u r e  I I I - 2 B ) ,  a n d  i n d e e d  i t  i s  t e m p t i n g  t o  s p e c u l a t e  t h a t  i t  i s  t h i s  
v e i y  f a i l u r e  o f  n e u t r o p h i l  f u n c t i o n  w h i c h  p e r m i t s  p a t h o g e n  g r o w t h  a n d  t h e  
r e s u l t a n t  i n f l a m m a t o r y  r e s p o n s e .
I t  i s  i n t e r e s t i n g  t o  n o t e  t h a t  w h i l s t  t h e  p a t i e n t s  w i t h  V A P  d i s p l a y e d  a n  i n t e n s e  
p u l m o n a r y  i n f l a m m a t i o n ,  t h o s e  w i t h  A R D S  d i d  n o t .  T h i s  c o n t r a s t s  w i t h  p r e v i o u s  
w o r k  w h i c h  s h o w s  a n  e a r l y  r i s e  c y t o k i n e s  s u c h  a s  I L - 8  i n  A R D S  ( D o n n e l l y  e t  a l .  
1 9 9 3 ) .  T h e  r e a s o n  f o r  t h i s  d i s p a r i t y  i s  l i k e l y  t o  b e  t h e  t i m i n g  o f  s a m p l i n g ,  w i t h  
t h e  c u r r e n t  c o h o r t  b e i n g  r e c r u i t e d  a t  a  m e d i a n  o f  8  d a y s  i n t o  t h e i r  I C U  s t a y ,  a n d  
s o  t h o s e  w i t h  A R D S  a r e  l i k e l y  t o  b e  a t  a  l a t e r  s t a g e  o f  t h e  d i s e a s e  t h a n  t h a t  
s a m p l e d  i n  p r e v i o u s  s t u d i e s .
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T h e  p i c t u r e  o f  t h e  i n n a t e  i m m u n e  s y s t e m  i n  t h i s  g r o u p  o f  p a t i e n t s ,  i . e .  c r i t i c a l l y  
i l l  p a t i e n t s  w i t h  c l i n i c a l l y  s u s p e c t e d  V A P ,  i s  a  c o m p l e x  p h e n o t y p e  d i s p l a y i n g  
f e a t u r e s  o f  b o t h  h y p e r - a c t i v i t y  a n d  h y p o - a c t i v i t y  s i m u l t a n e o u s l y .  T o  b o r r o w  a  
t e r m  f r o m  p a r t i c l e  p h y s i c s ,  t h e  i n n a t e  i m m u n e  s y s t e m  a p p e a r s  t o  b e  i n  a  
c o n d i t i o n  o f  ‘ s u p e r - p o s i t i o n ’ , s i m u l t a n e o u s l y  o c c u p y i n g  t w o  d i s t i n c t  a n d  
c o n t r a s t i n g  s t a t e s .  A s  m e n t i o n e d  a b o v e  t h e  c l a s s i c a l  d e s c r i p t i o n  o f  c r i t i c a l  i l l n e s s  
i s  o n e  o f  h y p e r - i n f l a m m a t o r y  S I R S .  A  h y p o - i n f l a m m a t o r y  c o m p o n e n t  o f  t h e  
p h e n o m e n o n  h a s  b e e n  r e c o g n i s e d  f o r  s o m e  t i m e  a n d  i n d e e d  t h e  t e r m  
c o m p e n s a t o r y  a n t i - i n f l a m m a t o r y  r e s p o n s e  s y n d r o m e  ( C A R S )  h a s  b e e n  c o i n e d  t o  
d e s c r i b e  t h i s  ( B o n e  1 9 9 6 ) .  H o w e v e r  t h e  s t a n d a r d  d e s c r i p t i o n  o f  t h e  t e m p o r a l  
r e l a t i o n s h i p  b e t w e e n  S I R S  a n d  C A R S  i s  a  b i - p h a s i c  p r o c e s s ,  w i t h  h y p e r -  
i n f l a m m a t i o n  p r e d o m i n a t i n g  a t  t h e  s t a r t  o f  c r i t i c a l  i l l n e s s  a n d  i m m u n o ­
c o m p r o m i s e  o c c u r r i n g  a s  t h e  d i s e a s e  p r o g r e s s e s  ( H o t c h k i s s ,  K a r l  2 0 0 3 ) .  M o r e  
r e c e n t l y  i t  h a s  b e e n  s u g g e s t e d  t h a t  t h i s  d e s c r i p t i o n  i s  r a t h e r  s i m p l i s t i c  a n d  t h a t  
t h e r e  i s  a n  a l t e r n a t i n g  p a t t e r n  o f  i m m u n o - c o m p r o m i s e  a n d  h y p e r - i n f l a m m a t i o n  
( W a n g ,  D e n g  2 0 0 8 ) ,  h o w e v e r  t h e  d a t a  p r e s e n t e d  a b o v e  s h o w s  t h a t  b o t h  s t a t e s  
c a n  o c c u r  s i m u l t a n e o u s l y .  T h i s  p r o d u c e s  t h e  w o r s t  p o s s i b l e  c o m b i n a t i o n ,  w i t h  
i m m u n e - m e d i a t e d  h o s t  d a m a g e  o c c u r r i n g  a t  t h e  s a m e  t i m e  a s  i n c r e a s e d  
v u l n e r a b i l i t y  i n f e c t i n g  o r g a n i s m s ,  r e s u l t i n g  i n  e i t h e r  p e r s i s t e n c e  o f  a  p r i m a r y  
i n f e c t i o n  o r  a l l o w i n g  s e c o n d a r y  i n f e c t i o n  t o  s u p e r v e n e .  F r o m  t h e  e v i d e n c e  
p r e s e n t e d  a b o v e ,  i t  i s  c l e a r  t h a t  s e c o n d a r y  i n f e c t i o n  i n  t h e  f o r m  o f  v e n t i l a t o r -  
a s s o c i a t e d  p n e u m o n i a  c a n  f u r t h e r  e n h a n c e  i n f l a m m a t i o n  a n d  t i s s u e  d a m a g e ,  s o  
a d d i n g  t o  a  v i c i o u s  c i r c l e  o f  h o s t  d a m a g e  a n d  p r o l i f e r a t i o n  o f  i n f e c t i n g  
o r g a n i s m s .  T h i s  d a t a  s u p p o r t s  t h e  i n i t i a l  h y p o t h e s i s  t h a t  c r i t i c a l l y  i l l  p a t i e n t s
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w i t h  s u s p e c t e d  V A P  w o u l d  e x i s t  i n  a  s t a t e  o f  s i m u l t a n e o u s  i m m u n e  a c t i v a t i o n  
a n d  s u p p r e s s i o n .
T h e  r e s u l t s  o f  t h i s  c h a p t e r  r a i s e  t h e  q u e s t i o n  a s  t o  w h a t  i s  m e d i a t i n g  t h e  v a r i o u s  
i m m u n e  e f f e c t s ,  a n d  t o  w h a t  e x t e n t  t h e  p r o - i n f l a m m a t o r y  m e d i a t o r s  d r i v e  t h e  
d y s f u n c t i o n  s e e n .  C l e a r l y  t h e s e  a r e  p o t e n t i a l l y  m a s s i v e  q u e s t i o n s ,  a n d  t h e r e f o r e  
a t t e n t i o n  w i l l  f o c u s  o n  o n e  s p e c i f i c  i m m u n e  d y s f u n c t i o n  n a m e l y  p h a g o c y t o s i s  b y  
n e u t r o p h i l s  w h i c h  f o r m s  t h e  b a s i s  f o r  t h e  n e x t  t w o  c h a p t e r s .
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A r t i c l e  I V .  A n  e x p l o r a t i o n  o f  t h e  m e d i a t o r ( s )  i n f l u e n c i n g  
t h e  d e f e c t  i n  p h a g o c y t o s i s  n o t e d  i n  p a t i e n t s  w i t h  
s u s p e c t e d  v e n t i l a t o r - a s s o c i a t e d  p n e u m o n i a
S e c t io n  4 .01  In t r o d u c t io n
I n  t h e  e x a m i n a t i o n  o f  t h e  i n n a t e  i m m u n e  s y s t e m  i n  s u s p e c t e d  V A P  i n  c h a p t e r  3 ,  
t h e r e  w a s  c l e a r  e v i d e n c e  o f  b o t h  i m m u n e  d y s f u n c t i o n  a n d  a c t i v a t i o n .  O n e  o f  t h e  
m o s t  s t r i k i n g  f i n d i n g s  w a s  t h a t  o f  d i m i n i s h e d  p h a g o c y t o s i s  b y  n e u t r o p h i l s ,  a s  t h i s  
d e f e c t  w a s  a c c o m p a n i e d  b y  i n c r e a s e d  n e u t r o p h i l  e n z y m e  r e l e a s e ,  e l e v a t e d  c e l l -  
s u r f a c e  m a r k e r s  o f  a c t i v a t i o n  a n d  e n h a n c e d  p r o - i n f l a m m a t o r y  i n t e r a c t i o n s  w i t h  
e p i t h e l i a l  c e l l s .  T h e  d e f e c t  i n  p h a g o c y t o s i s ,  a s  n o t e d  i n  t h e  I n t r o d u c t i o n  ( s e c t i o n  
1 . 0 7 ,  p a g e  5 9 )  a  k e y  a n t i b a c t e r i a l  f u n c t i o n ,  t h e r e f o r e  s e e m s  a n  i n t r i g u i n g  t a r g e t  
f o r  f u r t h e r  i n v e s t i g a t i o n .
I t  h a s  b e e n  n o t e d  i n  t h e  I n t r o d u c t i o n  ( s e c t i o n  1 . 0 7  b ,  p a g e  6 1 )  t h a t  p h a g o c y t o s i s  
i s  n o t  a  s i n g l e  p r o c e s s ,  b u t  r a t h e r  a  g r o u p  o f  p r o c e s s e s  w h i c h  a l l  r e s u l t  i n  t h e  
i n t e r n a l i s a t i o n  o f  p a r t i c l e s .  T h e  i n g e s t i o n  o f  s e r u m - o p s o n i s e d  z y m o s a n  p a r t i c l e s  
i s  a  c o m p l e m e n t - m e d i a t e d  r e s p o n s e  ( r e v i e w e d  i n  B l o m ,  H a l l s t r o m  &  R i e s b e c k  
2 0 0 9 )  w h i c h  i n v o l v e s  b i n d i n g  o f  C 3 b - o p s o n i s e d  p a r t i c l e s  t o  M A C - 1 / C D 1  l b / 1 8  
( r e v i e w e d  i n  L e e ,  H a r r i s o n  &  G r i n s t e i n  2 0 0 3 ) ,  w h i c h  t r i g g e r s  i n t r a c e l l u l a r  
s i g n a l l i n g  p a t h w a y s  w h i c h  r e s u l t  i n  t h e  a c t i v a t i o n  o f  R h o A  ( C a r o n ,  H a l l  1 9 9 8 ) ,  
p o l y m e r i s a t i o n  o f  a c t i n  ( K a p l a n  1 9 7 7 )  a n d  i n t e r n a l i s a t i o n  o f  t h e  p a r t i c l e  i n t o  a  
p h a g o s o m e .
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D e f e c t s  i n  p h a g o c y t o s i s  c o u l d  t h e r e f o r e  b e  m e d i a t e d  a t  s e v e r a l  l e v e l s  w i t h i n  t h i s  
p a t h w a y .  I f  t h e  p a t i e n t  s e r u m  w a s  d e f i c i e n t  i n  c o m p l e m e n t  t h e n  d e f i c i e n t  
o p s o n i s a t i o n  m a y  o c c u r .  I t  c o u l d  b e  t h a t  c e l l  s u r f a c e  C D 1  l b  e x p r e s s i o n  i s  
d i m i n i s h e d ,  o r  t h a t  i t  f a i l s  t o  a c t i v a t e  e f f e c t i v e l y ,  o r  t h e r e  m a y  b e  a n  a s  y e t  
u n c h a r a c t e r i s e d  s e r u m  c o m p o n e n t  w h i c h  b l o c k s  t h e  b i n d i n g  o f  p a r t i c l e s  t o  t h e  
r e c e p t o r .  A  f u r t h e r  p o s s i b i l i t y  c o u l d  b e  t h a t  a  m e d i a t o r ,  a c t i n g  v i a  n o n -  
p h a g o c y t i c  r e c e p t o r s ,  i s  a b l e  t o  i m p a i r  t h e  i n t r a - c e l l u l a r  m a c h i n e r y  r e q u i r e d  f o r  
e f f e c t i v e  p h a g o c y t o s i s .  F i n a l l y ,  i t  i s  p o s s i b l e  t h a t  t h e  n e u t r o p h i l s  f r o m  p a t i e n t s  
a r e  d e a d  o r  d y i n g  a n d  t h e r e f o r e  i n c a p a b l e  o f  a n y  e f f e c t i v e  f u n c t i o n s .
T h e  a i m  o f  t h i s  c h a p t e r ,  i n  c o n j u n c t i o n  w i t h  t h e  f o l l o w i n g  c h a p t e r  5 ,  i s  t o  e x p l o r e  
t h e  s e c o n d  p r i n c i p l e  h y p o t h e s i s  s e t  o u t  i n  t h e  i n t r o d u c t i o n ,  n a m e l y  t h a t  h u m a n  
n e u t r o p h i l  d y s f u n c t i o n  i n  c r i t i c a l  i l l n e s s  i s  d r i v e n  b y  e x c e s s i v e  p r o - i n f l a m m a t o r y  
s t i m u l a t i o n  b y  C 5 a ,  i . e .  t h e  p e n u l t i m a t e  p o t e n t i a l  m e c h a n i s m  s e t  o u t  i n  t h e  
p a r a g r a p h  a b o v e .  H o w e v e r  a s  t h e  o t h e r  p o t e n t i a l  m e c h a n i s m s  a r e  e q u a l l y  
p l a u s i b l e ,  t h e y  h a v e  w i l l  a l s o  b e  e x p l o r e d  i n  t h i s  c h a p t e r .
T h i s  c h a p t e r  s t a r t s  w i t h  a  c h a r a c t e r i s a t i o n  o f  t h e  p h a g o c y t o s i s  a s s a y  u s e d ,  
u n d e r t a k e n  u s i n g  n e u t r o p h i l s  f r o m  h e a l t h y  d o n o r s .  T h e r e  f o l l o w s  a n  e x p l o r a t i o n  
o i  e a c h  o f  t h e  p o t e n t i a l  m e c h a n i s m s  i n  n e u t r o p h i l s  f r o m  p a t i e n t s  w i t h  s u s p e c t e d  
V A P ,  o r  u s i n g  p a t i e n t  s e r u m  a p p l i e d  t o  h e a l t h y  d o n o r  n e u t r o p h i l s .  T h e  f i n a l  
p o t e n t i a l  m e c h a n i s m  ( n a m e l y  t h a t  p a t i e n t  n e u t r o p h i l s  a r e  d e a d  o r  d y i n g )  i s  n o t  
d i i e c t l y  a d d r e s s e d  i n  t h i s  c h a p t e r ,  b u t  w i l l  b e  e x p l o r e d  i n  c h a p t e r  5 .  A s  n o t e d  i n  
c h a p t e r  3 ,  a l v e o l a r  c e l l s  a l s o  d i s p l a y  i m p a i r e d  p h a g o c y t o s i s  i n  p a t i e n t s  w i t h
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s u s p e c t e d  V A P .  T h i s  c h a p t e r  e n d s  w i t h  a n  e x a m i n a t i o n  o f  t h i s  d e f e c t  a n d  
w h e t h e r  o r  n o t  t h i s  d i s p l a y s  a n y  s i g n a t u r e  o f  C 5 a  m e d i a t i o n .
S e c t io n  4 .0 2  R esu lts
( a )  V a l i d a t i o n  a n d  c h a r a c t e r i s a t i o n  o f  p h a g o c y t o s i s  a s s a y
T o  v a l i d a t e  a n d  c h a r a c t e r i s e  o u r  m o d e l  o f  c o m p l e m e n t - m e d i a t e d  n e u t r o p h i l  
p h a g o c y t o s i s  f o u r  e x p e r i e m e n t s  w e r e  u n d e r t a k e n .  F i r s t  t h e  r o l e  o f  n o n ­
s p e c i f i c / s c a v e n g e r  r e c e p t o r  v e r s u s  o p s o n i n - a s s i s t e d  p h a g o c y t o s i s  w a s  e x p l o r e d .  
N e u t r o p h i l s  f r o m  h e a l t h y  d o n o r s  w e r e  i n c u b a t e d  w i t h  z y m o s a n  t h a t  h a d  b e e n  
e i t h e r  o p s o n i s e d  i n  s e r u m  o r  i n c u b a t e d  i n  P B S  ( F i g u r e  I V - 1  b e l o w ) .
serum opsonin no opsonin
Figure IV-1: The effect of serum opsonisation on phagocytosis of 
zymosan particles.
Data shown as median and upper quartile, n=6 individual donors. *** 
p=0.0002 by Mann-Whitney test.
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T h e  s e c o n d  v a l i d a t i o n  e x p e r i m e n t  e x a m i n e d  t h e  e f f e c t  o f  h e a t - t r e a t i n g  t h e  s e r u m  
( 6 0 ° C  f o r  6 0  m i n u t e s )  t o  i n a c t i v a t e  c o m p l e m e n t  ( G o r d o n  1 9 5 3 ) .  T h e  r e s u l t s  o f  
t h i s  a r e  s h o w n  i n  f i g u r e  I V - 2  b e l o w .
^  tfl 50
s e r u m  o p s o n i n  h e a t  t r e a t e d  s e r u m
Figure IV-2: The effect of heat-treating serum on phagocytosis of 
zymosan particles.
Data shown as median and upper quartile, n=6 individual donors. *** 
p<0.0001 by Mann-Whitney test.
T h e  t h i r d  e x p e r i m e n t  e x a m i n e d  t h e  e f f e c t  o f  b l o c k i n g  o n e  o f  t h e  m a j o r  C 3 b  
r e c e p t o r s ,  C D 1  l b ,  w h i c h  i s  a  k e y  r e c e p t o r  f o r  c o m p l e m e n t - m e d i a t e d  
p h a g o c y t o s i s  ( M a n t o v a n i ,  R a b i n o v i t c h  &  N u s s e n z w e i g  1 9 7 2 ) .  T h e  r e s u l t s  a r e  
s h o w n  i n  f i g u r e  I V - 3 .
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Figure IV-3: The effect of pre-incubation of neutrophils with CD11b 
blocking antibody (M1/70) on phagocytosis.
n=4 individual donors, data shown as median and upper quartile. 
P=0.004 by Kruskal-Wallis, ** P<0.01 by Dunn’s post hoc test.
T h e  f o u r t h  e x p e r i m e n t  w a s  t o  d e t e r m i n e  t h e  t i m e  c o u r s e  o f  p h a g o c y t o s i s .  
N e u t r o p h i l s  f r o m  t h e  s a m e  d o n o r  w e r e  e x p o s e d  t o  z y m o s a n  f o r  5 ,  1 0 ,  1 5 ,  3 0  a n d  
6 0  m i n u t e s .  T h e  m a x i m u m  v e l o c i t y  o f  p h a g o c y t o s i s  ( %  c h a n g e  i n  p r o p o r t i o n  o f  
c e l l s  w i t h  z y m o s a n  p a r t i c l e s  i n )  w a s  a c h i e v e d  a t  5  m i n u t e s ,  a n d  m a x i m u m  
p h a g o c y t o s i s  w a s  a c h i e v e d  b y  3 0  m i n u t e s .  S i m u l t a n e o u s l y ,  t h e  l e v e l  o f  
p o l y m e r i s e d  a c t i n  w a s  d e t e r m i n e d  a t  e a c h  t i m e  p o i n t  u s i n g  n e u t r o p h i l s  f r o m  t h e  
s a m e  d o n o r s .  T h e  r e s u l t s  o f  t h e s e  t w o  a s s a y s  a r e  s h o w n  i n  f i g u r e  I V - 4 A  b e l o w .  
F i g u r e  I V - 4 B  s h o w s  e x a m p l e  d a t a  o f  a c t i n  p o l y m e r i s a t i o n  a s  d e t e n n i n e d  b y  f l o w  
c y t o m e t r y .
I
0 2mcg/ml 5mcg/ml 10mcg/ml
1 2 9
f-actin
Figure IV-4: Velocity of phagocytosis of zymosan particles, and change in 
polymerised actin (f-actin) content of neutrophils exposed to zymosan.
Data shown as mean and SEM from n=3 individual donors.
S am ple Geom . Mean:FL1-H
3  HD actin zym o 5 4414
□ 0  HD actin control 2681
FSC-H: FSC-Height FL1-H: FL1 -ROS/Phago
Figure IV-5: Example data of the actin polymersation experiment.
The right-hand panel shows the forward/side scatter characteristics of the 
neutrophils, and the left-hand shows the FL-1 channel fluorescence (indicating 
degree of phalloidin staining) in unstimulated cells (red) and those exposed to 
zymosan for five minutes (blue). The geometric mean fluorescence for each is 
displayed in the box above.
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T h e  r e s u l t s  a b o v e  s u p p o r t  t h e  a s s a y  u s e d  b e i n g  h e a t  l a b i l e  o p s o n i n - d e p e n d e n t ,  
p r e d o m i n a n t l y  m e d i a t e d  b y  t h e  C 3 b  r e c e p t o r  C D  1 l b / 1 8  a n d  s h o w i n g  a c t i n  
p o l y m e r i s a t i o n  a n d  d e p o l y m e r i s a t i o n  o v e r  a  s i m i l a r  t i m e  c o u r s e  t o  t h e  r a t e  o f  
p h a g o c y t o s i s .  T h e s e  f e a t u r e s  a r e  c o n s i s t e n t  w i t h  z y m o s a n  p h a g o c y t o s i s  b e i n g  
p r e d o m i n a n t l y  c o m p l e m e n t  m e d i a t e d .
(b) Examining the defect in patient phagocytosis
H a v i n g  i d e n t i f i e d  t h e  d e f e c t  i n  p h a g o c y t o s i s  i n  p a t i e n t s ’  n e u t r o p h i l s  n o t e d  i n  
c h a p t e r  3 ,  t h e  n e x t  s t e p  w a s  t o  t r y  a n d  i d e n t i f y  t h e  c a u s a t i v e  f a c t o r ( s )  a n d  
m e c h a n i s m  b y  w h i c h  t h e y  w o r k e d .  A s  s e t  o u t  i n  t h e  i n t r o d u c t i o n  a b o v e ,  t h e  
p r o c e s s  o f  e f f i c i e n t  p h a g o c y t o s i s  r e q u i r e s  s e v e r a l  s t a g e s .  T h e s e  a r e  n a m e l y  
o p s o n i s a t i o n ,  l i g a t i o n ,  i n t e r n a l i s a t i o n  a n d  p h a g o - l y s o s o m e  f o r m a t i o n .  T h e  
f o l l o w i n g  p o s s i b l e  m e c h a n i s m s  w e r e  e x p l o r e d :  1 )  d e f e c t i v e  o p s o n i s a t i o n  b y  
p a t i e n t  s e r u m ;  2 )  d e f e c t i v e  e x p r e s s i o n  o f  p h a g o c y t i c  r e c e p t o r s ;  3 )  d e f e c t i v e  
a c t i v a t i o n  o f  p h a g o c y t i c  r e c e p t o r s ;  4 )  s e r u m - b a s e d  i n h i b i t o r  o f  p h a g o c y t o s i s .
(c) Opsonising capacity of serum
T o  e x a m i n e  w h e t h e r  t h e  d e f e c t  i n  p h a g o c y t o s i s  w a s  d u e  t o  a  f a i l u r e  o f  
o p s o n i s a t i o n ,  h e a l t h y  v o l u n t e e r  n e u t r o p h i l s  w e r e  e x p o s e d  t o  z y m o s a n  p a r t i c l e s  
o p s o n i s e d  i n  s e r u m  f r o m  p a t i e n t s  a n d  h e t e r o l o g o u s  h e a l t h y  v o l u n t e e r s  ( t o  c o n t r o l  
f o r  a n y  e f f e c t  s e e n  b e i n g  d u e  t o  s e r u m  b e i n g  h e t e r o l o g o u s ) .  T h e  n e u t r o p h i l s  
w e r e  a d h e r e d  i n  1 0 %  a u t o l o g o u s  s e r u m  a n d  t h e n  e x p o s e d  t o  z y m o s a n  i n  s e r u m
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f r e e  I M D M  ( t o  p r e v e n t  o p s o n i s a t i o n  o c c u r r i n g  w i t h  a u t o l o g o u s  s e r u m ) .  N o  




Figure IV-6: The effect of patient serum opsonisation on 
phagocytosis
The experiment shown invovlved incubating healthy volunteer neutrophils 
with zymosan opsonised in heterologous serum from healthy volunteers 
and patients with poor (<40%) phagocytosis. Data shown as median and 
upper quartile. n=6 healthy donors. P=0.61 by Mann-Whitney test.
( d )  E x p r e s s i o n  o f  p h a g o c y t i c  r e c e p t o r s  b y  p a t i e n t  n e u t r o p h i l s
E x p r e s s i o n  o f  f o u r  o f  t h e  m a j o r  p h a g o c y t i c  r e c e p t o r s  w e r e  d e t e r m i n e d  b y  f l o w  
c y t o m t e r y ,  n a m e l y  t h e  C 3 b  r e c e p t o r  C D 1  l b  a n d  t h e  F e y  r e c e p t o r s  I ,  II a n d  III
1 3 2
( C D 6 4 ,  3 2  a n d  1 6  r e s p e c t i v e l y ) .  T a b l e  I V - 1  b e l o w  i l l u s t r a t e s  t h e  d i f f e r e n c e s  i n  
g e o m e t r i c  m e a n  f l u o r e s c e n c e  r e l a t i v e  t o  m a t c h e d  v o l u n t e e r s .
R e c e p t o r P a t i e n t  G e o m e t r i c
m e a n
( 9 5 %  C l )
M a t c h e d  
V o l u n t e e r  
g e o m e t r i c  m e a n  
( 9 5 %  C l )
P  V a l u e  ( t - t e s t  
o f  l o g -  
t r a n s f o r m e d  
g e o - m e a n s )
C D l l b 9 8 2  ( 6 9 6 - 1 3 8 5 ) 5 1 6  ( 3 2 7 - 8 1 3 ) 0 . 0 2
C D 1 6 3 8 8  ( 2 0 2 - 7 4 5 ) 9 1 4 ( 7 2 4 - 1 1 5 4 ) 0 . 0 4
C D 3 2 3 3  ( 2 2 - 5 2 ) 4 8  ( 3 7 - 6 1 ) 0 . 3
C D 6 4 3 3  ( 2 2 - 5 1 ) 8 ( 6 - 1 1 ) < 0 . 0 0 0 1
Table IV-1: Expression of phagocytic receptors on PBNs from 
patients and matched volunteers.
Data from 21 patients and 14 matched volunteers. Data shown as 
geometric mean and 95% confidence interval, p value by t-test of log- 
transformed geometric means.
(e) Role of CD16 in neutrophil phagocytosis.
F o l l o w i n g  t h e  f i n d i n g  i n  t a b l e  I V - 1  a b o v e  o f  d i m i n i s h e d  C D  1 6  e x p r e s s i o n  o n  
p a t i e n t  n e u t r o p h i l s ,  i t s  r o l e  i n  t h e  p h a g o c y t o s i s  a s s a y  w a s  a s s e s s e d  b y  b l o c k a d e  
w i t h  a n  m u r i n e  m o n o c l o n a l  a n t i - C D  1 6  a n t i b o d y  3 G 8 ( R o s e n b e r g ,  M e l n i c o f f  &  
W i l d i n g  1 9 8 5 ) .  A s  s h o w n  i n  f i g u r e  I V - 7  b e l o w ,  t h e r e  w a s  n o  r e d u c t i o n  i n  
p h a g o c y t o s i s  f o l l o w i n g  C D  1 6  b l o c k a d e ,  i n  m a r k e d  c o n t r a s t  t o  t h e  e f f e c t  s e e n  
w i t h  C D 1  l b  b l o c k a d e  s h o w n  i n  f i g u r e  I V - 3  a b o v e .
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Figure 1V-7: The effect of pre-incubation with murine anti-CD16 
antibody 3G8 or murine lgG1 isotype control on phagocytosis.
Results shown as median and upper quartile range from n=3 individual 
donors, p=0.8 by Kruskal-Wallis test.
( f )  C D l l b  a c t i v a t i o n  f o l l o w i n g  e x p o s u r e  t o  z y m o s a n .
E x p o s u r e  o f  n e u t r o p h i l s  t o  z y m o s a n  p a r t i c l e s  i n d u c e s  b o t h  u p - r e g u l a t i o n  o f  
C D  I l b  a n d  i n c r e a s e d  e x p o s u r e  o f  t h e  a c t i v a t i o n  e p i t o p e  ( D i a m o n d ,  T D  1 9 9 3 ) .  
T a b l e  I V - 2  s h o w s  t h e  e f f e c t  o f  b o t h  o p s o n i s e d  a n d  n o n - o p s o n i s e d  z y m o s a n  
e x p o s u r e  o n  C D 1  l b  e x p r e s s i o n  a n d  C D 1  l b  a c t i v a t i o n  i n  p a t i e n t s  a n d  m a t c h e d  
v o l u n t e e r s .  A s  c a n  b e  s e e n  a l t h o u g h  t h e r e  i s  a  t r e n d  t o w a r d s  i n c r e a s e d  b a s a l  
C D 1  l b  e x p r e s s i o n  b y  p a t i e n t  n e u t r o p h i l s ,  t h i s  i s  n o t  r e f l e c t e d  i n  a n  i n c r e a s e  i n  
t h e  a m o u n t  o f  a c t i v a t e d  C D 1  l b  p r e s e n t  b e f o r e  e x p o s u r e  t o  z y m o s a n .  T h e  l o s s  o f  
s i g n i f i c a n c e  i n  t h e  d i f f e r e n c e  b e t w e e n  p a t i e n t s  a n d  m a t c h e d  v o l u n t e e r  t o t a l  
C D 1  l b  ( c t  t a b l e  I V - 1 a b o v e )  i s  p r o b a b l y  d u e  t o  t h e  r e d u c t i o n  i n  n u m b e r s  o f  
i n d i v i d u a l s  e x a m i n e d .  F o l l o w i n g  e x p o s u r e  t o  b o t h  o p s o n i s e d  a n d  n o n - o p s o n i s e d  
z y m o s a n  b o t h  p a t i e n t s ’  a n d  v o l u n t e e r s ’  n e u t r o p h i l s  u p - r e g u l a t e d  t h e  a m o u n t  o f  
a c t i v a t e d  C D 1  l b  r e l a t i v e  t o  b a s a l  c o n d i t i o n s ,  a l t h o u g h  t h e r e  w e r e  n o  s i g n i f i c a n t  
d i f f e r e n c e s  b e t w e e n  t h e  g r o u p s  o f  p a r t i c i p a n t s  f o r  e a c h  s t i m u l a t i n g  c o n d i t i o n .
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V o l u n t e e r  n e u t r o p h i l s  w e r e  a b l e  t o  u p - r e g u l a t e  t o t a l  C D 1  l b  o n  s t i m u l a t i o n  w i t h  
b o t h  f o r m s  o f  z y m o s a n ,  i n  c o n t r a s t  t h e  p a t i e n t  n e u t r o p h i l s  w e r e  n o t  a b l e  t o  
s i g n i f i c a n t l y  e l e v a t e  C D 1  l b  e x p r e s s i o n  a b o v e  b a s a l  c o n d i t i o n s .  H o w e v e r  t h e  
a p p a r e n t  f a i l u r e  o f  C D  1 l b  u p  r e g u l a t i o n  b y  p a t i e n t  n e u t r o p h i l s  i s  a  r e l a t i v e  o n e ,  
d u e  t o  t h e  a l r e a d y  h i g h e r  b a s a l  l e v e l s ,  s u g g e s t i n g  t h a t  t h e  p a t i e n t  c e l l s  h a d  
a l r e a d y  a c h i e v e d  n e a r  m a x i m a l  C D 1  l b  e x p r e s s i o n .
P a t i e n t s M a t c h e d
v o l u n t e e r s
P  v a l u e
U n s t i m u l a t e d C D l l b 1 1 5 7  ( 8 4 5 -  
1 5 8 4 )
6 6 2  ( 3 5 9 -  
1 2 1 9 )
0 . 0 6
A c t i v a t e d
C D l l b
1 0 ( 8 - 1 2 ) 1 2 ( 8 - 1 9 ) 0 . 2
S t i m u l a t e d  
w i t h  n o n -  
o p s o n i s e d  
z y m o s a n
C D l l b 1 8 7 3  ( 1 2 1 1 -  
2 8 9 6 )
1 5 7 8  ( 5 8 8 -  
4 2 3 4 )
0 . 3
A c t i v a t e d
C D l l b
2 6  ( 1 6 - 3 5 ) 3 2  ( 2 7 - 3 8 ) 0 . 3
S t i m u l a t e d
w i t h
o p s o n i s e d
z y m o s a n
C D l l b 1 9 7 5  ( 1 3 1 2 -  
2 9 7 3 )
1 4 6 8  ( 8 9 9 -  
2 3 9 8 )
0 . 5
A c t i v a t e d
C D l l b
3 1 ( 1 9 - 4 3 ) 2 6  ( 2 1 - 3 1 ) 0 . 9 5
Table IV-2: CD11b expression and activation in neutrophils from 
patients and healthy volunteer neutrophils in basal and stimulated 
conditions
Stimuli were non-opsonised and serum opsonised zymosan. N = 1 8  
patients and 7 healthy volunteers, p value in right hand column by t-test 
of log-transformed geometric mean fluorescence, assessed using flow 
cytometry.
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B a s a l N o n -
o p s o n i s e d
O p s o n i s e d P  v a l u e
P a t i e n t s  -  
C D l l b
1 1 5 7  ( 8 4 5 -  
1 5 8 4 )
1 8 7 3  ( 1 2 1 1 -  
2 8 9 6 )
1 9 7 5  ( 1 3 1 2 -  
2 9 7 3 )
0 . 7 8
P a t i e n t s  -
a c t i v a t e d
C D l l b
1 0 ( 8 - 1 2 ) 2 6  ( 1 6 - 3 5 ) * * * 3 1  ( 1 9 - 4 3 ) * * * < 0 . 0 0 0 1
M a t c h e d
V o l u n t e e r s -
C D l l b
6 6 2  ( 3 5 9 -  
1 2 1 9 )
1 5 7 8  ( 5 8 8 -  
4 2 3 4 ) *
1 4 6 8 ( 8 9 9 -  
2 3 9 8 ) *
0 . 0 2
M a c t c h e d
V o l u n t e e r s -
a c t i v a t e d
C D l l b
1 2 ( 8 - 1 9 ) 3 2  ( 2 7 - 3 8 ) * * 2 6  ( 2 1 - 3 1 ) * * < 0 . 0 0 0 1
Table IV-3: CD11b expression and activation in neutrophils from 
patients and healthy volunteer neutrophils in basal and stimulated 
conditions
Stimuli being non-opsonised and serum opsonised zymosan). N=18 
patients and 7 healthy volunteers, p value in right hand column by one 
way ANOVA of log-transformed geometric mean fluorescence, assessed 
using flow cytometry. *p<0.05, *** P<0.001 by Bonferroni’s post-hoc test 
compared to unstimulated conditions. Note, this is the same data as 
presented in table IV-2, arranged to show comparisons within participant 
groups. The tables have been rearranged for clarity of statistical 
analysis.
( g )  S e r u m - b a s e d  f a c t o r  i n h i b i t i n g  p h a g o c y t o s i s  i n d e p e n d e n t  o f  
o p s o n i s a t i o n .
T o  e x a m i n e  a  p o s s i b l e  s e r u m - b a s e d  i n h i b i t o r  o f  p h a g o c y t o s i s ,  h e a l t h y  d o n o r  
n e u t r o p h i l s  w e r e  i n c u b a t e d  w i t h  s e r u m  f r o m  p a t i e n t s  w i t h  p o o r  p h a g o c y t o s i s
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( < 4 0 %  o f  c e l l s  p h a g o c y t i c ) .  T h e  r e s u l t s  s h o w n  i n  F i g u r e  I V - 8  b e l o w  i n d i c a t e  n o  
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Figure IV-8: Effect of patient serum on neutrophil phagocytosis.
Phagocytosis by healthy volunteer neutrophils incubated in autologous 
serum or pooled serum from 4 patients with poorly phagocytic (<40%) 
neutrophils. Data shown as median, interquartile (box) and range 
(whiskers) from n=8 healthy donors, p=0.64 by Wilcoxon rank sum test.
(h) Complement split product C5a as a mediator of impaired 
phagocytosis -  measuring C5a exposure.
T h e  a n a p h y l a t o x i n  C 5 a  i s  l a r g e l y  g e n e r a t e d  b y  p r o c e s s e s  d o w n - s t r e a m  o f  C 3  
a c t i v a t i o n ,  w h i c h  r e l e a s e s  C 3 a  a n d  b  ( r e v i e w e d  b y  W a r d ,  2 0 0 4 ) .  C 5 a ,  a n d  i n d e e d  
C 3 a ,  a r e  r a p i d l y  c o n v e r t e d  t o  t h e  c o n s i d e r a b l y  l e s s  p o t e n t  ‘ d e s - a r g ’  f o r m s  b y  
c a r b o x y p e p t i d a s e - m e d i a t e d  r e m o v a l  o f  t h e  a r g i n i n e  r e s i d u e  f r o m  t h e  c a r b o x y l  
e n d  o f  t h e  p r o t e i n s  ( C a m p b e l l  e t  a l .  2 0 0 2 ) .  F u r t h e r m o r e  C 5 a  i s  r e m o v e d  f r o m  t h e  
c i r c u l a t i o n  b y  b i n d i n g  t o  C D 8 8  a n d  b e i n g  i n t e r n a l i s e d  b y  a  v a r i e t y  o f  c e l l s  
i n c l u d i n g  n e u t r o p h i l s  ( C h e n o w e t h ,  H u g l i  1 9 7 8 ) ,  g i v i n g  i t  a  p l a s m a  h a l f - l i f e  o f  2  
t o  3  m i n u t e s  ( W e b s t e r ,  L a r s e n  &  F l e n s o n  1 9 8 2 ) .  T h e r e f o r e  a  s i m p l e  m e a s u r e  o l
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p l a s m a  C 5 a  c o n c e n t r a t i o n  i s  u n l i k e l y  t o  g i v e  a n  a c c u r a t e  i m p r e s s i o n  o f  i n - v i v o  
e x p o s u r e  o f  n e u t r o p h i l s  t o  C 5 a .
T w o  p r o x y  m e a s u r e s  o f  C 5 a  w e r e  u s e d .  F i r s t  s e r u m  l e v e l s  o f  C 3 a  d e s - a r g ,  a s  a  
m o r e  p e r s i s t e n t  m a r k e r  o f  a n a p h y l a t o x i n  a c t i v a t i o n .  S e c o n d ,  n e u t r o p h i l  s u r f a c e  
C D 8 8  l e v e l s  w e r e  m e a s u r e d .  F i g u r e  I V - 9  s h o w s  t h e  e f f e c t  o f  a d d i n g  r e c o m b i n a n t  
h u m a n  C 5 a  ( r h C 5 a )  t o  h e a l t h y  v o l u n t e e r  n e u t r o p h i l s  o n  t h e  s u r f a c e  e x p r e s s i o n  o f  
C D 8 8 ,  d e m o n s t r a t i n g  a  d o s e - d e p e n d e n t  r e d u c t i o n  w i t h i n  t h e  r a n g e  o f  C 5 a  

























Figure IV-9: Log-Log plot showing the dose response curve of 
neutrophil CD88 to increasing concentrations of rhC5a
Actual concentrations used were 0,1,10,100 and 1000nM, however 0 
point not displayed due to logarithmic axis, geometric mean fluorescence 
at 0 C5a was 777 (95% Cl 607-996). Data shown as mean and standard 
error of the mean from n=4 healthy donors, r=-0.91, dose at which CD88 
is reduced by 50% (EC50) 32nM.
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( i )  C o m p l e m e n t  s p l i t  p r o d u c t  C 5 a  a s  a  m e d i a t o r  o f  i m p a i r e d  
p h a g o c y t o s i s  -  p a t i e n t  d a t a
A s s e s s m e n t  o f  t h e  p o t e n t i a l  r e l a t i o n s h i p  b e t w e e n  C 5 a  a n d  p h a g o c y t i c  
d y s f u n c t i o n  w a s  e x p l o r e d  b y  m e a s u r i n g  t h e  c o r r e l a t i o n  b e t w e e n  C 3 a  d e s - a r g  a n d  
p h a g o c y t o s i s  o f  s e r u m  o p s o n i s e d  z y m o s a n ,  a s  w e l l  a s  t h e  c o r r e l a t i o n  b e t w e e n  
C D 8 8  a n d  p h a g o c y t o s i s  o f  s e r u m  o p s o n i s e d  z y m o s a n .  T h e  r e s u l t s  o f  t h e s e  a r e  
s h o w n  i n  f i g u r e s  I V - 1 0  a n d
I V - 1 2  b e l o w .  A l t h o u g h  t h e r e  a r e  p o t e n t i a l  p r o b l e m s  w i t h  u s i n g  C 5 a  d e s - a r g  a s  a  
m e a s u r e  o f  C 5 a  p r o d u c t i o n  ( s e e  a b o v e ) ,  t h e  c o r r e l a t i o n  b e t w e e n  C 5 a  d e s - a r g  a n d  
p h a g o c y t o s i s  i s  a l s o  s h o w n  b e l o w  i n  f i g u r e  I V - 1 0 .  H i g h  l e v e l s  o f  b o t h  C 5 a  d e s -  
a r g  a n d  C 3 a  d e s - a r g  w e r e  f o u n d  i n  p a t i e n t  s e r u m  ( s e e  t a b l e  I I I - 3 ,  p a g e  1 0 9 ) .
r=-0.519
% of cells with & 2 zymosan 
particles
Figure IV-10: Correlation between C3a des-arg and neutrophil 
phagocytosis.
r and p values by Spearman’s rho. Data from n=79 (67 patient and 12 
matched volunteer) study participants.
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Figure IV-11: Correlation between C5a des-arg and neutrophil 
phagocytosis.
r and p values by Spearman’s rho. Data from n=79 (67 patient and 12 
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Figure IV-12: correlation between neutrophil surface CD88 
expression and phagocytosis.
r and p values by Spearman’s rho, data derived from 22 (15 patient and 7 
matched volunteer) study participants.
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( j )  R e l a t i o n s h i p  b e t w e e n  p h a g o c y t o s i s  a n d  o t h e r  s e r u m  f a c t o r s  
a s s o c i a t e d  w i t h  i n f l a m m a t i o n
T o  e x a m i n e  w h e t h e r  t h e  r e l a t i o n s h i p s  n o t e d  a b o v e  w e r e  s p e c i f i c  f o r  c o m p l e m e n t  
a c t i v a t i o n ,  a n d  C 5 a  i n  p a r t i c u l a r ,  t h e  p o t e n t i a l  f o r  c o r r e l a t i o n s  b e t w e e n  o t h e r  
i n f l a m m a t o r y  m o l e c u l e s  ( I L - 6 ,  I L - 8 ,  T N F - a )  a n d  t h e  a n t i - i n f l a m a t o r y  c y t o k i n e  
I L - 1 0  a n d  p h a g o c y t o s i s  w a s  e x a m i n e d ,  a s  s h o w n  i n  t a b l e  I V - 3  n o  s i g n i f i c a n t  
c o r r e l a t i o n s  w e r e  f o u n d .  S i m i l a r l y  t o  e x a m i n e  w h e t h e r  t h e  C D 8 8  c o r r e l a t i o n  w a s  
s p e c i f i c ,  o r  s i m p l y  a  g e n e r a l i s e d  f e a t u r e  o f  a c t i v a t e d  n e u t r o p h i l s ,  t h e  p o t e n t i a l  f o r  
c o r r e l a t i o n s  b e t w e e n  o t h e r  m a r k e r s  o f  n e u t r o p h i l  a c t i v a t i o n  ( C D 1  l b ,  C D  1 6 )  a n d  
t h e  t w o  f u n c t i o n a l  F e y  r e c e p t o r s  ( C D 3 2  a n d  6 4 )  a n d  p h a g o c y t o s i s .  T h i s  d a t a  i s  
s h o w n  i n  t a b l e  I V - 4 ,  a g a i n  t h e r e  a r e  n o  s i g n i f i c a n t  c o r r e l a t i o n s .
r  ( b y  S p e a r m a n s  r h o ) p  ( b y  S p e a r m a n s  r h o )
I L - 6 - 0 . 1 8 5 0 . 2
I L - 8 - 0 . 0 1 0 . 4
T N F - a l p h a - 0 . 1 2 3 0 . 3
I L - 1 0 0 0 . 9
Table IV-4: Correlation co-efficient between cytokine concentration 
and phagocytosis of zymosan.
r and p values by Spearman’s rho, n=79 (67 patient and 12 matched 
volunteer) study participants for cytokines.
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r  ( b y  S p e a r m a n s  r h o ) p  ( b y  S p e a r m a n s  r h o )
C D l l b - 0 . 3 0 . 1
C D 1 6 0 . 3 0 . 1
C D 3 2 0 . 2 7 0 . 2
C D 6 4 - 0 . 3 0 . 1
Table IV-5: Correlation co-efficient between neutrophil phagocytic 
receptor expression and phagocytosis of zymosan.
Receptor expression defeined by flow cytometric geometric mean 
fluorescence, rand p values by Spearman’s rho, n=29 (21 patient and 8 
matched volunteer) study participants for phagocytic receptors.
( k )  C o m p l e m e n t  s p l i t  p r o d u c t  C 5 a  a s  a  m e d i a t o r  o f  i m p a i r e d  
s u p e r o x i d e  i o n  p r o d u c t i o n
A s  s h o w n  i n  C h a p t e r  3  ( f i g u r e  I I I - 3 ,  p a g e  1 0 2 ) ,  a l o n g s i d e  t h e  d e f e c t  i n  
p h a g o c y t o s i s ,  n e u t r o p h i l s  f r o m  p a t i e n t s  a l s o  p r o d u c e d  l e s s  s u p e r o x i d e  o n  
s t i m u l a t i o n  w i t h  P A F  a n d  f M L P .  T o  e x a m i n e  t h e  r e l a t i o n s h i p  b e t w e e n  C 5 a  a n d  
t h i s  n e u t r o p h i l  f u n c t i o n ,  w h i c h  h a s  p r e v i o u s l y  b e e n  d e m o n s t r a t e d  i n  a n i m a l  
m o d e l s  o f  s e p s i s  ( H u b e r - L a n g  e t  a l .  2 0 0 2 b ) ,  t h e  c o r r e l a t i o n s  b e t w e e n  s t i m u l a t e d  
s u p e r o x i d e  p r o d u c t i o n  a n d  e i t h e r  C 3 a  d e s - a r g  o r  C D 8 8  w e r e  p e r f o r m e d  ( s e e  
f i g u r e s  I V - 1 3  a n d  I V - 1 4  b e l o w ) .
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nM O- radicals per million cells
Figure IV-13:Correlation between serum C3a des-arg concentration 
and PAF/fMLP-stimulated superoxide production.
r and p values by Spearman’s rho, data derived from 20 (16 patient and 4 
matched volunteer) study participants.
nM O- radicals per million cells
Figure IV-14: Correlation between neutrophil surface CD88 
expression and PAF/fMLP-stimulated superoxide production.
r and p values by Spearman’s rho, data derived from 20 (16 patient and 4 
matched volunteer) study participants.
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A s  n o t e d  i n  C h a p t e r  3  ( s e c t i o n  3 . 0 2  c ,  p a g e  1 0 0 ) ,  t h e  c e l l s  o b t a i n e d  f r o m  t h e  
a l v e o l a r  s p a c e  o f  p a t i e n t s  d i s p l a y e d  m a r k e d l y  l e s s  p h a g o c y t i c  c a p a c i t y  t h a n  t h o s e  
f r o m  h e a l t h y  v o l u n t e e r s .  T h i s  w a s  d e s p i t e  a  m a r k e d  d i f f e r e n c e  i n  c o m p o s i t i o n  o f  
t h o s e  c e l l s ,  t h o s e  f r o m  p a t i e n t s  b e i n g  p r e d o m i n a n t l y  n e u t r o p h i l s  w h i l s t  t h o s e  
f r o m  m a t c h e d  v o l u n t e e r s  w e r e  a l m o s t  e x c l u s i v e l y  m a c r o p h a g e s .  T o  e x p l o r e  t h e  
d e f e c t  o c c u r r i n g  i n  t h e  a l v e o l a r  c e l l s ,  s o m e  o f  t h e  e x p e r i m e n t s  a b o v e  w e r e  
r e p l i c a t e d  u s i n g  c e l l - f r e e  l a v a g e  s u p e r n a t a n t  i n  p l a c e  o f  s e r u m .  L a v a g e  h a d  n o  
s i g n i f i c a n t  o p s o n i s i n g  e f f e c t  o n  z y m o s a n  ( d a t a  n o t  s h o w n ) ;  h o w e v e r  i n c u b a t i n g  
h e a l t h y  v o l u n t e e r  n e u t r o p h i l s  w i t h  l a v a g e  f r o m  p a t i e n t s  w i t h  s u s p e c t e d  V A P  
i n d u c e d  a  s i m i l a r  d e f e c t  i n  p h a g o c y t o s i s  ( f i g u r e  I V - 1 5  b e l o w ) .  N o t a b l y  t h i s  
e f f e c t  w a s  n o t  s e e n  w h e n  t h e  n e u t r o p h i l s  w e r e  i n c u b a t e d  w i t h  l a v a g e  f r o m  
m a t c h e d  v o l u n t e e r s .
(I) Patient lavage induces a similar defect in phagocytosis
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Figure IV-15: The effect of incubating healthy volunteers’ blood 
neutrophils in cell-free bronchoalveolar lavage fluid from patients or 
matched controls.
Data represent duplicates from 5 separate healthy PBN donors and are 
expressed as medians, interquartile ranges (box) and range (whiskers), 
*** p=0.0001 by Mann-Whitney U test.
(m) The observed bronchoalveolar lavage fluid-induced defect in 
neutrophil phagocytosis is not mediated by C5a
T o  i n v e s t i g a t e  w h e t h e r  t h e  l a v a g e  f a c t o r  w h i c h  i n h i b i t e d  p h a g o c y t o s i s  w a s  t h e  
s a m e  a s  i d e n t i f i e d  i n  t h e  p e r i p h e r a l  c i r c u l a t i o n  ( i . e .  C 5 a )  t h e  f o l l o w i n g  
e x p e r i m e n t s  w e r e  c o n d u c t e d .
H e a l t h y  d o n o r  n e u t r o p h i l s  w e r e  i n c u b a t e d  w i t h  e i t h e r  a n  a n t i b o d y  t h a t  p r e v e n t s  
C 5 a  b i n d i n g  t o  C D 8 8  ( m u r i n e  a n t i - h u m a n  C D 8 8 ,  c l o n e  S 5 / 1 )  o r  a  c o n t r o l  
a n t i b o d y  ( n o n - i m m u n e  m u r i n e  I g G l ) .  H o w e v e r  t h i s  w a s  u n a b l e  t o  p r e v e n t  t h e  




Figure IV-16: The effect of anti-CD88 antibody S5/1 on the ability of 
patient lavage to induce a defect in phagocytosis
Healthy volunteer neutrophils pre-incubated with S5/1 prior to exposure to 
patient lavage. Data are shown as median and upper quartile s of 
duplicates from n=3 separate PBN donors, p<0.001 by Kruskal-Wallis, 
*p<0.05 by Dunn’s post hoc test.
T o  d e t e r m i n e  w h e t h e r  t h e r e  w e r e  s i g n i f i c a n t  l e v e l s  o f  f u n c t i o n a l  C 5 a  i n  t h e  B A L  
f l u i d  f r o m  p a t i e n t s ,  h e a l t h y  d o n o r  n e u t r o p h i l s  w e r e  i n c u b a t e d  w i t h  p a t i e n t s ’  
l a v a g e  f o l l o w e d  b y  a  m e a s u r e m e n t  o f  s u r f a c e  C D 8 8  e x p r e s s i o n .  A s  
d e m o n s t r a t e d  a b o v e  ( f i g u r e  I V - 9 ,  p a g e  1 2 9 )  C 5 a  i s  a b l e  t o  r e d u c e  C D 8 8  
e x p r e s s i o n ,  h o w e v e r  l a v a g e  p r o d u c e d  n o  s i g n i f i c a n t  c h a n g e  ( F i g u r e  I V - 1 7 ,  
b e l o w ) .  T h i s  i s  c o n s i s t e n t  w i t h  t h e  c o m p a r a t i v e l y  l o w  l e v e l s  o f  C 3 a  d e s - a r g  a n d  
C 5 a  d e s - a r g  f o u n d  i n  l a v a g e ,  r e l a t i v e  t o  s e r u m  ( t a b l e s  I I I - 3  a n d  I I I - 4 ,  p a g e  1 0 9  
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Figure IV-17: Comparison of the effects of patients’ lavage or C5a on 
CD88 expression by healthy blood neutrophils.
Data represent duplicates from 3 separate healthy PBN donors and are 
expressed as mean and standard deviation, p<0.0001 by ANOVA, 
***p<0.001 by Bonferroni’s post hoc test.
S e c t io n  4 .0 3  C h a p te r  S u m m a ry  a n d  D iscuss ion
T h i s  w o r k  c o n f i r m s  t h e  f i n d i n g s  o f  p r e v i o u s  g r o u p s  t h a t  t h e  z y m o s a n  i n g e s t i o n  
a s s a y  u s e d  i s  c o m p l e m e n t - m e d i a t e d  a n d  a c t s  v i a  C D 1  l b / 1 8  ( A l l e n ,  A d e r e m  
1 9 9 6 ,  L e  C a b e c  e t  a l .  2 0 0 2 )  r e s u l t i n g  i n  a c t i n  p o l y m e r i s a t i o n  ( C a r o n ,  H a l l  1 9 9 8 ) .
S e v e r a l  m e c h a n i s m s  h a v e  b e e n  p r o p o s e d  t o  e x p l a i n  f i n d i n g s  o f  i m p a i r e d  
p h a g o c y t o s i s  i n  c r i t i c a l l y  i l l  p a t i e n t s .  D e f e c t s  i n  o p s o n i s a t i o n  h a v e  b e e n  r e p o r t e d  
i n  p a t i e n t s  a t  r i s k  o f  A R D S  ( A l e x a n d e r  e t  a l .  1 9 7 8 ) ,  a n d  s e r u m  i n h i b i t o r s  o f  
p h a g o c y t o s i s  f o u n d  i n  p a t i e n t s  w i t h  b u r n s  ( B j o m s o n ,  B j o m s o n  &  A l t e m e i e r  
1 9 8 1 ) .  D e f e c t s  i n  C D 1  l b  e x p r e s s i o n  w e r e  f o u n d  i n  n o n - s u r v i v o r s  w i t h  s e p s i s  
( M u l l e r  K o b o l d  e t  a l .  2 0 0 0 ) ,  w h i l s t  R o s e n b l o o m  a n d  c o l l e a g u e s  s h o w e d  d e f e c t s  
i n  C D 1  l b  a c t i v a t i o n  f o l l o w i n g  s t i m u l a t i o n  w i t h  T N F - a  i n  c r i t i c a l l y  i l l  p a t i e n t s  
( R o s e n b l o o m  e t  a l .  1 9 9 9 ) .  H o w e v e r  i t  i s  o f  n o t e  t h a t  w i t h  t h e  e x c e p t i o n  o f
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B j o m s o n ’ s  s t u d y ,  n o n e  o f  t h e  o t h e r  d e f e c t s  h a d  b e e n  l i n k e d  d i r e c t l y  t o  
i m p a i r m e n t  o f  p h a g o c y t o s i s .
I n  t h i s  s t u d y  t h e r e  w a s  n o  e v i d e n c e  o f  d e f e c t s  i n  s e r u m  o p s o n i s i n g  a b i l i t y  ( F i g u r e
I V - 6 ,  p a g e  1 2 3 ) ,  o r  i n d e e d  s e r u m  i n h i b i t o r s  o f  p h a g o c y t o s i s  ( F i g u r e  I V - 8 ,  p a g e  
1 2 8 ) .  A l t h o u g h  t o t a l  C D 1  l b  i n c r e a s e d  o n  b o t h  p a t i e n t  a n d  v o l u n t e e r  n e u t r o p h i l s  
o n  s t i m u l a t i o n  w i t h  z y m o s a n ,  o n l y  t h e  u p - r e g u l a t i o n  o n  v o l u n t e e r  n e u t r o p h i l s  
w a s  s t a t i s t i c a l l y  s i g n i f i c a n t  ( T a b l e  I V - 2 ,  p a g e  1 2 6 ) .  I t  a p p e a r s  t h a t  w h i l s t  p a t i e n t  
n e u t r o p h i l s  s h o w  a  r e l a t i v e  i n a b i l i t y  t o  f u r t h e r  i n c r e a s e  C D 1  l b  e x p r e s s i o n  i n  
r e s p o n s e  t o  a  s t i m u l u s ,  t h e y  a r e  a b l e  t o  a c t i v a t e  s i m i l a r  a m o u n t s  o f  r e c e p t o r  t o  
t h a t  a c h i e v e d  b y  h e a l t h y  n e u t r o p h i l s .  I t  i s  a l s o  n o t a b l e  t h a t  b o t h  o p s o n i s e d  a n d  
n o n - o p s o n i s e d  z y m o s a n  a c h i e v e  s i m i l a r  l e v e l s  o f  C D 1  l b  e x p r e s s i o n  a n d  r e c e p t o r  
a c t i v a t i o n ,  d e s p i t e  p r o d u c i n g  m a r k e d l y  d i f f e r e n t  p h a g o c y t i c  r e s p o n s e s  ( F i g u r e
I V - 1 ,  p a g e  1 2 4 ) .  T h e s e  d a t a  s u g g e s t  t h a t ,  i n  t h i s  p a t i e n t  p o p u l a t i o n  a t  l e a s t ,  t h e  
p h a g o c y t i c  d e f e c t  n o t e d  i s  n o t  d u e  t o  e i t h e r  d e f i c i e n t  C D 1  l b  e x p r e s s i o n  o r  f a i l u r e  
o f  C D 1  l b  a c t i v a t i o n .
I n  c o n t r a s t  t o  t h e  o t h e r  m e c h a n i s m s  e x p l o r e d ,  t h i s  s t u d y  i d e n t i f i e d  a  r e l a t i o n s h i p  
b e t w e e n  m a r k e r s  o f  C 5 a  e x p o s u r e  a n d  d e f e c t s  i n  p h a g o c y t o s i s  a n d  r e a c t i v e  
o x y g e n  s p e c i e s .  T h i s  i s  t h e  f i r s t  t i m e  s u c h  a  r e l a t i o n s h i p  h a s  b e e n  i d e n t i f i e d  i n  
h u m a n s ,  p o s s i b l y  b e c a u s e  o f  t h e  d i f f i c u l t i e s  i n  a c c u r a t e l y  d e t e r m i n i n g  t h e  
e x p o s u r e  o f  n e u t r o p h i l s  t o  C 5 a  i n  ‘ r e a l - l i f e ’  r a t h e r  t h a n  e x p e r i m e n t a l  s i t u a t i o n s .  
T h i s  r e l a t i o n s h i p  b e t w e e n  C 5 a  a n d  n e u t r o p h i l  d y s f u n c t i o n  i s  c o n s i s t e n t  w i t h  
a n i m a l  a n d  i n - v i t r o  e x p e r i m e n t a l  w o r k  b y  H u b e r - L a n g  a n d  c o l l e a g u e s  ( H u b e r -  
L a n g  e t  a l .  2 0 0 2 b ) w h o  d e m o n s t r a t e d  C 5 a - m e d i a t e d  d e f e c t s  i n  n e u t r o p h i l
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p h a g o c y t o s i s  i n  a  r a t  c a e c a l  l i g a t i o n  a n d  p u n c t u r e  ( C L P )  m o d e l  o f  s e p s i s  a s  w e l l  
a s  C 5 a - m e d i a t e d  i m p a i r m e n t  o f  p h a g o c y t o s i s  i n  h e a l t h y  h u m a n  n e u t r o p h i l s  
e x p o s e d  t o  r e c o m b i n a n t  C 5 a  i n - v i t r o .  T h e  s a m e  s t u d y  a l s o  d e m o n s t r a t e d ,  i n -  
v i t r o ,  t h a t  C 5 a  c o u l d  i m p a i r  s u p e r o x i d e  p r o d u c t i o n  b y  p r e v e n t i n g  t h e  
t r a n s l o c a t i o n  o f  p h o x 4 7  t o  t h e  p l a s m a  m e m b r a n e  t o  f o r m  p a r t  o f  t h e  N A D P H  
o x i d a s e  c o m p l e x  ( H u b e r - L a n g  e t  a l .  2 0 0 2 a )
I t  i s ,  h o w e v e r ,  i m p o r t a n t  t o  n o t e  t h a t  a t  l e a s t  o n e  o t h e r  m e c h a n i s m  i m p a i r i n g  
p h a g o c y t o s i s  i s  o c c u r r i n g  i n  p a t i e n t s .  W i t h i n  t h e  a l v e o l a r  s p a c e  a  f a c t o r ,  o r  
f a c t o r s ,  o t h e r  t h a n  C 5 a  p r e v e n t s  p h a g o c y t o s i s ,  a n  e f f e c t  t h a t  a p p e a r s  t o  b e  
s p e c i f i c  t o  l a v a g e  f l u i d  f r o m  t h e  l u n g s  o f  c r i t i c a l l y  i l l  p a t i e n t s ,  a s  i t  w a s  n o t  
i n d u c e d  b y  l a v a g e  f r o m  a g e -  a n d  s e x - m a t c h e d  v o l u n t e e r s .  A l t h o u g h  t h e s e  d a t a  
s u g g e s t  t h a t  t h e  p u l m o n a r y  i n h i b i t o r  i s  C 5 a - i n d e p e n d e n t ,  a t  p r e s e n t  t h e r e  a r e  n o  
f u r t h e r  d a t a  o n  w h a t  t h i s  i n h i b i t o r ( s )  m a y  b e .
T h e  f i n d i n g  o f  a  r e l a t i o n s h i p  b e t w e e n  C 5 a  a n d  n e u t r o p h i l  d y s f u n c t i o n  i s  b o t h  
i n t e r e s t i n g  a n d  t h o u g h t  p r o v o k i n g .  I n  c o n t r a s t  t o  t h e  c l a s s i c a l  s t o i y  o f  a  
‘ c o u n t e r - b a l a n c i n g ’  i m m u n o s u p p r e s s i v e  r e a c t i o n  t o  i n f l a m m a t i o n  d r i v i n g  
d y s f u n c t i o n ,  i n  t h i s  c a s e  i t  a p p e a r s  t o  b e  t h e  p r o - i n f l a m m a t o r y  m e d i a t o r  i t s e l f  t h a t  
i s  d i r e c t l y  m e d i a t i n g  t h e  d e f e c t .  H o w e v e r  b e f o r e  t h i s  p o s t u l a t e  c a n  b e  c o n f i r m e d ,  
t h e  r e l a t i o n s h i p  b e t w e e n  C 5 a  a n d  p h a g o c y t o s i s  r e q u i r e s  f u r t h e r  e x a m i n a t i o n  t o  
d e t e r m i n e  w h e t h e r  i t  i s  i n d e e d  a  c a u s a t i v e  o n e ,  a n d  i f  s o  w h a t  t h e  u n d e r l y i n g  
m e c h a n i s m  m a y  b e .  I t  i s  t o  t h i s  t o p i c  t h a t  t h e  n e x t  c h a p t e r  t u r n s ,  t o  f u r t h e r  
p u r s u e  t h e  h y p o t h e s i s  t h a t  C 5 a  i s  a  k e y  m e d i a t o r  o f  h u m a n  n e u t r o p h i l  
d y s f u n c t i o n  i n  c r i t i c a l  i l l n e s s .
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Article V. A n  examination of the mechanisms by which 
C5a inhibits phagocytosis.
Section 5.01 Chapter overview and introduction
In chapter 3 the co-existence of hyper-inflammation and immune suppression 
was demonstrated in ICU patients. Chapter 4 further expanded this ‘septic 
superposition’, by showing a relationship between a key pro-inflammatory 
molecule (C5a) and neutrophil dysfunction. Showing that a single molecule can 
induce immune cell dysfunction, alongside its more established pro- 
inflammatory effects which tend to be seen at lower concentrations (Huber-Lang 
et al. 2002c, Frohlich et al. 1998), provides some mechanistic insights into how 
the aforementioned state of‘septic superposition’ could be achieved.
However, simply showing a relationship between markers of C5a exposure and 
neutrophil dysfunction is not sufficient to prove causation. Therefore this 
chapter sets out to explore the mechanism(s) by which C5a is able to induce a 
defect in phagocytosis, one of the key anti-bacterial functions of the neutrophil.
The hypothesis is that, by ligating its predominant receptor (CD8 8 , not itself a 
phagocytic receptor), C5a would activate intracellular pathways that would in 
turn act to inhibit the signalling systems required for phagocytosis and so prevent 
phagocytosis from happening. C5a, and molecules which ligate receptors 
coupled to the same G-protein subunits such as fMLP, activate several 
intracellular pathways (Kelvin et al. 1993). The first pathway explored was the 
Protein Kinase A (PKA)/adenylate cyclase pathway, as this pathway is activated
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by beta-adrenoceptor agonists which also inhibit phagocytosis (Ignarro, Lint & 
George 1974). When this proved not to be the responsible pathway (see below), 
a new hypothesis was generated; that activation of PI3K would lead to inhibited 
phagocytosis.
PI3Ks are a family of key signal transduction molecules, which by catalysing the 
formation of phosphatidylinositol-trisphosphate, signal a wide range of 
intracellular pathways (Rommel, Camps & Ji 2007). Highly conserved across 
species, the PI3K family is divided into 3 sub-families; these are known as type 
I, II and III, dependent on their structure, regulation and in-vitro substrate 
specificity (Wymann, Pirola 1998). Type I PI3Ks remain the best studied, are 
ubiquitous across mammalian cells and catalyse the formation of 
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) from 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) (Hirsch et al. 2000). Type 
I enzymes consist of two components, a larger 1 1 0 kDa catalytic sub-unit 
(designated pi 10) and a smaller regulatory sub-unit. The regulatory sub-unit 
further subdivides the type I enzymes into class IA, with a p85 regulator, and 
class IB with a plOl or p84 regulatory sub-unit. There are three known type IA 
enzymes, designated PI3Ka, |3, and 8 respectively, each one indicating a distinct 
pi 10 subunit. There is only one known IB enzyme, the PI3Ky isoform (reviewed 
in Rommel, Camps & Ji 2007). P13Ky and 8 are largely confined to immune 
cells (Rommel, Camps & Ji 2007), and are intimately involved in inflammatory 
activation (Pinho et al. 2007) that has made them potentially attractive targets for 
pharmacological modulation.
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This chapter will set out a series of experiments designed to explore the 
mechanism by which C5a inhibits phagocytosis. Starting with confirmation of 
the ability of recombinant C5a to induce a similar defect in phagocytosis in 
healthy neutrophils to that seen in patients’ neutrophils, there then follows an 
exploration of the intracellular mechanisms that underpin this effect. Then 
follows an examination of the potential for treatment, using granulocyte- 
macrophage colony stimulating factor (GM-CSF), and its potential mechanistic 
features. The impact of C5a on two other neutrophil functions, namely 
bactericidal ability against live Pseudomonas and transmigration are examined. 
Finally, having built a mechanistic framework of C5a action, attention returns to 
neutrophils from critically ill patients to examine the intracellular signalling 
response to zymosan.
Section 5.02 Results 
(a) In-vitro C5a exposure can inhibit phagocytosis in healthy 
neutrophils
Following the finding that phagocytosis in patients correlated with measures of 
C5a exposure (Figures IV-10-12, pagesl30-131), experiments were undertaken 
to determine whether the application of recombinant human C5a (rhC5a) could 
reproduce the defect in healthy donor neutrophils. Incubation of healthy donor 
neutrophils with rhC5a could induce a dose-dependent defect in phagocytosis, 
which could be prevented by pre-incubation with the CD8 8 blocking antibody 
S5/1 as demonstrated in figure V-l below.
Of note incubation with lOOnM C5a for 1 hour did not alter the rate of apoptosis 
or cell necrosis compared to incubation with control (Median % viable cells at 1 
hour 93% and 95% respectively, p=0.1 by Mann-Whitney from n—3 healthy
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donors), therefore an increase in non-viable cells is unlikely to explain the effects 
seen, which is consistent with existing data showing C5a exerting an anti- 
apoptotic effect (Perianayagam et al. 2002)
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Figure V-1: The effect of recombinant C5a on the phagocytic 
capacity of healthy human neutrophils in vitro.
Upper graph shows data from neutrophils from healthy volunteers 
incubated with either S5/1 (a murine monoclonal antibody blocking CD88) 
or with control murine lgG1 antibody prior to C5a exposure. Data derived 
from duplicates (n=5 PBN donors) and presented as medians and upper 
quartile.
p<0.0001 by Kruskal-Wallis, *p<0.05 **p<0.01 by Dunn’s post hoc test. 
Lower photomicrographs left panel - control-treated neutrophils, white 
arrow indicates a cell which has ingested multiple zymosan particles (the 
grey circles with a clear rim around each; right panel - rhC5a-treated 


















Furthermore, incubation with rhC5a produced the expected reduction in surface 
CD8 8 expression and demonstrated a similar correlation with phagocytosis 
(Figure IV-2) to that seen inpatients in Figure IV-12 (page 131) above.
% cells with a 2 zymosan particles





Figure V-2: Correlation between phagocytosis and CD88 expression 
in healthy volunteer neutrophils exposed to escalating 
concentrations of C5a
n=3 PBN donors. Three separate donors’ neutrophils were exposed to 4 
separate doses of C5a, i.e. each symbol x is from a different donor’s 
neutrophils exposed to 1000nM C5a etc. r and p values by Spearman’s 
Rho.
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To explore the mechanisms underlying the defect in phagocytosis, the capability 
of other neutrophil activators to induce defects in phagocytosis was examined. 
Specifically fMLP was examined, as its receptor (fMLPR) is coupled to the same 
G„iSubunit as CD 8 8 (Skokowa et al. 2005, Bommakanti et al. 1995) and hence 
activates the same intracellular pathways. In equimolar concentrations fMLP 
was able to inhibit phagocytosis in a manner similar to C5a (figure V-3).
(b) Formyl methionyl leucyl phenylalanine (fMLP) and C5a induce a
similar defect in phagocytosis.
=igure V-3: The effects of C5a and fMLP on phagocytosis by healthy 
neutrophils.
Data are presented as median and inter-quartile ranges, p<0.0001 by 
<ruskal-Wallis, NS p>0.05, **p<0.01 by Dunn’s post-hoc test, (n=6 
ndividual PBN donors, all experiments performed in duplicate).
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(c) cAMP mediates beta-adrenoceptor agonist-induced defects in 
phagocytosis but not those of C5a and fMLP.
One downstream pathway of fMLP and C5a involves PKA and adenylate cyclase 
activation, resulting in increased levels of cyclic adenosine monophosphate 
(cAMP). As beta-adrenoceptor agonists are reported to impair phagocytosis via 
activation of cAMP (Ignarro, Lint & George 1974), the effect of isoproterenol on 
the phagocytosis assay was assessed. Neutrophils incubated with lOOuM 
isoproterenol ( a concentration used in previous studies (Ignarro, Lint & George 
1974)) showed impaired phagocytosis, an effect which could be blocked by pre­
incubating the cells with the adenylate cyclase inhibitor SQ22536 (Figure V-4).
A similar effect could be achieved by activation of adenylate cyclase by an 
alternative ligand, pituitary adenylate cyclase activating peptide (PACAP) 
(phagocytosis reduced from 74% to 45% by addition of PACAP, P=0.002 by 
Mann-Whitney, results from n=5 healthy donors). In marked contrast SQ22536 
pre-incubation was unable to prevent the effects of C5a and fMLP on 
phagocytosis (Figures V-5, V-6). These divergent results could be explained by 
the differential response of cAMP to the various stimulants, figure V-7 
demonstrating that cAMP is transiently elevated after C5a and fMLP, at 
concentrations of these agonists which inhibit phagocytosis, but experiences 
more prolonged and increasing elevation with isoproterenol.
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control Isoproterenol Iso +SQ
Figure V-4: Phagocytosis by healthy donor PBNs exposed to the 
beta-adrenoceptor agonist isoproterenol with or without pre­
incubation with the adenylate cyclase inhibitor SQ22536.
p=0.006 by Kruskal-Wallis, *p<0.05 by Dunn’s post-hoc test (n=5 
individual PBN donors, all assays performed in duplicate).
control C5a mC5a +SQ
Figure V-5: Phagocytosis by healthy donor PBNs exposed to 100nM 
C5a with or without pre-incubation with SQ22536.
p=0.003 by Kruskal-Wallis, *p<0.05, **p<0.01 by Dunn’s post-hoc test 
(n=5 individual PBN donors, all assays performed in duplicate).
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Figure V-6: Phagocytosis by healthy donor PBNs exposed to 100nM 
fMLP with or without pre-incubation with SQ22536.
p=0.003 by Kruskal-Wallis, *p<0.05, **p<0.01 by Dunn’s post-hoc test 
(n=5 individual PBN donors, all assays performed in duplicate).
■ f M L P
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Figure V-7: effect of three stimuli (100nM C5a, 100nM fMLP, 100pM 
isoproterenol) on cAMP levels in neutrophils.
Data shown as median values from n=4 healthy donors.
(d) C5a acts via PI3K to inhibit phagocytosis
Following the ruling out of cAMP as the mediator of C5a- (and fMLP-) induced 
defects in phagocytosis, attention turned to other intracellular mechanisms linked 
to actin polymerisation and phagocytosis. The phosphoinositide 3-kinase family 
have been implicated in a wide range of signalling pathways, however within
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leucocytes they are known to affect the small Rho GTPases that are key 
mediators of actin polymerisation, such as occurs during phagocytosis 
(Papakonstanti et al. 2008). Therefore the effect of inhibiting class I PI3K was 
examined using the broad-spectrum PI3K inhibitors wortmannin and LY294002 




Figure V-8: Phagocytosis by healthy donor PBNs exposed to 100nM 
C5a with or without pre-incubation with 10nM wortmannin.
P=0.0003 by Kruskal-Wallis, *p<0.05, ***p<0.001 by Dunn’s post-hoc 
test (n=5 individual PBN donors, all assays performed in duplicate).
Figure V-9: The effect of pre-incubation of healthy neutrophils with 
varying concentrations of LY294002 before exposure to 100nM C5a.
6.6pM being IC50 for PI3Ky Data are illustrated as median and inter­
quartile range, p=0.0002 by Kruskal-Wallis, **p<0.01 by Dunn’s post-hoc 
test (n=6 individual PBN donors, all experiments performed in duplicate).
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The effects of fMLP on phagocytosis were similarly affected by wortmannin 
(control 6 8 %, fMLP 20%, wortmannin +fMLP 70%, P=0.003 by Kruskal-'Wallis 
n=5 donors) and LY294002 (control 6 8 %, fMLP 22%, LY294002+fMLP 74%, 
P<0.001 by Kruskal-Wallis n=5 donors).
At the concentrations used, the PI3K inhibitors did not themselves affect 
phagocytosis. However in dose ranging experiements concentrations of 
LY294002 over 26p,M started to inhibit phagocytosis, and at the IC90 of PI3Ky - 
59p,M - phagocytosis fell from 70% to 12% (n=2), consistent with the 
involvement of PI3K in phagocytosis. Interestingly the ability of LY294002 to 
prevent C5-induced defects in phagocytosis persisted as concentrations dropped 
below 6 .6 p,M dose, the lowest dose examined being 1.06 p,M which is below the 
calculated IC15 for PI3Ky, but is the IC50 for another class IPI3K isoform,
PI3K6. However, although there is a degree of dose-related specificity of 
LY294002, the IC50s are too close to be sure that such a finding reflects a 
genuine isoform-specific effect (Ferrandi et al. 2007).
(e) C5a inhibits phagocytosis via PI3KS and not PI3Ky
Both wortmannin and LY294002 have been found to inhibit enzymes other than 
PI3K (Davies et al. 2000), and as noted above have relatively close values for the 
IC50 of the major class I PI3K isoforms (Ferrandi et al. 2007). To farther explore 
the relative roles of the isoforms PI3Ky and PI3k§, inhibitors with greater 
specificity were used. AS605240 has an IC50 of 8nM for PI3Ky compared to 
6 O11M  for PI3k6 (Smith et al. 2007), whereas IC87114 has an IC50 0.18|iM for
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PI3KS compared to 23 pM for PI3Ky (Knight et al. 2006) . The effects of these 
two compounds on C5a-induced defects in phagocytosis were examined (Figure 
V-10, V-l 1 A). A further investigation of the specificity and dose response of 
IC87114 is presented in figure V-l 1 B, demonstrating that increasing the dose to 
the IC50 of PI3Ky had no additional benefit on inhibiting C5a’s effect on 
phagocytosis. Furthermore the effect of IC87114 persisted down to 60nM, a 
concentration over 1 0 0-fold lower than that required to inhibit PI3Ky.
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Figure V-10: The effect of rhC5a on phagocytosis is not prevented 
by pre-incubation with PI3Ky inhibitor AS605240 at 8nM.
P=0.02 by Kruskal Wallis ANOVA, *p<0.05, **p<0.01 by Dunn’s post-hoc 
test. Data are shown as median and inter-quartile range (n=5 healthy 
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Figure V-11: The effect of rhC5a on phagocytosis is prevented by 
pre-incubation with the PI3K5 inhibitor IC87114.
Panel A: IC87114at 180nM (IC50 for PI3KS). P=0.008 by Kruskal-Wallis 
ANOVA, *p<0.05 by Dunn’s post-hoc test. Data are shown as median 
and inter-quartile range (n=5 healthy volunteers, all experiments 
performed in duplicate).
Panel B: Various concentrations of IC87114. Concentrations represent 
the IC50 of PI3Ky (23pM) and IC90, so, 25 and 10 of PI3K6. P=0.0006 by 
Kruskal-Wallis, *P<0.05 by Dunn’s post-hoc test. (n=6 healthy volunteers, 
all experiments performed in duplicate).
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To confirm that the AS605240 was functional, its ability to inhibit the 
phosphorylation of protein kinase B (PKB) was assessed by western blotting 
(figure V-12A). Further assessment of the specificity of IC87114 for the delta 
isoform was demonstrated by showing a failure to completely inhibit PKB 
phosphorylation at doses that inhibited phagocytosis (figure V-12B).
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0 23pM 180nM 60nM 20nM 0
[LY294002] 0 0 0 0 6.6pM
Figure V-12: Western blots showing phospho-PKB following 
stimulation with C5a.
Panel A shows the effects with and without pan-PI3K (LY294002) and 
PI3Ky (AS605240) inhibitors. Representative example of n=3 
experiements.
Panel B shows the effects of PI3K8 inhibitor IC87114 at varying 
concentrations at 5 minutes.
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Exposure of neutrophils to 740Y-P, a cell permeable specific activator of the p85 
subunit of class IA PI3Ks (i.e. PI3K a, (3, and 6 ) (Derossi et al. 1998), was able 




u control 740 Y-P (3|xM)740 Y-P (100 pM)
Figure V-13: Incubating neutrophils with the PI3KIA (a,(3,5) activator 
740Y-P inhibits phagocytosis.
P=0.01 by Kruskal-Wallis ANOVA, *p<0.05, **p<0.01 by Dunn’s post-hoc 
test. Data are shown as median and inter-quartile range (n=5 healthy 
volunteers).
(f) C5a activation of PI3K5 inhibits RhoA activation
RhoA is the key mediator of actin polymerisation during complement-mediated 
phagocytosis (Caron, Hall 1998), the process involved in ingestion of serum- 
opsonised zymosan. The effect of C5a treatment, and blockade of this by PI3K8 
inhibition, on zymosan-induced RhoA activation was examined. C5a prevented 
the activation of RhoA seen in control-treated neutrophils, and this inhibitory 
effect was dependent on the activation of PI3K8 (Figure V-14). Alternative Rho 
GTPases (RAC and CDC42) were not inhibited by C5a (median change in RAC 
0.13 pg/ml in control vs. 0.16pg/ml in C5a-treated cells, p=l by Mann Whitney. 
Median change in CDC42 -0.01 pg/ml in control vs.-0.02 pg/ml in C5a-treated 





Figure V-14: C5a inhibits the activation of neutrophil RhoA in 
response to opsonized zymosan, and pre-incubation with PI3K5 
inhibitor IC87114 prevents this inhibition.
Concentrations of reagents are the same as in the phagocytosis 
experiements shown in 5-11A (i.e. 100nM for C5a and 180nM for 
IC87114). P=0.005 by Kruskal-Wallis ANOVA, *p<0.05, **p<0.01 by 
Dunn’s post-hoc test. Data presented as median and inter-quartile ranges 
(n=10 healthy donors).
(g) C5a inhibits the polymerisation of actin in response to zymosan.
Actin polymerisation allows the engulfment of phagocytic targets, and paralysis 
of this system inhibits phagocytosis (May, Machesky 2001). As shown above 
(Figure IV-4, page 121) the polymerisation and depolymerisation of actin 
followed the same time course as the ‘velocity’ of phagocytosis in our model. 
Treatment of healthy volunteer neutrophils with C5a inhibited this 
polymerisation response (figure V-15). Indeed there was a small reduction in 
filamentous actin (f-actin) within neutrophils, consistent with the reduction in 
active RhoA noted in Figure V-14. Pre-treatment with the PI3K8 inhibitor 
IC87114 prevented this effect (hatched line in figure V-15), again mirroring the
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changes in RhoA activation. A similar effect was achieved with the pan PI3K 
inhibitor LY294002 (figure V-16).
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Figure V-15: Change in polymerised (f) actin following zymosan 
exposure with and without IC87114.
Data from time series in neutrophils treated with vehicle control 
(squares+solid line), rhC5a (triangles +hashed line) or IC87114 followed 
by rhC5a (circles +hashed line), then exposed to opsonised zymosan. 
Data shown as mean and standard error of the mean (SEM), p<0.0001 
for difference between treatment groups by two way ANOVA, *p<0.05 
between control and C5a treatment,+ P<0.05 between C5a+IC87114 and 
C5a treatment by Bonferroni’s post-hoc test (n=8 healthy donors).
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Figure V-16: Change in polymerised (f) actin following zymosan 
exposure with and without LY294002.
Data from time series in neutrophils treated with vehicle control 
(squares+solid line), rhC5a (triangles +hashed line) or LY294002 followed 
by rhC5a (open triangles +hashed line), then exposed to opsonised 
zymosan. Data shown as mean and standard error of the mean (SEM), 
p=0.0007 for difference between treatment groups by two way ANOVA, 
(n=5 healthy donors).
(h) GM-CSF can rescue phagocytosis after C5a exposure.
Ex-vivo application of GM-CSF to healthy donor neutrophils previously exposed 
to lOOnM C5a reversed the defect in phagocytosis (Figure V-17 below). In 
keeping with the pathway explored above, GM-CSF treatment was associated 
with a restoration of RhoA activation and actin polymerisation in response to 




Figure V-17: Addition of GM-CSF restores effective phagocytosis of 
opsonized zymosan in neutrophils exposed to C5a.
P0.0001 by Kruskal-Wallis, **p<0.01, ***p<0.001 by Dunn’s post hoc 









Figure V-18: Addition of GM-CSF restores RhoA activation in 
neutrophils treated with rhC5a and exposed to opsonised zymosan.
**P=0.007 by Mann-Whitney U-test. Data are displayed as median and 
inter-quartile range (n=10 healthy donors). Note: C5a data are the same 
as presented in Figure V-14 above, the GM-CSF data are shown 
separately for reasons of clarity - separation does not alter the statistical 









-a- C5a + GMCSF
Figure V-19: Addition of GM-CSF restores actin polymerisation in 
neutrophils treated with rhC5a and exposed to opsonised zymosan.
P=0.0001 for differences between treatments by two-way ANOVA, ** 
p<0.01 by Bonferroni’s post-hoc test. Data are shown as mean and SEM 
(n=8 healthy donors).
(i) GM-CSF does not exert its effect via restoration of CD88 
expression or PI3K-delta inhibition.
To explore the potential mechanism by which GM-CSF is able to restore 
phagocytosis, two avenues were explored. First, given the correlation between 
CD8 8 and phagocytosis, the effect on CD8 8 expression was examined. The 
addition of GM-CSF to C5a-treated cells did not restore CD8 8 expression (V- 
20). In contrast recombinant human interferon y that does increase CD8 8  
expression (Burg et al. 1995) and figure V-20) was unable to restore 






Figure V-20: CD88 expression following ex-vivo treatment of 
neutrophils with 100nM C5a, followed by addition of 0.3nM GM-CSF 
or 0.3nM INFy.
p=0.01 by ANOVA, * p<0.05 by Bonferroni’s post-hoc test. n=5 individual 
healthy donors.
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Figure V-21. Phagocytosis by neutrophils exposed to 100nM C5a, 
followed by 0.3nM IFNg or control.
p=0.009 by Kruskal-Wallis, ** p<0.01, ***p<0.001 by Dunn’s post-hoc 
test.
Second, given the effect of inhibiting PI3K and PI3K delta prior to C5a exposure 
on preventing phagocytosis, the ability of PI3K delta inhibition by IC87114 to 
rescue phagocytosis was examined (Figure V-22). Unlike GM-CSF, PI3Kdelta 
inhibition was unable to rescue phagocytosis suggesting that GM-CSF’s effects 
are independent of this mechanism of action.
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Figure V-22: Addition of PI3K6 inhibitor IC87114 after 30 minutes 
treatment with C5a fails to resurrect phagocytosis.
P=0.009 by Kruskal-Wallis, *P<0.05 by Dunn’s post-hoc test. Data are 
displayed as median and inter-quartile range (n=5 healthy donors).
(j) C5a impairs bactericidal capacity of neutrophils
Phagocytosis of zymosan involves the ingestion of large (3-4 micron) particles, 
which stimulate toll-like receptor 2 (TLR-2) (Dillon et al. 2006). Furthermore 
ingestion does not necessarily equate to killing (Garcia-Rodas et al. 2011). 
These issues were examined by investigating the effects ot C5a on neutrophil 
killing of Pseudomonas aeruginosa, a common bacterial cause of nosocomial
infections (Peleg, Hooper 2010) that stimulates TLR-4 (Dehus, Hartung & 
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Figure V-23: Effect of C5a on the bactericidal capacity of 
neutrophils.
P. aeruginosa strain PA01 was added for 30 minutes to wells containing 
no cells (left column), or to healthy neutrophils pre-incubated with either 
100nM C5a (middle column) or control medium (right column). Residual 
bacteria were quantified and expressed as colony forming units (CFU) 
above those at t0.
** p=0.003 by Mann-Whitney (duplicates of n=5 healthy PBN donors).
(k) C5a impairs transmigration of neutrophils
The effect of C5a on actin polymerisation, coupled with reports of 
transmigratory failure in sepsis (Ahmed et al. 1999) prompted an examination of 
the effects of C5a treatment on transmigration towards a chemotactic target 
(Figure V-24). This demonstrated that pre-incubation with C5a was able to 




Figure V-24: Transmigration of neutrophils across a 3 micron pore 
polystyrene membrane to a target of 100nM fMLP.
Neutrophils from healthy volunteers were pre-incubated in control media 
or 100nM C5a, treated cells applied at 100,000 per insert and incubated 
for 1 hour at 37°C. 
** p=0.008 by Mann-Whiney test (duplicates from n=5 healthy PBN 
donors).
To examine whether PI3K5 is central to the impairment of transmigration 
induced by C5a, the effects of the inhibitor (IC87114) and activator (740Y-P) on 
transmigration were assessed. In contrast to phagocytosis, IC87114 alone 
inhibited transmigration and 740 Y-P had no inhibitory effect (Figure V-25A). 
Unsurprisingly IC87114 was unable to prevent the defect in transmigration 
induced by C5a, however treatment with GM-CSF was (Figure V-25B), again 
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Figure V-25: The effects of C5a and PI3Kdelta modulation on 
neutrophil transmigration.
Panel A: transmigration by neutrophils across a 3micron transwell 
membrane towards an fMLP target following pre-treatment with 
vehicle control, 180nM IC87114 or 30pM 740 Y-P. Negative control is 
without fMLP. p=0.0029 by Kruskal-Wallis, *p<0.05, **p<0.01, NS p>0.05 
by Dunn’s post-hoc test.
Panel B shows transmigration by neutrophils across a 3micron 
transwell membrane towards an fMLP target following pre-treatment 
with vehicle control, 100nM C5a, 180nM IC87114 followed by 100nM 
C5a or 100nM C5a followed by 0.3nM GM-CSF. Negative control is 
without fMLP. p=0.0005 by Kruskal-Wallis, *p<0.05, **p<0.01, NS p>0.05 
by Dunn’s post-hoc test.
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(I) Defects in patient neutrophil phagocytosis mirror those seen in 
rhC5a-treated cells
Dissecting out the way in which rhC5a was able to inhibit zymosan phagocytosis 
in healthy human neutrophils suggested a number of targets to examine in 
neutrophils from critically ill patients. Neutrophils were taken from patients 
involved in the time-course study at time of study admission (see Methods 
section 2.03 d page 75), and their response to opsonised zymosan was examined. 
Figure V-26 demonstrates that phagocytosis was impaired to a similar degree to 
that seen in the VAP cohort (Figure III-1, page 100 above), Flowever these cells 
were obtained within 48 hours of ICU admission in contrast to the median 8 days 
in the VAP cohort.
***
Figure V-26: Phagocytosis by patients’ neutrophils is significantly 
reduced compared to healthy volunteers.
***p=0.001 by Mann-Whitney U-test. Data are shown as median (central 
line) inter-quartile range (box) and range (whiskers), (n=38 participants, 
28 patients and 10 healthy volunteers).
Again, as seen in the VAP cohort (Figure IV-12, page 131), there was a 
significant correlation between neutrophil surface CD8 8 expression and 
phagocytosis (Figure V-27). As before no such correlation was found with other
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markers of neutrophil activation, in that CD1 lb, CD16, CD64 and CD62L 
showed no significant correlation with phagocytosis (r=-0.05, 0.12,0.15, 0.01 
respectively, all p values >0.05 by Spearman’s Rlio).
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Figure V-27: Relationship between surface CD88 expression and 
phagocytosis by neutrophils.
n=28 individual patients, p and rvalues by Spearman’s Rho.
Having confirmed the relationship between C5a exposure (as measured by 
CD8 8 ) and phagocytosis, the next step was to evaluate the mechanistic features 
determined during exposure of healthy neutrophils to rhC5a. Patients’ 
neutrophils exposed to zymosan failed to activate RhoA (Figure V-28). Indeed, a 
small reduction was observed in RhoA relative to baseline, similar to that seen in 
rhC5a-treated cells (Figure V-14 page 158). Patients’ neutrophils were also 
unable to effectively polymerise actin in response to zymosan (Figure V-29A, 
page 171), in keeping with the effects described for healthy neutrophils exposed 
to C5a (Figure V-15 page 159). Figure V-29B shows example data from the
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flow cytometric analysis of actin polymerisation. In notable contrast to the 
results seen in healthy donor neutrophils (Figure V-4B, page 148) geometric 
mean fluorescence falls following exposure to zymosan.
Patients
Figure V-28: RhoA activation in response to zymosan is impaired in 
patient neutrophils.
**P=0.002 by Mann-Whitney U-test. Data are shown as median and inter­
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Figure V-29. Actin polymerisation by patient neutrophils in response 
to zymosan.
Panel A Actin polymerisation following 5 minutes of zymosan 
exposure is impaired in patients. **P=0.006 by t-test. Data are shown 
as mean and SEM (n=15; 10 patients and 5 healthy volunteers).
Panel B Example data for actin polymersation by patient neutrophils.
The left-hand panel shows the forward/side scatter characteristics of the 
neutrophils, and the right-hand shows the FL-1 channel fluorescence 
(indicating degree of phalloidin staining) in unstimulated cells (red) and 
those exposed to zymosan for five minutes (blue). The geometric mean 
fluorescence for each is displayed in the box above.
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(m) GM-CSF is able to 'rescue' phagocytosis by patient neutrophils.
In keeping with its ability to reverse rhC5a-induced phagocytic defects, ex-vivo 
application of GM-CSF to patient neutrophils was able to restore phagocytosis to 
levels similar to those seen in healthy volunteers (Figure V-30)
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Figure V-30: GM-CSF restores phagocytosis in patients’ neutrophils. 
Panel A: Data from patient neutrophils exposed to control or 0.3nM 
(5ng/ml) GM-CSF. ***p<0.001 by Wilcoxon rank-sum test. Solid lines 
indicate median values (n=24 patients).
Panel B: Example data from one patient’s neutrophils, illustrating the 
poor phagocytosis in the control treated cells and restored phagocytosis 
following GM-CSF. (X32 magnification)
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Section 5.03 Chapter summary and discussion
Chapter 4 demonstrated the association between markers of C5a exposure and 
defects in neutrophil function. Chapter 5 expands on this by exploring the 
mechanism that underlies this defect. C5a binds to its major receptor, CD8 8 , 
which activates the associated G-proteins. This in turn signals PI3Ks, both 
gamma and delta, to activate and act on their down-stream effector molecules. 
PI3K delta activation inhibits RhoA-GTP formation, consistent with work by 
other groups (Papakonstanti, Ridley & Vanhaesebroeck 2007), which then 
prevents the actin polymerisation response to phagocytic targets (i.e. zymosan). 
This results in the cell being unable to effectively phagocytose. Through 
mechanisms that remain partly opaque, GM-CSF is able to restore RhoA 
activation, actin polymerisation and phagocytosis. (Figures V-17 to 19). In a 
different group of patients from those explored in chapters 3 and 4, a similar 
degree of phagocytic defect was seen and the correlation between CD8 8 and 
phagocytosis confirmed (Figure V-27 page 169). Further strength was added to 
the supposition that the defect in patients is driven by C5a in the finding of close 
similarities in the intracellular response to zymosan, namely the impairment of 
Rho-GTP formation and actin polymerisation and the ability of GM-CSF to 
resurrect phagocytosis.
A potential weakness of this experimental approach relates to the relevance ot 
the assay used to assess phagocytosis. Zymosan particles are derived from yeast 
(,Saccharomyces cerevisiae) and are large compared to other phagocytic targets 
such as bacteria. Furthermore the use of cells adhered onto tissue culture plastic 
in IMDM may not fully reflect the physiological and pathophysiological
185
situations found in healthy and diseased humans. As such there remained a risk 
that the observations reflect in vitro artefacts specific to the model used. 
Therefore, a test of biological and clinical relevance was required. This forms 
the bulk of the next chapter, examining the relationship between C5a-mediated 
neutrophil dysfunction and a clinically significant outcome, namely acquisition 
of nosocomial infection.
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Article VI. A n  enquiry into patterns of C5a-mediated 
neutrophil dysfunction in critically ill patients and its 
relevance to immunophenotyping and the acquisition of 
nosocomial infection
Section 6.01 Chapter overview and introduction
Chapter 5 demonstrated the mechanism by which C5a can impair the
phagocytosis of zymosan, as well as indicating other potential impacts on 
neutrophil function. However the clinical relevance of these findings remained 
uncertain.
Although C5a-mediated neutrophil dysfunction is a novel finding in critically ill 
humans, it is not the only immune dysfunction characterised in this patient 
population. As shown in Chapter One, a variety of other immune cells are 
shown to be hypo-functional in sepsis and other forms of critical illness. It is 
therefore interesting to examine how C5a-mediated neutrophil dysfunction co­
exists, if at all, with these other cellular defects.
Although as Chapter I (section 1.05 pages 51-58) makes clear, immune cells in 
various compartments display defects in functioning in critical illness, circulating 
cells are those which are destined for potential sites of infection and represent a 
key part of the body’s response to any invading organism. Furthermore, cells in 
the blood which remain the most accessible both to researchers and clinicians, 
and hence findings from such cells are likely to be the most readily translatable 
into routine clinical practice. Therefore this chapter explores the patterns of
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dysfunction in three cells, neutrophils, peripheral blood monocytes and T-cells 
(specifically the percentage of immuno-suppressive, regulatory T-cells). These 
are then related to the occurrence of nosocomial infection, the outcome measure 
chosen for immune suppression.
The hypothesis for this chapter is that C5a-mediated neutrophil dysfunction will 
exist alongside other immune dysfunctions, will predict risk of nosocomial 
infection and that patients with more immune dysfunctions will be at greater risk 
of infections.
This chapter takes each examined cell type in turn, starting with the neutrophil. 
Firstly the definition of dysfunction is established, followed by an exposition of 
the temporal patterns of such dysfunctions and then an examination of the 
relationship between the dysfunction and the acquisition of nosocomial infection. 
The final section is an examination of the effects of combining measures of 
immune dysfunction on the ability to predict infection acquisition.
I am grateful to Dr Niall Anderson for his help and advice on the statistical 
analysis of data presented in this chapter.
Section 6.02 Results
(a) Defining neutrophil dysfunction.
Assays of cellular function are informative, in that they indicate what the cells 
are actually doing in response to an immune challenge within a patient.
Flowever they are time consuming, require specialised equipment and procedures 
and may not be easy to standardise. Therefore proxy measures of function are
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desirable, allowing more rapid throughput and assessment of a patient’s current 
immunophenotype. To this end, using the data from Chapters 4 and 5, a readily 
assessable measure of C5a-mediated neutrophil dysfunction was derived.
As previously discussed, neutrophil surface CD8 8 expression varies in response 
to C5a exposure as well as showing a strong correlation with a key function i.e. 
phagocytosis (Figures IV-12, page 131 and V-27, page 169), and as such its use 
as a proxy measure of neutrophil dysfunction was evaluated. Section 5.02 a 
(page 143) demonstrated that after exposure to lOnM C5a, phagocytosis by 
healthy donor neutrophils drops below 50%. Section 4.02 h, (page 128) 
demonstrated that exposure to lOnM C5a induced an approximate 20% reduction 
in surface CD 8 8 expression. lOnM C5a reduced CD8 8 expression from a mean 
of 319 arbitrary fluorescence units (AFU) to a mean of 249 AFU, hence a cut-off 
of 250 was chosen. A post-hoc examination of how this cut-off related to 
phagocytosis in patients was performed by regression analysis of the data 
presented in Figure V-26, (page 168) which revealed that a CD 8 8 expression 
level of 250 AFU equated to a phagocytic capacity of 50% (Figure V-27, page 
169) strikingly similar to the results achieved with in-vitro exposure to rhC5a 
(Figure V-l, page 144). A further examination of optimal cut-offs for CD8 8 is 
expounded below (Section 6.02 a).
(b) Recruitment of critically ill patients
Prior to recruitment starting a target was set by power calculation. An estimate
of the rate of infection amongst patients staying for a48 was made using existing 
infection surveillance data that showed a rate of 25%. As there was a lack of
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previous data on the effect of neutrophil dysfunction, an estimated doubling of 
the risk of nosocomial infection was assumed. Thus an intended recruitment of 
92 would have 80% power at an alpha of 0.05 to detect such a difference, whilst 
100 patients would have an anticipated event rate of 25, hence a recruitment 
target of 100 was selected. Ultimately a cohort of 96 patients was recruited. 
Figure VI-1 shows the consort diagram for recruitment. One patient had missing 
data on regulatory T-cells due to failure of flow staining, so was excluded 
leaving 95 patients to enter the final analysis.
591 patients screened
250 not eligible (no organ 
failures, or predicted stay 
<48 hours]
187 contraindications *
55 study team 
unavailable
3 study at capacity
 96 patients enrolled
Figure VI-1: Consort diagram showing screening and recruitment of patients.
* Reasons for exclusion are as follows; 50 consent not available or 
declined, 49 in an incompatible study, 43 receiving immunosuppressants 
other than cortico-steroids, 20 not expected to survive >24 hours, 12 
confirmed or suspected H1N1, 5 previously in study, 4 being transferred 
to another unit in <48 hours, 2 HIV, 2 pregnant.
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(c) Patterns of CD88 expression over time
At study admission (i.e. within 48 hours of ICU admission) the median CD8 8  
was 230 AFU (IQR 167-286), with 57 patients’ neutrophils (60%) being below 
the cut-off of 250. The scatter-gram of CD 8 8 values at the point of entry to the 
study is shown in Figure VI-2. By study day 4, 63 patients remained in ICU 
without having acquired infection, of whom 54 (8 6 %) were below the cut-off of 
250. Figure VI-3 shows the distribution of CD8 8 values at each time point for 
all patients, restricting this to the 23 patients with samples until day 8-10 showed 
a similar downward trend in median CD8 8 levels, although individual patients 
demonstrated various patterns of rising, falling or static CD8 8 values (data not 
shown).
Figure VI-2: Scatter-gram of neutrophil surface CD88 values on 
admission to the study.
n=95 patients, solid line indicates the cut-point for dysfunction (250 
arbitrary fluorescence units)
S  650-i § 600- eo
Study Admission
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Figure VI-3: Neutrophil surface CD88 expression at various time 
points.
Data shown as median (central line), inter-quartile range (box) and range 
(whiskers), line under graph indicates number of samples from each time 
point n=6 healthy donors (HD). CD88 expressed a geometric mean 
fluorescence (geoMCF) in arbitrary units. ADM=study admission (within 
48 hours of ICU admission). P<0.001 by Kruskal-Wallis ANOVA, all 
study time points differ significantly from healthy donors (HD, P<0.05 by 
Dunn’s post-hoc test). Hatched red line indicates the cut off for 
‘dysfunction’ derived below.
To permit analysis a summary measure was developed, allowing patients to be 
dichotomised into those with ‘dysfunction’ and ‘no dysfunction’. Patients who 
were admitted with CD8 8 < 250 AFU and remained below 250 AFU throughout 
were classified as ‘dysfunction’, similarly those who were admitted with CD 8 8  
>250 AFU but fell below 250 AFU, censored for 2 days prior to event in those 
acquiring infection, were classified as ‘dysfunction’. Those admitted with CD 8 8  
>250 AFU and who remained >250 AFU throughout were classified as ‘no 
dysfunction’, similarly those admitted with CD8 8 < 250 AFU but rising above
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Figure VI-4: Illustration dichotomising patients into ’dysfunction’ or 
‘no dysfunction’ groups.
Hatched line at 250=cut off for dysfunction. Example 1, all of a given 
patient’s results below cut-off=dysfunction. Example 2, values from a 
patient start high but fall below the cut-off =dysfunction. Example 3, ail of 
a given patient’s results are above the cut-off=no dysfunction. Example 4, 
a patient’s values start low but rise to above the cut off before any 
infection occurring=no dysfunction. ADM=study admission (within 48 
hours of ICU admission)
Overall, 69 patients fell into the ‘dysfunction’ group, whilst 26 were in the no 
dysfunction’ group. 83% of patients remained in the same group as admission, 
with 16 (17%) changing group; 13 moving from CD88>250 to < 250, whilst 3 
moved from < 250 to >250. Eleven changes occurred within the first two days
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of the study, and 13 within the first 4 days, with only 3 changes occurring later 
on in the admission.
(d) The characteristics of patients with and without C5a-mediated 
neutrophil dysfunction
Demographic and clinical characteristics of the patients, dichotomised by CD 8 8 - 
indicated dysfunction, are shown in table VI-1 below. Table VI-2 shows the 
outcomes, namely acquisition of infection and mortality. Those with C5a- 
mediated dysfunction showed a 5.4 (95% Cl 1.4-21.0) times relative risk of 
nosocomial infection compared to those without dysfunction. As a sensitivity 
analysis, the effect was compared excluding those with only ‘probable’ 
infections. This revealed a relative risk increase of 4.6 (95% Cl 1.2-18.0, 
p=0.008 by Fisher’s exact test), which did not differ significantly from the 
combined ‘confirmed’ and ‘probable’ infections analysis. Similarly, excluding 
those patients who shifted from one CD8 8 classification to another had no 
significant effect on relative risk of nosocomial infection (RR 4.7, 95% Cl 1.2- 
18.3, P=0.007 by Fisher’s exact test).
To examine the accuracy of the pre-defined cut-off point for CD 8 8 (i.e.
250AFU) a receiver operator characteristic (ROC) curve was constructed, 
comparing the sample most temporally related to infection (censored for two 
days prior) with samples from patients who did not develop infection. Youden’s 
method (Youden, 1950) indicated an optimal cut-off point of 246AFU, justifying 
the pre-defined definition.
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Table VI-1 contains details concerning the various risk factors set out in Chapter 
1 (table 1-2, page 23) that have been previously identified as being associated 
with nosocomial infection (reviewed by Vincent JL, 2003). Significant 
differences in these factors between the two groups could, therefore, confound 
any effects of C5a-mediated neutrophil dysfunction on nosocomial infection. Of 
note data on smoking (current or stopped within previous year) and alcohol use 
(defined as > 1 0  units or < 1 0  units consumption /week) are not included in the 
table as these data were poorly recorded in the ICU notes (data present for only 
58% of patients). However amongst those patients for whom it was recorded 
there were no significant differences between the two groups (alcohol >1 0units 
occurring in 47% and 42% of patients with and without dysfunction, p=l by 
Fisher’s exact test.; a history of smoking occurring in 47% and 48%, p=l by 
Fisher’s). Outcomes in terms of acquisition of nosocomial infection and 
mortality are shown in table VI-2 below.
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57 (43-71) 62 (46-72) 0.71 *
%  male 62% 6 6 % 0 . 8 §
%  admitted with
sepsis
44% 44% 1 §
%  surgical 
patients
25% 26% 1 §
%  trauma 
patients
1% 1 2% 0.07 §
%  receiving 
corticosteroids
28% 15% 0.29 §





3 (1-4.5) 3 (1-4) 0.74 *
%  with diabetes 
mellitus
2 0 % 15% o oo oCO
%  with chronic 
lung disease
17% 1 1% 0.75§
%  intubated 8 8 % 92% 050Ö
%  central venous 
catheter
8 8 % 92% 0.7 §
%  urinary 
catheter
94% 92% 0 .6 6 §




2 2 % 2 0 % 1§











9(7-11) 6 (4-9) 0.003 *
median (IQR) 
peak SOFA score
9(8-13) 6 (4-10) 0 .0 0 2 *
Table VI-1: Demographic and clinical details for patients with and 
without C5a-mediated neutrophil dysfunction.
IQR-inter-quartile range, SOFA sequential organ failure assessment, 
APACHE I -acute physiology and chronic health evaluation II, * p value 
by Mann-Whitney, § p value by Fisher’s exact test.
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Outcome Dysfunction No dysfunction P value
(Fisher’s exact 
test)
%  acquiring 
infection in ICU
43% 8 % 0 . 0 0 1
%  crude unit 
mortality
29% 15% 0 . 2
%  crude hospital 
mortality




0.72 0.62 1 . 0
Table VI-2: Outcomes for patients with and without dysfunction.
SMR calculated from APACHE I predicted mortality
Amongst patients in the dysfunction group there was significantly increased C3a 
concentrations over time, indicating persistent complement activation. In 
contrast, patients in the no dysfunction group showed a trend towards reducing 
C3a levels (Figure VI-5). This dichotomised pattern was not replicated for any 
of the cytokines examined (with the levels remaining unchanged or deci easing in 
both groups for IL-1 (3, 6 , 8 , 10 and TNF-a) and for the marker of neutrophil 
activation sCD62L (table VI-3). C5a rose by a small amount in both groups, 
although the rise was not significant in either (median rise 9ng/ml in the 
dysfunction group (p=0.058) and 2 ng/ml in no dysfunction group (p 0 .1, both p 
values by Wilcoxon rank sum test). As an alternative analysis, peak values for 
each of the cytokines, anaphylatoxins and soluble receptors were compared 
between patients with and without dysfunction (table VI-4). C3a was the only 
molecule that showed significantly higher levels in the dysfunction group than 
the non-dysfunction group, mirroring the results of the change over time analysis
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above. There were non-significant trends to higher levels of IL- 8 and sCD62L in 
the dysfunction group, but both IL-1|3 and TNF showed higher levels in the non­
dysfunction group suggesting that pro-inflammatory activation was not restricted 
to one group of patients or the other.
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Figure VI-5: Change in C3a levels between admission and study 
endpoint.
Endpoints being infection, death or discharge -in the case of infection 
censored for 2 days prior to infection) in patients with and without CD88 
defined neutrophil dysfunction. N=91 patients, 69 with dysfunction and 
22 without (4 patients had only one sample so could not be included in 














2 (0-5) 1(0-5) 4(2-7) 5(3-8)
IL- 6 (pg/ml) 242 (82-639) 90 (42-285)** 200 (113-521) 92 (39-168)**





25 (14-75) 17(9-39)*** 25 (16-46) 14(8-27)**
TNF (pg/ml) 2 (0-7) 3(0-8) 6(2-12) 5(3-11)
sCD62L
(ng/ml)
456(331-714) 494 (329-712) 402 (259-636) 415 (259-574)
Table VI-3: Change in cytokine levels between admission and
endpoint for patients with and without neutrophil dysfunction.
*P<0.05, **<0.01, ***<0.0001 by Wilcoxon Rank Sum test for difference 


















3(0-8) 7 (3-9) 0 (0-6) 0.03
IL- 6 (pg/ml) 364(119-
1021)
200(116-521) 0(0-11) 0.22
IL- 8 (pg/ml) 165 (66-464) 91 (36-209) 0 (0-7) 0.06
IL-10
(pg/ml)
31 (18-100) 31 (16-64) 0 (0-4) 0.95






Table VI-4: Peak cytokine levels in patients with and without 
neutrophil dysfunction.
P value is by Mann-Whitney U-test between patient groups. Values 
shown as median and inter-quartile range. Healthy volunteer values are 
provided for comparison purposes.
(e) C5a-mediated neutrophil dysfunction as a predictor of 
nosocomial infection
Although C5a-mediated neutrophil dysfunction is clearly associated with a 
significant increase in the risk of acquiring nosocomial infection in the ICU, it
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remains a possibility that this effect may result from the influence of 
confounding variables. Two possible groups of confounders present themselves, 
firstly ‘duration of exposure’, i.e. length of time in ICU, and secondly the risk 
factors identified in table VI-1 above as significantly different between the two 
groups. To analyse the effect of these a Cox hazards model was constmcted, 
including all variables with a significant difference between the ‘dysfunction’ 
and ‘no dysfunction’ groups although using a more liberal definition of 
‘significance’ of p<0 . 1 to avoid excluding factors with a clear trend but which 
narrowly avoided the standard significance cut off of <0.05. Accordingly the 
factors included alongside ‘dysfunction’, were ‘admission with trauma’, ‘blood 
transfusion’, ‘renal replacement therapy’ and ‘peak SOFA score’. Admission 
SOFA and peak SOFA showed significant co-linearity (r2=0.8), hence only one 
measure was chosen. Table VI-5 shows the results of the analysis. Only 
‘dysfunction’ showed any significant relationship with the acquisition of 
infection. Exclusion of co-variates with p value of >0.1 by backwards stepwise 
removal results in a model containing dysfunction alone, with an overall p value 
of 0.036.
Figure VI- 6 shows the Kaplan-Meier plot for infection in patients with and 
without dysfunction.
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P Value Hazard ratio (95% 
Confidence Interval)
‘Dysfunction’ 0.05 4.1 (1.0-17)
Blood Transfusion* 0.54 1.5 (0.7-3.4)
Trauma 0.91 1.3 (0.3-3.9)
Renal replacement therapy 0.18 0.63 (0.3-1.4)
Peak SOFA score 0.22 1 (0.9-1.1)
Table VI-5: Hazard ratios and P values for the variables included in 
the Cox hazards model of infection acquisition.
* Blood transfusion was included as a time-dependent co-variate as 
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Figure VI-6: Kaplan-Meier plot for patients with and without 
neutrophil dysfunction.
P=0.04 by log-rank test. Numbers underneath indicate numbers 
remaining in alive in ICU without infection at each time point.
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(f) Relationship between CD88 and infection.
In the VAP cohort (Chapters 3 and 4) the blood sample was taken on the day 
infection was diagnosed, so preventing assessment of whether the infection 
preceded the dysfunction or vice-versa. In the prospective cohort described in 
this Chapter samples were censored for 2 days prior to infection to try and 
minimise the effect of any infection on the results. To further test the potential 
relationship between infection and CD8 8 , surface expression was compared in 




Admission with sepsis Admission without sepsis
Figure VI-7: CD88 expression amongst patients admitted with and 
without sepsis. Data shown as median and inter-quartile range.
n= 95 patients, 42 with and 53 without sepsis. NS, p=0.5 by Mann- 
Whitney.
The prospective cohort also allowed assessment of CD8 8 levels before and after 
infection, comparing all those who developed infections and showing the trends 
over time in this group (Figure VI-8).
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XI T9-5 days before 3-4 days before 2 days before
Sample point relative to infection
i n f e c t i o n  + 1
Figure VI-8: CD88 expression before and after nosocomial infection.
Data from n=33 patients acquiring infections, p=0.74 by Kruskal-Wallis 
ANOVA. Hatched line indicates the cut-off value for ‘dysfunction’.
Interestingly, analysis of those patients admitted to ICU with sepsis sub-divided 
into those with hospital-acquired and those with community-acquired infections 
showed a divergence in CD8 8 expression (figure VI-9). All patients admitted to 
ICU with hospital-acquired infection had CD 8 8 levels below the 250 AFU cut-
Figure VI-9: CD88 expression in patients admitted with hospital- 
acquired (HA) or community-acquired (CA) sepsis.
Solid lines indicate median values. Hatched line indicates 250 AFU cut­
off for neutrophil dysfunction. N=42 patients, 9 with HA and 33 with CA 
sepsis. *p=0.02 by Mann-Whitney U test.
off.





(g) Other immune dysfunctions
Several other problems with the immune system have been examined in the
context of sepsis and critical illness (see section 1.05, pages 51-60). Two of these 
were examined in the prospective study cohort. First was monocyte deactivation, 
by measuring surface HLA-DR expression (Hoflich et al. 2002), and the second 
was the percentage of regulatory T-cells (Venet et al. 2009). These are discussed 
in more detail in the following sections.
(h) Monocyte deactivation
Several groups have now reported the presence of‘deactivated’ monocytes in the 
peripheral circulation of patients with sepsis (Docke et al. 1997), trauma 
(Asadullah et al. 1995) and fulminant hepatic failure (Berry et al. 2011). The 
cardinal feature of monocyte deactivation is the inability of the cells to mount an 
effective TNF-a response to a challenge of LPS. This was also demonstrated in 
the sub-set of patients in the VAP study in whom monocyte function was 
examined (see section 3.02 e, page 102). Baehr and colleagues demonstrated 
that monocyte HLA-DR expression could act as a marker for monocyte 
deactivation (Baehr et al. 1989).
In the 95 patients in the prospective cohort, monocyte HLA-DR expression was 
determined as per the Methods section 2.03 1 (page 87), using QuantiBRITE 
beads (BD Bioscience) to provide quantification of PE molecules per cell.
Meisel and colleagues used the same technique to guide GM-CSF therapy in 
critically ill adults (Meisel et al. 2009), and suggested a cut-ott of 8000
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molecules/cell for monocyte deactivation. Figure VI-10 shows the patterns of
HLA-DR expression over time. Patients showed depressed median HLA-DR 
expression relative to healthy donors at all time points sampled.
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Figure VI-10: HLA-DR expression by peripheral blood monocytes.
Data shown as median (central line), inter-quartile range (box) and range 
(whiskers), from n=95 patients at multiple time points and n=6 healthy 
donors (HD), numbers at each time point as per Figure VI-3 page 181. 
P=0.0013 by Kruskal-Wallis ANOVA, Dunn’s post hoc test <0.01 for 
patients vs. healthy donors at all time points except D8 (P<0.05) and D10 
(P>0.05).
(i) Deriving a cut-off and categorising monocyte 'deactivation'
As with neutrophil CD 8 8 , patients were divided into those with and without
monocyte deactivation on the basis of whether their results fell above or below
the cut-off. Those who changed from one side of the cut-off to the other were
categorised in the same way as for CD 8 8 (Figure VI-4, page 182).
Initial analysis of the patients using the cut-off proposed by Meisel (Meisel et al.
2009) of 8000 revealed 42 patients with monocyte deactivation. Using this cut-
off to define deactivation produced a relative risk of infection of 1.34 (95% Cl
0.7-2.3, P=0.39) compared to those without dysfunction.
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To determine whether this was the optimal cut-off, a ROC curve was 
constructed, comparing the sample most temporally related to infection 
(censored for two days prior) with samples from patients who did not develop 
infection. Youden’s method indicated an optimal cut-off point of 10,000 
molecules per cell.
This adjusted cut-off resulted in 62 patients being classified as having 
‘deactivated’ monocytes and 33 having ‘no deactivation’. 22 patients changed 
groups during their stay ( 1 1 moving from ‘deactivation’ to ‘no deactivation’ and 
11 moving in the other direction). Using this adjusted cut-off the relative risk of 
infection was 3 (95%CI 1.3-6.9, p=0.0035 by Fisher’s exact test).
(j) Regulatory (CD4+,CD25+,FoxP3+) T-cells
As discussed in the Introduction (section 1.05 e page 55), work by Monneret and 
colleagues (Venet et al. 2009) has demonstrated the presence of elevated levels 
of immuno-suppressive regulatory T-cells (T-regs) in patients with sepsis. They 
have also demonstrated an association between elevated levels of these cells and 
mortality in patients with sepsis and septic shock (Huang et al. 2010, Monneret et 
al. 2003).
Levels of T-regs, expressed as a percentage of total CD4+ve T-helper (Th) cells, 
were determined in patients. As shown in figure VI-11 there were higher levels 
of T-regs in patients than in healthy individuals, although the difference only 
became significant at day 6 . As the previous work had shown T-regs to be 
elevated in sepsis, patients were dichotomised into those with and without sepsis
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on admission for analysis of T-reg levels. Figure VI-12 shows the data from 
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Figure VI-11 : T-regs as a percentage of all CD4+ TH cells.
Data shown as median (central line), inter-quartile range (box) and range 
(whiskers), from n=95 patients at multiple time points and n=6 healthy 
donors (HD), numbers at each time point as per Figure VI-3 page 181. 
P=0.027 by Kruskal-Wallis ANOVA, ** p<0.01 by Dunn’s post hoc test for 
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Figure VI-12: T-reg levels by admission diagnosis.
Data shown as mean and SEM. N=95 patients, 42 with sepsis and 53 
without. P=0.11 for difference between the groups by two-way ANOVA.
It is therefore apparent that T-reg levels do not differ significantly between
patients with and without sepsis, and therefore likely that the elevated levels
represents a reaction to the inflammatory state that occurs in both septic and non-
septic critical illness.
(k) Setting a cut-off for 'elevated' T-reg cells
Amongst the healthy volunteers the median percentage of T-reg cells was 3.8%,
with a maximum of 10%. A similar maximum of 10% was found by Monneret 
(Venet et al. 2009), with similar values found in other work (Taams et al. 2001, 
Stephens et al. 2001) Therefore 10% was set as the cut-off for ‘normal’ levels of 
T-reg cells.
Thirty-seven patients had T-regs which rose above 10% prior to discharge, 
forming the ‘T-reg high’ group whilst 58 were in the ‘T-reg normal group. In 
contrast to HLA-DR and CD8 8 , patients whose levels rose above 10% were 
often in the ‘normal’ group at admission, 26 patients moving from normal to
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‘high’ levels of T-regs during admission, whilst 8 patients moved from ‘high’ to 
normal.
Those patients whose T-regs rose above 10% prior to discharge had a relative 
risk for developing infection of 2.4 (95%CI 1.3-4.2, p=0.002) compared to those 
patients whose T-regs remained below this level. As before the cut-off point was 
examined using an ROC curve, which produced an optimal cut-off point of 9.8%, 
close to that derived from using the healthy volunteer maximum.
(I) Details of ICU-acquired infections
Thirty three (35%) patients developed confirmed or suspected infection, 26




Blood stream infections - 4
Catheter-related blood stream 
infections -3
Urinary tract infections- 5
Surgical site/soft tissue infections-4Probable infections
Pneumonia- 4 (all VAP)
Intra-abdominal infection- 3
Table VI-6: Site of infections acquired in ICU.
In total 20 patients underwent adjudication panel review, 5 were ruled 
confirmed , 7 piobable and 8 ‘unlikely’. The organisms cultured are shown in 
table VI-7. Ot the non-confirmed adjudications, 6 of the 7 ‘probable’ infections 
had either negative cultures with other strong clinical evidence of infection or did 
not have cultures taken as care was being withdrawn but with strong clinical
210
evidence. The remaining ‘probable’ patient grew bacteria below the 104 CFU/rnl 
cut off for quantitative BAL fluid. Of the ‘unlikely’ infections, two had negative 
cultures with no potential focus of infection identified, 5 had positive cultures 
without any evidence of infection (termed ‘colonisation’) and 1 had persistence 
of the same organism cultured on admission with a change in antibiotic 
sensitivities.
211
I n f e c t i o n  c a t e g o r y O r g a n i s m F r e q u e n c y
C o n f i r m e d B u r k h o l d e r i a  c e p a c i a 1
C i t r o b a c t e r  b r a a k i i 1
E n t e r o b a c t e r  c lo a c a e 3
E s c h e r i c h i a  c o l i 5
C o l i f o r m  - n o  f u r t h e r  
s p e c i f i c a t i o n
1
E n t e r o c o c c u s  f a e c a l i s 2
K l e b s i e l l a  p n e u m o n i a e 2
H a e m o p h i l u s  in f lu e n z a e 1
P s e u d o m o n a s  a e r u g i n o s a 3
S t a p h y l o c o c c u s  a u r e u s 3
C o a g u l a s e  n e g a t i v e  
S t a p h y l o c o c c i
1
S t r e p t o c o c c u s
p n e u m o n i a e
1
O t h e r  S t r e p t o c o c c i 1
A n a e r o b e s 1
C a n d i d a  a l b i c a n s 4
H e r p e s  s i m p l e x 1
P r o b a b l e C u l t u r e  n e g a t i v e 4
N o  s a m p l e s  t a k e n  a s  c a r e  
w i t h d r a w n
2
S t a p h y l o c o c c u s  a u r e u s 1
U n l i k e l y C u l t u r e  n e g a t i v e 2
A c i n e t o b a c t e r  b a u m a n n i i I
H a e m o p h i l u s  in f lu e n z a e 1
K l e b s i e l l a  p n e u m o n i a e 1
C o a g u l a s e  n e g a t i v e  
S t a p h y l o c o c c i
2
S t r e p t o c o c c u s
p n e u m o n i a e
1
S t a p h y l o c o c c u s  a u r e u s 2
C a n d i d a  a l b i c a n s 1
Table VI-7: Culture results from patients with confirmed, suspected 
and unlikely infections.
Some patients grew more than one organism from the site of infection.
2 1 2
O f  t h e  p a t i e n t s  a c q u i r i n g  i n f e c t i o n  i n  t h e  I C U ,  1 2  h a d  s e p s i s  o n  a d m i s s i o n .  N o n e  
o f  t h e s e  g r e w  t h e  s a m e  o r g a n i s m  o n  a d m i s s i o n  a n d  f o l l o w i n g  t h e  a c q u i s i t i o n  o f  
i n f e c t i o n .  O n l y  o n e  p a t i e n t  d e v e l o p e d  i n f e c t i o n  a t  t h e  s a m e  s i t e  a s  t h e  s i t e  o f  
a d m i s s i o n  i n f e c t i o n ,  a  p a t i e n t  a d m i t t e d  w i t h  V a r i c e l l a  z o s t e r  p n e u m o n i a  w h o  
d e v e l o p e d  K l e b s i e l l a  p n e u m o n i a e  v e n t i l a t o r - a s s o c i a t e d  p n e u m o n i a  6  d a y s  a f t e r  
a d m i s s i o n .  I t  t h e r e f o r e  s e e m s  u n l i k e l y  t h a t  i n f e c t i o n s  p r e s e n t  a t  a d m i s s i o n  w e r e  
m i s t a k e n  f o r  n o s o c o m i a l  i n f e c t i o n .
(m) Characteristics of patients developing infection.
T h e  s e c t i o n s  a b o v e  h a v e  d e m o n s t r a t e d  t h a t  a  m a j o r i t y  o f  c r i t i c a l l y  i l l  p a t i e n t s  
h a v e  C 5 a - m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  a n d  t h a t  t h i s  i s  a s s o c i a t e d  w i t h  a n  
i n c r e a s e d  r i s k  o f  n o s o c o m i a l  i n f e c t i o n .  T h i s  r i s k  a p p e a r s  t o  b e  i n d e p e n d e n t  o f  
o t h e r  e s t a b l i s h e d  r i s k  f a c t o r s .  T h e r e  r e m a i n s  t h e  p o s s i b i l i t y  t h a t  p a t i e n t s  w h o  
d e v e l o p  i n f e c t i o n s  a r e  d i f f e r e n t  i n  o t h e r  w a y s  f r o m  t h o s e  w h o  d o  n o t ,  a n d  
t h e r e f o r e  a n  a n a l y s i s  w a s  u n d e r t a k e n  o f  t h e  c l i n i c a l  a n d  d e m o g r a p h i c  f e a t u r e s  o f  
t h o s e  p a t i e n t s  w h o  d i d  a n d  d i d  n o t  d e v e l o p  i n f e c t i o n .
2 1 3
Variable Infection No infection P value
N= 33 62
median (range) age 60 (20-88) 59 (16-85) 0.92*
%  male 61% 63% 0.418
%  admitted with 
sepsis
34% 50% 0.20s
%  surgical patients 30% 23% 0.46s
%  trauma patients 3% 5% 0.65s
%  receiving 
corticosteroids
30% 23% 0.46s





3 (1.5-4) 3(1-5) 0.42*
%  with diabetes 
mellitus
21% 11% 0.78s
%  with chronic 
lung disease
6% 21% © Ö oo CV
.
%  intubated 97% 85% 0.16s
%  central venous 
catheter
97% 85% 0.16s
%  urinary catheter 100% 90% 0.09s


















median (IQR) peak 
SOFA score
9 (8-12.5) 8(5-11) 0.16*
%  with neutrophil 
dysfunction
94% 62% 0.0007s
%  with monocyte 
deactivation
85% 55% 0.003s
%  with elevated T - 
regs
61% 27% 0.0016s
Table VI-8: Demographic and clinical features of patients who 
developed nosocomial infection and those who did not.
*P by Mann-Whitney, § P by Fisher’s exact test
(n) Immune dysfunction and nosocomial infection
I n  s e c t i o n s  6 . 0 2  a - f  t h e  p r e v a l e n c e  a n d  i m p a c t  o f  C 5 a - m e d i a t e d  n e u t r o p h i l  
d y s f u n c t i o n  i s  d i s c u s s e d ,  n o t i n g  i t s  i m p a c t  o n  a c q u i s i t i o n  o f  n o s o c o m i a l
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i n f e c t i o n .  S e c t i o n s  6 . 0 2  g - k  s h o w  t h a t  t h i s  a s s o c i a t i o n  i s  n o t  c o n f i n e d  t o  
n e u t r o p h i l s ,  b u t  a l s o  e x t e n d s  t o  d e a c t i v a t e d  m o n o c y t e s  a n d  e l e v a t e d  l e v e l s  o f  T -  
r e g s .  W i t h  t h e s e  t h i e e  f a c t o r s  b e i n g  t h e  o n l y  o n e s  w h i c h  d i f f e r e d  s i g n i f i c a n t l y  
b e t w e e n  p a t i e n t s  w i t h  a n d  w i t h o u t  n o s o c o m i a l  i n f e c t i o n  i n  t h e  s i m p l e  a n a l y s i s  i n  
t a b l e  V I - 8 .
T o  e x a m i n e  w h e t h e r  t h e  e f f e c t s  o f  e a c h  o f  t h e s e  t h r e e  i m m u n e  d e f e c t s  w e r e  
a d d i t i v e  o r  s i m p l y  o c c u r r e d  t o g e t h e r ,  s e v e r a l  a n a l y s e s  w e r e  c o n d u c t e d .  F i r s t  w a s  
a n  a n a l y s i s  o f  c o - l i n e a r i t y  b e t w e e n  t h e  t h r e e  d y s f u n c t i o n s .  N o n e  o f  t h e  t h r e e  h a d  
a  c o r r e l a t i o n  c o - e f f i c i e n t  o f  > 0 . 2 5 ,  i n d i c a t i n g  s u f f i c i e n t  i n d e p e n d e n c e  f o r  e n t r y  
i n t o  a  m u l t i p l e  r e g r e s s i o n  m o d e l .  S e c o n d ,  t h e  t h r e e  w e r e  p l a c e d  i n  a  b i n a r y  
l o g i s t i c  r e g r e s s i o n  m o d e l  w i t h  i n f e c t i o n  a s  t h e  d e p e n d e n t  v a r i a b l e .  T h e  r e s u l t s  
a r e  s h o w n  i n  t a b l e  V I - 9  b e l o w ,  w i t h  a l l  t h r e e  r e t a i n i n g  t h e i r  i n d e p e n d e n t  
p r e d i c t i v e  e f f e c t .
P a r a m e t e r O d d s  r a t i o  
( 9 5 % C I )  o f  
a c q u i s i t i o n  o f  
i n f e c t i o n
P  v a l u e
N e u t r o p h i l
d y s f u n c t i o n
7 . 6  ( 1 . 5 - 3 7 ) 0 . 0 1 3
M o n o c y t e
d e a c t i v a t i o n
4 . 7 ( 1 . 4 - 1 5 . 7 ) 0 . 0 1 3
E l e v a t e d  T - r e g s 4 . 3 ( 1 . 6 - 1 2 . 1 ) 0 . 0 0 4
Table VI-9: Logistic regression model for the relationship between 
individual immune dysfunctions and the acquisition of nosocomial 
infection
Interaction significant at P < 0 . 0 1  by binary logistic regression
F i n a l l y  t h e  e f f e c t  o f  c u m u l a t i v e  o c c u r r e n c e  o f  i m m u n e  d y s f u n c t i o n  w a s  a n a l y s e d .  
A l t h o u g h  t h e  p o i n t  e s t i m a t e s  f o r  t h e  r e l a t i v e  r i s k  ( a n d  r e g r e s s i o n - d e r i v e d  o d d s  
r a t i o s )  f o r  n o s o c o m i a l  i n f e c t i o n  d i f f e r e d  b e t w e e n  t h e  d y s f u n c t i o n s ,  t h e i r  
c o n f i d e n c e  i n t e r v a l s  o v e r l a p p e d  t o  a  h i g h  d e g r e e ,  p r e c l u d i n g  a n y  a s s i g n m e n t  o f
2 1 5
d i f f e r e n t i a l  r i s k .  A s  a  r e s u l t  a  v a l u e  o f  ‘  1 ’  w a s  a p p l i e d  t o  e a c h  d y s f u n c t i o n ,  a n d  
t h e  p a t i e n t s  a n a l y s e d  b y  w h e t h e r  t h e y  h a d  0 , 1 , 2  o r  3  d y s f u n c t i o n s  ( t a b l e  V I - 1 0 ) .
N u m b e r  o f  
d y s f u n c t i o n s  a
N = %  a c q u i r i n g  
n o s o c o m i a l  i n f e c t i o n  
( 9 5 %  C l )
0 1 1 0  ( 0 - 0 % )
1 2 1 1 0 %  ( 0 - 2 2 % )
2 4 3 3 7 %  ( 2 3 - 5 2 % )
3 2 0 7 5 %  ( 5 6 - 9 4 % )
Table VI-10: Relationship between burden of immunodysfunction 
and acquisition of nosocomial infection.
( i.e. C5a-mediated neutrophil dysfunction, monocyte deactivation and 
elevated regulatory T-cells). P=0.0004 by Chi squared test for trend.
(o) Interaction between immune dysfunction and other risk factors 
for infection.
A s  n o t e d  i n  S e c t i o n  1 . 0 2  c  ( p a g e  1 8 )  m u l t i p l e  f a c t o r s  h a v e  b e e n  a s s o c i a t e d  w i t h  
n o s o c o m i a l  i n f e c t i o n .  I t  r e m a i n s  p o s s i b l e  t h a t  t h e  a p p a r e n t l y  s t r o n g  a n d  a d d i t i v e  
e f f e c t s  o f  i m m u n e  d y s f u n c t i o n s  a r e  s i m p l y  e p i p h e n o m e n a  o f  o t h e r  e s t a b l i s h e d  
r i s k  f a c t o r s  f o r  i n f e c t i o n .  T o  e x a m i n e  t h i s  a  C o x  h a z a r d s  m o d e l  w a s  
c o n s t r u c t e d .  T o  s e l e c t  t h e  v a r i a b l e s  t o  b e  i n c l u d e d  i n  t h e  m o d e l  u n i v a r i a t e  
a n a l y s i s  w a s  p e r f o r m e d  f o r  r e l a t i o n s h i p  b e t w e e n  t h e  v a r i a b l e  a n d  a c q u i s i t i o n  o f  
i n f e c t i o n  ( T a b l e  V I - 1 1 ) ,  w i t h  v a r i a b l e s  w i t h  a  p - v a l u e  o f  < 0 . 1  b e i n g  e n t e r e d  i n t o  
t h e  m o d e l .  G i v e n  t h e  v a r i a b i l i t y  o f  T - r e g  c o u n t s  a n d  t h e i r  p r o p e n s i t y  t o  c h a n g e  
f r o m  ‘ h i g h ’  t o  T o w ’  o r  v i c e  v e r s a  d u r i n g  s t a y ,  t h e  m o d e l  w a s  c o n s t r u c t e d  w i t h  T -  
r e g s  a s  a  t i m e - d e p e n d e n t  v a r i a b l e .
T h e  r e s u l t s  o f  t h e  m o d e l  a r e  s h o w n  i n  t a b l e  V I - 1 2  b e l o w ,  d e m o n s t r a t i n g  t h a t  b o t h  
C 5 a - m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  a n d  e l e v a t e d  T - r e g  c e l l s  r e m a i n e d  
s i g n i f i c a n t  p r e d i c t o r s  o f  i n f e c t i o n  w h i l s t  m o n o c y t e  d e a c t i v a t i o n  l o s t  i t s
2 1 6
s i g n i f i c a n c e  ( p = 0 . 0 7 ) .  B o t h  t h e  c l i n i c a l  p r e d i c t o r s  o f  i n f e c t i o n  l o s t  t h e i r  
s i g n i f i c a n t  e f f e c t  o n c e  t h e y  e n t e r e d  t h e  m o d e l .
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V a r i a b l e I n f e c t i o n N o
i n f e c t i o n
P  v a l u e  f o r
u n i v a r i a t e
a n a l y s i s
P r e - m o r b i d
f a c t o r s
c o m o r b i d  
c o n d i t i o n s  
( m e d i a n / I Q R  
C h a r l s o n  i n d e x )
3  ( 1 . 5 - 4 ) 3  ( 1 - 5 ) 0 . 4 4
%  w i t h  c h r o n i c  
l u n g  d i s e a s e
6 % 2 1 % 0 . 2
%  w i t h  d i a b e t e s  
m e l l i t u s
2 1 % 1 1 % 0 . 8 9
m e d i a n  ( r a n g e )  a g e 6 0  ( 2 0 -  
8 8 )
5 9  ( 1 6 - 8 5 ) 0 . 7 7
%  m a l e 6 1 % 6 3 % 0 . 8 2
A d m i s s i o n  f a c t o r s m e d i a n  ( I Q R )  
a d m i s s i o n  S O F A  
s c o r e
9  ( 6 . 5 -  
1 1 )
8  ( 4 - 1 0 ) 0 . 2 7
m e d i a n  ( I Q R )  
a d m i s s i o n  
A P A C H E  I I  S c o r e
2 1  ( 1 8 -  
2 6 )
2 3 . 5 ( 1 8 . 5 -
2 9 )
0 . 5 5
a d m i s s i o n  w i t h  
s h o c k
7 7 % 5 6 % 0 . 0 7
a d m i s s i o n  w i t h  
s e p s i s
3 4 % 5 0 % 0 . 2 4
a d m i s s i o n  
f o l l o w i n g  s u r g e r y
3 0 % 2 3 % 0 . 3 9
a d m i s s i o n  
f o l l o w i n g  t r a u m a
3 % 5 % 0 . 0 5
C o n t i n u e d  o v e r  
p a g e
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I l l n e s s  c o u r s e /  
i n t e r v e n t i o n s  
p r i o r  t o  e n d - p o i n t  
a c h i e v e m e n t
m e d i a n  ( I Q R )  P e a k  
S O F A  s c o r e
9 ( 8 -
1 2 . 5 )
8 ( 5 - 1 1 ) 0 . 2 7
%  i n t u b a t e d 9 7 % 8 5 % 0 . 8 8
%  w i t h  c e n t r a l  
v e n o u s  c a t h e t e r
9 7 % 8 5 % 0 . 7 0
%  r e c e i v i n g  r e n a l
r e p l a c e m e n t
t h e r a p y
4 2 % 3 9 % 0 . 3 7
%  w i t h  
t r a c h e o s t o m y
9 % 6 % 0 . 7 7
%  w i t h  u r i n a r y  
c a t h e t e r
1 0 0 % 9 0 % 0 . 3 5
%  r e c e i v i n g  H ?  
a n t a g o n i s t / p r o t o n  
p u m p  i n h i b i t o r
1 0 0 % 9 3 % 0 . 1 4
%  r e c e i v i n g  
c o r t i c o s t e r o i d s
3 0 % 2 3 % 0 . 5 8
%  r e c e i v i n g  a  
b l o o d  t r a n s f u s i o n
5 2 % 4 4 % 0 . 4 2
%  r e c e i v i n g  t o t a l  
p a r e n t e r a l  n u t r i t i o n
2 7 % 1 8 % 0 . 2 6
m e d i a n  ( I Q R )  
l e n g t h  o f  s t a y  ( p r i o r  
t o  i n f e c t i o n )
6 ( 5 - 7 ) 5 ( 3 - 8 ) 0 . 2 2
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I m m u n e  p r o f i l i n g %  w i t h  e l e v a t e d  
T - r e g s
6 0 % 2 4 % 0 . 0 0 4
%  w i t h  l o w  C D 8 8 9 4 % 6 2 % 0 . 0 0 1
%  w i t h  l o w  H L A -  
D R
8 5 % 5 5 % 0 . 0 0 6
Table VI-11: Patient demographic and clinical factors amongst those 
with and without nosocomial infection.
Right hand column indicates p value for univariate analysis (regression 
for continuous/ordinal variables and phi coefficient for binary categorical 
variables).
V a r i a b l e P  v a l u e H a z a r d  R a t i o  ( 9 5 %  C l )
O v e r a l l  m o d e l  P  v a l u e 0 . 0 3 7 N A
S h o c k  o n  a d m i s s i o n 0 . 5 1 1 . 3  ( 0 . 6 - 3 . 2 )
A d m i s s i o n  w i t h  t r a u m a 0 . 6 5 0 . 7 5  ( 0 . 2 - 2 . 6 )
* E l e v a t e d  T - r e g s 0 . 0 5 2 . 1  ( 1 . 0 - 4 . 2 )
C 5 a - m e d i a t e d  n e u t r o p h i l  
d y s f u n c t i o n
0 . 0 5 4 ( 1 . 0 - 1 9 . 1 )
M o n o c y t e  d e a c t i v a t i o n 0 . 0 7 2 . 4  ( 0 . 9 2 - 6 . 5 )
Table VI-12: Cox model for occurrence of nosocomial infection.
*Elevated T-regulatory cells were expressed as a time-dependent co­
va ri ate.
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I n  C h a p t e r  5 ,  t h e  m e c h a n i s m  u n d e r p i n n i n g  C 5 a - m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  
w a s  d e t e r m i n e d .  H o w e v e r ,  a s  d i s c u s s e d ,  t h e  p h y s i o l o g i c a l  r e l e v a n c e  r e m a i n e d  
u n c e r t a i n .  F u r t h e r m o r e ,  a l t h o u g h  a  r e l a t i o n s h i p  b e t w e e n  n e u t r o p h i l  d y s f u n c t i o n  
a n d  v e n t i l a t o r - a s s o c i a t e d  p n e u m o n i a  w a s  i d e n t i f i e d  i n  C h a p t e r s  3  a n d  4 ,  t h e  
t e m p o r a l  r e l a t i o n s h i p  b e t w e e n  t h e s e  t w o  e n t i t i e s  r e q u i r e d  f u r t h e r  i n v e s t i g a t i o n .
C h a p t e r  6  a d d r e s s e s  t h e s e  t w o  i s s u e s .  C 5 a - m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  i s  
s h o w n  t o  b e  c o m m o n  a m o n g s t  c r i t i c a l l y  i l l  p a t i e n t s ,  a n d  t e n d s  t o  o c c u r  e a r l y  i n  
t h e  c o u r s e  o f  a d m i s s i o n  t o  I C U .  A l t h o u g h  s o m e  p a t i e n t s  e x p e r i e n c e  r e s o l u t i o n  o f  
t h i s  d y s f u n c t i o n  d u r i n g  t h e i r  I C U  s t a y ,  m a n y  h a v e  p e r s i s t i n g  d y s f u n c t i o n  u p  u n t i l  
t h e y  a r e  d i s c h a r g e d  o r  d e v e l o p  a  n o s o c o m i a l  i n f e c t i o n .  T h i s  c h a p t e r  a l s o  
d e m o n s t r a t e s  t h e  u t i l i t y  o f  n e u t r o p h i l  s u r f a c e  C D 8 8  a s  a  m a r k e r  f o r  t h i s  
d y s f u n c t i o n ,  r e v e a l i n g  t h a t  t h o s e  p a t i e n t s  w i t h  l o w  C D 8 8  ( a n d  h e n c e  C 5 a -  
m e d i a t e d  d y s f u n c t i o n )  h a v e  a  5 - f o l d  i n c r e a s e d  r i s k  o f  d e v e l o p i n g  n o s o c o m i a l  
i n f e c t i o n .  G i v e n  t h e  a s s o c i a t i o n  b e t w e e n  l o w  C D 8 8  e x p r e s s i o n  a n d  v e n t i l a t o r -  
a s s o c i a t e d  p n e u m o n i a  i d e n t i f i e d  i n  C h a p t e r  4 ,  i t  i s  i n t e r e s t i n g  t o  n o t e  t h a t  t h e r e  
i n f e c t i o n  i t s e l f  d i d  n o t  s e e m  t o  d e p r e s s  C D 8 8  f u r t h e r .  T h e s e  t w o  f i n d i n g s  
s u g g e s t  t h a t  n e u t r o p h i l  d y s f u n c t i o n  i s  a  r i s k  f a c t o r  f o r  n o s o c o m i a l  i n f e c t i o n  
r a t h e r  t h a n  s i m p l y  a n  e p i p h e n o m e n o n .
A s  n o t e d  i n  t h e  I n t r o d u c t i o n  ( C h a p t e r  1 ) ,  a n d  i n  C h a p t e r  3 ,  i t  i s  u n l i k e l y  t h a t  
n e u t r o p h i l  d y s f u n c t i o n  i s  t h e  s o l e  i m m u n e  d e f e c t  w i t h  r e l e v a n c e  t o  n o s o c o m i a l  
i n f e c t i o n  a c q u i s i t i o n .  C h a p t e r  3  r e v e a l e d  t h e  p r e s e n c e  o f  m o n o c y t e  d e a c t i v a t i o n  
i n  p a t i e n t s  w i t h  s u s p e c t e d  Y A P .  I n  C h a p t e r  6  t h i s  f i n d i n g  i s  c o n f i r m e d  a n d
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e x t e n d e d ,  d e m o n s t r a t i n g  t h a t  m a n y  c r i t i c a l l y  i l l  p a t i e n t s  h a v e  l o w  m o n o c y t e  
H L A - D R  e x p r e s s i o n  a n d  t h a t  t h i s  i s  a l s o  a  p r e d i c t o r  o f  n o s o c o m i a l  i n f e c t i o n .
R e g u l a t o r y  T - c e l l s  h a v e  b e e n  i d e n t i f i e d  i n  s e p s i s  a s  b e i n g  e l e v a t e d ,  a t  l e a s t  a s  a  
p r o p o r t i o n  o f  t o t a l  l y m p h o c y t e s  a n d / o r  C D 4  p o s i t i v e  l y m p h o c y t e s  ( V e n e t  e t  a l .  
2 0 0 9 ) .  T h i s  f i n d i n g  h a s  b e e n  e x t e n d e d  b y  s h o w i n g  s i m i l a r  e l e v a t i o n  i n  p a t i e n t s  
w i t h  n o n - s e p t i c  c r i t i c a l  i l l n e s s ,  s u g g e s t i n g  t h a t  i n c r e a s e s  i n  t h e s e  i m m u n o ­
s u p p r e s s i v e  c e l l s  i s  p a r t  o f  t h e  s t e r e o - t y p e d  ‘ C A R S ’  r e s p o n s e  t o  s y s t e m i c  
i n f l a m m a t o r y  i n s u l t s .  A g a i n ,  i n  k e e p i n g  w i t h  m o n o c y t e  d e a c t i v a t i o n  a n d  
n e u t r o p h i l  d y s f u n c t i o n ,  e l e v a t e d  l e v e l s  o f  T - r e g s  a r e  a  s i g n i f i c a n t  p r e d i c t o r  o f  
n o s o c o m i a l  i n f e c t i o n .
I t  i s ,  h o w e v e r ,  t h e  c o m b i n a t i o n  o f  t h e s e  t h r e e  i m m u n e  d y s f u n c t i o n s  t h a t  b r i n g s  
a b o u t  t h e  m o s t  i n t e r e s t i n g  f i n d i n g  i n  t h i s  c h a p t e r .  A b s e n c e  o f  a n y  d y s f u n c t i o n  
a p p e a r s  t o  p r o t e c t  a g a i n s t  n o s o c o m i a l  i n f e c t i o n ,  a l t h o u g h  c a u t i o n  m u s t  b e  
e x p r e s s e d  g i v e n  t h e  s m a l l  n u m b e r  o f  p a t i e n t s  w h o  h a d  n o  d y s f u n c t i o n .  
C u m u l a t i v e  a d d i t i o n  o f  i m m u n e  d y s f u n c t i o n s  s e e m s  t o  b r i n g  a b o u t  a n  a d d i t i v e  
i n c r e a s e  i n  t h e  r i s k  o f  a c q u i r i n g  i n f e c t i o n ,  t o  t h e  p o i n t  w h e r e  t h o s e  p a t i e n t s  w i t h  
a l l  t h r e e  h a v e  a  7 5 %  r i s k  o f  a c q u i s i t i o n  w h i c h  i s  f a r  a b o v e  t h a t  s e e n  i n  p a t i e n t s  
w i t h  s e v e r e  n e u t r o p a e n i a  f o l l o w i n g  c h e m o t h e r a p y  o r  b o n e  m a r r o w  a b l a t i o n  
( G I M E M A  a u t h o r s l 9 9 1 ) .  T h a t  t h i s  r i s k  a p p e a r s  t o  b e  i n d e p e n d e n t  o f  o t h e r  
f a c t o r s  p r e v i o u s l y  m o o t e d  a s  r i s k s ,  s u c h  a s  s e v e r i t y  o f  i l l n e s s ,  i n v a s i v e  d e v i c e s  
a n d  c o - m o r b i d  c o n d i t i o n s ,  a s  w e l l  a s  o f f e r i n g  a  m e c h a n i s t i c a l l y  p l a u s i b l e  r o l e  i n  
c a u s a t i o n  i s  p a r t i c u l a r l y  e x c i t i n g .  T h e  i m p l i c a t i o n s  o f  t h i s  w i l l  b e  d i s c u s s e d  i n  
C h a p t e r  7  ( D i s c u s s i o n  a n d  C o n c l u s i o n s ) .
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Article VII. Discussion and conclusions
Section 7.01 Inflammation and dysfunction
I n  t h e  w o i k  p r e s e n t e d  i n  C h a p t e r  3  i t  w a s  s h o w n  t h a t  c r i t i c a l l y  i l l  p a t i e n t s  w i t h  
s u s p e c t e d  V A P  h a d  e v i d e n c e  o f  i m m u n e  a c t i v a t i o n  a n d  i n f l a m m a t i o n .  P e r i p h e r a l  
b l o o d  n e u t r o p h i l s  d e m o n s t r a t e d  i n c r e a s e d  e x p r e s s i o n  o f  C D 1  l b ,  a l t h o u g h  a s  
t a b l e  I V - 2  ( p a g e  1 2 6 )  s h o w e d  i n  t h e  f o l l o w i n g  c h a p t e r  t h i s  w a s  n o t  a c c o m p a n i e d  
b y  i n c r e a s e d  b a s a l  o r  i n d u c e d  a c t i v a t i o n  o f  t h e  s a m e  r e c e p t o r .  S i m i l a r l y  s e r u m  
m a r k e r s  o f  n e u t r o p h i l  a c t i v a t i o n ,  H N E  a n d  M P O ,  w e r e  e l e v a t e d  i n  p a t i e n t s .  
S e r u m  h y p e r c y t o k i n a e m i a  w a s  a l s o  p r e s e n t ,  w i t h  e l e v a t i o n  s h o w n  i n  a  b r o a d  
r a n g e  o f  c y t o k i n e s ,  a n a p h y l a t o x i n s ,  c h e m o t a x i n s  a n d  c o l o n y  s t i m u l a t i n g  f a c t o r s .  
O f  n o t e  w a s  t h e  c o n c u r r e n t  e l e v a t i o n  o f  t h e  a n t i - i n f l a m m a t o r y  m o l e c u l e  I L - 1 0 .  
E x a m i n a t i o n  o f  n e u t r o p h i l - e p i t h e l i a l  i n t e r a c t i o n s  r e v e a l e d  i n c r e a s e d  p r o -  
i n f l a m m a t o r y  r e s p o n s e s  i n d u c e d  b y  n e u t r o p h i l s  f r o m  p a t i e n t s ,  s u g g e s t i n g  t h a t  t h e  
c e l l s  a r e  ‘ p r i m e d ’  i n - v i v o ,  a n d  r e s p o n d  e x c e s s i v e l y  t o  a  b a c t e r i a l  i n s u l t ,  
d e m o n s t r a t i n g  f u n c t i o n a l  c o n s e q u e n c e s  o f  t h e  n o t e d  i m m u n e  a c t i v a t i o n .
A c r o s s  m o s t  p l a s m a /  p e r i p h e r a l  b l o o d  c e l l  m e a s u r e s  t h e r e  w a s  l i t t l e  t o  
d i f f e r e n t i a t e  t h o s e  p a t i e n t s  w i t h  m i c r o b i o l o g i c a l l y  c o n f i r m e d  V A P  f r o m  t h o s e  
w h o s e  c l i n i c a l  d i a g n o s i s  w a s  n o t  c o n f i r m e d ,  a l t h o u g h  t h e r e  w e r e  d i f f e r e n c e s  i n  
C D  1 6  e x p r e s s i o n  a n d  s e r u m  H N E  l e v e l s .  T h i s  i s  i n  k e e p i n g  w i t h  t h e  e x i s t i n g  
w o r k  o n  S I R S  a n d  s e p s i s ,  d e m o n s t r a t i n g  t h a t  b o t h  s t e r i l e  a n d  i n f e c t i o u s  i n s u l t s
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i n d u c e  s y s t e m i c  a c t i v a t i o n  o f  t h e  i n n a t e  i m m u n e  s y s t e m  ( S a k a m o t o  e t  a l .  2 0 1 0 ,  
M c I L w a i n  e t  a l .  2 0 1 0 ,  M i y a o k a  e t  a l .  2 0 0 5 ) .  V A P  h a s  s o m e  a d d i t i o n a l  e f f e c t s  o n  
n e u t r o p h i l  a c t i v a t i o n ,  a l t h o u g h  t h i s  d o e s  n o t  a p p e a r  t o  t r a n s l a t e  i n t o  i n c r e a s e d  
s t i m u l a t e d  r e s p o n s e s  t o  L P S  w h e n  c o - c u l t u r e d  w i t h  t h e  A 5 4 9  t y p e  I I  a l v e o l a r  
e p i t h e l i a l  c e l l  l i n e .  I n  s t r i k i n g  c o n t r a s t ,  s a m p l i n g  t h e  p u l m o n a r y  c o m p a r t m e n t  
r e v e a l e d  a  p r o f o u n d  i n f l a m m a t o r y  r e s p o n s e  a c r o s s  a  r a n g e  o f  m e a s u r e s  a n d  
w h i c h  w a s  l a r g e l y  r e s t r i c t e d  t o  t h o s e  p a t i e n t s  w i t h  c o n f i r m e d  V A P ,  i n d e e d  t h e  
r e s p o n s e  w a s  s u f f i c i e n t l y  d i s c r i m i n a t o r y  a s  t o  o f f e r  d i a g n o s t i c  p o t e n t i a l  ( C o n w a y  
M o m s  e t  a l .  2 0 1 0 ) .
D e s p i t e  t h i s  a b u n d a n t  e v i d e n c e  o f  i m m u n e  a c t i v a t i o n  a n d  i n f l a m m a t i o n ,  t h e r e  
w e r e  m a r k e d  d e f i c i e n c i e s  i n  k e y  c e l l  f u n c t i o n s .  N e u t r o p h i l s  f r o m  p a t i e n t s  w e r e  
u n a b l e  t o  e f f i c i e n t l y  p h a g o c y t o s e ,  a n d  r e l e a s e d  d i m i n i s h e d  l e v e l s  o f  s u p e r o x i d e  
i o n s  i n  r e s p o n s e  t o  c l a s s i c  n e u t r o p h i l  s t i m u l i .  B o t h  t h e s e  p r o c e s s e s  a r e  c r u c i a l  t o  
n e u t r o p h i l s ’  a n t i - b a c t e r i a l  f u n c t i o n s  ( H a y w a r d  e t  a l .  1 9 7 9 ,  W i n k e l s t e i n  e t  a l .  
2 0 0 0 ) ,  a n d  t h e i r  d e f i c i e n c y  i s  l i k e l y  t o  r e n d e r  p a t i e n t s  v u l n e r a b l e  t o  i n f e c t i o n .  
S i m i l a r  d e f e c t s  i n  p h a g o c y t o s i s  w e r e  i d e n t i f i e d  i n  n e u t r o p h i l s  w h i c h  h a d  
t r a n s m i g r a t e d  i n t o  t h e  a l v e o l a r  s p a c e ,  r e f u t i n g  t h e  h y p o t h e s i s  t h a t  n e u t r o p h i l  
d y s f u n c t i o n  i n  c r i t i c a l  i l l n e s s  i s  a n  a r t i f a c t u a l  f i n d i n g  r e s u l t i n g  f r o m  s a m p l i n g  t h e  
p e r i p h e r a l  p o o l  w h e n  t h e  m o r e  a c t i v e  c e l l s  h a v e  m i g r a t e d  i n t o  i n f l a m e d  t i s s u e s .
I n  t h e  o t h e r  c e l l  t y p e  e x a m i n e d ,  m o n o c y t e s ,  a g a i n  t h e r e  w a s  e v i d e n c e  o f  
d i m i n i s h e d  f u n c t i o n  w i t h  r e d u c e d  p r o d u c t i o n  o f  T N F - a  i n  r e s p o n s e  t o  L P S  
s t i m u l a t i o n ,  a g a i n  a  d e f i c i e n c y  w h i c h  h a s  b e e n  l i n k e d  t o  i n c r e a s e d  r i s k  o f  
i n f e c t i o n  ( L a n d e l l e  e t  a l .  2 0 1 0 ) .
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T h e  f i n d i n g s  o f  h y p e r c y t o k i n a e m i a  a n d  c o m p l e m e n t  a c t i v a t i o n  h a v e  b e e n  f o u n d  
i n  m u l t i p l e  h u m a n  s t u d i e s  i n  c r i t i c a l  i l l n e s s  ( S a k a m o t o  e t  a l .  2 0 1 0 ,  M c I L w a i n  e t  
a l .  2 0 1 0 ,  M i y a o k a  e t  a l .  2 0 0 5 ) ,  a s  w e l l  a s  i n  a n i m a l  m o d e l s  o f  c o n d i t i o n s  s u c h  a s  
s e p s i s  ( S a f r a n e k  e t  a l .  2 0 0 6 ) ,  p a n c r e a t i t i s  ( D i b  e t  a l .  2 0 0 3 )  a n d  b u m s  ( L i u  e t  a l .
2 0 0 8 ) .  S i m i l a r l y  t h e  n e u t r o p h i l  a c t i v a t i o n  m e a s u r e s  r e p o r t e d  h a v e  b e e n  f o u n d  i n  
s i m i l a r  s t u d i e s  ( R a o o f  e t  a l .  2 0 1 0 ,  O g l e  e t  a l .  1 9 8 5 ) .  T h e  c o m p a r t m e n t a l i s e d ,  
p u l m o n a r y  i n f l a m m a t i o n  i n  c o n f i r m e d  V A P  i s  a l s o  c o n s i s t e n t  w i t h  p u b l i s h e d  
r e p o r t s  ( M i l l o  e t  a l .  2 0 0 4 ) ,  a l t h o u g h  t h e  d i a g n o s t i c  p o t e n t i a l  i s  a  n o v e l  f i n d i n g .
1 L - 1 0  i s  a  p o t e n t  a n t i - i n f l a m m a t o r y  c y t o k i n e  ( M o o r e  e t  a l .  2 0 0 1 ) ,  w h i c h  
i n f l u e n c e s  t h e  f u n c t i o n s  o f  n u m e r o u s  i m m u n e  c e l l s .  A l o n g s i d e  i n h i b i t o r y  e f f e c t s  
o n  n e u t r o p h i l s  ( S u n  e t  a l .  2 0 0 9 ) ,  i t  h a s  b e e n  i m p l i c a t e d  i n  t h e  p a t h o g e n e s i s  o f  
m o n o c y t e  d e a c t i v a t i o n  ( S f e i r  e t  a l .  2 0 0 1 a ) ,  p o l a r i s a t i o n  o f  m a c r o p h a g e s  t o w a r d s  
t h e  M 2  p h e n o t y p e  ( M a r t i n e z  e t  a l .  2 0 0 8 )  a n d  e x t e n d s  i t s  i n f l u e n c e  i n t o  t h e  
a d a p t i v e  i m m u n e  s y s t e m  b y  p o l a r i s i n g  T - c e l l s  t o w a r d s  a  r e g u l a t o r y  p h e n o t y p e  
( L a n g i e r ,  S a d e  &  K i v i t y  2 0 1 0 ) .  I n d e e d  e l e v a t e d  l e v e l s  o f  I L - 1 0  h a v e  b e e n  
p r o m o t e d  a s  a  k e y  m e d i a t o r ,  a n d  i n d i c a t o r ,  o f  t h e  C A R S .  T h e  s i m u l t a n e o u s  
e l e v a t i o n  o f  I L - 1 0  a n d  t h e  p r o - i n f l a m m a t o r y  c y t o k i n e s  n o t e d  i n  t h e  p a t i e n t  c o h o r t  
r e p o r t e d  h e r e  i s  t h e r e f o r e  a n  e x p e c t e d  f i n d i n g ,  a l t h o u g h  i t  i s  n o t a b l e  t h a t  t h i s  
a p p e a r s  t o  b e  l a r g e l y  r e s t r i c t e d  t o  t h e  p e r i p h e r a l  r a t h e r  t h a n  p u l m o n a r y  
c o m p a r t m e n t .  S e v e r a l  p r e v i o u s  i n v e s t i g a t o r s  h a v e  n o t e d  t h e  s i m u l t a n e o u s  
e l e v a t i o n  o f  p r o -  a n d  a n t i - i n f l a m m a t o r y  m e d i a t o r s ,  a n d  s u g g e s t e d  t h a t  C A R S  b e
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m o d i f i e d  t o  m i x e d  a n t i - i n f l a m m a t o r y  r e s p o n s e  s y n d r o m e  ( M A R S )  t o  e m p h a s i s e  
t h i s  d u a l i t y  ( B o n e  1 9 9 6 ,  O s u c h o w s k i  e t  a l .  2 0 0 6 ) .
W h a t  i s  a  n o v e l  o b s e r v a t i o n  i s  t h e  c o - o c c u r r e n c e  o f  i m m u n e  a c t i v a t i o n  a n d  
d y s f u n c t i o n  w i t h i n  t h e  s a m e  c e l l  t y p e ,  i n  t h i s  s i t u a t i o n  t h e  n e u t r o p h i l  w i t h  i t s  
f a i l u r e  o f  p h a g o c y t o s i s  a n d  R O S  p r o d u c t i o n  b u t  r e t a i n e d  a b i l i t y  t o  i n f l a m e  t i s s u e  
a n d  r e l e a s e  l y t i c  e n z y m e s  s u c h  a s  H N E .  W h e t h e r  t h e r e  a r e  f u n c t i o n a l l y  d i s t i n c t  
s u b - p o p u l a t i o n s  o f  n e u t r o p h i l s  r e s p o n s i b l e  f o r  t h i s  d i c h o t o m o u s  b e h a v i o u r ,  o r  i f  
t h e  c e l l s  a r e  t r u l y  c o n c u r r e n t l y  h y p e r  a n d  h y p o f u n c t i o n a l  r e m a i n s  t o  b e  
d e t e r m i n e d .  I t  i s  t e m p t i n g  t o  s p e c u l a t e  t h a t  t h e  i n t e n s e  p u l m o n a r y  i n f l a m m a t i o n  
i n  V A P  o c c u r s  p r e c i s e l y  b e c a u s e  o f  t h i s  d i c h o t o m o u s  b e h a v i o u r ,  w i t h  t h e  
d y s f u n c t i o n a l  n e u t r o p h i l s  u n a b l e  t o  c l e a r  i n v a d i n g  o r g a n i s m s  w h i c h  m u l t i p l y  t o  
t h e  p o i n t  w h e r e  t h e i r  ( t h e  m i c r o b e s ’ )  l e v e l  i s  s u f f i c i e n t  t o  s t i m u l a t e  t h e  r e l e a s e  o f  
c h e m o k i n e s  a n d  l y t i c  e n z y m e s ,  r e s u l t i n g  i n  f u r t h e r  r e c r u i t m e n t  o f  d y s f u n c t i o n a l  
n e u t r o p h i l s  a n d  t i s s u e  d a m a g e  a n d  f u r t h e r  w o r s e n i n g  r e s p i r a t o r y  f u n c t i o n .
T h i s  s t u d y  o f  V A P  b e n e f i t s  f r o m  h a v i n g  a  w e l l  c h a r a c t e r i s e d  c o h o r t  o f  p a t i e n t s ,  
s a t i s f y i n g  s t r i c t  p r e - d e f m e d  c r i t e r i a  f o r  c l i n i c a l l y  s u s p e c t e d  V A P ,  a n d  
r e p r e s e n t a t i v e  o f  a n  i m p o r t a n t  g r o u p  o f  p a t i e n t s  s e e n  i n  a l l  I C U s .  B y  s a m p l i n g  
b o t h  t h e  p e r i p h e r a l  a n d  p u l m o n a r y  c o m p a r t m e n t s  i t  w a s  p o s s i b l e  t o  i d e n t i f y  b o t h  
s i m i l a r i t i e s  a n d  c o n t r a s t s  b e t w e e n  t h e s e  t w o  a r e a s .  F u r t h e r m o r e ,  t h e  v o l u n t e e r s  
w e r e  c l o s e l y  m a t c h e d  t o  t h e  p a t i e n t s  i n  a g e  a n d  s e x ,  s o  l i m i t i n g  p o t e n t i a l  b i a s  b y  
c o m p a r i n g  w i t h  h e a l t h y  d o n o r s  w h o  w e r e  m u c h  y o u n g e r  a n d  f i t t e r .
226
H o w c v e i  s e v e i a l  i m p o r t a n t  c a v e a t s  r e m a i n .  F i r s t l y ,  t h e s e  p a t i e n t s  w e r e  s a m p l e d  
a t  a  s i n g l e  t i m e  p o i n t ,  n a m e l y  a t  t h e  t i m e  o f  c l i n i c a l  s u s p i c i o n  o f  V A P ,  a n d  t h i s  
w a s  t y p i c a l l y  8  d a y s  i n t o  t h e i r  I C U  a d m i s s i o n .  W h i l s t  i t  s e e m s  p l a u s i b l e  t h a t  t h e  
i m m u n e  d e f e c t s  p r e c e d e d  t h e  i n f e c t i o n ,  g i v e n  t h e  l a c k  o f  d i f f e r e n t i a t i o n  o f  t h o s e  
p a t i e n t s  w i t h  a n d  w i t h o u t  c o n f i r m e d  V A P  t h e  s t u d y  d e s i g n  p r e c l u d e s  e x c l u d i n g  
t h e  p o s s i b i l i t y  t h a t  i m m u n e  d y s f u n c t i o n  i s  a n  e p i p h e n o m e n o n  o f  I C U - A 1 .  
S i m i l a r l y  a l t h o u g h  t h e  i n t e n s e  p u l m o n a r y  c y t o k i n e  l e v e l s  m a y  w e l l  b e  t h e  
r e s p o n s e  t o  i n f e c t i o n ,  a g a i n  i t  i s  n o t  p o s s i b l e  t o  r u l e  o u t  t h e  a l t e r n a t i v e  
e x p l a n a t i o n  t h a t  p a t i e n t s  w i t h  p r e - e x i s t i n g  a l v e o l a r  i n f l a m m a t i o n  a r e  p r o n e  t o  
i n f e c t i o n s  ( M e d u r i  e t  a l .  1 9 9 5 ) .  F i n a l l y ,  a l t h o u g h  t h e  c o n t r o l  g r o u p  w e r e  a g e -  
a n d  s e x - m a t c h e d ,  t h e y  w e r e  n o t  m e c h a n i c a l l y  v e n t i l a t e d .  T h e r e f o r e  i t  i s  p o s s i b l e  
t h a t  v e n t i l a t i o n  o r  u n d e r l y i n g  c o - m o r b i d i t i e s  m a y  e x p l a i n  s o m e  o f  t h e  n e u t r o p h i l  
d y s f u n c t i o n  d e m o n s t r a t e d  i n  p a t i e n t s .
T h e  i m p l i c a t i o n s  f r o m  C h a p t e r  3  a r e  t h a t  c r i t i c a l  i l l n e s s ,  a t  l e a s t  l a t e r  o n  i n  t h e  
i n t e n s i v e  c a r e  s t a y ,  d o e s  n o t  r e s u l t  f r o m  e i t h e r  a  p u r e  h y p e r - i n f l a m m a t o r y  s t a t e  o r  
a  p u r e ,  s e c o n d a r y ,  h y p o - i n f l a m m a t o r y  r e s p o n s e .  I t  s h o u l d  p e r h a p s  b e  b e t t e r  
v i e w e d  a s  a  c o m p l e x  a n d  m a l a d a p t i v e  s t a t e  d i s p l a y i n g  f e a t u r e s  o f  b o t h  i m m u n e  
a c t i v a t i o n  a n d  s u p p r e s s i o n / d y s f u n c t i o n .  A  s i m i l a r  s i t u a t i o n  c a n  b e  f o u n d  i n  t h e  
c o a g u l a t i o n  s y s t e m  d u r i n g  d i s s e m i n a t e d  i n t r a v a s c u l a r  c o a g u l a t i o n  ( D I C ) ,  w h e r e  
s y s t e m i c  a n d  i n a p p r o p r i a t e  a c t i v a t i o n  o f  t h e  c o a g u l a t i o n  s y s t e m  r e s u l t s  i n  b o t h  
t h r o m b o t i c  i m p a i r m e n t  o f  p e r f u s i o n  a n d  s i m u l t a n e o u s  c o n s u m p t i v e  c o a g u l o p a t h y  
a n d  b l e e d i n g  r i s k  ( B i c k ,  A r u n  &  F r e n k e l  1 9 9 9 ) .
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F o l l o w i n g  t h e  d i s c o v e r y  o f  s i m u l t a n e o u s  i m m u n e  a c t i v a t i o n  a n d  n e u t r o p h i l  
s u p p r e s s i o n ,  t h e  n e x t  s t e p  w a s  t o  t r y  a n d  i d e n t i f y  t h e  m e c h a n i s m  u n d e r p i n n i n g  
t h e  d y s f u n c t i o n .  A l t h o u g h  a  r a n g e  o f  p l a u s i b l e  h y p o t h e t i c a l  m e c h a n i s m s  w e r e  
d e v e l o p e d ,  b a s e d  o n  t h e  p h a g o c y t i c  p a t h w a y  ( L e e ,  H a r r i s o n  &  G r i n s t e i n  2 0 0 3 )  
a n d  p o s s i b i l i t i e s  r a i s e d  b y  p r e v i o u s  s t u d i e s  ( M u l l e r  K o b o l d  e t  a l .  2 0 0 0 ,  
R o s e n b l o o m  e t  a l .  1 9 9 9 ,  A l e x a n d e r  e t  a l .  1 9 7 8 ,  B j o r n s o n ,  B j o m s o n  &  A l t e m e i e r  
1 9 8 1 ) ,  i t  u l t i m a t e l y  t r a n s p i r e d  t h a t  o n l y  t h e  C 5 a - b a s e d  m e c h a n i s m  f o u n d  a n y  
s u p p o r t  i n  m y  p a t i e n t  d a t a .
A s  n o t e d  i n  t h e  I n t r o d u c t i o n ,  t h e  m a j o r  i s s u e  w i t h  e x p l o r i n g  C 5 a  i n  h u m a n  
c r i t i c a l  i l l n e s s  i s  i t s  r a p i d  p l a s m a  c l e a r a n c e  a n d  c o n s e q u e n t  s h o r t  h a l f - l i f e  
( W e b s t e r ,  L a r s e n  &  H e n s o n  1 9 8 2 ) . .  T h e  b i n d i n g  o f  C 5 a  t o  C D 8 8  a n d  i t s  
s u b s e q u e n t  i n t e r n a l i s a t i o n  a n d  d o w n - r e g u l a t i o n  o f  s u r f a c e  e x p r e s s i o n  h a s  b e e n  
w e l l  e s t a b l i s h e d  ( C h e n o w e t h ,  H u g l i  1 9 7 8 )  a n d  p r e v i o u s  s t u d i e s  h a v e  s h o w n  
d i m i n i s h e d  C D 8 8  e x p r e s s i o n  o n  n e u t r o p h i l s  f r o m  c r i t i c a l l y  i l l  p a t i e n t s  ( F u r e b r i n g  
2 0 0 5 ) .  H o w e v e r  p r i o r  t o  t h i s  s t u d y  C D 8 8  h a d  n o t  b e e n  u s e d  a s  a  p r o x y  m e a s u r e  
f o r  n e u t r o p h i l  C 5 a  e x p o s u r e ,  a n d  t h e r e  h a d  b e e n  n o  p r e v i o u s  d e m o n s t r a t i o n  o f  
a n y  r e l a t i o n s h i p  b e t w e e n  C D 8 8  a n d  n e u t r o p h i l  f u n c t i o n s  s u c h  a s  p h a g o c y t o s i s .  
T h e  n e g a t i v e  c o r r e l a t i o n  w h i c h  e x i s t s  b e t w e e n  C 3 a  ( a n d  t o  a  l e s s e r  e x t e n t  C 5 a )  
a n d  p h a g o c y t o s i s ,  a l o n g s i d e  t h e  f a i l u r e  o f  a n y  o t h e r  c y t o k i n e  o r  c e l l  s u r f a c e  
m a r k e r s  e x a m i n e d  t o  c o r r e l a t e ,  f u r t h e r  s t r e n g t h e n e d  t h e  c a s e  f o r  t h e  d e f e c t  i n  
p h a g o c y t o s i s  b e i n g  a s s o c i a t e d  w i t h  c o m p l e m e n t  a c t i v a t i o n .
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I t  i s  i m p o r t a n t  t o  n o t e  t h a t  C 5 a  i s  n o t  t h e  o n l y  m o l e c u l e  k n o w n  t o  i n f l u e n c e  t h e  
e x p r e s s i o n  o f  C D 8 8 .  D a t a  f r o m  t h i s  s t u d y  d e m o n s t r a t e d  t h a t  i n t e r f e r o n - g a m m a  
c o u l d  i n c r e a s e  C D 8 8  e x p r e s s i o n  ( F i g u r e  V - 2 0 ,  p a g e  1 6 3 ) ,  w h i l s t  F u r e b r i n g  a n d  
c o l l e a g u e s  s h o w e d  T N F - c c  a n d  I L - 8  c o u l d  d i m i n i s h  i t s  e x p r e s s i o n  ( F u r e b r i n g  e t  
a l .  2 0 0 6 ) .  H o w e v e r  T N F - a  a n d  I L - 8  o n l y  r e d u c e d  C D 8 8  e x p r e s s i o n  w h e n  
a p p l i e d  a t  l e v e l s  t w o  t o  t h r e e  o r d e r s  o f  m a g n i t u d e  h i g h e r  t h a n  t h o s e  m e a s u r e d  i n  
t h e  p a t i e n t s  i n  t h e  s t u d i e s  p r e s e n t e d  h e r e  ( t a b l e  I I I - 3  p a g e  1 0 9  a n d  t a b l e s  V I - 3 , 4  
p a g e  1 8 9 ) ,  w h i l s t  t h e  c o n c e n t r a t i o n  o f  i n t e r f e r o n  g a m m a  u s e d  ( 5 n g / m l )  i s  h i g h e r  
t h a n  t h a t  s e e n  i n  p r e v i o u s  s t u d i e s  o f  s e v e r e  s e p s i s  a n d  o r g a n  f a i l u r e  ( P i n k s y  e t a l.  
1 9 9 3 ) .  T h e r e f o r e ,  a l t h o u g h  w e  c a n  b e  f a i r l y  c o n f i d e n t  t h a t  C D 8 8  e x p r e s s i o n  i s  
l a r g e l y  d e t e r m i n e d  b y  i n - v i v o  C 5 a  e x p o s u r e ,  w e  c a n n o t  d e f i n i t i v e l y  r u l e  o u t  t h e  
i n f l u e n c e  o f  o t h e r  i n f l a m m a t o r y  m o l e c u l e s  w h i c h  c o u l d  c o n f o u n d  t h e  a s s o c i a t i o n  
s e e n  a n d  r e d u c e  t h e  u s e M n e s s  o f  C D 8 8  i n  t h i s  c o n t e x t .
C 5 a  h a s  c l a s s i c a l l y  b e e n  v i e w e d  a s  a  p r o - i n f l a m m a t o r y  m o l e c u l e ,  w i t h  p o s i t i v e  
e f f e c t s  o n  n e u t r o p h i l  p r i m i n g  ( B a j a j  e t  a l .  1 9 9 2 ) ,  c h e m o t a x i s  ( S n y d e r m a n  e t  a l .  
1 9 7 5 ) ,  n e u t r o p h i l  r e c r u i t m e n t  ( S n y d e r m a n ,  P h i l l i p s  &  M e r g e n h a g e n  1 9 7 1 )  a n d  
d e g r a n u l a t i o n  ( B e n d e r ,  M c P h a i l  &  V a n  E p p s  1 9 8 3 ) .  H o w e v e r  t h e s e  e f f e c t s  
h a v e  l a r g e l y  b e e n  d e m o n s t r a t e d  a t  r e l a t i v e l y  l o w  c o n c e n t r a t i o n s  ( l O p M - l n M ) ,  
a n d  f o l l o w i n g  r e l a t i v e l y  s h o r t  d u r a t i o n s  o f  e x p o s u r e  ( s e c o n d s  t o  m i n u t e s ) .  
A n i m a l  m o d e l s ,  a n d  i n - v i t r o  w o r k ,  h a d  i d e n t i f i e d  C 5 a  i n  t h e  h i g h e r  
c o n c e n t r a t i o n s  s e e n  i n  s e p s i s  a s  a  m e d i a t o r  o f  n e u t r o p h i l  d y s f u n c t i o n ,  i n c l u d i n g  
b o t h  i m p a i r e d  p h a g o c y t o s i s  a n d  R O S  p r o d u c t i o n s  ( H u b e r - L a n g  e t  a l .  2 0 0 2 b ) .  
T h e s e  f i n d i n g s  h a d  b e e n  i d e n t i f i e d  i n  b o t h  s e p t i c  ( H u b e r - L a n g  e t  a l .  2 0 0 2 b )  a n d  
s t e r i l e  ( F l i e r l  e t  a l .  2 0 0 8 a )  a n i m a l  m o d e l s .  T h e  f i n d i n g s  f r o m  p a t i e n t s  m  t h i s
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w o r k  w a s  t h e  f i r s t  t i m e  t h i s  e f f e c t  h a d  b e e n  d e m o n s t r a t e d  i n  h u m a n s ,  a n d  i s  a n  
i m p o r t a n t  s t e p  i n  t r a n s l a t i n g  t h e  w o r k  f r o m  a n i m a l  s t u d i e s  i n t o  c l i n i c a l l y  u s e f u l  
r e s e a r c h .
D e v e l o p i n g  t h e  a s s o c i a t i o n  b e t w e e n  m a r k e r s  o f  C 5 a  e x p o s u r e  a n d  n e u t r o p h i l  
d y s f u n c t i o n  s h o w n  i n  C h a p t e r  4  i n t o  e v i d e n c e  f o r  a  c a u s a l  r e l a t i o n s h i p  r e q u i r e d  
e x p l o r a t i o n  o f  t h e  i n t r a - c e l l u l a r  p a t h w a y s  b y  w h i c h  a n y  e f f e c t  m a y  b e  m e d i a t e d .  
A s  t h e  d a t a  i n  C h a p t e r  5  d e m o n s t r a t e d ,  r e c o m b i n a n t  C 5 a  a p p l i e d  t o  h e a l t h y  
d o n o r  n e u t r o p h i l s  w a s  a b l e  t o  i n d u c e  n o t  o n l y  a  d e f e c t  i n  p h a g o c y t o s i s  ( f i g u r e  V -  
1 ,  p a g e  1 4 4 )  b u t  a l s o  r e p l i c a t e  t h e  c o r r e l a t i o n  b e t w e e n  C D 8 8  a n d  p h a g o c y t o s i s  
( f i g u r e  V - 2 ,  p a g e  1 4 5 ) .  T h e  e f f e c t  o f  C 5 a  o n  p h a g o c y t o s i s  w a s  p r e v e n t e d  b y  
b l o c k i n g  i t ’ s  b i n d i n g  t o  C D 8 8 ,  s o  p r o v i d i n g  t h e  f i r s t  s t e p  i n  t h e  m e c h a n i s t i c  
p a t h w a y .
L i g a t i o n  o f  C D 8 8 ,  i n  c o m m o n  w i t h  o t h e r  h e p t a h e l i c a l  r e c e p t o r s ,  r e s u l t s  i n  s i g n a l  
t r a n s d u c t i o n  v i a  t h e  c o u p l e d  G - p r o t e i n s  a n d  t h e i r  d o w n - s t r e a m  e f f e c t o r  
m o l e c u l e s .  C D 8 8  i s  c o u p l e d  t o  t h e  s a m e  G - p r o t e i n  a l p h a  s u b - u n i t  ( G „ i 2)  a s  t h e  
f M L P  r e c e p t o r  F M L R ,  a n d  l i g a t i o n  o f  t h i s  s e c o n d  r e c e p t o r  w i t h  e q u i m o l a r  
c o n c e n t r a t i o n s  o f  f M L P  i n d u c e d  t h e  s a m e  d e f e c t  i n  p h a g o c y t o s i s  a s  C 5 a  ( f i g u r e
V - 3  p a g e  1 4 6 ) .
T h e  d o w n - s t r e a m  p a t h w a y s  a c t i v a t e d  b y  C 5 a  ( a n d  f M L P )  i n c l u d e  t h e  a d e n y l a t e  
c y c l a s e / c A M P / p r o t e i n  k i n a s e  A  ( P K A )  p a t h w a y  ( T s u ,  A l l e n  &  W o n g  1 9 9 5 ) ,  
P I 3 K s  ( K o n r a d  e t  a l .  2 0 0 8 )  a n d  p r o t e i n  k i n a s e  C  ( P K C )  p a t h w a y  ( W r a i m  e t  a l .
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2 0 0 7 b ) .  B e t a - a d r e n o c e p t o r  a g o n i s t s  s u c h  a s  i s o p r o t e r e n o l  a r e  k n o w n  t o  i m p a i r  
p h a g o c y t o s i s ,  a n d  t h i s  i s  f a c i l i t a t e d  b y  a c c u m u l a t i o n  o f  c A M P  ( I g n a r r o ,  L i n t  &  
G e o r g e  1 9 7 4 ) , .  W h i l s t  t h i s  e f f e c t  o f  b e t a  a g o n i s t s  w a s  r e p r o d u c e d  i n  t h e  c u r r e n t  
s t u d y  ( f i g u r e  V - 4  p a g e  1 4 8 )  a n d  w a s  p r e v e n t e d  b y  t h e  i n h i b i t i o n  o f  a d e n y l a t e  
c y c l a s e ,  n e i t h e r  C 5 a  n o r  f M L P  a p p e a r e d  t o  m e d i a t e  t h e i r  i n h i b i t i o n  o f  
p h a g o c y t o s i s  b y  t h i s  r o u t e  ( f i g u r e s  V - 5  t o  V - 7  p a g e s  1 4 8 - 4 9 ) .
P I 3 K  w a s  t h e  n e x t  t a r g e t  m o l e c u l e  e x a m i n e d ,  g i v e n  i t s  k n o w n  e f f e c t s  o n  a c t i n  
p o l y m e r i s a t i o n  a n d  p h a g o c y t o s i s  ( P i n h o  e t  a l .  2 0 0 7 ,  C o x  e t  a l .  2 0 0 1 ) .  P r e ­
t r e a t m e n t  o f  n e u t r o p h i l s  w i t h  t w o  s e p a r a t e  i n h i b i t o r s  o f  P I 3 K ,  I C 8 7 1 1 4  a n d  
w o r t m a n n i n ,  w a s  a b l e  t o  p r e v e n t  C 5 a ’ s  e f f e c t s  o n  p h a g o c y t o s i s  ( f i g u r e  V - 8 ,  V - 9 ,  
p a g e  1 5 1 - 2 ) .  G i v e n  t h a t  P I 3 K  h a s  g e n e r a l l y  b e e n  s e e n  a s  a  p o s i t i v e  p r o m o t e r  o f  
p h a g o c y t o s i s  ( C o x  e t  a l .  1 9 9 9 ) ,  t h i s  f i n d i n g  w a s  i n i t i a l l y  r a t h e r  c o u n t e r - i n t u i t i v e .  
T w o  p o s s i b i l i t i e s  p r e s e n t e d  t h e m s e l v e s ,  e i t h e r  t h e  e f f e c t s  s e e n  c o u l d  b e  d u e  
e f f e c t s  o f  t h e s e  t w o  i n h i b i t o r s  o n  n o n - P I 3 K  e n z y m e s  ( D a v i e s  e t  a l .  2 0 0 0 )  o r  t h a t  
d i f f e r e n t i a l  i n v o l v e m e n t  o f  P I 3 K  i s o f o r m s  w a s  i n v o l v e d ,  w h i c h  w o u l d  n o t  b e  
c l e a r  f r o m  t h e  u s e  o f  n o n - s e l e c t i v e  i n h i b i t o r s  s u c h  a s  L Y 2 9 4 0 0 2  a n d  
w o r t m a n n i n .  G i v e n  t h a t  b o t h  n o n - s e l e c t i v e  i n h i b i t o r s  p r o d u c e d  t h e  s a m e  e f f e c t  i t  
s e e m e d  l e s s  l i k e l y  t h a t  t h i s  w a s  d u e  t o  n o n - P I 3 K  i n h i b i t i o n .  F u r t h e r m o r e  t h e  
e f f e c t  o f  L Y 2 9 4 0 0 2  p e r s i s t e d  w e l l  b e l o w  t h e  r e p o r t e d  I C 5o  f o r  P I 3 K y  ( f i g u r e  V - 9 ,  
p a g e  1 5 1 )  a l s o  a r g u e d  a g a i n s t  t h i s  a n d  i n  f a v o u r  o f  a n  i s o f o r m  s p e c i f i c  e t f c c t .
T h e  t w o  p r e d o m i n a n t  t y p e s  o f  c l a s s  I  P I 3 K s  f o u n d  i n  l e u k o c y t e s ,  i n c l u d i n g  
n e u t r o p h i l s ,  a r e  t h e  g a m m a  ( y )  a n d  d e l t a  ( 8 )  i s o f o r m s  ( R o m m e l ,  C a m p s  &  J i  
2 0 0 7 )  b o t h  o f  w h i c h  a r e  a c t i v a t e d  b y  C 5 a  ( K o n r a d  e t  a l .  2 0 0 8 ) .  T h e
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e x p e r i m e n t a l  d a t a  s u g g e s t  t h a t  t h e  e f f e c t s  o f  C 5 a  o n  p h a g o c y t o s i s  a r e  m e d i a t e d  
b y  t h e  6  f o r m  ( f i g u r e  V - 1 0 ,  V - l l ,  p a g e s  1 5 3 - 4 ) .  T h e  a b i l i t y  o f  A S 6 0 5 2 4 0  t o  
i n h i b i t  p r o t e i n  k i n a s e  B  ( P K B )  p h o s p h o r y l a t i o n  ( f i g u r e  V - 1 2 ,  p a g e  1 5 6 )  
d e m o n s t r a t e d  i t s  f u n c t i o n a l i t y ,  w h i l s t  c o n c e n t r a t i o n s  o f  I C 8 7 1 1 4  t h a t  w e r e  a b l e  
t o  f u l l y  i n h i b i t  C 5 a - m e d i a t e d  p h a g o c y t i c  d y s f u n c t i o n  d i d  n o t  f u l l y  i n h i b i t  P K B  
p h o s p h o r y l a t i o n  ( F i g u r e s  V - l  1 ,  V - 1 2 ,  p a g e s  1 5 4 - 5 6 ) .  T h i s ,  a l o n g s i d e  p u b l i s h e d  
e v a l u a t i o n s  o f  t h e  s p e c i f i c i t i e s  o f  t h e s e  t w o  i n h i b i t o r s  ( F e r r a n d i  e t  a l .  2 0 0 7 ,
S m i t h  e t  a l .  2 0 0 7 ,  K n i g h t  e t  a l .  2 0 0 6 )  a n d  t h e  f u n c t i o n i n g  o f  L Y 2 9 4 0 0 2  a t  l o w  
c o n c e n t r a t i o n s  s u p p o r t s  t h e  c o n t e n t i o n  t h a t  t h e  e f f e c t  i s  i n d e e d  s p e c i f i c  t o  t h e  8  
i s o f o r m .  S p e c i f i c  a c t i v a t i o n  o f  t h e  c l a s s  I A  P I 3 K s ,  u s i n g  7 4 0  Y - P ,  w a s  a b l e  t o  
i n d u c e  a  s i m i l a r  d e f e c t  i n  p h a g o c y t o s i s  t o  t h a t  a c h i e v e d  b y  C 5 a  ( f i g u r e  V - 1 3 ,  
p a g e  1 5 7 ) .
T h e  i n h i b i t i o n  o f  R h o A  d o w n s t r e a m  o f  P I 3 K 8  ( f i g u r e  V - l 4 ,  p a g e  1 5 8 )  i s  
c o n s i s t e n t  w i t h  w o r k  b y  o t h e r  g r o u p s  o n  t h e  e f f e c t s  o f  t h i s  i s o f o r m  i n  c e l l  l i n e s  
a n d  p r i m a r y  m a c r o p h a g e s  ( P a p a k o n s t a n t i  e t  a l .  2 0 0 8 ,  P a p a k o n s t a n t i ,  R i d l e y  &  
V a n h a e s e b r o e c k  2 0 0 7 ) .  I n t r i g u i n g l y ,  h i g h  i n t r a c e l l u l a r  c o n c e n t r a t i o n s  o f  c A M P  
a l s o  i m p a i r  p h a g o c y t o s i s  b y  i n h i b i t i n g  R h o A  ( K a m a n o v a  e t  a l .  2 0 0 8 ) ,  s u g g e s t i n g  
a  c o m m o n  f i n a l  p a t h w a y  t h r o u g h  w h i c h  b o t h  C 5 a  a n d  c A M P  m a y  w o r k  d e s p i t e  
d i s p a r a t e  u p - s t r e a m  m e c h a n i s m s  ( s e e  a b o v e ) .
A c t i n  p o l y m e r i s a t i o n  a n d  r e o r g a n i s a t i o n  i s  t h e  f i n a l  s t e p  i n  t h e  p r o c e s s  o f  
p h a g o c y t o s i s ,  a n d  i n  t h e  c o m p l e m e n t - m e d i a t e d  s i t u a t i o n  t h i s  i s  d e p e n d e n t  o n  
R h o A  a c t i v i t y  ( C a r o n ,  H a l l  1 9 9 8 ) .  l C 5 a  i m p a i r e d  a c t i n  p o l y m e r i s a t i o n ,  a n d  t h i s  
e l f e c t  c o u l d  b e  p r e v e n t e d  b y  b o t h  p a n  P I 3 K  i n h i b i t i o n  w i t h  L Y 2 9 4 0 0 2 ,  a n d  a l s o
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d e l t a - s p e c i f i c  i n h i b i t i o n  w i t h  I C 8 7 1 1 4 .  T h e  p r o p o s e d  p a t h w a y  f r o m  C 5 a  l i g a t i o n  
o f  C D 8 8  t h r o u g h  t o  i m p a i r e d  p h a g o c y t o s i s  i s  s h o w n  i n  f i g u r e  V I I - 1 b e l o w .
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Figure VII-1: Schematic representation of C5a’s proposed effects on 
neutrophil phagocytosis.
Reading sequentially from the top left - C5a engages its G-coupled 
receptor CD88 on the neutrophil surface. This activation activates (green 
arrow) the delta isoform of phosphoinositide-3-kinase (PI3K8). Activation 
of PI3K6 inhibits RhoA (red cross marked 1). Inhibition of RhoA results in 
failure to polymerise actin (red cross marked 2). As actin polymerisation 
is required for effective phagolysosome formation (red cross marked 3), 
the result is impaired phagocytosis of pathogens/pathogenic particles 
(represented by purple hexagons).
G r a n u l o c y t e - m a c r o p h a g e  c o l o n y  s t i m u l a t i n g  f a c t o r  ( G M - C S F )  w a s  f i r s t  
i d e n t i f i e d  a s  a  g r o w t h  f a c t o r  f o r  m y e l o i d  c e l l s ,  f a c i l i t a t i n g  p r o l i f e r a t i o n  a n d  
d i f f e r e n t i a t i o n  ( S t a n l e y  e t  a l .  1 9 7 6 ) .  H o w e v e r  i t  a l s o  h a s  r e c o g n i s e d  c y t o k i n e -
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l i k e  e f l e e t s  o n  i m m u n e  c e l l  p r i m i n g ,  r e a c t i v e  o x y g e n  s p e c i e s  p r o d u c t i o n  a n d  
t r a n s m i g r a t i o n ,  a s  w e l l  a s  i m p a c t s  o n  p u l m o n a r y  s u r f a c t a n t  p r o d u c t i o n  a n d  
a l v e o l a r  b a r r i e r  f u n c t i o n  ( r e v i e w e d  i n  H a m i l t o n ,  2 0 0 2 )  A  s t u d y  i n  n o n -  
n e u t r o p e n i c  s e p s i s  s u g g e s t e d  t h a t  G M - C S F  w a s  a b l e  t o  i m p r o v e  n e u t r o p h i l  
p h a g o c y t i c  c a p a c i t y  ( P r e s n e i l l  e t  a l .  2 0 0 2 ) ,  a n d  w i t h  s e r u m  l e v e l s  b e i n g  f o u n d  t o  
b e  l o w  i n  p a t i e n t s  w i t h  c l i n i c a l  V A P  ( T a b l e s  I I I - 3  a n d  I I I - 5 ,  p a g e s  1 0 9 - 1 0 ) ,  i t  
a p p e a r e d  t o  b e  a  p o t e n t i a l l y  u s e f u l  t h e r a p e u t i c  o p t i o n .  A s  t h i s  s t u d y  
d e m o n s t r a t e d ,  G M - C S F  w a s  a b l e  t o  r e s t o r e  p h a g o c y t o s i s  b y  h e a l t h y  n e u t r o p h i l s  
f o l l o w i n g  i n - v i t r o  e x p o s u r e  t o  C 5 a .
T h e  m e c h a n i s m  b y  w h i c h  G M - C S F  a c t s  t o  r e s t o r e  p h a g o c y t o t i c  e f f e c t i v e n e s s  
f o l l o w i n g  e x p o s u r e  t o  C 5 a  r e m a i n s  o b s c u r e .  H o w e v e r  i t  i s  c l e a r  f r o m  f i g u r e s  V -  
2 0 , 2 1  ( p a g e  1 6 3 )  t h a t  i t  d o e s  n o t  f u n c t i o n  b y  r e s t o r i n g  C D 8 8  e x p r e s s i o n .  I n  
k e e p i n g  w i t h  t h e  s u g g e s t e d  r o l e  o f  r e d u c e d  C D 8 8  a s  a  m a r k e r  o f  C 5 a  e x p o s u r e  
r a t h e r  t h a n  i t  a c t i n g  a s  a  p h a g o c y t i c  r e c e p t o r ,  r e s t o r i n g  C D 8 8  e x p r e s s i o n  t h r o u g h  
t h e  u s e  o f  i n t e r f e r o n  g a m m a  d i d  n o t  r e s u r r e c t  p h a g o c y t o s i s  ( f i g u r e  V - 2 0 ,  2 1 ) .  
F u r t h e r m o r e ,  t h e  a d d i t i o n  o f  t h e  P I 3 K 6  i n h i b i t o r  I C 8 7 1 1 4  a f t e r  e x p o s u r e  t o  C 5 a  
d i d  n o t  r e s t o r e  p h a g o c y t o s i s  i n  c o n t r a s t  t o  i t s  a b i l i t y  t o  b l o c k  t h e  e f f e c t s  o f  C 5 a  
w h e n  c e l l s  w e r e  t r e a t e d  p r i o r  t o  e x p o s u r e .  G M - C S F  i s ,  h o w e v e r ,  a b l e  t o  r e v e r s e  
t h e  d e f e c t s  i n  R J h o A  s i g n a l l i n g  ( F i g u r e  V - 1 8 ,  p a g e  1 6 1 )  a n d  r e s t o r e  a c t i n  
p o l y m e r i s a t i o n  ( F i g u r e  V - 1 9 ,  p a g e  1 6 2 ) .
T h e r e f o r e  i t  s e e m s  p r o b a b l e  t h a t  G M - C S F  a c t s  d o w n s t r e a m  o f  C D 8 8 / P I 3 K d e l t a  
( s e e  f i g u r e  7 - 1  a b o v e ) .  T h e  p a t h w a y  f r o m  G M - C S F  l i g a t i o n  o f  i t s  r e c e p t o r  t o  t h e  
r e s t o r a t i o n  o f  R h o A  a c t i v i t y  r e q u i r e s  f u r t h e r  s t u d y ,  b u t  p u b l i s h e d  d a t a  s u g g e s t s
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t h i s  m a y  b e  m e d i a t e d  v i a  t h e  l y n / s r c - k i n a s e s  ( w h i c h  c a n  i n  t u r n  a c t i v a t e  R l i o A  
( S h i  e t  a l .  2 0 0 6 a ,  Y o u s e f i  e t  a l .  1 9 9 6 ) .  W o r k  o n  t h i s  a r e a  i s  c u r r e n t l y  o n g o i n g .
T h e  i n h i b i t o r y  e f f e c t s  o f  C 5 a  o n  n e u t r o p h i l  f u n c t i o n  a r e  n o t  r e s t r i c t e d  t o  
p h a g o c y t o s i s .  C 5 a - t r e a t e d  n e u t r o p h i l s  d e m o n s t r a t e d  s i g n i f i c a n t  r e d u c t i o n s  i n  
b a c t e r i c i d a l  f u n c t i o n  a g a i n s t  P s e u d o m o n a s  a e r u g i n o s a  ( f i g u r e  V - 2 3 ,  p a g e  1 6 5 ) ,  
a n d  a l s o  i m p a i r e d  t r a n s m i g r a t i o n  t o w a r d s  f M L P  ( f i g u r e  V - 2 4 ,  p a g e  1 6 6 ) .  T h e  
i m p a i r m e n t  o f  t r a n s m i g r a t i o n  i s  a n  i n t e r e s t i n g  f i n d i n g  a s ,  i n  c o n t r a s t  t o  
p h a g o c y t o s i s ,  i t  d i d  n o t  a p p e a r  t o  b e  m e d i a t e d  b y  P I 3 K 6  ( F i g u r e  V - 2 5 ,  p a g e  
1 6 7 ) ,  i n d e e d  P I 3 K 8  i t s e l f  w a s  c r u c i a l  t o  f M L P - s t i m u l a t e d  t r a n s m i g r a t i o n  ( F i g u r e
V - 2 5 ) .
A l t h o u g h  t h e  f i n d i n g  o f  P I 3 K 5  i n h i b i t i o n  p r e v e n t i n g  t r a n s m i g r a t i o n  i s  c o n s i s t e n t  
w i t h  t h e  e x i s t i n g  l i t e r a t u r e  ( S a d h u  e t  a l .  2 0 0 3 ) ,  i t  i s  s u r p r i s i n g  g i v e n  t h e  k n o w n  
d e p e n d e n c e  o f  t r a n s m i g r a t i o n  o n  R h o A  ( W o r t h y l a k e  e t  a l .  2 0 0 1 ) .  I t  i s  n o t a b l e  
t h a t  P a p a k o n s t a n t i ’ s  s t u d y  ( P a p a k o n s t a n t i  e t  a l .  2 0 0 8 )  s h o w e d  P I 3 K 8  i n h i b i t i o n  
p r e v e n t e d  t r a n s m i g r a t i o n  d e s p i t e  t h e  s i m u l t a n e o u s  a n d  e x p e c t e d  r i s e  i n  R h o A .  I t  
a p p e a r s  t h a t  t r a n s m i g r a t i o n  r e l i e s  o n  a  d e l i c a t e  b a l a n c e  o f  i n t r a c e l l u l a r  R h o A  
l e v e l s .  W h i l s t  i n h i b i t i o n  i m p a i r s  t r a n s m i g r a t i o n  ( W o r t h y l a k e  e t  a l .  2 0 0 1 ) ,  
h e i g h t e n e d  l e v e l s  c a n  i m p a i r  r a t h e r  t h a n  p r o m o t e  t r a n s m i g r a t i o n  ( R i d l e y ,  
C o m o g l i o  &  F l a i l  1 9 9 5 ) .  I n  a d d i t i o n ,  o t h e r  i n v e s t i g a t o r s  r e p o r t  a  t h r e s h o l d  e f f e c t  
o f  R h o A ,  w h e r e  o n l y  h i g h  c o n c e n t r a t i o n s  o f  R h o A  i n h i b i t o r  i m p a i r e d  
t r a n s m i g r a t i o n  ( N o b e s ,  H a l l  1 9 9 9 ) .  F u r t h e r m o r e ,  t h e  e f f e c t s  o f  P I 3 K d  i n h i b i t i o n  
o n  n e u t r o p h i l  t r a n s m i g r a t i o n  d o  n o t  a p p e a r  t o  a c t  t h r o u g h  i m p a i r m e n t  o f  a c t i n
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p o l y m e r i z a t i o n  ( S a d h u  e t  a l .  2 0 0 3 ) .  I n  c o n t r a s t ,  t h e  w o r k  a b o v e  d e m o n s t r a t e d  
t h a t  a c t i n  p o l y m e r i s a t i o n  w a s  c e n t r a l  t o  t h e  e f f e c t s  o f  P I 3 K d  i n h i b i t i o n  o n  
p h a g o c y t o s i s .  I t  t h e r e f o r e  s e e m s  p l a u s i b l e  t h a t  P I 3 K d  i n h i b i t i o n  r e s t o r e s  
s u f f i c i e n t  R h o A  t o  a l l o w  e f f i c i e n t  p h a g o l y s o s o m e  f o r m a t i o n  a n d  p h a g o c y t o s i s  i n  
C 5 a - t r e a t e d  n e u t r o p h i l s ,  b u t  t h a t  l e v e l s  o f  R h o A  a r e  i n s u f f i c i e n t  t o  r e s t o r e  
t r a n s m i g r a t i o n  ( a n d / o r  t h a t  i n  d y s f u n c t i o n a l  n e u t r o p h i l s  r e s t o r a t i o n  o f  
t r a n s m i g r a t i o n  r e q u i r e s  P I 3 K d / R h o A - i n d e p e n d e n t  p a t h w a y s ) .  A s  n o t e d  a b o v e ,  
e l e v a t e d  c A M P  i m p a i r s  p h a g o c y t o s i s  b y  i m p a i r i n g  R h o A  a c t i v a t i o n  ( K a m a n o v a  
e t  a l .  2 0 0 8 ) ,  h o w e v e r  e l e v a t e d  c A M P  d o e s  n o t  a p p e a r  t o  i n h i b i t  t r a n s m i g r a t i o n  
( D a n i e l s  e t  a l .  1 9 9 3 ) ,  a g a i n  s u g g e s t i n g  t h a t  C 5 a ’ s  i n h i b i t i o n  o f  t r a n s m i g r a t i o n  
m a y  w o r k  v i a  a n  a l t e r n a t i v e  m e c h a n i s m ( s ) .
I n t e r e s t i n g l y ,  t h e  d i s s o c i a t e d  e f f e c t s  o f  P I 3 K d  i n h i b i t i o n  o n  p h a g o c y t o s i s  a n d  
t r a n s m i g r a t i o n  i n  d y s f u n c t i o n a l ,  C 5 a - t r e a t e d  n e u t r o p h i l s  c o u l d  e x p l a i n  w h y  P I 3 K  
i n h i b i t o r s  h a v e  n o t  p r o v e n  b e n e f i c i a l  i n  s e p s i s  ( W r a m i  e t  a l .  2 0 0 7 a ) .  C e r t a i n l y  
t h e s e  f i n d i n g s  d o  n o t  s u g g e s t  a  t h e r a p e u t i c  p l a c e  f o r  P I 3 K d  o r  R h o A  i n h i b i t o r s  
f o r  p r e v e n t i o n  o f  i n f e c t i o n  i n  c r i t i c a l l y  i l l  p a t i e n t s ,  i n  c o n t r a s t  t o  t h e  p o t e n t i a l  f o r  
G M - C S F .
T h e  p a t h w a y  b y  w h i c h  r e c o m b i n a n t  h u m a n  C 5 a  i s  a b l e  t o  i m p a i r  p h a g o c y t o s i s  
a p p e a r s  r e l a t i v e l y  w e l l  d e l i n e a t e d  i n  t h e  a b o v e  e x p e r i m e n t s ,  h o w e v e r  t h e  k e y  t o  
t r a n s l a t i n g  t h i s  i n t o  a  c l i n i c a l l y  u s e f u l  f i n d i n g  i s  s e e i n g  w h e t h e r  t h e  n e u t r o p h i l s  
f r o m  c r i t i c a l l y  i l l  p a t i e n t s  d e m o n s t r a t e  s i m i l a r  f e a t u r e s .  S i m i l a r  t o  n e u t r o p h i l s  
f r o m  p a t i e n t s  w i t h  V A P  ( C h a p t e r  3 ) ,  t h o s e  r e c r u i t e d  a t  a n  e a r l i e r  t i m e - p o i n t ,  
p r i o r  t o  a c q u i r i n g  n o s o c o m i a l  i n f e c t i o n ,  d i s p l a y e d  i m p a i r e d  p h a g o c y t o s i s ,
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d i m i n i s h e d  C D 8 8  e x p r e s s i o n  a n d  a  s t r o n g  c o r r e l a t i o n  b e t w e e n  t h e s e  t w o  
m e a s u r e s  ( F i g u r e s  V - 2 6 ,  2 7 ,  p a g e s  1 6 8 - 9 ) .  A l t h o u g h  C D 8 8  h a s  b e e n  s h o w n ,  i n -  
v i t r o ,  t o  b e  d e p r e s s e d  b y  I L - 6  a n d  T N F - a  a s  w e l l  a s  C 5 a  ( F u r e b r i n g  e t  a l .  2 0 0 6 ) ,  
t h e s e  e f f e c t s  o c c u r r e d  o n l y  a t  v e r y  h i g h  c o n c e n t r a t i o n s ,  f a r  a b o v e  t h o s e  s e e n  e v e n  
i n  s e p s i s  ( T a b l e  I I I - 3 ,  p a g e  1 0 9 ) .  I n  c o n t r a s t  C 5 a  i s  a b l e  t o  p r o d u c e  a  s i m i l a r  
d i m i n u t i o n  i n  C D 8 8  t o  t h a t  s e e n  i n  p a t i e n t s  a t  c o n c e n t r a t i o n s  f o u n d  i n  s e p s i s  
( S o l o m k i n  e t  a l .  1 9 8 1 ) .
F u r t h e r  e v i d e n c e  o f  C 5 a - m e d i a t e d  p h a g o c y t i c  d y s f u n c t i o n  i n  p a t i e n t  n e u t r o p h i l s  
c o m e s  f r o m  t h e  d e m o n s t r a t i o n  o f  i m p a i r e d  R l i o A  a c t i v a t i o n  i n  r e s p o n s e  t o  
z y m o s a n  ( F i g u r e  V - 2 8 ,  p a g e  1 7 0 ) ,  c o u p l e d  w i t h  a  s i m i l a r l y  i m p a i r e d  a c t i n  
p o l y m e r i s a t i o n  ( F i g u r e  V - 2 9 ,  p a g e  1 7 1 ) .  G M - C S F ,  a p p l i e d  e x - v i v o ,  w a s  a b l e  t o  
r e s u r r e c t  p h a g o c y t o s i s .  D e f e c t i v e  a c t i n  p o l y m e r i s a t i o n  r e s p o n s e s  h a v e  b e e n  
n o t e d  i n  n e u t r o p h i l s  f r o m  p a t i e n t s  w i t h  b u m s  ( V i n d e n e s ,  B j e r k n e s  1 9 9 7 ) .  R h o A  
d o w n - r e g u l a t i o n  h a s  b e e n  n o t e d  i n  s e p t i c  m y o c a r d i u m  f o l l o w i n g  p r o l o n g e d  
c G M P  e x p o s u r e  ( S a u z e a u  e t  a l .  2 0 0 0 ,  B u c k l e y ,  S i n g e r  &  C l a p p  2 0 0 6 ) ,  a l t h o u g h  
i t  h a d  n o t  p r e v i o u s l y  b e e n  i d e n t i f i e d  i n  c r i t i c a l l y  i l l  h u m a n s  g e n e r a l l y  o r  
n e u t r o p h i l s  s p e c i f i c a l l y .
T h e  a b i l i t y  o f  a  p r o - i n f l a m m a t o r y  m o l e c u l e  t o  p r o v o k e  a  d y s f u n c t i o n a l  s t a t e  b e g s  
t h e  q u e s t i o n  a s  t o  h o w  s u c h  a n  a p p a r e n t l y  m a l a d a p t i v e  s i t u a t i o n  e v o l v e d .  I t  m a y  
b e  s i m p l y  t h a t  t h e  s o r t s  o f  i n s u l t s  t h a t  p r o v o k e  t h e  m a s s i v e ,  s y s t e m i c  r e l e a s e  o f  
c o m p l e m e n t  w o u l d  n o r m a l l y  b e  u n s u r v i v a b l e  w i t h o u t  m o d e m  i n t e n s i v e  c a r e ,  a n d  
t h e r e f o r e  t h e  m a l a d a p t i v e  p r o c e s s e s  e n c o u n t e r e d  i n  s u c h  a  s i t u a t i o n  w o u l d  b e
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u n a b l e  t o  a p p l y  a n y  s e l e c t i v e  p r e s s u r e .  I t  m a y  a l s o  b e  a n  u n f o r t u n a t e  s i d e  e f f e c t  
o f  a t t e m p t e d  c o u n t e r - r e g u l a t o r y  m e c h a n i s m s .  F o r  i n s t a n c e  R h o A  a p p e a r s  t o  p l a y  
a  d u a l  r o l e  i n  n e u t r o p h i l s ,  i n h i b i t i n g  N F k a p p a B - d e p e n d e n t  T N F - a  r e l e a s e  i n  t h e  
r e s t i n g  s t a t e  b u t  p r o m o t i n g  t h e  s a m e  p a t h w a y  i n  t h e  L P S - a c t i v a t e d  s t a t e  ( F e s s l e r  
e t  a l .  2 0 0 7 ) .  I t  m a y  b e  t h a t  t h e  e f f e c t s  o f  C 5 a  a r e  a n  a t t e m p t  b y  t h e  c e l l  t o  i n h i b i t  
R h o A ,  s o  d o w n - r e g u l a t i n g  p r o - i n f l a m m a t o r y  m o l e c u l e  p r o d u c t i o n  b u t  r e s u l t i n g  
i n  t h e  u n w a n t e d  s i d e  e f f e c t  o f  i m p a i r e d  p h a g o c y t o s i s .
A s  a l l  t h e  w o r k  o n  t h e  m e c h a n i s m  b y  w h i c h  C 5 a  i n h i b i t s  p h a g o c y t o s i s  w a s  
c o n d u c t e d  i n  p r i m a r y  h u m a n  n e u t r o p h i l s ,  a n d  i n c l u d e d  f i n d i n g s  i n v o l v i n g  
n e u t r o p h i l s  f r o m  c r i t i c a l l y  i l l  p a t i e n t s ,  i t  i s  l i k e l y  t h a t  t h i s  r e p r e s e n t s  f i n d i n g s  o f  
d i r e c t  r e l e v a n c e  t o  t h e  c l i n i c a l  s i t u a t i o n .  T h e  s i g n i f i c a n t  d i f f e r e n c e s  b e t w e e n  
h u m a n  a n d  m u r i n e  i m m u n e  s y s t e m s  i n  g e n e r a l  ( M e s t a s ,  H u g h e s  2 0 0 4 )  a n d  
s i g n a l l i n g  p a t h w a y s  s p e c i f i c a l l y  ( C o n d l i f f e  e t  a l .  2 0 0 5 )  s u g g e s t  t h a t  f i n d i n g s  
f r o m  a n i m a l  m o d e l s  m a y  n o t  b e  d i r e c t l y  t r a n s f e r a b l e  t o  h u m a n s .  S i m i l a r l y  t h e  
u s e  o f  i m m o r t a l i s e d  c e l l  l i n e s ,  e v e n  t h o s e  d e r i v e d  f r o m  h u m a n  c e l l s ,  c a n  b e  
q u e s t i o n e d  a s  d i f f e r e n t  i s o f o r m s  o f  k e y  e n z y m e s  s u c h  a s  P I 3 K  c a n  p r e d o m i n a t e  
c o m p a r e d  t o  p r i m a r y  c e l l s  ( P a p a k o n s t a n t i  e t  a l .  2 0 0 8 ) .
H o w e v e r ,  a l t h o u g h  t h e  w o r k  w a s  c o n d u c t e d  i n  p r i m a r y  h u m a n  c e l l s ,  a  p o t e n t i a l  
i s s u e  w i t h  t h i s  s t u d y  r e l a t e s  t o  t h e  r e l e v a n c e  o f  t h e  a s s a y  u s e d  t o  a s s e s s  
p h a g o c y t o s i s .  Z y m o s a n  p a r t i c l e s  a r e  d e r i v e d  f r o m  y e a s t  ( S a c c h a r o m y c e s  
c e r e v i s i a e )  a n d  a r e  l a r g e  c o m p a r e d  t o  o t h e r  p h a g o c y t i c  t a r g e t s  s u c h  a s  b a c t e r i a .  
F u r t h e r m o r e  t h e  u s e  o f  c e l l s  a d h e r e d  o n t o  t i s s u e  c u l t u r e  p l a s t i c  i n  t i s s u e  c u l t u r e
239
m e d i u m  m a y  n o t  f u l l y  r e f l e c t  t h e  p h y s i o l o g i c a l  a n d  p a t h o p h y s i o l o g i c a l  s i t u a t i o n s  
f o u n d  i n  h e a l t h y  a n d  d i s e a s e d  h u m a n s .  A s  s u c h  t h e r e  r e m a i n e d  a  r i s k  t h a t  t h e  
o b s e r v a t i o n s  r e f l e c t  in  v i t r o  a r t e f a c t s  s p e c i f i c  t o  t h e  m o d e l  u s e d .  T h i s  i s s u e  w a s  
a d d r e s s e d  i n  t h e  s t u d y  r e p o r t e d  i n  C h a p t e r  6 ,  d i s c u s s e d  b e l o w ,  i n t o  t h e  a b i l i t y  o f  
C 5 a - m e d i a t e d  d y s f u n c t i o n  t o  p r e d i c t  r i s k  o f  n o s o c o m i a l  i n f e c t i o n  a c q u i s i t i o n .
T h e  i d e n t i f i c a t i o n  o f  C 5 a  a s  a  k e y  m e d i a t o r  o f  n e u t r o p h i l  d y s f u n c t i o n  h a s  s e v e r a l  
i m p o r t a n t  i m p l i c a t i o n s .  C 5 a  i s  r e l e a s e d  e a r l y  i n  c r i t i c a l  i l l n e s s  ( B ô t t i g e r  e t  a l .  
2 0 0 2 ,  F o s s e  e t  a l .  1 9 9 8 ) ,  s u g g e s t i n g  t h a t  d y s f u n c t i o n  m a y  a l s o  o c c u r  e a r l i e r  t h a n  
h a s  b e e n  p r o p o s e d  f o r  a  c l a s s i c a l  C A R S  r e s p o n s e  ( S c h e f o l d  e t  a l .  2 0 0 8 ) .  
C o m p l e m e n t  a c t i v a t i o n  o c c u r s  i n  a  v a r i e t y  o f  d i s e a s e s  t h a t  p r e c i p i t a t e  c r i t i c a l  
i l l n e s s  a n d  t h i s  m a y  e x p l a i n  t h e  a p p a r e n t l y  u b i q u i t o u s  n a t u r e  o f  t h e  i n c r e a s e d  r i s k  
o f  n o s o c o m i a l  i n f e c t i o n  a m o n g s t  p a t i e n t s  a d m i t t e d  t o  t h e  I C U  ( V i n c e n t  2 0 0 3 ) .  
W h a t  s t i m u l a t e s  t h e  s y s t e m i c ,  a p p a r e n t l y  u n c o n t r o l l e d  a c t i v a t i o n  o f  c o m p l e m e n t  
a n d  r e l e a s e  o f  C 5 a  i n  c r i t i c a l  i l l n e s s  r e m a i n s  u n c e r t a i n .  A  v a r i e t y  o f  c o m p l e m e n t  
a c t i v a t i o n  m e c h a n i s m s  m a y  b e  p r e s e n t  i n  c r i t i c a l  i l l n e s s ,  i n c l u d i n g  c o a g u l a t i o n  
( A m a r a  e t  a l .  2 0 1 0 a ) ,  h u m a n  n e u t r o p h i l  e l a s t a s e  ( H N E ) - m e d i a t e d  c l e a v a g e  o f  
I g G  t o  f o r m  F ( a b ’ )  p o r t i o n s  ( F u m i a  e t  a l .  2 0 0 8 ) ,  H N E  i t s e l f  ( V o g t  2 0 0 0 )  a n d  
s y s t e m i c  r e l e a s e  a n d  c i r c u l a t i o n  o f  b a c t e r i a l  p e p t i d e s  ( T h o r g e r s e n  e t  a l .  2 0 0 9 ) .  
W h e t h e r  s y s t e m i c  a c t i v a t i o n  o c c u r s  s i m p l y  b e c a u s e  t h e s e  a c t i v a t o r s  a r e  r e l e a s e d  
i n  l a r g e  q u a n t i t i e s ,  o r  w h e t h e r  t h e r e  a r e  u n d e r l y i n g  d e f e c t s  i n  t h e  c o m p l e m e n t  
r e g u l a t o r y  m e c h a n i s m s ,  r e m a i n s  t o  b e  d e t e r m i n e d .
T h e  s t r o n g  c o r r e l a t i o n  b e t w e e n  n e u t r o p h i l  C D 8 8  e x p r e s s i o n  a n d  p h a g o c y t o s i s  
s u g g e s t s  t h a t  C D 8 8  m a y  b e  a b l e  t o  a c t  a s  a  b i o m a r k e r  f o r  d y s f u n c t i o n ,  w h i c h
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w o u l d  a i d  t h e  c l i n i c a l  u t i l i t y  o f  t h i s  f i n d i n g  a s  i t  w o u l d  r e m o v e  t h e  n e e d  f o r  
l a b o r i o u s  a n d  t e c h n i c a l l y  c h a l l e n g i n g  s e p a r a t i o n  o f  n e u t r o p h i l s  a n d  s u b s e q u e n t  
p h a g o c y t o s i s  a s s a y s .
G M - C S F  o f f e r s  a  p o t e n t i a l l y  e x c i t i n g  t h e r a p e u t i c  o p t i o n .  T o  d a t e  t h e r e  h a v e  
b e e n  s e v e r a l  s m a l l  t r i a l s  o f  G M - C S F  i n  n o n - n e u t r o p a e n i c  s e p s i s  ( M e i s e l  e t  a l .  
2 0 0 9 ,  P r e s n e i l l  e t  a l .  2 0 0 2 ,  O r o z c o  e t  a l .  2 0 0 6 ,  R o s e n b l o o m  e t  a l .  2 0 0 5 ) ,  o f  
w h i c h  o n l y  o n e  ( t h e  s m a l l e s t )  d i r e c t e d  t h e r a p y  t o w a r d s  p a t i e n t s  w i t h  i d e n t i f i e d  
i m m u n e  d y s f u n c t i o n ,  i . e .  m o n o c y t e  d e a c t i v a t i o n  ( M e i s e l  e t  a l .  2 0 0 9 ) .  P r e s n e i l l  
a n d  c o l l e a g u e s  d e m o n s t r a t e d  G M - C S F - m e d i a t e d  i m p r o v e m e n t s  i n  p h a g o c y t o s i s  
( P r e s n e i l l  e t  a l .  2 0 0 2 ) ,  a n d  e n c o u r a g i n g l y  a l t h o u g h  a l l  s t u d i e s  s h o w e d  t h e  
e x p e c t e d  i n c r e a s e  i n  b l o o d  n e u t r o p h i l  c o u n t s  n o n e  s h o w e d  a n y  e v i d e n c e  o f  h a r m .  
I n d e e d  G M - C S F  i m p r o v e d  r a t h e r  t h a n  w o r s e n e d  p u l m o n a r y  f u n c t i o n  i n  p a t i e n t s  
w i t h  A R D S ,  p o s s i b l y  t h r o u g h  i t s  e f f e c t s  o n  s u r f a c t a n t  p r o d u c t i o n  ( P e l a e z  e t  a l .  
2 0 0 4 ) .  E x i s t i n g  t r i a l s  h a v e  b e e n  t o o  s m a l l  t o  s h o w  c o n v i n c i n g  e f f e c t s  o n  
o u t c o m e s ,  h o w e v e r  t h e  s t u d y  b y  O r o z c o  a n d  c o l l e a g u e s  d i d  i n d i c a t e  a  r e d u c t i o n  
i n  i n t r a - a b d o m i n a l  i n f e c t i o n s .
G M - C S F  m a y  n o t  b e  t h e  o n l y  p o t e n t i a l  t h e r a p y ,  a l t h o u g h  i t s  p l u r i p o t e n t  e f f e c t s  
a n d  e f f e c t i v e  a c t i o n  i n  t h e  p r e s e n c e  o f  e s t a b l i s h e d  d y s f u n c t i o n  m a k e  i t  a n  
a t t r a c t i v e  o p t i o n .  S e v e r a l  s m a l l  m o l e c u l e  C D 8 8  a n t a g o n i s t s  e x i s t ,  i n c l u d i n g  
P M X 5 3  t h a t  h a s  u n d e r g o n e  h u m a n  t r i a l s  ( V e r g u n s t  e t  a l .  2 0 0 7 )  a n d  a p p e a r s  s a f e  
a n d  w e l l  t o l e r a t e d  i n  i n f l a m m a t o r y  d i s e a s e .  I t s  a p p a r e n t  s a f e t y  n o t  w i t h s t a n d i n g ,  
P M X 5 3  d i d  n o t  h a v e  a  s i g n i f i c a n t  e f f e c t  o n  r h e u m a t o i d  d i s e a s e  a c t i v i t y ,  a n d  
f u r t h e r m o r e  b l o c k i n g  C D 8 8  m a y  a l s o  p r e v e n t  b e n e f i c i a l  f u n c t i o n s  o f  C 5 a  o n
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n e u t r o p h i l  r e c r u i t m e n t  a n d  b a c t e r i a l  k i l l i n g .  S t u d i e s  o f  C D 8 8  k n o c k o u t  m i c e  
s h o w  i m p a i r e d  c l e a r a n c e  o f  t h e  i m p o r t a n t  n o s o c o m i a l  p a t h o g e n  P s e u d o m o n a s  
( H o p k e n  e t  a l .  1 9 9 6 ) ,  s o  m a k i n g  t h i s  p o t e n t i a l  t h e r a p e u t i c  a v e n u e  l e s s  a t t r a c t i v e .  
P r e - c l i n i c a l  s t u d i e s  h a v e  s h o w n  a n t i - C 5 a  a n t i b o d i e s  t o  b e  e f f e c t i v e  a t  p r e v e n t i n g  
s e p s i s  i n d u c e d  i m m u n e  d y s f u n c t i o n  ( H u b e r - L a n g  e t  a l .  2 0 0 1 ) ,  h o w e v e r  t h e y  h a v e  
n o t  y e t  b e e n  d e m o n s t r a t e d  t o  b e  e f f e c t i v e  i n  a  t r e a t m e n t  s i t u a t i o n  a n d  i n d e e d  
h a v e  y e t  t o  b e  t r a n s l a t e d  i n t o  a  h u m a n i s e d  f o r m  s u i t a b l e  f o r  t h e  c l i n i c a l  
e n v i r o n m e n t .  C 5 a  c o u l d  a l s o  b e  r e m o v e d  f r o m  t h e  c i r c u l a t i o n  b y  e x t r a - c o r p o r e a l  
a b s o r p t i o n ,  a  t e c h n i q u e  w h i c h  a l r e a d y  h a s  b e e n  d e m o n s t r a t e d  i n  h u m a n s  a n d  
w h i c h  r e s u l t s  i n  a  r e s t o r a t i o n  o f  C D 8 8  e x p r e s s i o n  ( S c h e f o l d  e t  a l .  2 0 0 7 ) .  W i t h  
t h e  r e c e n t  b e n e f i c i a l  f i n d i n g s  f r o m  e x t r a c o r p o r e a l  L P S  a b s o r p t i o n  ( C r u z  e t  a l .  
2 0 0 9 ) ,  o n e  c o u l d  e n v i s a g e  a  c o m b i n e d  a b s o r b e r  t h a t  m a y  b e  e f f e c t i v e ,  a l t h o u g h  
e x t r a c o r p o r e a l  c i r c u l a t i o n  b r i n g s  i t s  o w n  r i s k s  ( Z i m p f e r  e t  a l .  2 0 0 6 ) .
I t  i s  i m p o r t a n t  t o  n o t e  t h a t  C 5 a  i s  n o t  t h e  o n l y  m e d i a t o r  o f  n e u t r o p h i l  d y s f u n c t i o n  
i d e n t i f i e d .  T h e  B A L F  f r o m  p a t i e n t s  c o n t a i n s  a  p o t e n t  i n h i b i t o r ( s )  o f  p h a g o c y t i c  
f u n c t i o n  t h a t  i s  d i s t i n c t  f r o m  C 5 a ,  a n d  i m p o r t a n t l y  t h i s  i n h i b i t o r  w a s  n o t  f o u n d  i n  
B A L F  f r o m  m a t c h e d  v o l u n t e e r s ,  s u g g e s t i n g  t h a t  i t  i s  s p e c i f i c  t o  t h e  i n f l a m e d  
l u n g s  f o u n d  i n  c r i t i c a l  i l l n e s s .  A l t h o u g h  t h i s  s t u d y  w a s  a b l e  t o  e x c l u d e  C 5 a  a s  
t h e  c a u s a t i v e  f a c t o r ,  t h e  a c t u a l  n a t u r e  o f  t h e  i n h i b i t o r ( s )  a n d  i t s  m e c h a n i s m  o f  
a c t i o n  r e m a i n  o b s c u r e .  H o w e v e r  t h e  p r e s e n c e  o f  a  s p e c i f i c  p u l m o n a r y  i n h i b i t o r  
m a y  e x p l a i n  t h e  h i g h  p r e v a l e n c e  o f  p u l m o n a r y  i n f e c t i o n s  a m o n g s t  c r i t i c a l l y  i l l  
p a t i e n t s  ( V i n c e n t  e t  a l .  1 9 9 5 ,  V i n c e n t  e t  a l .  2 0 0 9 )
2 4 2
S e c t io n  7 .0 3  C lin ica l im p lic a t io n s  o f  C 5 a -m e d ia ted  n e u tro p h il  
d y s fu n c t io n  a n d  o th e r  im m u n e  d y s fu n ctions
H a v i n g  i d e n t i f i e d  C 5 a  a s  a  k e y  m e d i a t o r  o f  n e u t r o p h i l  d y s f u n c t i o n  a n d  d e f i n e d  
t h e  m e c h a n i s m  b y  w h i c h  i t  i n h i b i t s  p h a g o c y t o s i s ,  t h e  q u e s t i o n  a r i s e s  o f  c l i n i c a l  
r e l e v a n c e  a n d  t i m e  c o u r s e .  I n  t h e  s t u d y  o f  p a t i e n t s  w i t h  s u s p e c t e d  V A P  t h e  
s a m p l e s  w e r e  t a k e n  a t  t h e  t i m e  o f  c l i n i c a l  s u s p i c i o n ,  w h i c h  a s  t a b i c  I I I - l  ( p a g e  
9 8 )  s h o w s  w a s  t y p i c a l l y  8  d a y s  a f t e r  a d m i s s i o n  t o  I C U ,  a n d  t h e r e f o r e  i t  w a s  n o t  
p o s s i b l e  t o  d e t e r m i n e  w h e t h e r  C 5 a - m e d i a t e d  d y s f u n c t i o n  p r e c e d e d ,  o r  w a s  a  
c o n s e q u e n c e  o f ,  n o s o c o m i a l  i n f e c t i o n .  I n  a d d i t i o n ,  a l t h o u g h  i m m u n e  d e p r e s s i o n  
i s  s u g g e s t e d  t o  b e  a  l a t e  p h e n o m e n o n  i n  c r i t i c a l  i l l n e s s  ( H o t c h k i s s ,  K a r l  2 0 0 3 ,  
S c h e f o l d  e t  a l .  2 0 0 8 ) ,  C 5 a  r e l e a s e  o c c u r s  e a r l y  ( F o s s e  e t  a l .  1 9 9 8 )  a n d  t h e r e f o r e  i f  
t h e  h y p o t h e s i s  i s  c o r r e c t  d y s f u n c t i o n  s h o u l d  o c c u r  s i m i l a r l y  e a r l y .
T h e  c o r r e l a t i o n  b e t w e e n  C D 8 8  a n d  i m p a i r e d  p h a g o c y t o s i s ,  t h e  h a l l m a r k  o f  C 5 a -  
m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  i n  h u m a n s ,  w a s  f o u n d  i n  s a m p l e s  t a k e n  e a r l y  i n  
t h e  p a t i e n t ’ s  I C U  s t a y  ( F i g u r e  V - 2 6 ,  p a g e  1 6 8 ) ,  i m p o r t a n t l y  b e f o r e  a n y  I C U -  
a c q u i r e d  i n f e c t i o n  h a d  o c c u r r e d .  F i g u r e s  V I - 2  a n d  V I - 3  ( p a g e s  1 8 0 - 1 )  
d e m o n s t r a t e  t h a t  n e u t r o p h i l  C D 8 8  w a s  b e l o w  l e v e l s  s e e n  i n  h e a l t h y  v o l u n t e e r s  i n  
t h e  m a j o r i t y  o f  p a t i e n t s  a t  s t u d y  a d m i s s i o n  ( i . e .  < 4 8  h o u r s  a f t e i  I C U  a d m i s s i o n ) ,  
w i t h  c o u n t s  t e n d i n g  t o  f a l l  f u r t h e r  d u r i n g  a d m i s s i o n  s u g g e s t i n g  o n g o i n g  
c o m p l e m e n t  a c t i v a t i o n .  I n t e r e s t i n g l y  w h e n  C 3 a  ( a  p r o x y  m e a s u r e  o f  C 5 a  
r e l e a s e )  w a s  e x a m i n e d  t h e r e  w a s  a  m a r k e d  d i c h o t o m y  a m o n g s t  p a t i e n t s  w i t h  a n d  
w i t h o u t  d y s f u n c t i o n  -  t h o s e  w i t h  d y s f u n c t i o n  s h o w e d  i n c r e a s e s  i n  C 3 a  
c o n c e n t r a t i o n s  d u r i n g  t h e i r  I C U  s t a y ,  w h i l s t  t h o s e  w i t h o u t  d y s f u n c t i o n  s h o w e d  a  
t r e n d  t o w a r d s  d e c r e a s i n g  C 3 a  ( F i g u r e  V I - 5 ,  p a g e  1 8 7 ) .  S i m i l a r l y  p e a k  C 3 a
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l e v e l s  w e r e  h i g h e r  i n  t h e  g r o u p  w i t h  d y s f u n c t i o n  ( t a b l e  V I - 4 ,  p a g e  1 8 8 ) .  T h e s e  
f i n d i n g s  a r e  s u g g e s t i v e  o f  o n - g o i n g  c o m p l e m e n t  a c t i v a t i o n  i n  t h e  p a t i e n t s  w i t h  
n e u t r o p h i l  d y s f u n c t i o n / l o w  C D 8 8 .  N o t a b l y ,  t h e r e  w a s  n o  s u c h  d i c h o t o m y  
b e t w e e n  t h e  g r o u p s  i n  t h e  c a s e  o f  o t h e r  i n f l a m m a t o r y  m e d i a t o r s  ( t a b l e  V I - 3  a n d  
V I - 4 ,  p a g e  1 8 8 ) .
P a t i e n t s  w i t h  n e u t r o p h i l  d y s f u n c t i o n  h a d  a  c o n s i d e r a b l y  h i g h e r  r i s k  o f  
n o s o c o m i a l  i n f e c t i o n  ( R R  5 . 4  9 5 %  C l  1 . 4 - 2 1 . 0 ) .  A s  t h i s  e f f e c t  c o u l d ,  
p o t e n t i a l l y ,  b e  b i a s e d  b y  l e n g t h  o f  s t a y  i t  w a s  r e a s s u r i n g  t h a t  t h e  t i m e - s e r i e s  
a n a l y s i s  s h o w e d  a  s i g n i f i c a n t  d i f f e r e n c e  b e t w e e n  t h e  t w o  g r o u p s ,  w i t h  t h e  
d y s f u n c t i o n  g r o u p  s h o w i n g  a  s t e a d y  i n c r e a s e  i n  i n f e c t i o n s  o v e r  t h e i r  s t a y  w h i l s t  
t h o s e  w i t h o u t  d y s f u n c t i o n  r e m a i n e d  r e l a t i v e l y  r e s i s t a n t  t o  i n f e c t i o n  e v e n  i f  t h e y  
r e m a i n e d  i n  t h e  I C U  f o r  s o m e  t i m e  ( f i g u r e  V I - 6 ,  p a g e  1 9 0 ) .  T h i s  e f f e c t  r e m a i n e d  
s i g n i f i c a n t  i f  c o r r e c t e d  f o r  d e m o g r a p h i c  a n d  c l i n i c a l  d i f f e r e n c e s  b e t w e e n  t h o s e  
w i t h  a n d  w i t h o u t  d y s f u n c t i o n  i n  a  C o x  m o d e l  ( t a b l e  V I - 5 ,  p a g e  1 8 9 ) .
C 5 a  c a n  i n h i b i t  a  r a n g e  o f  n e u t r o p h i l  f u n c t i o n s  i n c l u d i n g  t r a n s m i g r a t i o n  a n d  
r e a c t i v e  o x y g e n  s p e c i e s  p r o d u c t i o n  ( H u b e r - L a n g  e t  a l .  2 0 0 2 b ,  B l a c k w o o d  e t  a l .  
1 9 9 6 ) .  T h e r e f o r e  o n e  c a n n o t  b e  c e r t a i n  t h a t  t h e  p h a g o c y t i c  d e f e c t  s p e c i f i c a l l y  
l e a d s  t o  t h e  i n c r e a s e d  r i s k  o f  n o s o c o m i a l  i n f e c t i o n  o b s e r v e d .  I n d e e d  i t  i s  l i k e l y  
t h a t  m u l t i p l e  d e f e c t s  a c t  s y n e r g i s t i c a l l y  t o  p r o d u c e  t h e  i m m u n o p a r a l y s i s  t h a t  
a p p e a r s  t o  c h a r a c t e r i s e  n e u t r o p h i l s  i n  s u c h  s e v e r e l y  i l l  p a t i e n t s .
A l t h o u g h  s t e p s  w e r e  t a k e n  t o  r e d u c e  t h e  r i s k  o f  s i m p l y  d e t e c t i n g  a n  
e p i p h e n o m e n o n  o f  i n f e c t i o n ,  b y  c e n s o r i n g  d a t a  f o r  2  d a y s  p r i o r  t o  d i a g n o s i s  o f
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i n f e c t i o n ,  t h e r e  r e m a i n s  a  p o s s i b i l i t y  t h a t  s u b - c l i n i c a l  i n f e c t i o n  w a s  r e s p o n s i b l e  
f o r  t h e  d i f f e r e n c e s  s e e n  i n  C D 8 8  e x p r e s s i o n .  H o w e v e r ,  w e r e  t h i s  t o  b e  t h e  c a s e ,  
o n e  m i g h t  e x p e c t  t o  s e e  l o w e r  C D 8 8  e x p r e s s i o n  i n  p a t i e n t s  a d m i t t e d  w i t h  
i n f e c t i o n s  ( i . e .  s e p s i s )  c o m p a r e d  t o  s t e r i l e  i n s u l t s ,  o r  r e d u c t i o n s  i n  C D 8 8  a f t e r  t h e  
a c q u i s i t i o n  o f  n o s o c o m i a l  i n f e c t i o n .  I n  f a c t  n o  s u c h  e f f e c t s  w e r e  s e e n  ( F i g u r e s
V I - 7 ,  V I - 8 ,  p a g e  1 9 1 ) ,  r e d u c i n g  t h e  l i k e l i h o o d  t h a t  t h e  e f f e c t  w a s  a n  
e p i p h e n o m e n a  o f  i n f e c t i o n .
I t  i s  i n t e r e s t i n g  t o  n o t e  t h a t  p a t i e n t s  a d m i t t e d  t o  t h e  I C U  w i t h  h o s p i t a l - a c q u i r e d  
i n f e c t i o n s  u n i v e r s a l l y  d e m o n s t r a t e d  C D 8 8  l e v e l s  b e l o w  t h e  c u t - o f f  f o r  
d y s f u n c t i o n  i n  c o n t r a s t  t o  p a t i e n t s  w i t h  c o m m u n i t y  a c q u i r e d - i n f e c t i o n s  ( F i g u r e
V I - 9 ,  p a g e  1 9 2 ) .  T h i s  s u g g e s t s  t h a t  C 5 a - m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  m a y  
n o t  b e  r e s t r i c t e d  t o  p a t i e n t s  i n  t h e  I C U ,  a n d  m a y  b e  p r e s e n t  i n  t h o s e  g e n e r a l  w a r d  
p a t i e n t s  a t  r i s k  o f  n o s o c o m i a l  i n f e c t i o n .  T h i s  s t u d y  w a s  n o t  d e s i g n e d  t o  a n s w e r  
t h i s  q u e s t i o n ,  b u t  i t  r a i s e s  i n t e r e s t i n g  q u e s t i o n s  f o r  f u t u r e  s t u d y .
N e u t r o p h i l s  a r e  o n l y  o n e  o f  a  n u m b e r  o f  i m m u n e  c e l l s  t h a t  h a v e  b e e n  i m p l i c a t e d  
i n  c r i t i c a l - i l l n e s s  r e l a t e d  f a i l u r e  ( s e e  s e c t i o n  1 . 0 5 ,  C h a p t e r  I ) .  W i t h i n  t h e  
c i r c u l a t i n g  c o m p a r t m e n t ,  b o t h  d e a c t i v a t e d  m o n o c y t e s  a n d  e l e v a t e d  l e v e l s  o f  T -  
r e g s  h a v e  b e e n  d e m o n s t r a t e d  ( V e n e t  e t  a l .  2 0 0 9 ,  V o l k  e t  a l .  1 9 9 6 ) .  M o n o c y t e  
d e a c t i v a t i o n  i s  t h e  b e s t - s t u d i e d  e x a m p l e  o f  i m m u n e  d y s f u n c t i o n  i n  c r i t i c a l  
i l l n e s s ,  a n d  h a s  b e e n  l i n k e d  t o  n o s o c o m i a l  i n f e c t i o n s  ( L a n d e l l e  e t  a l .  2 0 1 0 ,  
C h e r o n  e t  a l .  2 0 1 0 )  a l t h o u g h  t h i s  f i n d i n g  i s  n o t  u n i v e r s a l  ( L u k a s z e w i c z  e t  a l .
2 0 0 9 ) .  H i g h  l e v e l s  o f  T - r e g s ,  o n  t h e  o t h e r  h a n d ,  h a d  n o t  b e e n  l i n k e d  t o  t h i s  
o u t c o m e  b e f o r e  t h e  c u r r e n t  s t u d y .
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T h i s  w o r k  c o n f i r m e d  t h e  r e s u l t s  o f  o t h e r  g r o u p s ,  i d e n t i f y i n g  e v i d e n c e  o f  
m o n o c y t e  d e a c t i v a t i o n  u s i n g  H L A - D R  e x p r e s s i o n  ( H o f l i c h  e t  a l .  2 0 0 2 ) .
H o w e v e r  i n  c o n t r a s t  t o  s o m e  p u b l i s h e d  e v i d e n c e  ( M o n n e r e t  e t  a l .  2 0 0 6 ) ,  
m o n o c y t e  d e a c t i v a t i o n  w a s  f o u n d  t o  o c c u r  e a r l y  o n  i n  t h e  I C U  s t a y  i n  a  m a i m e r  
s i m i l a r  t o  n e u t r o p h i l  d y s f u n c t i o n .  R e g u l a t o r y  T - c e l l s  w e r e  a l s o  f o u n d  t o  m a k e  
u p  a n  i n c r e a s e d  p r o p o r t i o n  o f  t h e  p a t i e n t s ’  T - c e l l s ,  a l t h o u g h  t h e  p e a k  f o r  t h i s  
t e n d e d  t o  o c c u r  a t  a  l a t e r  t i m e  p o i n t  t h a n  t h e  o t h e r  d y s f u n c t i o n s  ( F i g u r e  V I - 1 1 ,  
p a g e  1 9 6 ) ,  a n d  d i s p l a y e d  a  g r e a t e r  d e g r e e  o f  v a r i a b i l i t y  d u r i n g  t h e  c o u r s e  o f  t h e  
I C U  s t a y  ( F i g u r e  V I - 1 1 ) .
B o t h  m o n o c y t e  d e a c t i v a t i o n  a n d  e l e v a t e d  l e v e l s  o f  r e g u l a t o r y  T - c e l l s  s h o w e d  a n  
a s s o c i a t i o n  w i t h  t h e  a c q u i s i t i o n  o f  n o s o c o m i a l  i n f e c t i o n ,  a l t h o u g h  m o n o c y t e s  l o s t  
t h e i r  s i g n i f i c a n c e  i n  t h e  C o x  m o d e l  ( T a b l e  V I - 1 2 ,  p a g e  2 0 8 ) .  I n t e r e s t i n g l y  t h e r e  
a p p e a r e d  t o  b e  a n  a d d i t i v e  e f f e c t  o f  i m m u n e  d y s f u n c t i o n  o n  t h e  r i s k  o f  
n o s o c o m i a l  i n f e c t i o n ,  w i t h  a  g r e a t e r  b u r d e n  o f  i m m u n e  d y s f u n c t i o n  p r e d i c t i n g  a  
p r o g r e s s i v e l y  g r e a t e r  r i s k  o f  a c q u i r i n g  i n f e c t i o n  ( T a b l e  V I - 1 0 ,  p a g e  2 0 4 ) .
T h i s  s t u d y  h a s  a  n u m b e r  o f  s t r e n g t h s .  I t  i n v o l v e d  a s s e s s m e n t  o f  s e v e r a l  d i s t i n c t  
m e c h a n i s m s  o f  i m m u n e  d y s f u n c t i o n ,  a n d  a l l o w e d  f o r  d y n a m i c  c h a n g e s  i n  
i m m u n e  c e l l  f u n c t i o n  r a t h e r  t h a n  r e l y i n g  o n  a  s i n g l e  t i m e  p o i n t .  I m m u n o -  
p h e n o t y p i n g  i n  c r i t i c a l  i l l n e s s  i s  a  n e w  f i e l d ,  h o w e v e r  i t  i s  e n c o u r a g i n g  t h a t  t w o  
o u t  o f  t h r e e  c u t - o f f  v a l u e s  f o r  d i c h o t o m i s i n g  p a t i e n t s  i n t o  ‘ d y s f u n c t i o n ’  o r  ‘ n o  
d y s f u n c t i o n ’ ,  d e r i v e d  f r o m  p r e l i m i n a r y  w o r k ,  p e r f o r m e d  w e l l  a t  t h a t  c u t - o f f  a n d  
d i d  n o t  r e q u i r e  f u r t h e r  p o s t - h o c  a d j u s t m e n t  w h i c h  c o u l d  b e  a  s o u r c e  o f  b i a s .  T h e
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i n f e c t i o n s  h a d  t o  m e e t  r i g o r o u s ,  r e p r o d u c i b l e  c r i t e r i a  a n d  a n y  c a s e s  t h a t  d i d  n o t  
m e e t  t h e s e  c r i t e r i a  w e r e  r e v i e w e d  b y  e x p e r i e n c e d  c l i n i c i a n s  w h o  w e r e  b l i n d e d  t o  
t h e  i m m u n e  c e l l  d a t a .
T h e  s a m p l e  s i z e  w a s  r e l a t i v e l y  s m a l l ,  h o w e v e r  i t  w a s  c l o s e  t o  t h e  i n t e n d e d  s i z e  
d e r i v e d  f r o m  t h e  p o w e r  c a l c u l a t i o n .  A s  w i t h  a n y  o b s e r v a t i o n a l  s t u d y  o n e  c a n n o t  
b e  c e r t a i n  t h a t  a n y  a s s o c i a t i o n s  a r e  c a u s a t i v e ,  h o w e v e r  s t e p s  w e r e  t a k e n  t o  
m i n i m i s e  t h e  r i s k  o f  p i c k i n g  u p  e p i p h e n o m e n a l  c h a n g e s  a s s o c i a t e d  w i t h  i n f e c t i o n  
a n d  t h e r e f o r e  o n e  c a n  b e  r e a s o n a b l y  c e r t a i n  t h a t  t h e  c h a n g e s  i n  i m m u n e  f u n c t i o n  
p r e c e d e d  t h e  a c q u i s i t i o n  o f  i n f e c t i o n .  F u r t h e r m o r e ,  t h e  s u p p o s i t i o n  t h a t  i m m u n e  
d y s f u n c t i o n  i s  c a u s a l l y  l i n k e d  t o  t h e  a c q u i s i t i o n  o f  n o s o c o m i a l  i n f e c t i o n  i s  
b i o l o g i c a l l y  p l a u s i b l e .  A l t h o u g h  r e s i d u a l  c o n f o u n d i n g  f r o m  u n m e a s u r e d  
v a r i a b l e s  c a n n o t  b e  r u l e d  o u t ,  m a n y  o f  t h e  r i s k  f a c t o r s  p r e v i o u s l y  m o o t e d  f o r  
n o s o c o m i a l  i n f e c t i o n  h a v e  b e e n  e x a m i n e d  ( V i n c e n t  2 0 0 3 ) .  H o w e v e r  i t  i s  
i m p o r t a n t  t o  n o t e  t h a t  m o s t  c l i n i c a l  r i s k  f a c t o r s  h a v e  b e e n  a n a l y s e d  i n  a  b i n a r y  
( i . e .  p r e s e n t / a b s e n t )  f a s h i o n ,  w h i c h  d o e s  n o t  t a k e  i n t o  a c c o u n t  t h e  d u r a t i o n  o f  
t h e i r  p r e s e n c e  ( e . g .  n u m b e r  o f  d a y s  o f  m e c h a n i c a l  v e n t i l a t i o n  o r  c e n t r a l  v e n o u s  
a c c e s s ) .  T h e  r e l a t i v e l y  s m a l l  n u m b e r  o f  i n f e c t i o n  e v e n t s  p r e c l u d e d  b u i l d i n g  c o x  
m o d e l s  w i t h  m u l t i p l e  t i m e - d e p e n d e n t  v a r i a b l e s ,  w h i c h  w o u l d  b e  r e q u i r e d  t o  
d i s e n t a n g l e  t h e  e f f e c t s  o f  l e n g t h  o f  s t a y  f r o m  d u r a t i o n  o f  s p e c i f i c  c l i n i c a l  r i s k  
f a c t o r s .  T h e s e  c o n s i d e r a t i o n s  w i l l  i n f o r m  t h e  d e s i g n  o f  t h e  p l a n n e d  v a l i d a t i o n  
s t u d y  w h i c h  w i l l  s e e k  t o  r e p l i c a t e  t h e  r e s u l t s  d e m o n s t r a t e d  a b o v e .
S e v e r a l  p r e v i o u s  s t u d i e s  h a v e  d e m o n s t r a t e d  e l e v a t e d  l e v e l s  o f  T - r e g s  i n  p a t i e n t s  
w i t h  s e p s i s  ( V e n e t  e t  a l .  2 0 0 9 ,  V e n e t  e t  a l .  2 0 0 8 ) ,  a n d  r e c e n t  a n i m a l  a n d  i n - v i t r o
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w o r k  h a s  s h o w n  T - r e g s  m e d i a t i n g  i m p a i r e d  T - c e l l  p r o l i f e r a t i v e  r e s p o n s e s  i n  t h i s  
d i s e a s e  ( V e n e t  e t  a l .  2 0 0 9 ) .  A l t h o u g h  s u c h  i m p a i r e d  p r o l i f e r a t i v e  r e s p o n s e s  h a v e  
b e e n  k n o w n  f o r  s o m e  t i m e  ( H o t c h k i s s ,  K a r l  2 0 0 3 ,  M a h l k n e c h t  e t  a l .  1 9 9 6 ) ,  t h e  
m e c h a n i s m ( s )  h a d  r e m a i n e d  u n c e r t a i n .  T h e  c u r r e n t  s t u d y  e x t e n d s  t h e  f i n d i n g s  o f  
e l e v a t e d  T - r e g  c e l l s  t o  c r i t i c a l l y  i l l  p a t i e n t s  w i t h o u t  s e p s i s ,  s u g g e s t i n g  t h a t  t h e i r  
e l e v a t i o n  i s  p a r t  o f  a  s t e r e o t y p e d  r e s p o n s e  t o  s y s t e m i c  i n f l a m m a t i o n  r a t h e r  t h a n  a  
s p e c i f i c  r e s p o n s e  t o  s e v e r e  i n f e c t i o n .
T h i s  i s  t h e  f i r s t  s t u d y  t o  e x a m i n e  s e v e r a l  d i f f e r e n t  m a r k e r s  o f  i m m u n e  
d y s f u n c t i o n  s i m u l t a n e o u s l y ,  a n d  t o  d e m o n s t r a t e  a n  a d d i t i v e  e f f e c t  w h e n  i t  c o m e s  
t o  p r e d i c t i n g  n o s o c o m i a l  i n f e c t i o n .  I t  r e m a i n s  a  d i s t i n c t  p o s s i b i l i t y  t h a t  t h e  
e f f e c t s  a r e  n o t  s i m p l y  a d d i t i v e ,  b u t  m a y  i n d e e d  b e  s y n e r g i s t i c ,  f o r  i n s t a n c e  T - r e g s  
m a y  i n d u c e  a l t e r n a t i v e  m a c r o p h a g e  a c t i v a t i o n  ( T i e m e s s e n  e t  a l .  2 0 0 7 )  a n d  s o  
p o s s i b l y  a l t e r  m o n o c y t e  f u n c t i o n  i n  a  s i m i l a r  m a i m e r .  T - r e g s  a l s o  a l t e r  
n e u t r o p h i l  f u n c t i o n s  i n - v i t r o  ( L e w k o w i c z  e t  a l .  2 0 0 6 ) .  T h e  i n v e s t i g a t i o n  o f  
p o t e n t i a l  i n t e r a c t i o n s  w i l l  b e  t h e  s u b j e c t  o f  f u t u r e  s t u d i e s .
I t  i s  i n t e r e s t i n g  t o  s p e c u l a t e  w h y  t h i s  s t u d y  d i d  n o t  s h o w  s i g n i f i c a n t  e f f e c t s  o f  
d e m o g r a p h i c  a n d  c l i n i c a l  f a c t o r s  t h a t  h a v e  b e e n  p r e v i o u s l y  l i n k e d  t o  n o s o c o m i a l  
i n f e c t i o n  ( V i n c e n t  2 0 0 3 ) .  I t  i s  i m p o r t a n t  t o  n o t e  t h a t  a l t h o u g h  t h e r e  a r e  a  v a r i e t y  
o f  a c k n o w l e d g e d  r i s k  f a c t o r s ,  i n c l u d i n g  s e v e r i t y  o f  i l l n e s s ,  i n t u b a t i o n ,  t o t a l  
p a r e n t e r a l  n u t r i t i o n  a n d  t r a c h e o s t o m y  ( P r a t i k a k i  e t  a l .  2 0 0 8 ,  N o u r d i n e  e t  a l .  1 9 9 9 ,  
C r o w e  e t  a l .  1 9 9 8 ,  B r o o k  e t  a l .  2 0 0 0 ) ,  t h e  v a r i o u s  s t u d i e s  s h o w i n g  t h e s e  e f f e c t s  
o f t e n  p r o d u c e  d i f f e r e n t  c o m b i n a t i o n s  o f  f a c t o r s  a n d  s h o w  r e a s o n a b l e  
d i s a g r e e m e n t  b e t w e e n  s u c h  c o m b i n a t i o n s  ( P r a t i k a k i  e t  a l .  2 0 0 8 ,  S u g e r m a n  e t  a l .
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1 9 9 7 ,  M o r o ,  V i g a n o  &  C o z z i  L e p r i  1 9 9 4 ) .  M o r e o v e r ,  m a n y  s t u d i e s  d o  n o t  
a d e q u a t e l y  a c c o u n t  f o r  t h e  r e l a t i o n s h i p  b e t w e e n  i n t e r v e n t i o n s  s u c h  a s  
t r a c h e o s t o m y ,  b l o o d  t r a n s f u s i o n  a n d  t o t a l  p a r e n t e r a l  n u t r i t i o n ,  a n d  l e n g t h  o f  s t a y  
( i . e .  d u r a t i o n  o f  r i s k  e x p o s u r e ) ,  i n  t h a t  t h e  l o n g e r  o n e  h a s  t o  r e m a i n  i n  I C U  t h e  
m o r e  l i k e l y  o n e  i s  t o  r e c e i v e  o n e  o f  t h e s e  i n t e r v e n t i o n s  ( C r o w e  e t  a l .  1 9 9 8 ,  
L e v i n e  e t  a l .  2 0 1 0 ) ,  w i t h  t h e  a d d e d  c o n f o u n d e r  t h a t  t h o s e  a c q u i r i n g  n o s o c o m i a l  
i n f e c t i o n  s u b s e q u e n t l y  t e n d  t o  s t a y  o n  I C U  l o n g e r  ( B e y e r s m a n n  e t  a l .  2 0 0 8 ) .  
M a n y  e p i d e m i o l o g i c a l  s t u d i e s  o f  i n f e c t i o n  i n  I C U  i n c l u d e  a l l  c o m e r s ,  w h e r e a s  i n  
t h i s  s t u d y  w e  d e l i b e r a t e l y  r e c r u i t e d  a  g r o u p  w h o  w e r e  t h o u g h t  t o  b e  a t  h i g h  r i s k .  
A l l  t h e  p a t i e n t s  h a d  s o m e  f o r m  o f  i n v a s i v e  d e v i c e  i n  p l a c e ,  b e  i t  e n d o t r a c h e a l  
t u b e ,  c e n t r a l  v e n o u s  c a t h e t e r  o r  h a e m o f i l t r a t i o n  l i n e ,  t o  f a c i l i t a t e  t h e  o r g a n  
s u p p o r t  t h a t  w a s  a n  e n t r y  c r i t e r i o n .  W i t h  a  m e d i a n  A P A C H E  I I  s c o r e  o f  2 2  ( I Q R  
1 8 - 2 8 ) ,  t h e s e  p a t i e n t s  w e r e  a  s i c k e r  s u b s e t  o f  a l l  p a t i e n t s  a d m i t t e d  t o  t h e  u n i t  i n  
q u e s t i o n  ( S c o t t i s h  I n t e n s i v e  C a r e  S o c i e t y  A u d i t  G r o u p ,  2 0 0 9 ) .  A s  s u c h  i t  i s  
l i k e l y  t h a t  t h e  e f f e c t s  o f  o t h e r  f a c t o r s  o n  n o s o c o m i a l  i n f e c t i o n  h a d  b e e n  r e d u c e d ,  
a l l o w i n g  a  c l e a r e r  v i e w  o f  t h e  e f f e c t  o f  i m m u n e  d y s f u n c t i o n .  T h i s  s e l e c t i v i t y  
m a y  h a v e  s o m e  l i m i t i n g  e f f e c t  o n  w i d e r  a p p l i c a b i l i t y ,  h o w e v e r  i t  i s  l i k e l y  t h a t  
a n y  t h e r a p e u t i c  o r  p r e v e n t a t i v e  i n t e r v e n t i o n s  f o r  n o s o c o m i a l  i n f e c t i o n s  w o u l d  b e  
c o n c e n t r a t e d  o n  p a t i e n t s  s u c h  a s  t h o s e  w h o  e n t e r e d  t h i s  s t u d y .
T h e  s a m p l i n g  s c h e d u l e  w a s  d e r i v e d  f r o m  p r a g m a t i c  c o n s i d e i a t i o n s ,  b a l a n c i n g  t h e  
d e s i r e  f o r  a s  c o m p l e t e  a  p i c t u r e  a s  p o s s i b l e  o f  i m m u n e  c e l l  c h a n g e s  w i t h  t h e  
f e a s i b i l i t y  o f  c o l l e c t i o n  a n d  a n a l y s i s  o f  f r e s h  b l o o d  s a m p l e s .  P r i o r  t o  u n d e r t a k i n g  
t h i s  s t u d y  t h e  t i m e  c o u r s e  o f  i m m u n e  d y s f u n c t i o n  w a s  u n c l e a r ,  s o  t h e  s a m p l i n g  
s c h e d u l e  w a s  b a s e d  o n  r e a s o n a b l e  s u p p o s i t i o n  a s  t o  t h e  l i k e l y  t i m i n g  o t  a n y
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d e f e c t s .  T h e s e  t w o  f a c t o r s  m e a n  t h a t  w e  h a v e  l i t t l e  d a t a  o n  t h e  v e r y  e a r l y  p h a s e s  
o f  h o s p i t a l  a n d  I C U  a d m i s s i o n  o f  t h e  p a t i e n t s ,  w h i l s t  n o t  h a v i n g  s a m p l i n g  
b e y o n d  t h e  a c q u i s t i o n  o f  f i r s t  i n f e c t i o n  o r  d i s c h a r g e  f r o m  t h e  u n i t .  T h e s e  f a c t o r s  
w i l l  h e l p  i n f o r m  t h e  d e s i g n  o f  t h e  p l a n n e d  v a l i d a t i o n  c o h o r t  s t u d y  a r i s i n g  f r o m  
t h i s  w o r k .
T h e  i m m u n o p h e n o t y p i n g  w e  p e r f o r m e d  u s e d  b a s i c ,  t h r e e  c o l o u r  f l o w  c y t o m e t r y .  
A s  s u c h  t h i s  w o r k  c o u l d  b e  r e a d i l y  t r a n s l a t e d  i n t o  c l i n i c a l  p r a c t i c e  i n  a n y  h o s p i t a l  
w i t h  a c c e s s  t o  a  f l o w  c y t o m e t e r .  T h e  s u g g e s t i o n  t h a t  i n t r a c e l l u l a r  F O X - P 3  
s t a i n i n g  c a n  b e  r e p l a c e d  b y  s u r f a c e  C D  1 2 7  n e g a t i v i t y  ( V e n e t  e t  a l .  2 0 0 9 )  w o u l d  
f u r t h e r  s i m p l i f y  m a t t e r s  a n d  s p e e d  u p  a s s e s s m e n t ,  g i v i n g  a  ‘ r e a d  o u t ’  o f  i m m u n e  
s t a t u s  w i t h i n  3 0  m i n u t e s  o f  s a m p l e  a r r i v a l .  T h e  r e l i a b i l i t y  a n d  v a r i a n c e  o f  t h e  
m e a s u r e s  o f  i m m u n e  f u n c t i o n  w i t h i n  a  s i n g l e  p a t i e n t  s a m p l e  h a v e  n o t  b e e n  
a d d r e s s e d  i n  t h i s  s t u d y ,  b u t  s u c h  a s s e s s m e n t s  w i l l  b e  n e c e s s a r y  b e f o r e  a n y  
c l i n i c a l l y  v a l i d  i m m u n o - p h e n o t y p i n g  a s s a y  c o u l d  b e  d e v e l o p e d .
T h e  p o t e n t i a l  u s e s  o f  s u c h  i m m u n e  p r o f i l i n g  a r e  s e v e r a l .  B y  e n a b l i n g  r i s k  
s t r a t i f i c a t i o n  o f  p a t i e n t s  i t  c o u l d  a l l o w  t a r g e t e d  i m m u n o - s t i m u l a t o r y  
i n t e r v e n t i o n s  ( M e i s e l  e t  a l .  2 0 0 9 ) ,  a n d  a l l o w  f o r  m o r e  c a r e f l i l l y  d e s i g n e d  t r i a l s  o f  
s u c h  i n t e r v e n t i o n s .  A n o t h e r  u s e  m a y  b e  t o  i d e n t i f y  t h o s e  a t  g r e a t e s t  r i s k  a n d  
d i r e c t  p r o p h y l a c t i c  m e a s u r e s  a t  t h e m ,  s o  m i n i m i s i n g  t h e  u s e  o f  e x p e n s i v e  a n d  
p o t e n t i a l l y  h a r m f u l  i n t e r v e n t i o n s  a m o n g s t  p a t i e n t s  w h o  a r e  u n l i k e l y  t o  b e n e f i t .  
F i n a l l y  i t  m a y  h e l p  a n s w e r  s o m e  o f  t h e  q u e s t i o n s  a r o u n d  r e d u c t i o n s  i n  
n o s o c o m i a l  i n f e c t i o n s ,  a l l o w i n g  e f f e c t i v e  c o m p a r i s o n s  b e t w e e n  a n d  w i t h i n  u n i t s
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b y  c o r r e c t i n g  f o r  b a s e l i n e  r i s k  p r i o r  t o  a n y  p a t i e n t  s a f e t y / q u a l i t y  i m p r o v e m e n t  
p r o g r a m m e s  ( C o n w a y  M o r r i s ,  A  2 0 1 1  b ) .
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Section 7.04 Future work
T h i s  w o r k  p r o v o k e s  a s  m a n y  q u e s t i o n s  a s  i t  a n s w e r s ,  a n d  s u g g e s t s  a  r a n g e  o f  
a v e n u e s  f o r  f u t u r e  w o r k .  O n  t h e  m e c h a n i s t i c  l e v e l ,  t h e r e  i s  t h e  q u e s t i o n  o f  h o w  
G M - C S F  i s  a b l e  t o  r e s t o r e  R l i o A  a c t i v a t i o n  a n d  p h a g o c y t o s i s ,  a s  w e l l  a s  i t s  
e f f e c t s  o n  t r a n s m i g r a t i o n .  S e c o n d  i s  t h e  p o s s i b i l i t y  o f  t r a n s l a t i n g  t h e  G M - C S F  
t h e r a p y  f r o m  t h e  l a b  t o  t h e  p a t i e n t ,  t e s t i n g  w h e t h e r  i t  c a n  r e s t o r e  p h a g o c y t i c  
f u n c t i o n  i n  t h e  f i r s t  i n s t a n c e  a n d  a l s o  w h e t h e r  d o i n g  s o  w i l l  r e d u c e  t h e  r i s k s  o f  
a c q u i r i n g  n o s o c o m i a l  i n f e c t i o n .  W i t h  G M - C S F  a l s o  h a v i n g  e f f e c t s  o n  m o n o c y t e  
d e a c t i v a t i o n ,  w h i c h  c o - e x i s t s  w i t h  n e u t r o p h i l  d y s f u n c t i o n ,  i t  m a y  h a v e  a  k e y  r o l e  
t o  p l a y  i n  t h e  m a n a g e m e n t  o f  i m m u n e  s u p p r e s s i o n  i n  t h e  I C U .  I n  o r d e r  t o  t a r g e t  
t h e r a p y  a t  t h o s e  p a t i e n t s  m o s t  l i k e l y  t o  b e n e f i t ,  C D 8 8  s h o w s  p r o m i s e  a s  a  
b i o m a r k e r ,  t h o u g h  t h e  f i n d i n g  o f  i t s  a s s o c i a t i o n  w i t h  n o s o c o m i a l  i n f e c t i o n  
r e q u i r e s  c o n f i r m a t i o n  i n  a n  i n d e p e n d e n t  c o h o r t .  F i n a l l y ,  s e v e r a l  a r e a s  t h a t  h a v e  
r e c e i v e d  l e s s  f o c u s  i n  t h i s  t h e s i s  m a y  a l s o  p r o v e  f r u i t f u l  a v e n u e s  f o r  e x p l o r a t i o n .  
T h e  f i n d i n g  o f  i n t e n s e  p u l m o n a r y  i n f l a m m a t i o n  i n  m i c r o b i o l o g i c a l l y  c o n f i r m e d  
V A P  h a s  i m p o r t a n t  i m p l i c a t i o n s  f o r  p o t e n t i a l  d i a g n o s t i c  b i o m a r k e r s ,  a n d  t h i s  
b a c k g r o u n d  f o r m e d  t h e  b a s i s  o f  a  s t u d y  t h a t  h a s  r e c e n t l y  b e e n  f u n d e d  ( H I C F  
0 5 1 0 - 0 7 8 ) .  T h e  n a t u r e  o f  t h e  p u l m o n a r y  i n h i b i t o r  o f  p h a g o c y t o s i s  r e q u i r e s  
f u r t h e r  c l a r i f i c a t i o n ,  a s  w e l l  a s  a n  e v a l u a t i o n  o f  p o t e n t i a l  t h e r a p i e s  t o  c o u n t e r a c t  
i t s  e f f e c t s .  F i n a l l y  t h e  w o r k  o n  C D 8 8  m a y  h a v e  i m p l i c a t i o n s  o u t s i d e  t h e  I C U ,  
a m o n g s t  g e n e r a l  w a r d  p a t i e n t s  a n d  s h o u l d  t h e  v a l i d a t i o n  s t u d y  p r o v e  p o s i t i v e  i t  
w o u l d  b e  t h e  n e x t ,  l o g i c a l  p l a c e  t o  t a k e  t h i s  w o r k .
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Section 7.05 Conclusions
T h i s  s t u d y  h a s  d e m o n s t r a t e d  t h a t  c r i t i c a l  i l h i e s s  i s  c h a r a c t e r i s e d  b y  a  c o m p l e x  
i n f l a m m a t o r y  s t a t e ,  w i t h  f e a t u r e s  o f  b o t h  i m m u n e  h y p e r - a c t i v a t i o n  a n d  
s u p p r e s s i o n  p r e s e n t  s i m u l t a n e o u s l y  a n d  w i t h i n  s i n g l e  c e l l  t y p e s .  T h i s  
r e m a r k a b l e  d u a l i t y  i s  i l l u s t r a t e d  b y  t h e  a b i l i t y  o f  a  p r o - i n f l a m m a t o r y  m o l e c u l e ,  
C 5 a ,  t o  d r i v e  t h e  n e u t r o p h i l  d y s f u n c t i o n  s e e n  i n  c r i t i c a l  i l l n e s s .  T h i s  f i n d i n g  
f r o m  p a t i e n t s  w a s  d e v e l o p e d  b y  i n - v i t r o  m a n i p u l a t i o n  o f  h e a l t h y  c e l l s  t o  
d e m o n s t r a t e  a  s p e c i f i c  i n t r a c e l l u l a r  p a t h w a y  b y  w h i c h  t h e  p h a g o c y t i c  m a c h i n e r y  
c a n  b e  i n h i b i t e d ,  b e f o r e  r e t u r n i n g  t o  p a t i e n t  n e u t r o p h i l s  t o  d e m o n s t r a t e  s i m i l a r  
m e c h a n i s t i c  f e a t u r e s .  I n  G M - C S F  a  p o t e n t i a l  t r e a t m e n t  h a s  b e e n  i d e n t i f i e d .  
F i n a l l y ,  t h i s  w o r k  h a s  d e m o n s t r a t e d  t h a t  C 5 a - m e d i a t e d  n e u t r o p h i l  d y s f u n c t i o n  
p r e c e d e s  n o s o c o m i a l  i n f e c t i o n  a n d  a c t s  a s  m a r k e r  o f  r i s k  f o r  s u c h  a n  a d v e r s e  
o u t c o m e .  T h e  u s e  o f  s i m p l e  c e l l  s u r f a c e  m a r k e r  q u a n t i f i c a t i o n  b y  f l o w  
c y t o m e t r y  r a i s e s  t h e  p o t e n t i a l  f o r  t h i s  t o  b e  u s e d  t o  i d e n t i f y  c l i n i c a l l y  u s e f u l  
b i o m a r k e r s  o f  d y s f u n c t i o n ,  a l l o w i n g  t h e  t a r g e t i n g  o f  t h e r a p i e s  s u c h  a s  G M - C S F .  
N e u t r o p h i l  d y s f u n c t i o n  d o e s  n o t  e x i s t  i n  i s o l a t i o n ,  c o - o c c u r r i n g  w i t h  a t  l e a s t  t w o  
f u r t h e r  i m m u n e  f a i l u r e s  i . e .  h y p o a c t i v e  m o n o c y t e s  a n d  e x c e s s i v e  l e v e l s  o f  
r e g u l a t o r y  T - c e l l s .  T h e s e  c e l l u l a r  d y s f u n c t i o n a l  s t a t e s  c a n  a l s o  b e  r e a d i l y  
p h e n o t y p e d  u s i n g  s i m p l e  t o o l s ,  a n d  t h i s  r a i s e s  t h e  p o s s i b i l i t y  o f  e f f e c t i v e  i m m u n e  
s y s t e m  m o n i t o r i n g  t o  c o m p l e m e n t  t h e  m o n i t o r i n g  o f  o t h e r  o r g a n  s y s t e m s  t h a t  i s  
u n d e r t a k e n  i n  t h e  i n t e n s i v e  c a r e  u n i t .
T h e  f i n d i n g s  o f  p r o f o u n d  i m m u n e  s u p p r e s s i o n  p r o v i d e  t h e  p a t h o p h y s i o l o g i c a l  
r a t i o n a l e  f o r  i m m u n o - s t i m u l a t o r y  t h e r a p i e s ,  w h i l s t  t h e  i d e n t i f i c a t i o n  o f  s p e c i f i c  
p a t h w a y s  a n d  a g e n t s  t h a t  m o d u l a t e  t h e s e  p a t h w a y s  s u g g e s t s  w h a t  s u c h  î m m u n o -
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s t i m u l a t o r y  a g e n t s  m a y  b e .  T h e  e r a  o f  i m m u n o - s u p p r e s s i v e  t h e r a p i e s  f o r  s e p s i s  
a n d  S I R S  h a s  n o w  l a r g e l y  p a s s e d ,  w i t h  f e w  i f  a n y  e f f e c t i v e  t r e a t m e n t s  r e m a i n i n g  
f r o m  t h i s  c o n c e p t .  P e r h a p s  n o w  t h e  t i m e  h a s  c o m e  t o  l o o k  a t  a n d  t r e a t  t h e  o t h e r  
s i d e  o f  i m m u n e  ( d y s ) f u n c t i o n  i n  c r i t i c a l  i l l n e s s .
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